Fluorescent Iron Oxide Nanoparticles for Molecular MR and Optical Imaging by Jayapaul, Jabadurai
 INAUGURAL - DISSERTATION 
 
 
 
Zur 
Erlangung der Doktorwürde 
der 
Naturwissenschaftlich-Mathematischen Gesamtfakultät 
der 
Ruprecht-Karls-Universität Heidelberg 
 
 
vorgelegt von 
Jabadurai Jayapaul MSc 
aus Melur (Indien)  
 
 
 
 
 Tag der mündlichen Prüfung: 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fluorescent Iron Oxide Nanoparticles for 
Molecular MR and Optical Imaging 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Gutachter:  Prof. Dr. Peter Comba 
         Prof. Dr. Fabian Kiessling
  
 
 
 
 
 
 
 
 
 
  
 
 
 
This work was performed at the department of experimental 
molecular imaging (ExMI), University clinics, RWTH 
Aachen University in co-operation with Helmholtz Institute 
for Applied Medical Engineering, Aachen and German 
Cancer Research Center (DKFZ), Heidelberg 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
     To my parents, brothers and sisters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
List of abbreviations: 
 
acac    acetylacetonate 
AEP    2-aminoethylphosphonic acid 
AFM    Atomic force microscopy 
ANDS    7-amino-1, 3-naphthalene disulfonic acid 
APTMS   3-aminopropyl trimethyl silane  
DAPI    4`,6-diamidino-2-phenylindole  
DEAD    Diethyl azodicarboxylate 
DIPEA   N,N-diisopropylethylamine  
DLS    Dynamic light scattering 
EDC    1-ethyl-3-(3-dimethylamino propyl) carbodiimide   
EDTA    Ethylene diamine tetraacetic acid 
EDX    Energy dispersive X-ray 
EPR    Enhanced permeation and retention 
ESI-MS   Electron spray ionization mass spectrometry 
FACS    Fluorescence assisted cell sorting (Flow cytometry) 
FAD USPIO   Flavin adenine dinucleotide coated Ultrasmall 
FAD    Flavin adenine dinucleotide 
FBS    Fetal bovine serum 
FLUSPIO   Fluorescent Ultrasmall Super Paramagnetic Iron Oxides    
FMN    Flavin mononucleotide 
FMT    Fluorescence mediated tomography 
FRET    Fluorescence resonance energy transfer 
FT-IR    Fourier transform infrared spectrometry 
H-acid    4-amino-5-hydroxy-2,7-naphthalene disulfonic acid 
HOBt    1-hydroxybenzotriazole 
ICP-MS   Inductively coupled plasma mass spectrometry 
ICP-OES   Inductively coupled optical emission spectrometry 
JCPDS    Joint committee on powder diffraction standards 
LDH    Lactate dehydrogenase 
Ln-USPIO   Lanthanide doped Ultrasmall SuperParamagnetic Iron Oxides  
MALDI-MS   Matrix assisted laser desorption ionization mass spectrometry 
MRI    Magnetic resonance imaging 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NMR    Nuclear magnetic resonance 
NUSPIO   Naphthalene coated Ultrasmall SuperParamagnetic Iron Oxides  
PBS    Phosphate buffered saline 
PDI    Polydispersity index 
Pen/Strep   Penicillin/Streptomycin 
PET    Positron emission tomography 
r    Relaxivity 
R2, R1    Relaxation rates 
RCP    Riboflavin carrier protein 
RET    Resonance energy transfer 
RF    Radiofrequency 
Rf    Riboflavin 
RPMI medium  Roswell Park Memorial Institute medium 
SEM    Scanning electron microscopy 
SPECT   Single photon emission computed tomography 
SQUID   Superconducting quantum interface device 
     Super Paramagnetic Iron Oxides  
T1    spin-lattice relaxation (longitudinal relaxation) 
T2    spin-spin relaxation (transverse relaxation)
 TE    Echo time 
TEM    Transmission electron microscopy 
TEOS    Tetraethyl orthosilicate 
TGA    Thermogravimetric analysis 
TLC    Thin layer chromatography 
TOF-SIMS   Time of flight secondary ion mass spectrometry 
TR    Repetition time 
TUNEL   Terminal deoxynucleotidyl transferase dUTP nick end labeling 
US    Ultrasound 
USPIO    Ultrasmall Super Paramagnetic Iron Oxides 
XRD    X-ray diffraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgement: 
I would like to extend my sincere gratitude and heartfelt thanks to my supervisor and friendly guide Prof. Fabian 
Kiessling, Department of Experimental imaging (ExMI), University Clinics, RWTH Aachen University. I am 
grateful to him, for providing me an excellent research facility and for introducing me to the fascinating field of 
MRI and molecular imaging. I thank him for his belief in me during hard times in research and for his timely 
encouragement towards achieving my research goals. I learned a lot about molecular imaging from his lectures. 
I would also like to thank my supervisor Prof. Peter Comba, Institute of Inorganic Chemistry, Heidelberg 
University for his excellent guidance and support. I thank him for his innovative suggestions and helpful 
solutions for solving research problems during hard times. He is easily approachable, kind, induces new ideas 
and has a great concern towards his students. I really enjoyed my association as graduate student under his 
guidance. I remember him saying that “try to learn new things in research and focus on finding a permanent 
position as soon as possible” which intensely increased my appetite for research. 
I would like to thank and appreciate the excellent guidance of Dr. Jessica Gaetjens, ExMI department, 
University Clinics, RWTH Aachen University during the past two years. Thank you for listening to my ideas 
and for improvising them with your timely and helpful suggestions/comments. I would like to specifically thank 
you for your immense patience in correcting my papers and thesis. I learned from you in terms of writing a 
scientific paper and how to bring out a complete story so that it is interesting for the scientific audience. Thanks 
for your belief in my hardwork. I would like to thank you for your continuous support and encouragement that 
you have extended during my research stay in Aachen.  
I extend my heartfelt thanks to Dr. Michael Hodenius, for introducing me to the new techniques in nanoparticle 
synthesis. I thank him for teaching me more material chemistry aspects and for the fruitful discussions which we 
had in Helmholtz Institute during the late working hours. I would like to thank Dr. Wiltrud Lederle for her help, 
suggestions and support regarding the in vitro and in vivo experiments. Further, I would like to thank her for 
correcting my manuscript. I thank Dr. Twan Lammers for his help in organizing the measurements with 
Molecular Profiles, UK and for his comments towards my manuscript.  
I would like to thank my sister Susanne Arns for helping and supporting me in most of the cell and animal 
experiments which I have performed in University clinics Aachen. I thank her for teaching me cell culture, 
histology, animal handling, excising the animal, intravenous injection etc. I thank her for the fruitful discussions 
and ideas which we had towards different experiments. I thank for her patience in explaining facts and for 
allowing me to do experiments myself. 
I thank Mrs. Natascha Mertens for her extended help during different experiments. I would like to thank her 
specially for teaching me MRI and for allowing me to work individually. Further, I thank her for suggestions, 
comments towards my experiments. I also thank Ms. Anne Rix for her help in different experiments and for the 
discussions and suggestions.  
I would like to specially thank Mrs. Birgit Tiemann for her help in organizing my research stay in Aachen. I 
thank her for the patience, support and friendship. Further, I would like to thank other PhD students from the 
ExMI department of University Clinics Aachen for their support, suggestions, and comments during my 
research stay in Aachen. I thank Mr. Lotfi for his help in western blot; Mr. Dennis for his immense help with the 
computers and programmes during my thesis writing; Mr. Stanley for his friendship, fruitful discussions and for 
teaching FACS. I thank Mr. Sijumon Kunjachan for his support, friendship and comments and help in research. 
I would like to sincerely extend my thanks to the patience and guidance provided by Dr. Jochen Huppert, DKFZ 
Heidelberg, Heidelberg University, during the initial two years of my PhD thesis work.  He was a big source of 
teaching, suggestion, experimenting things along with me. I thank him for introducing me to Prof. Peter Comba 
as a supervisor for my PhD thesis from the Institute of Inorganic Chemistry, Heidelberg University.  He used to 
insist me that “I should try to do independent research and if nothing works in the lab, just go and relax on the 
banks of river Neckar”. I greatly admired his patience in handling research difficulties. I miss the fruitful 
interaction, the fun in research which we had together in DKFZ Heidelberg.  
I thank Prof. Semmler for providing me support during my initial PhD thesis work in DKFZ Heidelberg. I 
learned a lot about imaging from his lectures. I thank him for his kind heart, cheerfulness and helping tendency. 
I am grateful to Dr. Tobias Bäulere for his constant support and help during my research work in DKFZ. 
Further, I thank Dr. Manfred Jugold for his friendship, valuable discussions, suggestions, and comments and for 
the fun we had together in research. He is a man of ideas and tries to help a lot by providing inputs. I thank him 
for introducing me to the biological concepts and perspectives. I would like to thank Dr. Bartling for introducing 
me to CT imaging and for his friendship. 
I would like to thank Dr. Stefan Zwick for his excellent friendship, guidance, helpfulness, and for teaching many 
aspects about physics of MRI. Specially, I would like to thank him for his guidance and help during my hard 
times in research. He was a big motivation for me, in terms of doing research in a systematic way. I miss the fun 
which we had together in research and his good friendship. 
I extend my deep sense of gratitude to Mrs. Renate Bangert, for introducing me to the basic cell experiments and 
for performing various in vitro studies for me. I thank Dr. Ute for her guidance during the synthesis of organic 
compounds. I thank Dr. Dörte Oltmanns, radiopharmaceutics department, DKFZ for her constant support and 
help with different measurements. 
I thank Dr. Christina Haaf, Dr. Christoph Busche and Mr. Maik Jacob from the group of Prof. Peter Comba for 
extending their help in performing various measurements and for their availability to discuss problems related to 
the measurements. I would like to thank Mrs. Marlies Schilli and Mrs. Karin Stelzer for their administration 
help. 
I would like to thank the following persons for helping me with various measurements: Dr. Ute Resch (Quantum 
yield and fluorescence lifetime, BAM, Berlin), Mr. Christian Würth (Quantum yield and fluorescence lifetime, 
BAM, Berlin), Dr. Paul Müller (powder XRD, Inorganic chemistry department, RWTH Aachen); Dr. Christina 
Graf (TEM, FU Berlin), Mr. Manfred Spieldrich (SQUID, Inorganic chemistry department, RWTH Aachen); 
Ms. Ioana Slabu (phosphate estimation, AME, Helmholtz Institute Aachen); Dr. Matt Bunker (DLS, powder 
XRD, SIMS, XPS, Molecular Profiles, UK); Dr. Chunfu Zhang (TEM, China); Dr. Hanswalter Zentgraf (TEM, 
DKFZ Heidelberg); Dr. Jochen Huppert (TEM, DLS, ICP-OES, INM Saarbruken); Dr. Jörg Bornemann (TEM, 
University clinics, RWTH Aachen); Mr. Manfred Bovi (SEM/EDX, University clinics, RWTH Aachen); Mr. 
Sörnen (ICPMS, University clinics, RWTH Aachen); Mr. Sebastian Schwarz (FACS, University clinics, RWTH 
Aachen); Mr. Stefan Weinandy (Fluorescence microscope, University clinics, RWTH Aachen); Ms. Eva Siepert 
Maria (western blot, AME, Helmholtz Institute Aachen); Ms. Claudia Rösgen (plate reader, AME, Helmholtz 
Institute Aachen); Dr. John Wong (DLS, DWI Aachen); Ms. Andreea (DLS, DWI Aachen) 
The financial supports provided by the DFG grant KI 1072/1-3 “Dual mode contrast agents for MRI and optical 
imaging techniques” and by the InnoMeT grant z0909im008a “Entwicklung und Bildgebung 
patientenoptimierter Implantate” for carrying out this thesis work are greatly acknowledged. 
I would like to thank my sisters Suguna and Sivaasankari for their support, care, guidance, patience. I would like 
to also thank my brothers Jebaraj, Viji and Alwin for their support and care. I would like to thank my parents for 
believing in me, for their emotional, financial and physical support under all circumstances. I miss you all. 
Finally I would like to thank the Lord Almighty for being with me in all circumstances and for His guidance and 
for His eternal love.  
 
 
 
List of Publications: 
1. Jabadurai Jayapaul, Michael Hodenius, Susanne Arns, Wiltrud Lederle, Twan 
Lammers, Peter Comba, Fabian Kiessling, Jessica Gaetjens. “FMN-coated fluorescent 
iron oxide nanoparticles for RCP-mediated targeting and labeling of metabolically 
active cancer and endothelial cells”. Biomaterials, 2011, 32(25), 5863-5871.  
2. Kiessling  F., Huppert  J., Zhang C., Jayapaul J., Zwick S., Woenne E.C., Mueller 
M.M., Zentgraf H., Eisenhut M., Addadi Y., Neeman M., Semmler W. “RGD-labeled 
USPIO inhibit adhesion and endocytotic activity of αvβ3 integrin expressing glioma 
cells and only accumulate in the vascular tumor compartment” Radiology, 2009, 253, 
462 – 469. 
3. Michael Hodenius*, Christian Würth*, Jabadurai Jayapaul, John Wong, Twan 
Lammers, Jessica Gätjens, Susanne Arns, Natascha Mertens, Ioana Slabu, Gergana 
Ivanova, Jörg Bornemann, Marcel De Cuyper, Ute Resch-Genger, Fabian Kiessling. 
“Fluorescent magnetoliposomes as a platform technology for functional and molecular 
MR and optical imaging” Contrast Media and Molecular Imaging (accepted).  
4. Sijumon Kunjachan, Jabadurai Jayapaul, Marianne E. Mertens, Gert Storm, Fabian 
Kiessling, Twan Lammers. “Theranostic systems and strategies for monitoring 
nanomedicine-mediated drug targeting”. Current Pharmaceutical Biotechnology 2011 
(Revew article in press) 
The original research articles (1-3) can be found after the Appendix section at the end of the 
thesis. 
 
Abstracts: 
1. Jayapaul, J.; Hodenius, M.; Buhl, A.; Comba, P.; Kiessling, F.; Gaetjens, J.;  
“Novel non-polymeric fluorescent bimodal contrast agent for magnetic resonance and 
optical imaging”  
6. Coordination chemistry meeting 2010, Mainz, Germany.       
2. Jabadurai Jayapaul, Michael Hodenius, Alexandra Buhl, Peter Comba, Fabian 
Kiessling, Jessica Gaetjens 
“Dual modal contrast agent with novel non-polymeric fluorescent coating 
(FLUSPIO)” 
World Molecular Imaging Congress, 2009, Montreal, Canada. 
3. Jochen Huppert, Chunfu Zhang, Jabadurai Jayapaul, Stefan Zwick, Eva C. Woenne, 
Margartea M. Mueller, Hanswalter Zentgraf, Michael Eisenhut, Yoseph Addadi, 
Michael Neeman, Wolfhard Semmler, Fabian Kiessling 
“Opposing effects of RGD-labeled USPIO on glioma and endothelial cells” 
World Molecular Imaging Congress, 2008, Nice, France. 
  
 
 
 
 
 
Table of contents 
Abstract ...................................................................................................................................... 1 
Chapter 1. ................................................................................................................................... 5 
Introduction and Background .................................................................................................... 5 
1.1. Multimodal contrast agents ........................................................................................... 10 
1.2. Magnetic Resonance Imaging (MRI) ............................................................................ 12 
1.3. Inorganic Nanoparticles as contrast agents ................................................................... 15 
1.3.1. Iron oxide nanoparticles ......................................................................................... 16 
1.3.2. Biomedical applications of magnetic nanoparticles ............................................... 17 
1.4. In-vivo fluorescence imaging ........................................................................................ 19 
1.5.1. Intrinsic fluorophores ............................................................................................. 22 
1.5.2. Extrinsic fluorophores ............................................................................................ 25 
1.5.3. Contrast agents for MR and Optical imaging ......................................................... 28 
1.5.4. Magnetofluorescent nanoparticles .......................................................................... 30 
1.6. Riboflavin carrier protein as a biological target ............................................................ 31 
1.6.1. Riboflavin cellular internalization pathway ........................................................... 32 
1.6.2. Role of RCP expression in cancers ......................................................................... 34 
1.6.3. RCP targeting ......................................................................................................... 35 
1.6.4. FMN/FAD coated iron oxide nanoparticles for RCP targeting .............................. 35 
Aim of the thesis ...................................................................................................................... 37 
Chapter 2. ................................................................................................................................. 39 
Results and Discussion ............................................................................................................ 39 
2.1. Generation of bimodal contrast agents (MR and Optical imaging) .............................. 41 
2.2. Ligand systems used for coating of iron oxide nanoparticles ....................................... 42 
2.3. Synthesis of iron oxide cores ........................................................................................ 53 
2.4. Estimation of iron concentration in nanoparticles......................................................... 58 
2.5. Different magnetic nanoparticles .................................................................................. 61 
2.6. Synthesis of Ln-USPIO nanoparticles .......................................................................... 61 
2.6.1. Physico-chemical characterization of Ln-USPIO ................................................... 65 
2.7. Magnetofluorescent nanoparticles via dye conjugation (APTMS USPIO) .................. 69 
2.8. Synthesis of NUSPIO nanoparticles ............................................................................. 70 
2.8.1. Physico-chemical characterization of NUSPIO ..................................................... 71 
2.8.2. In vitro results of NUSPIO ..................................................................................... 78 
2.9. USPIO coated with different naphthalene sulfonates ................................................... 81 
2.9.1. USPIO coated with new non-polymeric ligands .................................................... 82 
2.10. Synthesis of FLUSPIO nanoparticles .......................................................................... 82
2.10.1. Physico-chemical characterization results of FLUSPIO .......................................... 83 
2.10.2. In vitro evaluation of FLUSPIO ........................................................................... 92 
2.11. Synthesis of FAD USPIO nanoparticles ................................................................... 101 
2.11.1. Physico-chemical characterization results of FAD USPIO ................................ 102 
2.11.2. In vitro evaluation of FAD USPIO ..................................................................... 108 
2.11.3. In vivo evaluation of FAD USPIO ..................................................................... 114 
Chapter 3. ..................................................................................................................................... 
Conclusion and Outlook ........................................................................................................ 119 
Chapter 4. ............................................................................................................................... 123 
Experimental section .............................................................................................................. 123 
4.1. Materials ...................................................................................................................... 125 
4.2. Methods ....................................................................................................................... 126 
4.3. Ligand synthesis .......................................................................................................... 135 
4.3.1. Synthesis of (2-([2-(Diethoxy-phosphoryl)ethyl]-naphthalen-1-ylmethyl-amino)-
ethyl)-phosphonic acid diethyl ester ............................................................................... 135 
4.3.2. Synthesis of [2-naphthalen-1-ylmethyl-(2-phosphono-ethyl)amino]ethyl]-
phosphonic acid .............................................................................................................. 136 
4.3.3. Synthesis of 4-(9-aminoacridinium-10-yl)butane-1-sulfonate ............................. 137 
4.3.4. Synthesis of 4-(4-((R)-hydroxy((2S,4S,8R)-8-vinylquinuclidin-2-yl)methyl)-6-
methoxyquinolinium-1-yl)butane-1-sulfonate................................................................ 137 
4.3.5. Synthesis of  sodium 3,3‟-(1‟Z)-(4,4‟-((E)-ethene-1,2-diyl)bis(4,1-
phenylene))bis(diazene-2,1-diyl)bis(5-amino-4-hydroxynaphthalene-2,7-disulfonate) 138 
4.3.6. Synthesis of sodium 3,3‟-(1‟Z)-(4,4‟-((E)-ethene-1,2-diyl)bis(3-sulfonato-4,1-
phenylene))bis(diazene-2,1-diyl)bis(5-amino-4-hydroxynaphthalene-2,7-disulfonate) 139 
4.3.7. Synthesis of 2-(6-hydroxy-2-naphthamido)ethyl phosphonic acid ...................... 140 
4.3.8. Synthesis of 1-(6-hydroxy-2-naphthoyloxy)ethane-1,1-diyldiphosphonic acid by 
Mitsunobu reaction ......................................................................................................... 141 
4.3.9. Synthesis of potassium (S)-7-(2-amino-3-(1Hindol-3-yl)propanamido)-3-
sulfonaphthalene-1-sulfonate.......................................................................................... 141 
4.3.10. Synthesis of sodium 4-hydroxy-5-oleamido-7-sulfonaphthalene-2-sulfonate ... 142 
4.3.11. Synthesis of potassium 7-oleamido-3-sulfonaphthalene-1-sulfonate ................. 143 
4.3.12. Synthesis of (S)-2-(2-amino-3-(1H-indol-3-yl)propanamido)ethyl phosphonic 
acid.................................................................................................................................. 144 
4.4. Iron oxide nanoparticles synthesis (USPIO) ............................................................... 145 
4.4.1. Synthesis of iron oxide nanoparticles (10-12 nm) ................................................ 145 
4.4.2. Synthesis of iron oxide nanoparticles (10 nm) ..................................................... 145 
4.4.3. Synthesis of iron oxide nanoparticles (5-6 nm) .................................................... 145 
4.4.4. Synthesis of 2-pyrrolidione stabilized iron oxide nanoparticles (5 nm) ............... 146
4.4.5. Synthesis of oleic acid stabilized iron oxide nanoparticles (7 nm) ...................... 147 
4.4.6. Synthesis of oleic acid stabilized iron oxide nanoparticles (8 nm) ...................... 147 
4.4.7. Commercial iron oxide nanoparticles (EMG 911) ............................................... 148 
4.4.8. Synthesis of lanthanide-doped iron oxide nanoparticles (10-12 nm) ................... 148 
4.4.9. Synthesis of iron nanoparticles with TMAOH ..................................................... 148 
4.5. Estimation of total iron concentration in nanoparticles .............................................. 149 
4.6. Different coating strategies for iron oxide nanoparticles. ........................................... 152 
4.6.1. Silane coating of iron oxide nanoparticles (10 nm) .............................................. 152 
4.6.2. Mixed silane coating of iron oxide nanoparticles (10 nm) ................................... 153 
4.6.3. Synthesis of NUSPIO ........................................................................................... 153 
4.6.4. Synthesis of FLUSPIO ......................................................................................... 155 
4.6.5. Synthesis of FAD USPIO ..................................................................................... 156 
4.7. Different purification techniques used for magnetofluorescent nanoparticles............ 156 
4.8. Total phosphate determination of FLUSPIO and FAD USPIO .................................. 160 
4.9. Conjugation of dyes/biomolecules to APTMS coated nanoparticles .......................... 160 
4.10  In vitro experiments .................................................................................................. 163 
4.11. Cell culture ................................................................................................................ 166 
4.12. Mycoplasm test ......................................................................................................... 171 
4.13. Cell viability assays ................................................................................................... 172 
4.14. Fluorescence microscopy .......................................................................................... 177 
4.15. TEM - FLUSPIO uptake by prostate cancer cells ..................................................... 180 
4.16. Quantification of FLUSPIO intracellular uptake (ICP-MS) ..................................... 180 
4.17. In vitro MR relaxometry ........................................................................................... 181 
4.18. In vitro competitive blocking of FLUSPIO/FAD USPIO uptake by different cells . 183 
4.19. Fluorescence imaging (Fluorvivo300 Indec imaging system) .................................. 184 
4.20. In vivo experiments with FAD USPIO ..................................................................... 185 
References .............................................................................................................................. 189 
Appendices ............................................................................................................................. 201 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
Abstract 
 
The thesis focuses on design and development of iron oxide nanoparticle-based dual 
modal contrast agent for magnetic resonance (MR) and optical imaging (OI). Iron oxide cores 
of size 5-6 nm with low polydispersity index were generated by co-precipitation under 
aqueous reaction conditions. Firstly, we tested lanthanide-doped iron oxide nanoparticles 
(Ln-USPIO), which seemed to exhibit no florescence due to lower levels of lanthanide 
incorporated into the iron crystal structure, which can be explained by the size-based 
difference between lanthanide and iron cations, thus, limiting doping efficiency considerably. 
Secondly, we attempted fluorescence coating of the nanoparticles using naphthalene 
disulfonic acids and it´s modified analogues, which also proved unsuccessful (although 
stable) due to quenching (accounted to the prominent electron transfer between aromatic ring 
of naphthalene sulfonates and iron oxide particles). Thereafter, we explored coating (ligand) 
molecules, which are essentially non-quenching and relatively stable. To this end, we 
researched on flavin analogues (flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD))- relatively simple structured molecules, which are endogenous and 
internalized by highly over-expressed riboflavin carrier protein (RCP) in 
cancer/metabolically active cells.  
Based on the advantages exhibited by flavin analogues, biocompatible, fluorescent 
and non-polymeric FMN- and FAD-decorated USPIO (FLUSPIO and FAD USPIO) were 
developed as versatile MR contrast agents. Stable flavin adsorbed nanoparticles were 
generated by sonicating USPIO with FMN/FAD. It was then coated with GMP (guanosine 
monophosphate) under aqueous conditions. The core diameter, surface morphology and 
surface coverage of FLUSPIO and FAD USPIO were evaluated using TEM, DLS, SEM, 
AFM, powder XRD, EDX, and TGA. The magnetic properties of FLUSPIO and FAD USPIO 
were studied using MRI and SQUID. The fluorescence properties of FLUSPIO and FAD 
USPIO were analyzed using fluorescence- spectroscopy, microscopy and imaging. Cell 
viability/biocompatibility of FLUSPIO and FAD USPIO was evaluated using Trypan blue 
and 7-AAD staining, and TUNEL assay. In vitro evaluation of FLUSPIO/FAD USPIO 
labeling efficiency and their specificity towards RCP was studied using MRI and 
fluorescence microscopy. The pharmacokinetic behavior of FAD USPIO was analyzed in 
CD1 nude mice after its intravenous injection by fluorescence spectroscopy. The in vivo 
uptake of FAD USPIO nanoparticles was assessed using MRI in CD1 male nude mice 
bearing subcutaneous prostate tumors (LnCap) and duly compared with Resovist and further 
tested using Prussian blue staining and immunohistochemistry.  
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The high relaxivities (r2 and r1) and super paramagnetic behavior of FLUSPIO\FAD 
USPIO was confirmed by MRI and SQUID. The biocompatibility of FLUSPIO and FAD 
USPIO was proven via different cell viability assays and staining. FLUSPIO/FAD USPIO 
high efficiency in labeling cancer (PC-3, DU-145, LnCap) and activated endothelial 
(HUVEC) cells and their specificity for RCP was confirmed by MRI, ICP-MS and 
fluorescence microscopy. The in vivo uptake of FAD USPIO by experimental prostate 
carcinomas was significantly higher than the uptake of the commercial SPIO contrast agent 
Resovist.  
In summary, of our different attempts to generate magnetoflourescent iron oxide 
nanoparticles for optical and MR imaging, those with FAD/FMN-adsorptive coating were 
most promising. These particles showed a strong RCP-mediated uptake by cancer- and 
activated endothelial cells and also strongly accumulated in tumors after intravenous 
injection. Thus, RCP-targeting may be a new and promising way to transport nanoparticles 
and drugs into metabolically active cells.  
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Kurzfassung 
 
Der Fokus dieser Arbeit liegt im Design und der Herstellung von Eisenoxyd-
Nanopartikeln zur Verwendung als Kontrastmittel für die Magnetresonanztomographie 
(MRT) sowie die optische Bildgebung (OI). Eisenoxyd Kerne der Größe 5-6 nm, mit 
niedrigem Polydispersitäts-Index wurden durch Kopräzipitations-Strategien unter wässrigen 
Reaktionsbedingungen hergestellt. Zunächst wurden lanthanid-dotierte Nanopartikel (Ln-
USPIO) getestet, welche scheinbar aufgrund von zu geringen Mengen von, in das 
Eisenkristallgitter inkorporierten, Lanthaniden nicht fluoreszent waren. Dies lässt sich durch 
die größenbasierenden Unterschiede zwischen Lanthaniden und Eisenkationen erklären, 
welche die Dotierungseffizienz entscheidend verringern. Als zweites haben wir eine 
Fluoreszenzummantelung der Nanopartikel durch Naphthalin-Sulfonsäure und deren 
modifizierter Analoge verwendet, was allerdings (trotz vorhandener Stabilität) ebenfalls 
erfolglos blieb, da die Partikel nicht fluoreszent waren. Grund war das Quenchings der 
Fluoreszenz aufgrund von Elektronenübertragung zwischen den aromatischen Naphthalin-
Sulfatringen und den Eisenoxyd-Partikeln. Danach erforschten wir adsoptive 
Coatingsubstanzen, welche nicht quenchen und relativ stabil sind. Erfolgversprechend 
erwiesen sich Flavinanaloga (Flavinmononukleotid (FMN) und Flavin Adenin Dinukleotid 
(FAD)). Dies sind relativ simpel strukturierte, endogene Moleküle, die von Krebs- oder 
metabolisch aktiven Zellen, über den Flavin Rezeptor (RCP) internalisiert werden. 
Biokompatible, fluoreszierende und nicht-polymere FMN-und FAD-beschichtete USPIO 
(FLUSPIO und FAD USPIO) konnten als vielseitiges MR-Kontrastmittel entwickelt. 
Herstellung stabiler flavin adsorbierter Nanopartikel durch Beschallung der USPIO mit 
FMN/FAD mit anschließender GMP-Beschichtung unter wässrigen Bedingungen. 
Der Kerndurchmesser, die Oberflächenmorphologie und die Oberflächenbedeckung 
der FMN- und FAD-ummantelten USPIO (FLUSPIO; FAD USPIO) wurden mittels TEM, 
DLS, SEM, AFM, Power XRD, EDX und TGA ermittelt. Die magnetischen Eigenschaften 
der FLUSPIO und FAD USPIO wurden mit Hilfe von MRT und SQUID untersucht. Die 
Analyse der Fluoreszenzeigenschaften von FLUSPIO and FAD USPIO erfolgte durch 
Fluoreszenz -Spektroskopie, Mikroskopie und Bildgebung. Zellvitalität und 
Biokompatibilität der FLUSPIO und FAD-USPIO wurden durch Trypanblau-, 7-AAD- und 
TUNEL-Färbung ermittelt. Die in vitro-Evaluierung der Labelingeffizienz sowie der 
Spezifität bezüglich RCP wurde mittels MRT und Fluoreszenzmikroskopie untersucht. Das 
pharmakokinetische Verhalten von FAD USPIO wurde in CD1 Nacktmäusen nach 
intravenöser Injektion durch Fluoreszenzspektroskopie gezeigt. Die in vivo Aufnahme der 
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FAD USPIO Nanopartikel wurde in männlichen, subkutane Prostatakarzinome tragenden 
CD1 Nacktmäusen ermittelt. Die Aufnahme wurde mit der des klinisch verwendeten SPIO-
Kontrastmittels Resovist verglichen und weiterhin getestet durch Berliner Blau- sowie 
immunhistologische Färbungen an Tumorschnitten. 
Die hohe Relaxivität (r2 und r1), sowie das superparamagnetische Verhalten der 
FLUSPIO / FAD USPIO wurden mittels MRT und SQUID validiert. Die Biokompatibilität 
der FLUSPIO und FAD USPIO wurde durch verschiedene Zellvitalitätsassays und Färbungen 
nachgewiesen. Die hohe Effizienz der FLUSPIO / FAD USPIO in Bezug auf die Markierung 
von Krebszellen (PC-3, DU-145, LnCaP) sowie aktivierter Endothelzellen (HUVEC) und 
ihre Spezifität für RCP wurde durch MRT, ICP-MS und Fluoreszenzmikroskopie bestätigt. 
Die in vivo-Aufnahme der FAD USPIO durch experimentell erzeugte Prostatakarzinome war 
signifikant höher als die Aufnahme des kommerziellen SPIO-Kontrastmittels Resovist.  
Zusammenfassend lässt sich sagen, dass sich in unseren Ansätzen magnetisch-
fluoreszente Eisenoxyd-Nanopartikel mit FAD/FMN Beschichtung als am aussichtsreichsten 
erwiesen.  Diese Partikel zeigten eine starke RCP-vermittelte Aufnahme durch Krebs – und 
aktivierte Endothel-Zellen sowie eine starke Akkumulation innerhalb der Tumoren, nach 
intravenöser Injektion. Die Möglichkeit des RCP-Targeting könnte demnach ein neuer 
vielversprechender Weg sein, um Nanopartikel und Arzneimittel in metabolisch aktive 
Krebszellen einzuschleusen.  
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Introduction 
Imaging has become an indispensable tool in cancer research, clinical trials and 
medical practice. Biomedical imaging can be sub-divided into anatomical, functional and 
molecular imaging. Anatomical imaging deals with the visualization of organs or tissues, in 
general, with a resolution of centimetres to millimetres. Functional imaging conveys 
information related to physiological processes such as tissue perfusion and vessel 
permeability. In contrast, molecular imaging deals with the visualization of physiological 
processes at the cellular and molecular level
[1]
. Molecular imaging enables the determination 
of both, temporal and the spatial distribution of biological and patho-physiological processes 
[2]
.  
Imaging systems can be grouped by the energy used to derive visual information (X-
rays, positrons, photons or sound waves), the spatial resolution that is attained (macroscopic, 
mesoscopic or microscopic) or the type of information that is obtained (anatomical, 
physiological, cellular or molecular) respectively
[3]
. Macroscopic imaging systems such as 
magnetic resonance imaging (MRI), computed tomography (CT) and ultrasound (US) are 
widely used in (pre-)clinics to provide anatomical and physiological information. The 
increased metabolic activities of tumors can be imaged via positron emission tomography 
(PET) by specific accumulation of radiolabeled tracers (fluorodeoxyglucose (FDG))
[4]
. 
Quantitative kinetic data of an imaged site (tumor) can be acquired repeatedly using PET
[5]
. 
In mice and humans, rapid screening for pathologies (e.g., bladder tumors), blood flow 
measurement
[6-8]
 and developing embryos examination
[9]
 was also performed using US 
imaging. Angiogenesis, inflammatory response and release of therapeutic compounds rely on 
US detection of microbubbles that contain gas
[10;11]
. Bone metastasis is often imaged using 
CT, owing to their high spatial resolution and fast imaging time. Additionally, CT promotes 
hybrid anatomical imaging in combination with other imaging modalities, e.g., in PET-CT 
and SPECT-CT.  
Characterising vascularisation, cell tracking and functional brain imaging are domains 
of MRI.  MR spectroscopy can detect individual molecules (metabolites) in tumors without 
using magnetically labelled affinity molecules.  When MRS is used in combination with 
MRI, concurrent anatomical and biochemical information are generated. Intra-operative cell 
labeling, mammography, diagnosis and staging in arthritis in future may be guided by optical 
imaging. In line with this, fluorescence mediated tomography (FMT) is useful in pre-clinical 
research, as it helps to quantify protein expression or localization in vivo without radioactive 
labeling. 
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All these imaging modalities have strengths and limitations (Table 1.1). PET is a 
highly sensitive, minimally-invasive technology that is ideally suited for pre-clinical and 
clinical imaging of cancer biology. PET is ideally suited for monitoring molecular events 
early in the course of a disease, as well as during pharmacological or radiation therapy and 
further used to acquire prognostic information and to image disease recurrences
[12;13]
. 
However, the spatial resolution of PET is comparably poor. It yields no anatomical 
information and is limited by radioactive isotopes with short half-lifetimes. US display high 
spatial and temporal resolution and provide detailed anatomical information. Additionally, 
US imaging is economical, and allows real-time imaging. The limitations of US imaging are 
user-dependency, inability to promote whole-body imaging and the restriction of targeted 
imaging to the vascular compartment. CT displays high spatial resolution, which is needed to 
visualize fine anatomical details. The radiation dose of CT, however, is not negligible and 
this limits repeated imaging in human studies due to health risks
[14]
.  
MR tomography serves as an exquisite tool for anatomic and functional imaging with 
high penetration depth and excellent spatial resolution but lacks high sensitivity for contrast 
agents. The two main advantages of MRI are its excellent soft tissue contrast and lack of 
ionizing radiation
[15]
. However, sensitivity of MR to contrast agents is still poor although it 
has been improved by recent developments in MR radiofrequency/coil technology, pulse 
sequences, by increasing the field strength of the scanners and by new MR contrast agents
[16-
22]
. Optical imaging applied in microscopy, endoscopy or whole-body small-animal imaging, 
has a high sensitivity and spatial resolution but suffers from a low penetration depth and high 
background signals due to photon scattering
[23-27]
. Additionally, optical imaging is versatile, 
cost-effective, easy to handle, helps in rapid screening of molecular events and allows 
performing multichannel imaging via multiple probes, respectively.  
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Table 1.1 summarizes the spatial resolution, depth penetration, imaging time and cost of available imaging 
systems
[28]
  
Technique Resolution Depth 
Acquisition 
Time 
Quantitative 
Imaging 
agents 
Target Clinical use 
MRI 10-100 µm 
No 
limit 
Minutes to 
hours 
Yes 
Paramagnetic 
chelates, 
magnetic 
nanoparticles 
Anatomical, 
physiological, 
molecular 
Yes 
CT 50 µm 
No 
limit 
Minutes Yes 
Iodinated 
molecules 
Anatomical, 
physiological 
Yes 
Ultrasound 50 µm cm 
Seconds to 
minutes 
Yes Microbubbles 
Anatomical, 
physiological 
Yes 
PET 1-2 mm 
No 
limit 
Minutes to 
hours 
Yes 
18F-, 64Cu, 11C- 
labelled 
compounds 
Physiological, 
molecular 
Yes 
FMT 1mm 
<10 
cm 
Minutes to 
hours 
Yes 
Near-infrared 
fluorochromes 
Physiological, 
molecular 
In 
development 
 
The combination of imaging systems significantly helps in data quantification and 
validation, and brings together information about morphology, tissue function and molecular 
target expression. Platforms that combine different imaging technologies are emerging and 
these multimodality platforms allow for meaningful interpretation of the images in terms of 
its sensitivity and resolution. The true strength of a hybrid system is that high-resolution 
structural images that can be annotated with molecular information derived from an 
inherently registered data set. For example PET-MRI, MRI-CT, and MRI-FMT are widely 
used currently to extract relevant information pertaining to diseases such as tumor or arthritis 
etc. 
Based on the afore-mentioned advantages of combining imaging systems, the 
combination of MR and fluorescence imaging constitutes an attractive concept for preclinical 
research.  In line with this, MRI is favourably suited for whole body imaging, e.g., tumor 
staging, while optical imaging has its strengths in characterizing superficial tissues or for 
diagnosis during surgery (endoscopy, laparoscopy and histological validation). Therefore, 
combining optical imaging with MRI provides an accurate anatomical reference for 
fluorescence imaging data and thereby enables the correlation of molecular with high quality 
structural/functional information
[29]
. However, progress in the multi-modality imaging 
systems can be extensively made if there is a parallel effort to synthesize and develop 
multimodal contrast agents. Development of dual/tri-modal contrast agents can considerably 
improve the utility of multimodality imaging per se and can end up in further advancement in 
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this area. To this end, the development of dual probes valid for MRI and optical (bi-modal) 
imaging is an attractive task that might help to improve the sensitivity and spatial resolution 
of the images obtained from both modalities and consequently help in the co-validation of 
results gained from different image data sets respectively. 
 
1.1. Multimodal contrast agents 
Multimodal contrast agents were synthesized using inorganic nanoparticles, polymers, 
liposomes, and rare earth metals (lanthanide chelates) as the backbone. Their physico-
chemical properties can be tuned to impart more specific moieties (e.g., fluorescent dyes 
(optical imaging), radioactive tracers (PET, SPECT imaging) which may facilitate 
multimodal imaging. The functional units which are commonly used to generate (molecular) 
multimodal contrast agents comprise of different endogenous coating molecules, antibodies 
and peptides (Figure 1.1.1).  
 
 
 
 
 
 
 
 
 
 
Figure 1.1.1. Schematic diagram shows different types of platform used for designing and generating 
multimodal imaging probes. Polymers (A), viral vectors (B), liposomes (C) and inorganic nanoparticles (D) 
serve as a basic platform to generate multifunctional probes by functionalization with NIR dye, antibody, 
peptides, spacers, transfection agent and radiotracer which makes them suitable for multimodal imaging  
respectively. 
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             Nanoparticles generated using organic materials like liposomes, micelles and 
polymers have been explored in addition to inorganic nanoparticles as contrast agents for 
molecular imaging purposes
[30;31]
.  Most of the generated organic materials were used as a 
carrier for metallic nanoparticles by means of encapsulation and as a platform for conjugation 
of fluorescent dyes, and as coordination compounds. Most organic materials that can be 
easily and conveniently processed as nanoparticles lack relevant imaging qualities like 
paramagnetism and fluorescence with few exceptions such as dye-based contrast agents used 
for optical imaging. Some of the organic nanomaterials such as conjugated polymers display 
tunable fluorescence properties suitable for optical imaging. However, there could be 
problems arising due to synthesis and purification of polymer-based materials and further, 
elimination of organic materials from the body might be slow. Therefore, the inorganic 
nanoparticles have gained much more momentum as versatile contrast agents for molecular 
imaging (different modalities) due to their inherent properties (magnetism: (Ultrasmall) Super 
Paramagnetic Iron Oxides ((U)SPIO)), fluorescence (quantum dots (QD)) compared to 
organic nanomaterials.  However, the toxicity of inorganic nanoparticles is a crucial issue that 
could hinder their application in biomedical imaging e.g., QDs might become cytotoxic due 
to the oxidative and/or photolytic destruction of their surface coatings
[32]
.  Further, it is 
important to use a minimal dose of inorganic nanoparticles for imaging in order to avoid 
possible in vivo toxicity. 
 
1.1.1. Contrast agents in MRI 
There are two different types of MR contrast agents which are widely being used in 
clinics based on their contrast enhancement properties in tissues. They are the Gd-based 
paramagnetic species used for generating positive T1 contrast enhancement and the iron oxide 
nanoparticle-based superparamagnetic species for negative T2 contrast enhancement (cuts 
down the signal enhancement), respectively.  Gd(III) complexes are used as versatile T1 
contrast agent in clinics and they are thermodynamically stable, water-soluble and highly 
paramagnetic and display high relaxivity (r1). However, these Gd-based systems suffer from 
relatively short pharmacokinetic profile (short accumulation time) in the vascular system, 
thereby reducing considerably the MR imaging time. Therefore, nanoparticles-based contrast 
agents can be efficiently employed for MR imaging as they internalize into the cells in large 
amounts when conjugated with specific ligands and thereby increase the MR imaging time. In 
order to modulate the pharmacokinetic properties of Gd-based systems, several attempts were 
made to tag the paramagnetic species (Gd(III)) to polymers, dendrimers, polypeptides, 
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polysaccharides, liposomes and further, chelated Gd(III) ions were also anchored onto the 
surface of nanoparticles).  
Iron oxide nanoparticles with intrinsic superparamagnetic properties exhibit a 
negative MR contrast enhancement, and are used as versatile T2 contrast agents in clinics e.g., 
Ferridex and Combidex (iron oxide nanoparticles coated with polysaccharides).  However, 
clinical applications of these T2 contrast agents are limited as they suffer from negative 
contrast effect and magnetic susceptibility effects respectively
[33]
. 
 
1.2. Magnetic Resonance Imaging (MRI) 
               The superparamagnetic behavior exhibited by magnetic nanoparticles (at critical 
size) is exploited for MR imaging in biomedical applications. Resonance is an energy 
coupling that causes the individual nuclei, when placed in a strong external magnetic field, to 
selectively absorb, and later release, energy unique to those nuclei and their surrounding 
environment. The magnetic field gradients are used to localize the NMR signal and to 
generate images that display magnetic properties of the proton, reflecting clinically relevant 
information.  
 
1.2.1 Relaxation 
                 Relaxation of the protons under the influence of the external magnetic field occurs 
after the application of RF pulse, by releasing the absorbed energy and return to their original 
equilibrium state. There are two major processes contributing to their return to the 
equilibrium state: T1 and T2 relaxation times
[34]
.  
 
T1 relaxation  
            T1 termed as “longitudinal” relaxation time, is a measure of how long a substance 
needs to regain its longitudinal magnetization following an RF pulse. T1 relaxation time 
represents the correlation between the frequency of molecular motions and the Larmor 
frequency. The frequencies of small molecules (e.g., water) and large molecules (e.g.,  
proteins) are significantly different from Larmor frequency and thereby have long T1. 
Contrarily, cholesterol (a medium-sized molecule), has natural frequencies similar to those 
employed in MRI, thereby it has a short T1. The T1 relaxation time of the MR contrast agents 
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can decrease due to the interaction between the unpaired electrons in the paramagnetic iron 
(or Gd ions) and the protons in water. 
 
T2 relaxation  
              T2 termed as “transverse” relaxation time, is a measure of how long the resonating 
protons of a substance can be coherent or rotated after a 90° RF pulse. Depending on 
alignment of protons in response to the external magnetic field (align with/against), the local 
regions of increased /decreased magnetic fields can be created by the fluctuating magnetic 
fields of the substance. Subsequently, after the 90° RF pulse the protons can lose their 
coherence and transverse magnetization resulting in T2 relaxation of the protons.  
 
T2* relaxation 
              T2* relaxation is the loss of signal seen with dephasing of individual magnetizations. 
It is characterized macroscopically by loss of transverse magnetization at a rate greater than 
T2. It is caused by magnetic field inhomogeneity and occurs in all magnets.  
 
1.2.2. Pulse sequences
 
              MR relies on three major pulse sequences: spin echo, inversion recovery, and 
gradient recalled echo. When these are used in conjugation with localization methods (i.e. the 
ability to spatially encode the signal to produce an image), “contrast-weighted” images are 
obtained.  Spin echo (SE) sequences generally produce the best quality images but they take a 
relatively long time. Inversion recovery (IR) sequences can produce excellent T1-weighted 
images of tissues with relatively long TR (Repetition times) by selectively suppresing the T1 
contributions from fluid or fat. Gradient echo (GE) sequences can produce images with 
shorter TR`s than SE sequences, so they have shorter scan times. However they are highly 
depending on the quality of the main magnetic field as well as on timing parameters
[35]
.  
 
T1-weighted images 
               T1-weighted images can be produced using either the SE or the GE sequence. A 
“T1-weighted” spin echo sequence is designed to produce contrast based on the T1 
characteristics of tissues by de-emphasizing T2 contributions. This is achieved with the use of 
a relatively short TR to maximize the differences in longitudinal magnetization during the 
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return to equilibrium, and a short TE (Echo time) to minimize T2 dependency during signal 
acquisition.  
 
T2-weighted images 
                  T2-weighted contrast can be produced by using SE sequences. SE T2 images 
require long TR and long TE, so they take longer to acquire than T1-weighted images (scan 
time depends on TR).  
 
T2* weighted images 
                    GE sequences are used to generate T2* weighted images based on the effects 
which originates from imperfect magnetic field: a perfectly uniform magnetic field can‟t be 
produced, as even the patient would make it imperfect due to susceptibility effects. Air 
pockets (sinuses or intestines), dense bone (skull base), and iron-rich blood breakdown 
products (met-haemoglobin or haemosiderin) all change the main magnetic field in their 
immediate vicinity, so tissues around such inhomogeneities will experience  different 
magnetic fields. In a GE sequence, the combined effect of T2 and magnetic field 
inhomogeneities is observed. This relaxation is called the „apparent‟ relaxation time and in 
short called T2*.  
 
1.2.3. Advantages of MRI 
The advantage of using MRI is that it produces sectional images of equivalent 
resolution in any projection across multiple planes without moving the patient. Therefore, 
MRI is considered as a versatile diagnostic tool for planning surgical treatments. 
Additionally, a number of advanced contrast imparting agents and techniques have emerged 
that render MRI a highly versatile imaging tool in clinics
[36;37]
. Novel contrast agents that 
modulate T1 and T2 relaxivities, combined with molecular targeting strategies provided by 
advances in nanotechnology, have yielded a significant progress in developing MRI as a 
platform for visualizing cellular and subcellular events
[38;39]
.   
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1.3. Inorganic Nanoparticles as contrast agents 
             Inorganic nanoparticles including iron oxide, rare earth metal-doped, rare earth metal 
and gold nanoparticles along with semiconductor quantum dots are usually desired for 
generating contrast agents for different imaging modalities as they explicitly display 
electronic, optical, scattering, x-ray attenuation and magnetic properties compared to the non-
metallic nanoparticles (traditional counterparts) e.g., Si-based nanoparticles.  Inorganic 
nanoparticles could be tailored and tuned by controlling the composition, geometry and 
structure of the nanoparticles. Table 1.2 summarizes inorganic nanoparticles which are 
explored as contrast agents for (pre-)clinical molecular imaging purposes.  
Table 1.2. Inorganic nanoparticles-based contrast agents for molecular imaging (adapted from Eun Chul Cho 
et.al, Trends in Molecular medicine, 2010)
[40]
. 
 
 
 
 
 
 
 
 
 
 
 The inorganic nanoparticles provide opportunity for developing new imaging agents 
(multimodal) based on surface engineering of their composition, crystal structure, size, and 
shape, respectively. The surface of the inorganic nanoparticles were covered with coating 
molecules like silica, (bio-)polymers, non-polymeric molecules, to increase their stability 
under physiological conditions and to provide a platform for further functionalization with 
components that will generate multimodal imaging agents (Figure 1.1.2). The surface 
modification should be performed to preserve the imaging properties (like fluorescence, 
magnetism). The cellular uptake of inorganic nanoparticles could be enhanced by conjugating 
them to transfection agents such as protamine sulphate, poly-lysine, poly-arginine and HIV-
tat, thereby facilitating their high accumulation in the cancer cells and tumors. The specificity 
of the probes for receptors expressed (in vitro and in vivo) could be modulated by attaching 
target specific antibodies, peptides. During conjugation, the structure and conformation of 
Nanoparticle type Imaging modality 
Semiconductor quantum dots Fluorescence imaging 
Magnetic nanoparticles MR imaging 
Gold colloids Photoacoustic tomography 
 Surface enhanced Raman spectroscopy 
 Multiphoton luminescence imaging 
 X-ray (Computed tomography) 
Rare-earth doped nanoparticles Luminescence imaging 
 MR and near-infrared imaging 
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macromolecules (proteins and antibodies) should be preserved from denaturation
[41-43]
.  
Polyethylene glycol (PEG) spacers with different molecular weights are coupled to inorganic 
nanoparticles to prolong their circulation time in blood thus facilitating imaging for a longer 
period of time. The interaction between a targeting ligand and the receptor on the cell surface 
is sensitive and influenced by their chemical and molecular structures
[44;45]
.  
 
 
Figure 1.1.2. Schematic diagram of a multimodal contrast agent. Metallic nanoparticles (Fe, Au, CoFe, PtFe 
and LnFe) can be used as platform for generating multimodal contrast agents due to their useful physico-
chemical properties. Radiotracer incorporation helps in SPECT, PET imaging. Optical imaging is facilitated by 
conjugation with NIR dyes. Specific targeting is achieved by functionalization using target specific antibodies 
and peptides. Cellular uptake of the multimodal contrast agents is enhanced by adding a transfection agent. The 
in vivo pharmacokinetics of nanoparticles can be tuned by introducing spacers like polyethylene glycol with 
different molecular weights respectively. 
 
1.3.1. Iron oxide nanoparticles 
Iron oxide nanoparticles find application in different fields such as magnetic data 
storage, bio-sensing, (bio-)medical applications (targeted drug delivery), and as contrast 
agents in MRI. The MR imaging applications require the nanoparticles to exhibit high 
magnetization values, a size smaller than 100 nm with a narrow particle size distribution.  
Iron oxide nanoparticles, such as ultrasmall superparamagnetic iron oxides (USPIO, 50 nm 
(hydrodynamic diameter)) and superparamagnetic iron oxides (SPIO, 50-500 nm 
(hydrodynamic diameter)), are used as agents that cause negative contrast effects (decreased 
MRI signal) on T2 and T2*-weighted MR images
[46]
. The major challenges in developing iron 
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oxide nanoparticle-based versatile MR contrast agents are coating, surface functionalization 
with specific ligands (for tumor accumulation) and long circulation of the iron oxide-based 
nanoparticles in the blood. 
 
1.3.2. Biomedical applications of magnetic nanoparticles 
Iron oxide nanoparticles are intensely used in MR-cellular labeling and cell tracking 
studies. The contrast enhancement achieved in MR depends on the size of the nanoparticles 
used and the molecular imaging is facilitated by using target specific ligands conjugated 
nanoparticles. 
 
1.3.2.1. Cellular labeling (MRI) 
The ability to load iron oxide nanoparticles (µM Fe) in cells via cell-permeable 
peptide or transfection agents, in combination with negative surface charged magnetic 
nanoparticles is used to label and track cells in vivo by MRI
[47;48]
. The first cellular imaging 
studies were performed with unfunctionalized iron oxide nanoparticles for labeling 
leukocytes, lymphocytes, etc.
[49-52]
. Cells loaded with nanoparticles can be tracked using MRI 
with a resolution equal to size of a single cell
[53]
. To increase the cellular uptake of magnetic 
iron oxide nanoparticles, they are conjugated with  peptides, vitamins e.g., folic acid-coated 
magnetic particles for targeting folate receptors
[54;55]
. Bulte has used MRI to provide 
information on the location and migration of cells after transplantation or transfusion which 
requires magnetic prelabeling of the cells
[56]
.   
 
1.3.2.2. Molecular Imaging  
Herschman defined molecular imaging as “non-invasive, quantitative and repetitive 
imaging of targeted macromolecules and biological processes in living organisms”[57]. 
Wickline stated that molecular imaging can be used “to improve diagnostic accuracy and 
sensitivity by providing an in-vivo analogue in immunocytochemistry or in situ 
hybridization”[58]. Molecular imaging employs contrast agents that are used to identify 
particular biomarkers or pathways with high sensitivity and selectivity
[59]
. The contrast agents 
would ideally accumulate (selectively) at the target site and would interact with the target 
physically, (bio-)chemically and thereby altering the attained image contrast. Molecular 
imaging approaches using magnetic nanoparticles was used to detect apoptosis by MRI
[60]
. 
The therapeutic response from tumor cells can be studied using MRI based on MR image 
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contrast that reflects the morphological features of apoptosis, such as cell shrinkage and 
membrane blebbing
[61]
. Magnetic nanoparticles accumulate inside the tumors either 
unspecifically through the enhanced permeation and retention (EPR) effect (passive 
targeting) or specifically (active targeting).  
 
1.3.2.3. Passive targeting  
The difference in vasculatures between the normal and cancerous tissues plays a 
crucial role towards the accumulation of the nanoparticles in solid tumors. Endothelial cells 
in normal tissues are aligned and tightly packed, whereas those of solid tumors are relatively 
leaky
[62-64]
.  Due to their large sizes, the magnetic nanoparticles circulating in the blood 
stream are unable to extravasate in normal tissues (endothelial cells). However, they are 
readily taken up by the solid tumors due to the leaky blood vessels. This type of selective 
accumulation of the magnetic nanoparticles in solid tumors is due to the EPR effect or 
passive targeting which is extensively used for systemic delivery of nanoparticles and 
macromolecular drugs
[65-67]
. EPR based passive targeting of iron oxide nanoparticles is highly 
dependent on the sizes and surface modification of the nanoparticles as well as on the pore 
cutoff size of the endothelial boundary in different tumors. Smaller nanoparticles display 
relatively longer circulation time in the blood stream compared to larger nanoparticles, which 
has been applied to study the increase in sensitivity in perfusion imaging  e.g., organ 
perfusion imaging
[68;69]
, functional MRI (fMRI)
[70;71]
  
 
1.3.2.4. Specific targeting 
To increase the accumulation, the efficiency in delivery and to retain the nanoparticles 
inside the cancer cells, they should adhere to specific receptors over-expressed on the surface 
of the cancer cells. The highly specific and selective interaction between the targeting ligand 
and the receptor is termed as active targeting, which in combination with passive targeting 
leads to the intense accumulation of nanoparticles in cancer cells/tissues
[72]
. Active targeting 
of the endothelial inflammatory cells was achieved using E-selectin functionalized magnetic 
nanoparticles
[73]
. Similarly, Montent, et al., employed cRGD coupled-CLIO nanoparticles for 
active targeting of integrins on BT-20 tumor models
[74;75]
. 
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1.4. In-vivo fluorescence imaging 
Three-dimensional fluorescence images of the internal structures of humans or small 
animals can be generated by in-vivo fluorescence imaging techniques. In-vivo imaging based 
on fluorescence could be traced to the suggestion made by Chance and co-workers who 
demonstrated that images could be obtained from the diffusive migration of photons in 
scattering tissues
[76-78]
.  A strong absorption, high scattering and low penetration of photons 
in the tissues (become translucent) are prevalent at wavelengths below 650 nm (Figure 1.1.3). 
The translucent tissue properties could be seen upon trans-illumination of a mouse using a red 
light at 670 nm
[79]
. When light with long-wavelength (680 – 850 nm) pass through tissues, the 
light is anticipated to migrate in a diffusive manner similar to molecules in the gas phase. 
However, the absorbed photons move in a straight line until they are scattered due to tissue 
specific characteristics. The extent of light scattering in tissues is described by the scattering 
coefficient µs. The light absorbed through the tissue could be expressed as the absorption 
coefficient µa. Different types of tissues and different regions of tissue display different 
values of µs and µa, and affect the photon migration (rate and distance) in tissues. The 
concept of photon migration imaging (PMI) was used to measure spatially dependent 
transport of photons in tissues. The problems associated with  PMI technique are numerous 
scattering and the limited contrast from different regions of tissues, which can be eliminated 
by using fluorescent  dyes such as indocyanine green
[80;81]
.  
 
Figure 1.1.3.  Absorption coefficient of a typical tissue. The insert shows the trans-illumination of a mouse at 
670 nm [adapted from Weissleder, Ntziachristos, Nature Med, 2003]. 
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1.4.1. Optical properties of tissues 
The design of fluorescent probes for clinical applications is determined partly by 
considering the influence of the optical properties of water and tissues on fluorescence 
emission of a fluorophore. In general, the auto fluorescence emerging from tissues or any 
biological sample is usually lower for longer excitation wavelengths and further the use of 
longer wavelengths (>650 nm) also prevent light (photon) absorption by haemoglobin and 
melanin (Figure 1.1.4).  
 
Figure 1.1.4. Optical absorbance of tissues including water, melanin, and haemoglobin
[82]
. 
The near-infrared (NIR) spectral window (650 to 900 nm) is suitable for in vivo 
fluorescence imaging investigations as it takes advantage over the low absorbance of tissue 
chromophores such as oxy- and deoxy-haemoglobin, water, melanin and fat (Figure 1.1.4). 
At NIR wavelengths, µs>µa compared to lower wavelengths (<650 nm). The current state of 
the art is that majority of in vivo fluorescence imaging approach reported was based on planar 
detection of fluorescent light emerging out of the tissues. This planar fluorescence imaging 
approach has shown limitation in deriving quantitative information. The non-linearity 
problem related to depth at which the fluorescent signal is generated could be avoided by 
using fluorescence molecular tomography (FMT), with improved signal quantification
[83-85]
.  
 
1.4.2. Advantages of fluorescence imaging  
Fluorescence based-imaging techniques are known to possess several attractive 
characteristics, such as: 
i. The ability to concurrently resolve several distinct biological targets by 
utilizing fluorophores that emit at different spectral bands (wavelengths) 
ii. Offers high flexibility in developing and utilizing fluorescent reporters 
(fluorophores) for diverse cellular processes and molecular pathways 
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iii. High detection sensitivity reaching limits in the sub-picomole range for 
common organic fluorochromes (small animal imaging), and even to higher 
sensitivity for imaging superficial activity (e.g., in endoscopic and 
intraoperative applications) 
iv. Provides high resolution images for imaging events at superficial depths from 
fluorescence based-microscopy (epifluorescence, confocal, two photon, 
histopathological correlation etc.) techniques 
 
1.4.3. Fluorescence lifetimes and Quantum yields 
The fluorescence of any biological molecule (fluorophore) is characterized by its 
quantum yield and its lifetime. The fluorescence quantum yield is the ratio of the number of 
photons emitted to the number absorbed. Substances with the largest quantum yields 
(approaching unity), such as rhodamines display the brightest emissions. The lifetime 
determines the time available for the fluorophore to interact with or diffuse in its 
environment, and hence the information (lifetime) is available from its emission. The 
emissive rate of the fluorophore (Г) and its rate of non-radiative decay (knr) to ground state 
were determined. The rate constants Г and knr both depopulate the excited state of the 
fluorophores. The fraction of the fluorophores that decay through emission, and hence the 
quantum yield is given by the following expression  
                   Q = Γ/Γ+knr                                Equation 1                                                                                                
   
The quantum yield can be close to unity if the radiationless decay rate is much smaller than 
the rate of radiative decay, that is knr< Г.  
The lifetime of the excited state is defined by the average times the molecule spends in the 
excited state prior to its return to the ground state. Generally, fluorescence lifetimes are 
around 10 ns. The lifetime of a fluorophore is given by 
                                                      τ = 1/Γ+knr      Equation 2   
Heavy atoms such as iodine typically result in shorter lifetimes and lower quantum yields. 
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1.5. Fluorophores 
Fluorophores are divided into two general classes, namely intrinsic and extrinsic 
fluorophores. Intrinsic fluorophores are those that occur naturally (fluorescent biomolecules). 
Extrinsic fluorophores are those which are added to a sample of interest that does not display 
the desired spectral properties (organic dyes for fluorescent labeling of peptides, antibodies 
etc.).  
 
1.5.1. Intrinsic fluorophores 
Intrinsic fluorophores are the biological molecules which exist in cells (normal and 
malignant), tissues, organs, animal models and exhibits relatively weak endogenous 
fluorescence. These endogenous fluorophores include amino acids, structural proteins, 
enzymes and co-enzymes, vitamins, lipids and porphyrins. The excitation maxima range of 
these endogenous fluorophores lies between 250 and 450 nm, while their emission maxima 
range lies between 280 and 700 nm (Table 1.3). Intrinsic fluorescence from protein are 
known to originate from the aromatic amino acids
[86-88]
 such as tryptophan (trp), tyrosine 
(tyr), and phenylalanine (phe). The indole groups of the tryptophan residues are the dominant 
source of UV absorbance and fluorescence emission in different proteins. The weak 
fluorescence in proteins occurs owing to the native form of the tryptophan amino acid 
residues and further, its fluorescence could be enhanced on denaturation of the protein. Thus, 
the change in fluorescence of tryptophan could ideally serve as a valid fluorescence-based 
technique to study the conformational changes involved in the protein.  
Among other known biological molecules present in cells/tissues, one could also 
observe fluorescence contribution from reduced nicotinamide adenine dinucleotide (NADH) 
and from oxidized flavins (FAD, flavin adenine dinucleotide, and FMN, flavin 
mononucleotide) respectively (Figure 1.1.5). The isoalloxazine rings of Rf, FMN, and FAD 
absorb light in the visible range (450 nm) and display emission around 535 nm. The oxidized 
forms of flavins are fluorescent, in contrast to the reduced forms of NADH (fluorescent). 
Typical fluorescence lifetimes for FMN and FAD are 4.7 and 2.3 ns. The quenching of flavin 
fluorescence in FAD occurs due to the complex formation between the flavin and the 
adenosine moieties
[89]
. The latter process is referred to as static quenching. Most of the auto 
fluorescence observed from different cells are due to the presence of inherent NADH and 
flavins
[90;91]
.  
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Table 1.3. Excitation and emission maxima of some of the endogenous fluorophores (adapted from Ramanujam, 
Neoplasia, 2000) 
Endogenous fluorophores Excitation maxima (nm) Emission maxima (nm) 
Tryptophan 280 350 
Tyrosine 275 300 
Phenylalanine 260 280 
Collagen 325, 360 400, 405 
Elastin 290, 325 340, 400 
FAD, flavins 450 535 
NADH 290, 351 440, 460 
Vitamin B12 275 305 
Phospholipids 436 540, 560 
Porphyrins 400-450 630, 690 
 
 
 
Figure 1.1.5. Schematic diagram of few intrinsic biochemical fluorophores.  
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The fluorescence lifetime measurements of flavins (FMN, FAD) could be explained 
in terms of two different configurations (open or stacked configuration) of flavins in solution 
as shown in Figure 1.1.6. The nature of the flavin quenching by the adenine moiety was 
studied by fluorescence intensity decay measurements. The fluorescence intensity decay of 
the flavin alone (FMN) displayed a single exponential with a decay time of 4.89 ns. However, 
FAD displayed a double-exponential decay with a decay time of 3.38 ns and of 0.12 ns, 
respectively. The observed short decay component (0.12 ns) of FAD was assigned to the 
stacked forms, thus facilitating the calculation of different fraction of FAD present in the 
stacked and open configurations. The long fluorescence lifetime of 3.38 ns might be due to 
the dynamic quenching of the flavin by the adenine moiety (Figure 1.1.6) 
 
Figure 1.1.6. Intensity decays of FAD and FMN at pH 7.5, 3 ºC. Also shown is the laser pulse profile. The 
deviations are for fits to the FAD intensity decay (adapted from Visser AJWG, Photochem Photobiol 1984). 
 
Guanosine monophosphate (GMP) is one of the most important nucleotide which is 
incorporated into DNA and RNA during hybridization in order to increase their stability and 
to preserve the imparted genetic informations. The aromatic moiety of GMP absorbs light in 
UV region and displays weak emission around 350 nm. Photo induced electron transfer that 
occurs (by UV light) in GMP leads to quenching of its fluorescence and result in loss of 
hybridization in DNA. GMP exists in three different forms like cyclic GMP (cGMP), di- and 
tri- phosphates (GDP, GTP), respectively. The human guanylate binding proteins (hGBP) 
which belongs to the family of GTPases enzymes are actively involved in hydrolyzing the 
different forms of guanosine triphosphate (GTP) into a mixture of GDP and GMP with 
unequal ratios
[92]
. The quenching effect exhibited by the guanine moiety in dimer GMP 
(dGMP) on different fluorophores is used to design molecular beacons for monitoring 
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different molecular and cellular processes
[93]
 and  in addition it was also applied to RNA 
based structural studies
[94]
. Further, GMP serves as an efficient template for different 
nanomaterials synthesis, and enhances the electronic properties of the generated 
nanomaterials
[95]
. Furthermore, GMP undergoes self-assembly with different transition metal 
ions via chelation to form new nanomaterials
[96]
. 
 
1.5.2. Extrinsic fluorophores 
Based on their emission wavelength (UV, visible and NIR), the extrinsic fluorophores 
were selected as fluorescent agents for the detection of various cellular and sub-cellular 
events. Extrinsic fluorophores are exogenous fluorophores which are widely being used to 
label a target tissue, protein, and biomolecules, and further, used to assess changes at the 
molecular level based on fluorescence. The advantage of using exogenous fluorophores is 
due to their known properties i.e. photophysical and pharmacokinetic properties, used for 
labeling biomolecules and for delineating the malignant tissues from normal ones 
[97]
. The 
exogenous fluorophores display fluorescence with high intensity compared to their 
endogenous counterparts. Some exogenous fluorophores were used as DNA specific labeling 
agents that facilitate the study of the conformational changes and molecular events that occur 
in the DNA by fluorescence technique.  A wide variety of organic dyes like acridines, 
ethidium bromide, 4´,6-diamidino-2-phenolindole (DAPI) and other planar cationic species 
bind spontaneously to DNA which are often used to visualize and identify chromosomes. The 
macromolecules are fluorescent labeled for different biological application using extrinsic 
probes such as dansyl chloride DNS-Cl (1-dimethylamino-5-naphthylsulfonyl chloride) and 
fluorescein isothiocyanate (FITC).  The sulfonyl (DNS-Cl) and isothiocyanate (FITC) groups 
of these probes react with free amino groups of the macromolecules (proteins), and results in 
proteins that display blue (DNS) or green (FITC) fluorescence (Figure 1.1.7). 
 
Figure 1.1.7. Fluorophores for covalent labeling of DNA and biomolecules. 
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To this end, the first type of exogenous dyes that were selected based on emission 
wavelengths are the ones with UV fluorescence e.g., naphthalene sulfonates. Naphthalene 
disulfonic acids are highly water soluble due to the inherent sulphonic acid groups and their 
absorption and emission occur in the UV spectral region (200-400 nm). These naphthalene 
sulfonates are usually coupled to specific ligands, proteins, dyes, sensors, nanomaterials, in 
order to make them hydrophilic and further used for sensing the biologically relevant targets 
and mechanisms using fluorescence. Azo compounds based on amino and hydroxyl 
naphthalene sulfonates are used as metal chelators (dyes), acid-base indicators and as 
histological stains
[98-101]
. H-acid (Figure 1.1.8) is one of the most important dye intermediates 
and often used in chemical and textile, as well as in the pharmaceutical industries for the 
direct synthesis of acidic, reactive and azoic dyes
[102;103]
. Non-symmetric derivaties of 
cholesterol linked to H-acid acts as a small molecule based selective inhibitors for HIV-1 RT 
(reverse transcriptase) by facilitating the inhibitory effect on catalytic activity of RNA-
dependent DNA polymerases (RDDP)
[104]
.  ANDS (Figure 1.1.8) conjugated oligosaccharides 
(mono- to hexa- saccharides) are used in fluorimetric assays due to the availability of two 
fixed negative charges (from sulphonic acids) on the naphthalene moieties and these 
conjugates are analyzed with high sensitivity using capillary zone electrophoresis
[105;106]
.  
ANDS is also employed as a reagent in a colorimetric method in which the proteolytic 
degradation of feed proteins by rumen microorganisms are determined using ANDS 
fluorescence
[107]
. Further, ANDS is used in a facile, accurate and sensitive non-radioactive 
method for detection and analysis of lipid-linked oligosaccharides (LLO) via fluorophore-
assisted electrophoresis of carbohydrates
[108]
. Furthermore, ANDS is used as a labeling agent 
for capillary zone electrophoresis for simple and mild determination of fatty acids (with C1-
C10) via the condensation reactions respectively
[109]
. 
 
 
Figure 1.1.8. Schematic diagram shows the structures of 7-amino-1,3-naphthalene disulfonic acid (ANDS) and 
4-amino-5-hydroxy-2,7-naphthalene disulfonic acid (H-acid) respectively. 
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The second type of exogenous dyes that was selected based on emission wavelengths 
is the one with NIR fluorescence e.g., cyanine dyes. The most commonly used dyes that emit 
at long-wavelengths are the cyanine dyes i.e. Cy-3, Cy-5 and Cy-7, which is predominantly 
used for in vivo optical imaging techniques. These dyes display absorption and emission 
wavelengths above 550 nm
[110-112]
. The cyanine dyes typically display a small Stokes shift, 
with the absorption maxima (about 30 nm) blue shifted from the emission maxima. Charged 
side chains are incorporated into these dyes in order to improve their water solubility and to 
prevent self-association of these dyes, which often results in self-quenching, respectively. 
The cyanine dyes with reasonable photostability are widely used for optical imaging, 
histological analysis (in conjugation to the antibodies) and for fluorescence microscopy 
techniques. 
Rare earth metal ions were also employed as exogenous agents to induce fluorescence 
for various biological applications (e.g., lanthanides). Lanthanides are widely used in high 
sensitive detection of immunoassays, by utilizating its infra-red fluorescence emission 
[113;114]
. The lanthanides are unique fluorescent metals that display emission in aqueous 
solution with decay times ranging from 0.5 to 3 ms
[115-118]
.  Emission of the lanthanide ions 
are known to occur due to transitions that involve 4f orbitals, which usually are spin- and 
parity forbidden. As a result the absorption coefficients of these transitions are very low (<10 
M
-1
cm
-1
), and the emissive rates are slow, thus leading to long fluorescence lifetimes for 
lanthanides. The lanthanide (metal-)ions behave like independent atoms and display line 
spectra characteristics specific for the metal atoms. Due to the lanthanides weak photon 
absorptions, they are usually not excited directly, but rather excited via the chelated organic 
ligands that contain a fluorophore. The excited fluorophore must transfer the absorped energy 
through its emission, to match the energy required for the lanthanide excitation. The chelators 
complexed to the lanthanide increase the quantum yield of the lanthanide by displacing the 
bound water molecules that act as fluorescence quenchers. Further, the chelator also acts as a 
versatile platform to bind the lanthanide metal ion to a biomolecule (such as peptides, 
antibodies), using standard coupling chemistry. Therefore, the excitation spectrum obtained 
from the lanthanide-chelator complex reflects only the absorption spectrum of the bound 
ligand (chelator) and not that of lanthanide. The lanthanides suffer from several limitations, 
the chelator (ligand) with conjugated fluorophores is required for its excitation and the 
absence of polarized emission prevents it from fluorescence-based anisotropy measurements.  
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1.5.3. Contrast agents for MR and Optical imaging  
Iron oxide nanoparticles are widely explored in order to develop a nanoparticle-based 
system that is active to both MR and optical imaging techniques. These nanoparticles when 
reduced to a critical size, the prevalent multiple magnetic domains change into a single 
domain and cause the spins of the nuclei to flip under an external magnetic field (magnetic 
moments), thus leading to a superparamagnetic behavior and an active MR signal
[119]
. The 
magnetic properties (relaxivities) displayed by the iron oxide nanoparticles are highly 
dependent on its core size as illustrated in Table 1.4. In MRI, the administration of exogenous 
imaging agents enhances the quality of the acquired anatomical data  and provides additional 
information on physiological parameters
[120]
. Iron oxide nanoparticles are relatively non-toxic 
compared to other inorganic nanoparticles and accumulate intensely in the biological 
targets
[121;122]
. The size of these nanoparticles and surface modifications are regulated to 
display reasonable circulation times and to arrive at the tissue targets by avoiding the 
organism´s particle filter (i.e. reticulo-endothelial system).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Contrast agents generated for optical imaging are based on NIR fluorescent dyes, 
which are usually coupled to target-specific ligands and carriers such as antibodies, proteins, 
peptides, nanoparticles or polymers, and small molecules. However, they suffer from certain 
limitations (like quenching, unspecific uptake) due to the bulky nature of the dye 
molecules
[123;124]
.  Combined MRI and optical agents are being explored due to their ability to 
enhance contrast (complementary information) in both modalities
[125]
 e.g., as they could be 
used for preoperative imaging and intraoperative tumor delineation,
[126;127]
 on the basis of the 
key features that occur during in vivo nanoparticle metabolism and due to their imaging 
properties (i.e. optical and magnetic), respectively.  
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Table 1.4. T2 relaxivities of magnetic nanoparticles (adapted from Eun Chul Cho et.al, Trends in Molecular 
medicine, 2010) 
Types of magnetic 
nanoparticles 
Core size (nm) T2 relaxivities [mM
-1
s
-1
] 
USPIO, transferrin-coated 5 52.1 
Cross-linked iron oxides 
(CLIO), cyclic RGD 
(cRGD) modified 
28 111 
Cross-linked iron oxides 
(CLIO), scrambled 
36 118 
Dextran-coated iron oxides 2-4 72 
 6-8 95 
 10-15 185 
 15-20 242 
 20-25 320 
Fe3O4 9 265 
 6 208 
 12 218 
MnFe2O4 12 358 
CoFe2O4 9 134 
 6 109 
 12 172 
NiFe2O4 12 152 
Gold-coated Co 
nanoparticles 
- 107 
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1.5.4. Magnetofluorescent nanoparticles 
Magnetofluorescent nanoparticles serves as a platform for hybrid imaging with the 
co-registration of MR and fluorescence images acquired under different geometries enabling 
better visualization
[128]
. Figure 1.1.9 shows different types of magnetofluorescent 
nanoparticles designed and developed in this thesis. Iron oxide nanoparticles (USPIO) were 
generated by adopting the co-precipitation synthesis strategy. Initially, lanthanide-doped iron 
oxide nanoparticles with anticipated NIR emission were developed and stabilized with a 
silane coating (Figure 1.1.9 A). Further, naphthalene sulfonates coated iron oxide 
nanoparticles with anticipated UV emission were synthesized and characterized (Figure 1.1.9 
B). Finally, mixed coating of iron oxide nanoparticles with endogenous flavin analogues 
(anticipated visible emission) in combination with GMP were developed and characterized 
(Figure 1.1.9 C). The importance and cellular internalization pathways of the endogenous 
flavin analogues (FMN and FAD) used for coating the iron oxide nanoparticles and its 
specificity towards the riboflavin carrier protein (RCP) will be discussed in the following 
sections. 
 
 
 
Figure 1.1.9. Schematic diagram displays different attempts made in generating magnetofluorescent 
nanoparticles. (A) Lanthanide-doped magnetic nanoparticles coated with silane molecules (APTMS/TEOS), (B) 
H-acid/ANDS coated iron oxide nanoparticles and (C) endogenous FMN/FAD and GMP coated fluorescent iron 
oxide nanoparticles respectively. 
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1.6. The Riboflavin carrier protein as a biological target  
Riboflavin (Rf), also known as Vitamin B2, is a water-soluble vitamin essential for 
normal cellular function, growth and development. In its coenzyme forms like FAD and 
FMN, Rf performs key metabolic functions and acts as an intermediate in the electron 
transfer in the biological oxidation-reduction (redox) reactions. Rf deficiency leads to variety 
of clinical abnormalities including growth retardation, anemia, skin lesions and degenerative 
changes in the nervous system
[129]
. In order to avoid Rf deficiency in cells, the cellular uptake 
of Rf is enhanced and mediated by a membrane protein known as the riboflavin carrier 
protein (RCP), which strongly binds and transports Rf into the cells.  
RCP is a growth- and development-specific protein proven to be highly conserved 
through amphibians, reptiles, and birds
[130-132]
. Chicken RCP (cRCP) is a 37 kDa 
phosphoglycoprotein found in chicken egg white, egg yolk and the plasma of egg laying 
hens. The human RCP has a molecular weight of 38 kDa (confirmed by siRNA inhibition 
analysis), similar to cRCP and shares physico-chemical characteristics, such as isoelectric 
point, electrophoretic mobility, and molecular weight (~ 36 kDa) with its chicken analogue.  
The crystal structure of cRCP shows the binding mode of Rf with cRCP that occurs in 
a cleft with the isoalloxazine ring of Rf stacked between the parallel planes of Tyr75 and 
Trp156 as shown in Figure 1.2.1 respectively. The isoalloxazine ring of flavins is amphiphile 
since the xylene portion is hydrophobic and the pyrimidine moiety hydrophilic. The major 
interactions of the isoalloxazine ring with the protein are hydrophobic in nature (Figure 1.2.0 
and 1.2.1). A characteristic feature of a ligand interaction to RCP is the fluorescence 
quenching which is clearly elucidated from the binding of Rf, and its analogs to RCP.  
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Figure 1.2.0. Ribbon diagram of the Rf-binding protein molecule. The ligand-binding domain is colored in 
green and the phosphorylated motif in red. The vitamin is represented by the yellow stick drawing. The letters 
„N‟ and „C‟ identify the N- and C-termini of the protein, the labels CHO-36 and CHO-147 indicate the positions 
of the oligosaccharide chains. The gap between the two helices in the red motif is the disordered part of the 
molecule which corresponds to the phosphorylated region between Leu184 and Glu199. The diagram was 
produced with the program MOLSCRIPT (Kraulis, 1991) (adapted from Monaco, The EMBO journal, 1997). 
  
 
 
Figure 1.2.1. Schematic representation of the interactions showing the amino acids in the ligand-binding site 
that are in closest contact with the bound vitamin
[133]
. 
 
1.6.1. Riboflavin cellular internalization pathway  
The Rf internalization in cells occurs via non-specific and specific cellular uptake 
pathways, respectively.  Cellular internalization of Rf via non-specific transport is facilitated 
by albumin (co-transport or binding with Rf) and by Rf binding immunoglobins. It is 
believed that specific transport for delivering Rf into cells was mediated by carrier proteins 
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called “riboflavin binding/carrier protein (RCP)”. Though the mechanism of the Rf transport 
process remains elusive, it is believed that more than one mode of transport process may 
exist. 
 
 Saturable (active) transport (in vitro) 
The Rf transport velocity and affinity constants for Rf-receptor binding were studied 
using different cell types expressing active Rf transport. The discrepancies observed in the Rf 
uptake could be related to the existence of different Rf uptake mechanisms (varied expression 
in cell lines) or due to highly mutant prone characteristics of cancer cell lines. Despite these 
observed differences, the Rf uptake mechanism seems to be highly specific and saturable. 
Competitve analog assays showed that FMN, FAD, lumiflavin, lumichrome, iso-Rf, and 8-
[NH2]-Rf display significant inhibition on cellular Rf uptake
[134-138]
. The temperature, 
osmalarity, metabolic inhibitors, ion substitutions, organic anions, anion exchangers, organic 
ion transport, modulators targeting cAMP, protein tyrosine kinase, protein kinase A, G, C and 
calmodulin-mediated pathways are also known to display inhibitory action on Rf transport 
which was elucidated through divergent cell models. 
 
Passive diffusion component in Rf uptake 
At Rf concentrations higher than in human plasma (> 12 nM), Huang, et al., reported 
Rf absorption in intestinal epithelial cells (Caco-2), which displayed predominantly passive 
diffusion kinetics, whereas, saturation kinetics are observed at Rf concentrations (~ 12 nM ).  
 
 Receptor-mediated or carrier mediated transport of riboflavin 
 The criteria used to define the active Rf transport in cells, i.e. energy dependency and 
saturation transport kinetics; does not pave way to distinguish the carrier-mediated transport 
from the receptor-mediated endocytosis (RME). Receptor-mediated events (transport) 
typically involve endocytosis followed by subsequent microtubule driven vesicular sorting to 
various cellular organelles respectively
[139]
. To account for the RME pathway, the sub-
cellular localization of Rf in BeWo cells was studied
[140]
 using rhodamine-labeled Rf and 
FITC-labeled transferrin (FITC-Tf) to trace the sub cellular distribution patterns of these 
compounds upon its cellular uptake. The sub cellular localization investigation was evaluated 
using fluorescence microscopy, which showed a distinct perinuclear staining pattern for 
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rhodamine-Rf conjugates, with co-localization of FITC-Tf suggested that Rf transport in 
BeWo cells involves RME pathway. 
The rate and extent of Rf internalization and its sub cellular trafficking were evaluated 
using breast cancer cell line (MCF-7),
[141]
 and it displayed an alteration in Rf trafficking 
pathways due to the modifications that originated from the cellular environment, such as 
changes in temperature, compartmental pH, ligand concentration, and cytoskeletal networks 
respectively. Some of the limitations of this model: first, the permeation of ligand in and out 
of vesicles via passive diffusion was ignored; second, the effect on trafficking of enzymatic 
Rf conversion into its coenzyme forms (FMN and FAD), an efficient mechanism for 
capturing and storing Rf within the cell referred as “metabolic trapping”[142] has not been 
determined and may affect or influence the Rf trafficking kinetics. 
 
1.6.2. Role of RCP expression in cancers 
The increase in metabolic activity of cancer cells are expected to have a higher 
demand for Rf. The Rf uptake in cells is facilitated by RCP. Therefore, the increased uptake 
of Rf by metabolically active (cancer) cells points to an up regulation of RCP expression, 
respectively. In line with this, the (over-)expression of RCP has been reported in breast 
adenocarcinoma tumors, which was accompanied by high serum levels, suggesting its 
potential use as a (bio-)marker for early detection of breast cancer
[143;144]
. Further, the (over-) 
expression of RCP is also reported in different cancer tumors like ovarian adenocarcinoma, 
endometrial adenocarcinoma and hepatocellular carcinoma
[145]
.  
The RCP generation in the liver has been shown to be influenced by estrogen, 
however, its expression was also highly regulated in androgen sensitive LnCap, as well as 
androgen insensitive (PC-3 and DU-145) prostate cancer cells/tumors. This unique finding 
indicates that the expression level of RCP is independent of the hormonal regulation in 
prostate cancers. The internalization of Rf may involve a RME pathway as shown in several 
adenocarcinomas, including  prostate, and placental trophoblast cells
[146]
. Studies using sera 
from prostate cancers of various stages will be necessary to evaluate and validate the 
potential of RCP to serve as a serum marker for early detection of prostate cancer. 
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1.6.3. RCP targeting  
RCP receptors can be targeted by conjugating carriers like nanomaterials, liposomes, 
polymers, drugs with RCP specific endogenous ligands (Rf, FMN, FAD), respectively. To 
increase the delivery of macromolecules into cultured cells Rf was conjugated to 
macromolecules like bovine serum albumin (BSA) via the vitamin´s ribityl side chain. The 
RCP mediated high uptake of Rf-BSA by KB, A549, SK-LU-1 or SK-OV cells was 
compared to the unconjugated BSA where the former displayed high  internalization (> 10
6
 
molecules/cell)
[147]
. Thomas, et al., also showed that the design of Rf conjugatedG5 
dendrimer would provide key possibilities required for targeted (drug) delivery based on 
RME pathway respectively
[148]
.  
 
1.6.4. FMN/FAD coated iron oxide nanoparticles for RCP targeting 
The vast majority of (pre-)clinically used MR contrast agents based on iron oxide 
nanoparticles are functionalized with polymers like dextran, carboxydextran and polyethylene 
glycol. However, with few exceptions
[149]
, polymeric coated magnetic nanoparticles are 
known to display relatively large hydrodynamic diameters and therefore display limitations in 
tissue penetration, diffusion,  bio-distribution and metabolic clearance and might even induce 
side effects.  To overcome the afore-mentioned setbacks of polymer coatings, a thin layer of 
non-polymeric coating using organic biocompatible molecules was introduced in a simple 
and straightforward synthetic method. Based on the advantages of non-polymeric coatings, 
we here report fluorescent and non-polymeric FMN and FAD-decorated iron oxide 
nanoparticles as versatile MR contrast agents. FMN and its precursor Rf mediate various 
redox reactions that regulate the metabolism of carbohydrates, amino acids and lipids
[150]
. 
The cellular uptake of Rf is mediated by RCP, which strongly binds and transports Rf into the 
cell
[142;151]
.  RCP is up regulated in cells with high metabolic activity like tumor cells
[152;153]
 
and activated endothelial cells.  The current state of the art is that fluoro-2-deoxy-D-glucose 
(
18
F-FDG) used for positron emission tomography (PET) imaging is the only clinically 
approved diagnostic agent for labeling cells with high metabolic activity
[154-156]
. On that basis, 
it was reasoned that besides 
18
F-FDG-uptake, also the uptake of FMN/FAD-functionalized 
probes by RCP could serve as an effective metabolic marker for diagnostic (and therapeutic) 
interventions using non-invasive imaging modalities.  
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Aim of the thesis 
 
The specific aims of this thesis are the following 
1. To develop stable, biocompatible and fluorescent iron oxide nanoparticles (bimodal 
probes) for MR and optical imaging. 
2. To generate the fluorescent USPIO by employing different strategies such as non-
polymeric coating, conjugation of nanoparticles to organic dyes and via loading 
lanthanides into iron crystal lattices. 
3. To evaluate the suitability of the generated magnetofluorescent nanoparticles 
(FLUSPIO/FAD USPIO) for cellular labeling. 
4. To evaluate the in vivo target specificity of FAD USPIO for RCP using MRI and 
further to co-validate the MR findings through histology.  
 
The scheme below shows the different synthesis strategies adapted in generating the 
fluorescent iron oxide nanoparticles as dual modal contrast agents for MRI and optical 
imaging techniques respectively. 
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Chapter 2. 
Results and Discussion 
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Dual modal fluorescent and magnetic iron oxide nanoparticles were generated by 
following different synthesis strategies. The first synthetic strategy was employed to generate 
iron oxide nanoparticles (USPIO) loaded (doped) with lanthanide metal ions (Ln) into its 
crystal lattice (Ln-USPIO). Subsequently, after doping surface coating was achieved with a 
protective layer of silane. However, the incorporation of lanthanides into the iron crystal 
lattice did not yield fluorescent nanoparticles, likely due to improper loading of lanthanides 
and due to the discrepancies observed in size between lanthanides and iron metal ions 
respectively. The second synthetic strategy, which was implemented to generate fluorescent 
nanoparticles, is by employing a thin layer of non-polymeric coating using fluorescent (UV 
emission) and biocompatible naphthalene sulfonates. Interestingly, the naphthalene sulfonates 
modified iron oxide nanoparticles (NUSPIO) displayed reasonable stability with a slight 
degree of agglomeration (pH 6) observed by visual inspection. However, NUSPIO did not 
show any fluorescence due to the quenching that occurred via electron transfer, due to the 
interaction of the aromatic naphthalene sulfonates moiety with the paramagnetic species (iron 
oxide nanoparticles). Therefore, these Ln-USPIO and NUSPIO could not be used as dual 
modal contrast agents for MR and optical imaging.   
In order to overcome the above mentioned shortcomings from other coating/synthetic 
strategies used for generating fluorescent iron oxide nanoparticles, we used fluorescent, 
biocompatible and endogenous ligands (FMN, FAD and GMP) to achieve a thin layer of 
protective non-polymeric coating for the USPIO. The FMN/FAD based nanoparticles 
(FLUSPIO and FAD USPIO) displayed a reasonable stability and high intensity fluorescence 
without showing any agglomeration under physiological conditions. The fluorescent 
nanoparticles can be excited in a wide wavelength range (250-500 nm), resulting in an 
intense green emission at 530 nm. Further, the imaging properties (magnetism and 
fluorescence) of these newly generated nanoparticles were evaluated for their cellular 
labeling efficiency and for in vivo MR imaging.  
 
2.1. Generation of bimodal contrast agents (MR and Optical imaging) 
In this section, the synthesis, physico-chemical characterization, in vitro and in vivo 
evaluation results of different types of generated iron oxide nanoparticles (i.e. Ln-USPIO, 
NUSPIO, FLUSPIO, and FAD USPIO) based bi-modal contrast agents will be discussed. In 
this respect, new non-polymeric fluorescent ligand systems were synthesized and 
immobilized on the surface of iron oxide nanoparticles. The resulting bimodal probes 
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(FLUSPIO and FAD USPIO) were evaluated for their suitability for in vivo MR imaging and 
subsequently the MR findings were co-validated using histological analysis respectively. 
 
2.2. Ligand systems used for coating of iron oxide nanoparticles 
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Most of the simple fluorescent non-polymeric and non-fluorescent polymeric ligand 
systems were obtained from commercial sources and used directly for coating iron oxide 
nanoparticles without any further purification.  Additionally, new hybrid fluorescent non-
polymeric ligand systems were also designed and synthesized by coupling together the 
surface binding moiety (i.e. sulphonic acid, phosphonic acid) to a fluorescent aromatic 
moiety. Most of the fluorescent hybrid ligand synthesis was carried out in polar solvents and 
purified by using re-crystallization technique. The overall reaction yield at the end of the 
ligand generation was about 50 to 60%. After ligands synthesis, their fluorescence 
characteristics were checked by fluorescence spectroscopy prior to their coating on iron oxide 
nanoparticles.  
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Naphthalene bis(phosphonate) (2) (abv. Naph 7) was synthesized using a reported 
procedure
[211]
. The synthesis was carried out in two steps, where in the first step, 
aminomethyl naphthalene was treated with diethyl vinylphosphonate to produce the tetra 
ester (1), followed by the second deprotection step using bromomethylsilane.  The 
deprotection step was quite fast but the reaction yield was low. The reaction was carried out 
under neutral conditions as the presence of acids or bases result in decomposition or 
incomplete or no reaction. The fluorescence (UV emission) originates from naphthalene 
moiety and the non-polymeric ligand was adsorbed to the metallic nanoparticles via the 
bis(phosphonate) groups.  
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Acridine and quinine are treated with 1,4-butane sultone to form quaternary salts 
having hydrophilic sulphonic acid groups (3 and 4) for the respective fluorophores via the 
quaterization reaction. The quaternary salt formation can be clearly seen from a change in 
colors during and after completion of the reaction. These salts are highly water soluble due to 
the presence of sulphonic acid groups. The 1,4-butane sultone introduces four carbons to the 
tertiary amine of the aromatic moiety and additionally a sulphonic acid group at the terminal 
carbon. Quaterization reaction carried out with 1,4-butane sultone resulted in better yields 
and reaction efficiency (i.e. reaction completion) than 1,3-butane sultone which was 
inefficient due to the reaction carried out at solid state  and at elevated temperatures
[157]
. 
However, acridine and quinine quaterization reaction using 1,4-butane sultone in toluene 
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proceed via long reaction time (24 to 48 h)
[212]
. The pure crystals of the quaterized 
compounds were obtained by applying re-crystallization techniques.  
 
 
 
The stilbene-based azo dye (5) was prepared according to reported literature
[213]
. The 
primary amine of the stilbene undergoes nitrosation (diazotization) with nitrous acid 
(generated in situ from sodium nitrite and a strong acid like HCl) at low temperatures. The 
diazotized stilbene salt was treated with amino naphthalene sulfonates (H-acid) at low 
temperature and at basic conditions to generate the azo dye. The azo dye was formed due to 
the electrophilic substitution of the diazotized stilbene salt at the ortho position of hydroxyl 
group of H-acid which renders stilbene-based azo dyes linear and coplanar which occurs due 
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to the hydrazone formation via intramolecular hydrogen bonds
[158]
. The stilbene-based azo 
dye was precipitated from the solution using sodium chloride and purified by crystallization 
technique. The proton peaks involved in hydrogen bonds are known to appear at much lower 
field in NMR than the normal proton peak of hydroxyl group
[159]
.  
 
 
 
The stilbene-based azo dye (6) was prepared by a slight modification of the reported 
procedure
[214]
. In this synthesis, 4,4´-diamino stilbene-2,2´-disulfonic acid was used as the 
substrate for diazotization which proceeds via electrophilic substitution at the H-acid 
respectively. The stilbene-azo dye exhibits a linear and coplanar geometry after diazotisation. 
The resulting azo dye could not be precipitated from the solution by the addition of sodium 
chloride, which could be attributed to the presence of more hydrophilic sulphonic acid groups 
 48 
and low ionic strength prevailing at the reaction medium. Hence, the crude product with 
sodium chloride was recovered from the reaction solution by rotatory evaporation and re-
crystallization was performed in water, in order to generate pure crystals of the azo dye. 
However, the re-crystallization technique did not yield any crystals of the generated azo dye 
respectively.  
 
 
 
The carboxylic acid of the naphthalene substrate was activated by using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) at low temperature. 1-hydroxybenzotriazole 
(HOBt) serves as a catalytic additive for the efficient conversion of acid and amine to 
amide
[160;161]
. The amide bond formation proceeds via the catalytic amounts of HOBt and 
stoichiometric EDC concentration
[215]
.  N,N-diisopropylethylamine (DIPEA) serves as a base 
that facilitate the EDC coupling to form amides. The activated carboxylic acid was treated 
with amine substrate (AEP) at ambient temperature. The TLC showed that the conversion of 
the carboxylic acid to amide (7) was only 50% after overnight reaction. Increasing the 
reaction time, did not improve the reaction yield and the amine conversion to amide. The side 
products like urea and unreacted HOBt were removed by washing the final residue with 
ether. The pure product was recovered by re-crystallization from water. 
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The Mitsunobu reaction was carried out between 6-hydroxy-2-naphthoic acid and 1-
hydroxyethane-1,1´-diyldiphosphonic acid (Etidrionic acid) to form ester (8). This reaction 
involves the dehydrative coupling of an alcohol with an acidic component (carboxylic acid) 
to form esters using a combination of a reducing (phosphine) and an oxidizing (azo) reagent. 
Iodosobenzene diacetate is known to oxidize 1,2-dicarbethoxyhydrazine to diethyl 
azodicarboxylate  (DEAD), in line with this, it might be possible to use iodosobenzene 
diacetate as the stoichiometric oxidant and DEAD as a catalyst in Mitsunobu reactions
[162]
. 
The Mitsunobu reaction inverts the stereochemistry of the alcohol that was used as the 
starting material
[163]
. However, a significant drawback of these reactions is the requirement of 
four reagents and starting materials (an alcohol, an acid/pro-nucleophile, a phosphine, and an 
azo reagent), which leads to difficulty in the separation of the desired product from the excess 
starting materials/reagents and by-products
[216]
. The mitsunobu reaction completion was 
monitored using TLC and the residue obtained after evaporation was soluble in water under 
sonication.  The final product in aqueous solution was re-crystallized with a moderate 
reaction yield. 
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The carboxylic acid of the amino acid (tryptophan) was activated by using EDC at 
ambient temperature. The amine (ANDS) was added to the activated amino acid followed by 
HOBt and DIPEA at ambient temperature and further the reaction was allowed to proceed at 
RT.  The amide (9) formation was monitored using TLC, which showed that the amide 
formation was only upto 50% after overnight reaction and the reaction yield remained 
unchanged even with increase in the reaction time. The side products like urea and unreacted 
HOBt were removed by washing the final residue with diethyl ether. The generated amide 
product was recovered from methanol by triturating the filterate with ether.  
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The carboxylic acid of the oleic acid was activated by using zero length cross linker 
carbodiimide (EDC) at low temperature. The amine (H-acid) was added to the activated oleic 
acid followed by addition of HOBt and DIPEA at ambient temperature. HOBt serves as a 
catalytic additive and DIPEA acts as a base to facilitate the efficient conversion of acid and 
amine to amide. The amide formation (10) was regularly checked using TLC and the side 
products (urea) and unreacted components (HOBt) in methanol was neutralized and removed 
by rotator evaporation. The amide product was recovered from methanol by trituration of the 
residue with ether.  
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The peptide bond (in compound (11)) was achieved between the oleoyl chloride and 
ANDS substrate at high temperature under inert atmosphere via a modified literature 
procedure
[217]
. The slow addition of dry pyridine into the heated reaction mixture (oleoyl 
chloride and ANDS) resulted in the evolution of HCl gas from the reaction. The completion 
of the reaction was monitored using TLC for 2 days. The excess pyridine from the reaction 
was removed by distillation. The resulting solid residue was soluble in chloroform which was 
in contradiction to the reports from the literature, wherein the obtained solid residue was only 
soluble in methanol (could be due to usage of different unsaturated acids). However, the 
sticky product could be obtained by washing with methanol and followed by trituration with 
ether. These products were only amenable to negative ion FAB mass spectral analysis, as 
reported for most of the naphthalene sulfonates
[164]
.  
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The carboxylic acid of the amino acid (tryptophan) was activated by using EDC and 
the amine (AEP) was added to the activated amino acid, followed by addition of HOBt and 
DIPEA at ambient temperature. Further, the reaction was allowed to proceed overnight at RT. 
The amide formation was continuously monitored using TLC and after reaction completion 
the side products and excess reagents were removed by washing the residue with ether. 
However, the amide (12) could not be completely recovered from methanol by ether 
extraction and via re-crystallization from aqueous solution. Therefore, the product was 
recovered by rotatory evaporation from the reaction mixture. 
 
2.3. Synthesis of iron oxide cores 
Magnetic nanoparticles used for medical and diagnostic imaging applications can be 
synthesized via different methods like micro-emulsions
[165]
, sol-gel syntheses
[166]
, 
sonochemical reactions
[167]
, hydrothermal reactions
[168]
, hydrolysis and thermolysis of 
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precursors
[169]
, flow injection syntheses
[170]
, and electrospray syntheses
[171]
. In this thesis, the 
cores of the iron oxide nanoparticles were synthesized by employing two different methods 
namely co-precipitation (aqueous phase) and thermal decomposition (organic phase) 
respectively. One of the major limitations of co-precipitation synthetic strategy is that it 
yields only polydispersed nanoparticles, however, the reaction yield from co-precipitation is 
very high and further facilitates MR imaging as the synthesized nanoparticles are available as 
aqueous suspensions. Conversely, nanoparticles prepared by thermal decomposition are 
highly monodispersed, but suffers from low yield and problems related to their transfer from 
organic into aqueous phase. 
 
2.3.1. Synthesis of Iron oxide nanoparticles (10 nm) by the co-precipitation method 
The iron oxide nanoparticles with 10 – 12 nm core diameters were prepared via co-
precipitation of ferric and ferrous salts (2:1 molar ratio) by using alkaline bases like sodium 
hydroxide, ammonia or tetramethyl ammonium hydroxide (TMAOH) (pH range between 8 
and 14). The first controlled preparation of superparamagnetic iron oxide nanoparticles was 
performed and reported by Massart
[172]
. In our study, magnetic nanoparticles were prepared 
by a modified Massart method, in which the iron precursors in acidic solutions are 
simultaneously added into a base in order to propagate the growth of the nanoparticles. The 
particles synthesized with Fe
2+
/Fe
3+ 
ratios between 0.4 and 0.6 are effective enough to be 
used as MR contrast agents
[173-175]
.  The Fe3O4 formation may be represented chemically as 
follows 
  
       Fe
2+
 + 2Fe
3+
 + 8OH
-
                 Fe3O4 + 4H2O 
 
 The co-precipitation was carried out under inert atmosphere and at 80°C in order to 
remove the dissolved oxygen from the aqueous medium which might induce oxidation of the 
iron cores (Fe3O4) to form maghemite. Bubbling nitrogen gas through the solution not only 
protects against critical oxidation of the magnetite but also reduces the particle size when 
compared to synthetic methods without removing oxygen
[176;177]
. 
             The magnetite is immediately formed as a black precipitate due to the addition of the 
base (NaOH) that induces nanoparticle nucleation. The crystal growth of the magnetite is 
allowed to proceed for 20 min by stirring them at 1000 rpm. In magnetite, Fe
3+
 ions are 
distributed in the octahedral (Oh) and tetrahedral (Td) sites, and Fe
2+
 ions are distributed in 
the octahedral (Oh) sites of the inverted spinel structure ( Fe3O4: [Fe
3+
]Td[Fe
3+
Fe
2+
]OhO4).  
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In order to stabilize the as-prepared nanoparticles in solution without any aggregation, the 
negative surface charge of the nanoparticles (originating from hydroxyl groups and oxo-
bridges) was protonated by addition of aqueous HCl acid (pH 2) and converted into positively 
charged surface. The high proton (H
+
) concentration also converts the magnetite into 
maghemite without any change in the particle size
[178]
.  
 
Fe3O4 + 2H
+
                 γFe2O3 + Fe
2+
 + H2O 
 
Under acidic conditions, surface Fe
2+
 ions are desorbed as hexa-aqua complexes in 
solution. In line with this, the size sorting process was reported on cationic Massart 
nanoparticles using nitric acid as an electrolyte and allowed to fractionate the particle size 
distribution with a very good yield
[179]
.  
The size, shape and composition of the synthesized magnetic nanoparticles depends 
on the type of salts used (e.g., chlorides, sulfates, nitrates), the Fe
2+
/Fe
3+
 ratio, the reaction 
temperature, the pH value and ionic strength of the media. Table 2.1.0 displays different 
reaction conditions which are optimized to yield nanoparticles with reasonable dispersity that 
suits their use in biomedical applications. 
In another synthetic strategy, iron oxide nanoparticles (10 nm) were prepared in a 
rapid and economical method at ambient temperature without using inert atmosphere and 
elevated temperature. In this method, the Fe
2+
/Fe
3+
 salts in water were stirred for 10 min at 
RT, in order to completely dissolve the iron salts and to form a homogeneous solution. 
Further, the co-precipitation was achieved by addition of ammonia into the above iron salt 
solution. The magnetite crystal growth was allowed to proceed for 10 min at 1200 rpm at 
ambient temperature. Excess of ammonium ions, chloride anions from the magnetic fluid 
suspensions were removed by washing three times with de-ionized water. The removal of 
free chloride anions from the solution was confirmed by testing an aliquot with silver nitrate 
solution which results in curdy white precipitate with chloride anions. Finally, the magnetic 
fluids were suspended in aqueous hydrochloric acid (pH 2) at low temperatures.  
Additionally, iron oxide nanoparticles were prepared by co-precipitation and 
stabilized via using a non-polymeric binding of alkaline tetramethyl ammonium hydroxide 
(TMAOH).  After washing with water, the pH of the magnetic particles was slightly basic 
(around 8 – 8.5) and further with increase in storage time, the nanoparticle agglomerates and 
sediments down which makes them unsuitable for coating purposes. The agglomeration could 
be avoided by removing the big aggregates via centrifugation. 
Furthermore, lanthanides doped magnetic nanoparticles with 10 nm average diameter 
were prepared by a modified Massart (co-precipitation) method. It is known that doped 
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nanoparticles generated using co-precipitation display physico-chemical characteristics 
almost similar to that of undoped magnetite nanoparticles
[180]
. 
 
Table 2.1.0. Stabilization of different parameters involved in the synthesis of cores of iron oxide nanoparticles. 
The highlighted conditions (in italics and underlined) indicate the optimized parameters necessary to yield 
highly dispersed nanoparticles. 
 
 
2.3.2. Synthesis of iron oxide nanoparticles (5-6 nm) by the co-precipitation method 
Iron oxide nanoparticles (5-6 nm) were prepared in a simple and facile way at ambient 
temperature without the influence of inert atmosphere and high temperature. In this method, 
the Fe
3+
/Fe
2+ 
salts (2:1 molar ratio) in water was stirred for 10 min at RT to generate a 
homogeneous solution. The aqueous solution of iron salts were co-precipitated by using 
ammonia. The magnetite crystal growth was allowed to proceed for 20 min at 1200 rpm at 
ambient temperature. It is known that, with increasing in the reaction time the size of the 
nanoparticles decreases (i.e. 10 nm to 5-6 nm). Excess of ammonium ions, chloride anions 
from the magnetic fluid suspensions were removed by washing three times with de-ionized 
water. The free chloride anions removal was confirmed by silver nitrate test. Further, the 
magnetic fluids were suspended and stabilized without agglomeration in aqueous 
hydrochloric acid (pH 2). The big agglomerates in the magnetic fluid were removed by 
sonication at ambient temperature which was aided by filtration through 0.22 µm filter units. 
Furthermore, high-speed centrifugation removes the remnant agglomerates from the magnetic 
fluid. The supernatant solution containing highly dispersed nanoparticles was collected and 
stored at low temperature.    
 
 
 
Temperature (°C) 
NaOH 
concentration (M) 
Stirring speed 
(rpm) 
Reaction time (min) 
Stability in solvents 
and solutions 
 
80 
 
0.5 
Mechanical stirring 
(1000 rpm) 
 
20 
Stable in glucose, 
diethyl glycol, DMF, 
DMSO, methanol 
 
20, 40, 60 
 
1.0, 1.5 
Magnetic stirring 
(1000 – 1200 rpm) 
 
20 
Unstable in citric acid, 
acetonitrile, PBS buffer, 
and saline solution. 
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2.3.3. Synthesis of iron oxide nanoparticles by the thermal decomposition method 
2-pyrrolidione (2-Py) serves as a solvent for high-temperature thermal decomposition 
reaction and also involves in surface modification of the generated magnetite nanocrystals via 
coordination, which renders them water-soluble and increases the colloidal stability of 
nanoparticles
[181]
. Trace amount of water in 2-Py was removed by using molecular sieves 4A 
and Fe(acac)3 addition to 2-Py resulted in red color solution which was sonicated for 7 min 
and refluxed at 250-300 °C under inert atmosphere. The carbon monoxide produced during 
the synthesis was quenched by purging into a transition metal complex solution. The reaction 
intermediate (azetidine) is known to be actively involved in the catalytic hydrolysis of the 
iron acetylacetonate precursor
[182]
. Iron oxide nanoparticles generated by thermal 
decomposition resulted in black solution, which could not be precipitated using methanol. 
The final residue obtained after rotatory evaporation was washed several times with acetone 
and dried in hot air oven. 2- Py adsorbed magnetic nanoparticles were dispersed in water with 
sonication. The size and shape of these magnetic nanoparticles can be tuned by altering the 
reaction time and temperature respectively. 
Oleic acid is a surfactant widely used to stabilize the magnetic nanoparticles via the  
coordination that occurs between the carboxylic acid groups (oleic acid) and the 
nanoparticles
[183;184]
. The interaction between carboxylates and metal atom is known to occur 
via carboxylate head in four different forms: monodentate, bridging (bidentate), chelating 
(bidentate), and through ionic interaction
[185]
. Thermal decomposition of iron precursor (Fe 
(acac)3) in the presence of oleic acid was carried out in organic phase under nitrogen 
atmosphere. The magnetite crystal growth increases at high temperature as displayed by the 
change in color (red to yellow to black). The magnetic particles could not be precipitated 
from black solution by ethanol addition. Therefore, excess ethanol was rotatory evaporated 
and nanoparticles were recovered by centrifugation. The nanoparticles displayed 
agglomeration which prevented them from re-dispersing in water. In line with this, Sun, et 
al., reported the thermal decomposition of Fe(acac)3 in presence of surfactants like oleic acid 
and oleylamine to generate monodispersed magnetite nanoparticles
[186]
.  
In another synthesis strategy, oleic acid based stabilization of the magnetic 
nanoparticles was demonstrated. Here, the nanoparticles were generated using iron (II) 
precursor at elevated temperature. The iron (II) in the alkaline iron (II) precursor solution was 
oxidized to iron (III) by using (NH4)2S2O8 and resulted in black solution respectively. The 
black solution was formed by (NH4)2S2O8 (oxidant) addition, to the alkaline iron (II) 
precursor solution. Oleic acid in toluene was added to the reaction mixture and heated to 
generate the oleic acid capped magnetic nanoparticles, and isolated by precipitation in 
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acetone. A dark sticky precipitate was obtained in a low yield. The magnetic nanoparticles 
(solid) were highly soluble in toluene, chloroform and tetrahydrofuran thus providing stable 
organosols. The transfer of the oleic acid stabilized nanoparticles into water was not 
successful. 
The surface of the commercial ferrofluid (EMG 911) extracted from mineral oil was 
covered by oleic acid and could be readily re-dispersed in toluene. These hydrophobic 
nanoparticles displayed a mean diameter around 10 nm and resulted in agglomerates upon 
drying due to strong hydrophobic interactions between their surfaces
[220]
. The ferrofluid 
(EMG 911) served as control particles and the properties (physical and chemical) of them 
after coating with silica were compared to the magnetic nanoparticles generated in our 
laboratory, thus paving way for efficient designing of versatile MR contrast agents. Indeed, 
there were problems associated with EMG 911 during silica coating like aggregation, phase 
separation etc.  
 
2.4. Estimation of the iron concentration in nanoparticles 
The total iron concentration of the magnetic nanoparticles was determined by using 
three different techniques/methods such as titrimetry, colorimetry and mass spectrometry 
(ICP-MS) respectively. Inductively coupled mass spectrometry (ICP-MS) estimates the total 
iron concentration in nM, but has drawbacks like long measurement time and high cost. 
Titrimetry and colorimetry are fast and convenient techniques used to determine iron 
concentration in µM range. The total iron (Fe
3+
) concentration of the uncoated and coated 
nanoparticles was determined prior to their in vitro and in vivo investigations. 
 
2.4.1.Titrimetry 
Total iron content of the magnetic nanoparticles was estimated using EDTA standard 
solution (Idranal for metal titration). EDTA was standardized using the standard zinc solution 
(0.01 M) in bicarbonate-carbonate buffered solution (pH = 10.0). Eriochrome Black T acts as 
an indicator under basic conditions and displays the end point by change in color from wine 
red to purple blue.  
The total iron in the magnetic fluids was dissolved by boiling them with HCl acid and 
the color of solution changes from black to slight yellow. In this method, the iron in the 
sample was completely oxidized to Fe
3+
 by an oxidizing agent ((NH4)2S2O8) which turns the 
solution completely into yellow. The Fe
3+
 forms a wine red complex with sulfosalicylic acid 
(Figure 2.1.0) and a buffer is added additionally to stabilize the Fe (III) complex. The 
solution is titrated with standardized EDTA to give yellow color as the end point. The total 
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iron content of magnetic nanoparticles with 10 nm and 5-6 nm core diameters was 
determined by titration as 233 mM and 143 mM respectively. 
 
 
 
 
Figure 2.1.0. Schematic diagram of complex formed between iron (III) and sulfosalicylic acid during the 
titrimetric estimation of iron concentration. 
 
 
2.4.2. Colorimetry 
Magnetic nanoparticles (Fe(II)) were completely oxidized to Fe(III) by aqua regia 
(3HCl/HNO3). Fe(III) forms a red complex with disodium-1,2-dihydroxy-3,5-benzene 
disulfonic acid (tiron) as shown in Figure 2.1.1. The complexation (via two hydroxyl groups) 
is facilitated under basic conditions by using a phosphate buffer (pH 9-10). The total iron 
content of magnetic nanoparticles with 10 nm and 5-6 nm core diameters determined by tiron 
colorimetric method is in line with the results obtained from titration. 
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Figure 2.1.1. Tiron complexes with iron (III) under basic conditions to form the tiron coordinated red complex  
 
2.4.3. Mass spectrometry 
Iron oxide nanoparticles were digested and oxidized using nitric acid and hydrogen 
peroxide under microwave irradiation. Further, these digested acidic solutions were diluted in 
water and the total iron content of the samples was estimated based on the standard 
calibration in nM concentration. Table 2.1.1 shows ICP-MS results of total iron concentration 
of different magnetic cores prepared using different base concentration (NaOH, NH3).  
 
 
Table 2.1.1. Total iron concentration of the iron cores prepared using different base concentration as determined 
by ICP-MS. 
 
 
 
 
 
No. Base used 
Iron cores 
(uncoated) 
Elements in the sample 
Total iron 
concentration 
mg/mL 
1. 1.5 M NaOH Uncoated Fe, O, H 20.211 
2. 0.5 M NaOH Uncoated Fe, O,H 9.247 
3. 1.0 M NaOH Uncoated Fe, O, H 4.596 
4. 25% NH3 Uncoated Fe, O, H 8.000 
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2.5. Different magnetic nanoparticles  
In this section, different magnetic nanoparticles generated based on various coating 
strategies will be discussed. In magnetic nanoparticles, the surface iron atoms act as Lewis 
acids and coordinate with molecules that donate lone-pair electrons. Therefore, in aqueous 
solutions, the Fe atoms coordinate with water, which dissociates readily to leave the iron 
oxide surface hydroxyl functionalized. These hydroxyl groups are amphoteric and may react 
with acids or bases
[179]
.  The magnetic nanoparticles can be stabilized by using any one of the 
following coatings such as monomeric stabilizers (carboxylates, phosphates), inorganic 
materials (silica, gold), polymer stabilizers (dextran, polyethylene glycol, polyvinyl alcohol, 
alginate, chitosan) respectively. This thesis deals with the design and development of new 
bimodal MR contrast agents based on silane, mixed silane, non-polymeric, and fluorescent 
non-polymeric coatings. The specificity of the MR contrast agents was promoted by 
conjugation to peptides, which can be further visualized (imaged) in cells and animals by 
including a fluorescent tag. Most of the conjugation chemistry in this thesis was achieved via 
the available free amine groups from different coatings.  The physico-chemical properties of 
different magnetic nanoparticles were studied using various techniques and their suitability as 
versatile MR contrast agents was evaluated successfully for intended in vitro and in vivo bio-
medical applications. 
 
2.6. Synthesis of Ln-USPIO nanoparticles 
The first synthesis strategy in generating multimodal contrast agents was performed 
by doping the iron oxide nanoparticles with lanthanide (Ln) metal ions via a modified co-
precipitation protocol respectively. Here, magnetic fluids were synthesized by using different 
concentrations of base (NaOH) in order to generate nanoparticles with different sizes.  
Lanthanides like Eu,Gd,Tb were incorporated into the crystal lattice of the iron oxide 
nanoparticles, so that its emission at long wavelength could be efficiently used for 
fluorescence imaging. Due to insufficient loading of lanthanides into the iron lattice, the 
anticipated fluorescence was not observed either by fluorescence (spectroscopy and 
microscopy) techniques. It is reported in the literature that the effective lanthanide emission 
could be accomplished by conjugating  the organic dyes, whose  emission matches the 
absorption of lanthanides, so that it could act as antenna in transferring the absorbed energy 
to the lanthanides
[187;188]
.  In line with this, fluorescent naphthalene sulfonates (ANDS and H-
acid) were used as an antenna to transfer the absorbed energy. However, the fluorescent 
antenna conjugated lanthanides showed diminished fluorescence, due to the low level of 
loaded lanthanides inside the iron crystal lattice and further, the emission of naphthalene 
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sulfonates did not spectrally match with the lanthanides absorption wavelength (discussed in 
detail under section 2.6.1).   
During the doping synthesis of magnetite, the iron (III) ions are replaced by different 
molar equivalents of either one or more lanthanide ions namely Gd(III), Eu(III) and Tb(III) as 
indicated in Table 2.1.2. The synthesis of Ln-doped USPIO (Ln-USPIO) was achieved in 
aqueous phase (single step) via co-precipitation of iron and lanthanide salts together. With 
increase in the amount of lanthanides replacing iron (i.e. up to 20%) did not lead to any 
fluorescence originating from the doped magnetic core. The nanoparticles were stored at pH 
2 after doping, to prevent them from agglomeration.  However, the doped lanthanides might 
get lost from the magnetite crystal lattice due to their storage under highly acidic solution that 
could promote leaching of the lanthanide from the crystal lattice. The reason for failure in 
generating Ln-USPIO is due to the considerable difference in size observed between iron (III) 
(Fe(III): 69.0 to 78.5 pm (cationic radius) and Fe(II): 75.0 to 92.0 pm (cationic radius)) and 
lanthanide (III) metal ions (Gd(III), Eu(III), Tb(III): 100.8 to 108.7 pm (cationic radius)), 
which does not facilitate replacement by lanthanides.  In line with our observation, it was 
shown that only less amount of gadolinium (III) can be incorporated into the iron crystal 
lattice
[189]
. It was shown that using dextran polymers during doping synthesis might facilitate 
loading of more lanthanides into the iron crystal lattice. However, it is not fully demonstrated 
by the authors, how the fluorescence originating from Ln-USPIO could be efficiently used for 
optical imaging purposes both at the in vitro and in vivo levels
[190]
.  In addition, Ln-USPIO 
could also be synthesized in organic phase which involves many steps and yields highly 
mono-dispersed magnetic crystals
[191]
. Inspite of their excellent physico-chemical properties, 
they do suffer from loss of fluorescence from lanthanides and from change in the magnetic 
properties compared to undoped magnetites. To increase the stability of the Ln-USPIO, and 
to prevent the leaching of the lanthanides from the crystal lattice of magnetites, they were 
further coated with either 3-aminopropyl trimethoxysilane (APTMS) or tetraethyl 
orthosilicate (TEOS) or via mixed coating of APTMS and TEOS in organic phase 
respectively. One of the main advantages of having magnetic nanoparticle surface covered 
with silica is the availability of free surface silanol groups that could react with coupling 
agents covalently in order to attach the target specific ligands
[192;193]
. For example, amine 
groups have been introduced on the surface of silica-coated magnetite nanoparticles by 
hydrolysis and condensation of an organosilane such as APTES (3-aminopropyl triethoxy 
silane), which facilitates further functionalization with biomolecules
[194-196]
.  
Prior to in vitro evaluation, the total iron concentration of APTMS coated Ln-USPIO 
was determined using ICP-MS. The results clearly indicated the drop in the iron 
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concentration after silica coating of non-doped magnetite synthesized using different base 
concentration (Table 2.1.3) in comparison to the uncoated ones as shown in Table 2.1.1. The 
drop in iron concentration may be attributed to loss of magnetic nanoparticles during the 
work up due to their extensive exchange between aqueous and organic phase.  Contrarily, the 
total iron concentration of Eu-doped magnetic fluid synthesized using 1.5 M NaOH remained 
unchanged before and after silane coating.  
The TEOS coating of the magnetic nanoparticles leaves free silanol groups, which 
could be used for further conjugation with biomolecules. These silanol groups were generated 
in situ through the hydrolysis and condensation reaction of the TEOS that occurs on the  
nanoparticles surface
[197-199]
. Further, the silica-coated magnetic particles were coated with 
APTMS to introduce stability as well as free amino groups that might enable further 
functionalization with biomolecules or fluorescent dyes (Figure 2.1.2). Silica coating of Ln-
USPIO with TEOS and APTMS does not solve the problem of lanthanides leaching from the 
iron crystal lattice. Further, silica coating could also be influenced by different parameters 
like change in pH, solvents/solutions, temperature, stirring speed etc. Therefore, these 
paramaters have to be carefully tuned and checked in order to achieve a protective thin layer 
of silane coating respectively. 
 
Table 2.1.2. Different types of generated lanthanides (Eu, Gd, Tb) doped USPIO coated with silane were listed 
in this table.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fe molar 
percentage 
(%) 
Lanthanides Molar percentage (%) 
Eu (III) Gd (III) Tb (III) 
95 5 - - 
95 - 5 - 
95 - - 5 
90 - 5 5 
98 - 2 - 
98 - - 2 
96 - 2 2 
96 2 2 - 
96 - 2 2 
85 15 - - 
80 20 - - 
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Table 2.1.3. Total iron concentration of silica coated and Ln-USPIO (coated and silica uncoted) as determined 
by ICP-MS. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.1.2.  Schematic diagram of mixed silane coating (TEOS and APTMS) achieved for lanthanide 
(Eu,Gd,Tb)doped iron oxide nanoparticle.  
 
No. Base 
Iron cores 
(coated/uncoated) 
Elements in the 
sample 
Total iron 
concentration 
mg/mL 
1. 
1.5 M 
NaOH 
coated Fe,C,N,Si,O,H 1.575 
2. 
0.5 M 
NaOH 
coated Fe,C,N,Si,O,H 1.363 
3. 
1.0 M 
NaOH 
coated Fe,C,N,Si,O,H 2.619 
4. 
 
5. 
 
1.5 M 
NaOH 
1.5 M 
NaOH 
 
uncoated 
 
coated 
Fe,O,Eu,H 
 
Fe,C,N,Si,Eu,O,H 
10.125 
 
3.404 
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2.6.1. Physico-chemical characterization of Ln-USPIO 
The physical and chemical properties of Ln-USPIO were evaluated using TEM, 
powder XRD, fluorescence spectroscopy and ICP-OES techniques. Further evaluation of Ln-
USPIO was not performed due to lack of plausible imaging properties (fluorescence and high 
magnetization) that are suitable for in vivo MR and optical imaging techniques. 
TEM measurements indicated that there is difference observed in core diameters of 
Eu-doped magnetic nanoparticles synthesized by using different base concentration (0.5 and 
1.5 M NaOH) respectively. TEM measurements of 5% Eu-doped USPIO coated with 
APTMS showed spherical nanoparticles with an average core diameters of 7.78 ± 1.35 nm 
(0.5 M NaOH) and 10.46 ± 1.41 nm (1.5 M NaOH) respectively (Figure 2.1.3A, 2.1.3B). In 
addition, TEM measurements of USPIO prepared by using base at different concentration and 
coated with APTMS also displayed spherical nanoparticles with an average core diameters of 
12.73 ± 2.47 nm (0.5 M NaOH); 14.86 ± 2.79 nm (1.0 M NaOH); and 10.46 ± 1.81 nm (1.5 
M NaOH) as shown in Figure 2.1.3C, 2.1.3E, 2.1.3D. TEM measurements of USPIO (0.5 M 
NaOH) coated with mixed silanes (APTMS and TEOS) displayed a mean core diameter of 
10.35 ± 1.74 nm (Figure 2.1.3F). On comparing the core diameters of the doped nanoparticles 
with the non-doped ones, one could clearly visualize that lanthanide doping does not 
influence the overall mean core diameter of the nanoparticles. However, in contrast to the 
nanoparticles prepared by using 0.5 M NaOH, there are notable discrepancies over the mean 
diameter of the doped with the non-doped ones, which could be attributed to the problems 
associated with the synthesis strategy and size analysis.  
The crystallinity and chemical composition of 2% Gd-doped USPIO coated with 
TEOS was measured using powder XRD technique. These measurements indicated that the 
nanoparticles are crystalline with low amounts of amorphous constituents (Figure 2.1.4). The 
diffraction patterns of doped nanoparticles coated with TEOS are in close agreement with the 
diffraction patterns reported for the magnetite, which clearly indicated that the lanthanide 
(Gd) incorporation into the crystal lattice is relatively low and it does not alter the crystal 
lattice of the magnetite.  
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Figure 2.1.3. TEM images of 5% Eu-doped USPIO synthesized using 0.5 M NaOH and coated with APTMS 
(A); 5% Eu-doped USPIO (1.5 M NaOH) coated with APTMS (B); USPIO (0.5 M NaOH) coated with APTMS 
(C); USPIO (1.5 M NaOH) coated with APTMS (D); USPIO (1.0 M NaOH) coated with APTMS (E) and 
USPIO (0.5 M NaOH) coated with APTMS and TEOS (F) respectively. 
 
 
 
Figure 2.1.4. Powder X-ray diffraction pattern of 2% Gd doped USPIO coated with TEOS. 
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           To generate fluorescence from the lanthanide, inside the Ln-USPIO nanoparticles, 
they were coated with aromatic molecules such as naphthalene sulfonates, which could act as 
an antenna in transferring the energy to the lanthanides. To this end, ANDS and H-acid (as 
ligands for antenna effect) are used for coating the lanthanide doped magnetic cores. 
Unfortunately, the anticipated energy transfer did not occur between the coated naphthalene 
sulfonates and the doped lanthanides due to relatively large difference between the emission 
wavelength of aromatic moieties and the excitation wavelength of lanthanides. Therefore, the 
naphthalene‟s failed to act as antenna´s in transferring energy to the lanthanides as  shown via 
the absorption and fluorescence spectroscopy of 20% Eu-doped USPIO coated with ANDS 
(Figure 2.1.5A and 2.1.5B) and H-acid (Figure 2.1.5C and 2.1.5D) respectively. The spectra 
in Figure 2.1.5 clearly indicated that the absorption and emission originated only from the 
naphthalene sulfonates, which were coated over the Ln-USPIO despite of being loaded with 
lanthanides.  Further, coating trials should be performed with a fluorophore which could 
spectrally overlap with lanthanide´s absorption respectively. 
 
 
Figure 2.1.5. Absorption and fluorescence spectra of the magnetofluorescent nanoparticles in water. Absorption 
spectrum of 20% Eu-doped USPIO coated with ANDS (A); fluorescence spectrum of 20% Eu-doped USPIO 
coated with ANDS (B); absorption spectrum of 20% Eu-doped USPIO coated with H-acid (C); and fluorescence 
spectrum of 20% Eu-doped USPIO coated with H-acid. 
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The amount of lanthanide doped inside the crystal lattice of the iron oxide 
nanoparticles was measured by ICP-OES. These measurements explicitly showed that only 
very low percentage of lanthanides (Eu, Gd, Tb) were incorporated inside the core of the 
nanoparticles (Table 2.1.4). These observations are in line with reports that claimed low 
percentage of doped lanthanide inside the metallic nanoparticles
[189]
.   
 
Table 2.1.4. Weight percentage of lanthanides (Eu, Gd, Tb) in Ln-USPIO coated with silane as determined by 
ICP-OES. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the lack of anticipated fluorescence and low loading of lanthanides in Ln-
USPIO, these nanoparticles could not be employed as an ideal candidate for multimodal 
imaging techniques. In spite of different experimental trials in increasing the percentage of 
doped lanthanides in the iron nanoparticles, we were unable to develop a promising 
multimodal nanoparticle formulation that facilitates the bio-medical application. Therefore, 
the focus of the work was shifted in search of new molecules and iron nanoparticles 
(monodispersed) for generating the magnetofluorescent nanoparticles respectively. 
 
 
Sample 
Fe weight 
percentage 
(%) 
Si weight 
percentage 
(%) 
Eu weight 
percentage 
(%) 
Gd weight 
percentage 
(%) 
Tb weight 
percentage 
(%) 
5 % Eu-
USPIO-
APTMS 
2.736 ± 
0.018 
0.103 ± 
0.001 
0.024 ± 
0.0002 
- - 
5% Gd-
USPIO-
APTMS-
TEOS 
5.942 ± 
0.030 
0.304 ± 
0.002 
- 
0.011 ± 
0.0004 
- 
5% Tb-
USPIO-
APTMS-
USPIO 
4.983 ± 
0.044 
0.194 ± 
0.001 
- - 
0.009 ± 
0.0004 
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2.7. Magnetofluorescent nanoparticles via dye conjugation (APTMS USPIO) 
 
Figure 2.1.6. Chemical structures of different dyes conjugated to APTMS-USPIO. (A) 5-carboxy fluorescein 
diacetate-N-succinimidyl ester; (B) Fluorescein isothiocyanate (FITC) and (C) Rhodamine B-isothiocyanate 
(RITC) respectively.   
The amino group available in the silane (APTMS) coated USPIO were conjugated to 
the fluorophores (FITC, RITC etc.) either through activated carboxylic groups (succinimidyl 
ester) (Figure 2.1.6A) or via isothiocyanate groups (Figure 2.1.6B, 2.1.6C). The conjugation 
of 5-carboxy fluorescein diacetate-N-succinimidyl ester occurs only under basic reaction 
conditions. The dye conjugation was achieved by incubation at low temperature in the dark 
respectively.  The excess of unreacted dye was removed through dialysis against water at low 
temperature for 2 days. The fluorescence microscopy and spectroscopy techniques revealed 
reasonable fluorescence intensity for FITC and RITC nanoparticles (see appendices section). 
However, these nanoparticles suffered from low stability due to agglomeration, which could 
be attributed to the DMSO that was used to dissolve the fluorophores induces agglomeration 
on admixing with aqueous USPIO solution. In addition, the APTMS-USPIO was conjugated 
to biomolecules like streptavidin via well known glutaraldehyde conjugation techniques. 
Further, the FITC-labeled biotin (bio-FITC) was conjugated to the streptavidin functionalized 
nanoparticles at low temperature in the dark. The excess bio-FITC dye was removed by 
extensive dialysis against water at low temperature which was frequently monitored using 
fluorescence spectroscopy. However, due to insufficient conjugation and silane coating, these 
nanoparticules were de-stabilized due to agglomeration after storing them for extended period 
of time. Although, these conjugation techniques generated promising multimodal contrast 
agents for MR and optical imaging, these systems did not show stability under physiological 
conditions which paves way for further rigorous experiments. 
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2.8. Synthesis of NUSPIO nanoparticles 
Due to the failure of Ln-USPIO in creating fluorescence suited for optical imaging, 
the second synthesis strategy for generating multimodal contrast agents was focused on non-
polymeric coatings, which could be achieved via biocompatible naphthalene sulfonates 
respectively. Naphthalene USPIO (NUSPIO) nanoparticles were synthesized by coating 
USPIO with the non-polymeric molecules (ANDS and H-acid) to achieve a thin layer of 
coating at ambient temperature.  After incubation, the modified USPIO was purified either by 
dialysis or by resin exchange technique.  
NUSPIO were prepared using H-acid (80 mmoles/mL) and USPIO (10 mg/mL, pH 2) 
by incubation for 1h at ambient temperature
[226]
.  Purification of the NUSPIO was performed 
using cellulose ester dialysis membrane with 10/100 kD molecular weight cut off or by using 
visking membrane (dialysis) with similar molecular weight cut off. Excess of uncoated H-
acid was removed by dialysing NUSPIO against water at 4 °C. Slight reddish brown color 
originating due to the diffusion of unreacted H-acid into the water is observed after dialysing 
NUSPIO for 2-3 h. The dialysing water was replaced for every 4 h in order to facilitate 
removal of excess H-acid from NUSPIO which was often monitored using fluorescence 
spectroscopy. The final pH of the NUSPIO remains acidic (pH 4-5) after dialysis against 
water for 2-3 days. In order to increase their stability under physiological conditions which 
facilitate the in vitro and in vivo applications, NUSPIO were dialysed against solutions and 
buffers (pH 7) at low temperature (4 °C).  
Resin exchange technique is also employed for the purification of NUSPIO by gliding 
them through the activated acidic resin and subsequently washed with water (several times) 
to remove the unreacted H-acid respectively. The resulting resin exchanged nanoparticles 
displayed pH 4 and further it was glided through the activated basic resin for neutralization. 
The total iron concentration of the NUSPIO was low after passing through the basic resin and 
further, due to washing several times with water. The NUSPIO after exchange with basic 
resin resulted only in agglomerated nanoparticles, which could be attributed to the acidic 
nature of H-acid which strongly interacts with the basic resin thus leading to the shearing of 
the coating from the surface of the nanoparticles. However, dialysing the NUSPIO against 
water at low temperature and further exchanging them with basic resin generated 
nanoparticles with reasonable stability. The NUSPIO displayed stability in buffers (HEPES, 
MES, MOPS), dextran, glucose solutions and in cell culture media respectively. NUSPIO 
displayed agglomeration when dialysed against PBS buffer and 0.15 M NaCl solution. 
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2.8.1. Physico-chemical characterization of NUSPIO 
The physical and chemical properties of NUSPIO were evaluated using TEM, MRI, 
DLS, powder XRD, FT-IR, Raman, UV-Vis, fluorescence spectroscopy and cyclic 
voltammetry. The most relevant physical-chemical characterization results of NUSPIO 
required for the evaluation of its imaging properties (characteristics) are presented in this 
section.  
NUSPIO were generated by coating the iron oxide nanoparticles with a thin layer of 
monomeric organic biocompatible molecules. These molecules attach to the iron oxide 
nanoparticles based on their fixation site i.e. phosphonates, phosphonic acids, sulfonic acids, 
carboxylic acids etc. The Figure 2.1.7 shows a binding mode of H-acid via two sulphonic 
acid groups to the iron oxide nanoparticles.  
 
 
 
Figure 2.1.7. Schematic diagram shows the USPIO coated with non-polymeric H-acid respectively. 
 
 
TEM measurements of NUSPIO indicated spherical morphology with low 
aggregation and displayed a significant change in the diameters of NUSPIO, prepared using 
different purification methods (dialysis and resin exchange technique) respectively. The 
anticipated core diameter for uncoated USPIO was about 10 - 15 nm. The core diameters of 
the NUSPIO generated by H-acid coating purified by dialysis against water and neutralized 
by PBS/0.15 M NaCl solution were 23.75 ± 5.93 nm and 19.11 ± 3.93 nm respectively 
(Figure 2.1.8A, 2.1.8B). The size of the nanoparticles after dialysis with PBS/NaCl increased 
due to anticipated agglomeration that occurred due to high concentration of phosphate anions 
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(PBS) and high ionic strength (NaCl). These observations might be attributed to the strong 
interaction of phosphate anions with USPIO compared to the naphthalene sulfonates (H-
acid).  Whereas, the core diameter of the NUSPIO generated by dialysis against water, and 
exchanged via basin resin for neutralization resulted in 12.51 ± 1.93 nm (Figure 2.1.8C). In 
addition, the average diameter of the iron oxide nanoparticles doped with 10% H-acid (pH 
~ 
5) dialysed against water indicated 10.08 ± 1.74 nm (Figure 2.1.8D) without showing any 
deviation from the expected mean diameter of the nanoparticles. Increase in pH (pH 7) of the 
H-acid-doped USPIO may lead to agglomeration and will result in increase in overall 
diameters of the nanoparticles. The stability of these nanoparticles could be increased without 
any agglomeration by dialysing against HEPES buffer (pH 7.2). 
 
 
 
Figure 2.1.8. TEM images of NUSPIO (H-acid) purified by different ways: (A) dialysed against water and PBS; 
(B) dialysed against water and NaCl solution (0.15 M); (C) dialysed against water and neutralized by exchange 
with basic resin (amberlite IRA 95); and (D) USPIO doped with 10% H-acid and dialysed against water. All 
dialysis procedures were carried out at low temperature. 
 
 
Dynamic light scattering (DLS) results of NUSPIO (H-acid) purified by dialysis 
against water and neutralized by different buffers are shown in Figure 2.1.9. Nanoparticles 
with low hydrodynamic diameter (Dh)  was reported to foster reasonable pharmacokinetic 
characteristics thus facilitating their intended in vivo application
[200]
.  The Dh of 10% H-acid 
doped USPIO after dialysis against water displayed few micrometers (~2 µm; Figure 2.1.9A). 
The large Dh could be attributed to the agglomeration that occurred due to lack of protective 
coating for the iron oxide nanoparticles. NUSPIO after dialysis against water and HEPES 
buffer exhibited a mean Dh around 300 nm (Figure 2.1.9B). However, NUSPIO prepared 
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after purification by dialysis against water and neutralized by 0.15 M NaCl, and PBS buffer 
showed mean Dh of 600 nm (Figure 2.1.9C) and 1 µm (Figure 2.1.9E) respectively. In 
addition, NUSPIO purified by dialysis against water and neutralized by exchanging them 
with basic resin displayed mean Dh of about 300 nm with an additional size distribution at 1 
µm (Figure 2.1.9D). These Dh results clearly show that NUSPIO agglomerates heavily in the 
PBS buffer and in addition, the role of basic resin in removing excess H-acid is questionable 
due to their inefficiency in discriminating the monodispersed nanoparticles fraction from 
their agglomerated counterparts. The NUSPIO prepared by dialysis against water and 
neutralized by NaCl solution displayed a large Dh due to high concentration of salts that 
induce agglomeration. The commercially available USPIO (EMG 911) with 10 nm core 
diameter, dispersible in toluene were used as control nanoparticles (as gold standard) for 
evaluating the characteristics of NUSPIO. The H-acid coating of EMG 911 was achieved in 3 
days by using two phase (aqueous and organic) system and purified by dialysis against water 
at low temperature. The H-acid coated EMG 911 indicated Dh around 50 nm (Figure 2.1.9F). 
The two phase reaction system between H-acid and EMG 911suffered from slow reaction and 
low reaction yield due to the insufficient interaction of H-acid with the surfactant covered 
EMG 911 surface respectively. 
 
 
 
Figure 2.1.9. Hydrodynamic size analysis (DLS) of NUSPIO (H-acid) and purified by different methods 
(dialysis and resin exchange technique): A-F: (A) USPIO doped with 10% H-acid and dialysed against water; 
(B) dialysed against water and HEPES buffer; (C) dialysed against water and 0.15 M NaCl solution; (D) 
dialysed against water and neutralized by exchange with basic resin (amberlite IRA 95);  (E) dialysed against 
water and PBS buffer; and (F)  EMG 911 coated with H-acid and purified by dialysis against water. 
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The crystal structure of the NUSPIO purified by dialysis against water was confirmed 
by powder XRD measurements. These XRD results indicated that NUSPIO are crystalline 
with negligible amounts of amorphous constituents (Figure 2.2.0), which was in close 
agreement with the reported diffraction patterns emerging from the crystal structure of 
magnetite. However, as expected additional peaks with very low intensities related to the 
diffraction patterns of haematite are also found in Figure 2.2.0, which could be attributed to 
the discrepancies arising due to the utilized synthesis strategy (co-precipitation).     
 
 
 
Figure 2.2.0. Powder diffraction pattern of NUSPIO (H-acid) purified by dialysis against water at low 
temperature. 
 
The MR relaxivity measurements of the NUSPIO were performed in buffers (HEPES, 
PBS) or in de-ionized water at RT using a clinical MR scanner (Siemens Symphony, 1.5 T). 
The high relaxivities and contrast enhancement of iron oxide nanoparticles obtained in MRI 
are highly dependent on the crystalline nature of the iron cores respectively
[201;202]
. In line 
with this, the NUSPIO purified by dialysis against water and HEPES buffer displayed high 
relaxivity values with r2 = 138.12 ± 4.25 s
-1
mM
-1
 and r1 = 1.0058 ± 0.45 s
-1
mM
-1 
respectively 
(Figure 2.2.1A). These NUSPIO neutralized by HEPES buffer displayed stability and 
exhibited high T2 relaxation times without showing any visible agglomeration under the 
influence of the external magnetic field of (1.5 T). The relaxivity values of NUSPIO purified 
by dialysis against water and PBS buffer were r2 = 81.99 ± 4.54 s
-1
mM
-1
 and r1 = 4.7917 ± 
0.42 s
-1
mM
-1 
(Figure 2.2.1B).  However, these NUSPIO stabilized by PBS buffer showed 
relatively low stability (high agglomeration) due to the shearing of the H-acid coating 
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because of their strong interaction of phosphate anions with the nanoparticle surface 
compared to the sulfonates. Therefore, the insufficient surface coverage of iron oxide 
nanoparticles by H-acid leads to observed low relaxivity values.  
 
 
 
 
 
  
 
Figure 2.2.1. MR relaxivity of NUSPIO (H-acid) purified by dialysis. A-B: dialysis against water and HEPES 
buffer (A); and dialysis against water and PBS buffer (B) respectively. 
 
 
Functional groups in H-acid and NUSPIO were characterized by using FT-IR 
spectroscopy [Perkin Elmer - Spectrum 100 FT-IR Spectrometer] using the KBr pellet 
technique with a resolution of 4 cm
-1
.  USPIO showed anticipated ν(Fe-O) bands at 562 and 
627 cm
-1
.  H-acid displayed unbound ν(S=O) bands at 1072 and 1090 cm-1; ν(S-O) band at 
869 cm
-1; ν(SO3
-
) asymmetric stretch bands at 1147,1167,1188 and 1221 cm
-1; and ν(SO3
-
) 
symmetric stretch band at 1030 cm
-1
 respectively (Figure 2.2.2A). The ν(S-O) band 
disappeared due to binding of H-acid in NUSPIO which indicated the binding of the sulfonate 
groups to the nanoparticles. The ν(S=O) band of H-acid in NUSPIO shifted to 1041 cm-1 and 
ν(SO3
-
) asymmetric stretch band shifted to 1183 cm
-1
.  Additionally, an intense broad band 
appeared at 575 cm
-1
 after binding of H-acid with USPIO (Figure 2.2.2B). 
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Figure 2.2.2. FT-IR spectra of (A) H-acid; and (B) NUSPIO (H-acid). 
 
 
 
The fluorescence properties of H-acid were evaluated using fluorescence 
spectroscopy. The fluorescence emission of H-acid in water occurred at 430 nm when excited 
at 340 nm or at 360 nm. The fluorescence spectroscopy results showed a red shift in the 
emission maxima of H-acid (416 to 430 nm) with increase in pH , which could be attributed 
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to the deprotonation of H-acid at alkaline pH (Figure 2.2.3A) and further due to the 
phototautomerization that occurs in the excited state
[203]
. Furthermore, under acidic 
conditions, H-acid exists in the protonated form and displayed a blue shift with decreased 
fluorescence intensity. Additionally, a peak at 380 nm with very low fluorescence intensity 
was also observed under acidic conditions (Figure 2.2.3A). 
 
 
 
Figure 2.2.3. Fluorescence emission spectra of H-acid shown in water. A-F: (A) H-acid in different pH  (pH 2 -
12) ; (B) different H-acid coating concentration (30 – 80 mmoles); (C) different H-acid concentration  (10-1 M to 
10
-6
 M) and (D) change in fluorescence of different naphthalene sulfonates and pyrene sulfonate after addition 
of Fe(II) and Fe(III) ions respectively. 
 
 
 
H-acid is known to exist in two forms (i.e. protonated and as zwitterions) in the 
excited state under acidic conditions or in neutral solution (pH 7)
[204]
. The fluorescence 
spectra of H-acid in water indicated an increase in the fluorescence intensity with increasing 
H-acid coating concentrations (30-80 mmoles) (Figure 2.2.3B). Further, the fluorescence 
emission maxima of H-acid under acidic conditions were red shifted (405 nm to 441 nm) 
with increase in concentration (10
-6
M to 10
-1
M) (Figure 2.2.3C).  The change in fluorescence 
of ANDS, H-acid, Naphthol blue black (Naph 3), 1-hydroxy-3,6-naphthalene disulfonic acid 
monosodium salt (Naph 4), 3-hydroxy-2.7-naphthalene disulfonic acid monosodium salt 
(Naph 5), Sodium 5-acetamido-4-hydroxy-3-(phenyldiazenyl) naphthalene-2,7-disulfonate 
(Naph 6), and pyrene trisulfonic acid after addition of aqueous solution of iron salts 
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(2Fe
3+
/Fe
2+
) was studied by fluorescence spectroscopy (Figure 2.2.3D).  Addition of iron salts 
to different naphthalene sulfonates and pyrene sulfonate resulted in the formation of 
coordination complexes that displayed distinct color with small change in fluorescence 
emission compared to free ligands (color, fluorescence) respectively. Further, ammonia 
addition to these complexes resulted in the generation of iron oxide nanoparticle via quick 
degradation of the coordination complexes (see appendices section for further fluorescence 
spectra). The fluorescence ability of USPIO (10 mg/mL) coated with ANDS and H-acid (80 
mmoles/mL) were evaluated using fluorescence microscopy. The NUSPIO coated with 
ANDS and purified by dialysis (water, PBS/HEPES buffer) displayed blue fluorescence 
under the fluorescence microscope. (see appendices section).  
 
2.8.2. In vitro results of NUSPIO 
The biocompatibility of NUSPIO was evaluated using different assays (TUNEL and 
LDH assays) and trypan blue staining. Further, the cellular uptake of NUSPIO was evaluated 
using fluorescence microscopy respectively. 
The cytotoxicity was evaluated using the TUNEL assay in which RPMI8226 cells 
were incubated with NUSPIO (H-acid) for 3 h. The TUNEL positive cells (apoptotic cells) 
were stained red by the TUNEL reagents and nuclei of the cells were stained blue with DAPI 
(Figure 2.2.4). The TUNEL positive and negative cells were counted using fluorescence 
microscope with 10X magnification by choosing five to six fields of view.  
 
 
 
Figure 2.2.4. Cytotoxicity of NUSPIO (H-acid) determined by using TUNEL assay. RPMI8226 cells incubated 
for 3 h with NUSPIO. A-F: (A) Medium; (B) TUNEL negative control; (C) TUNEL positive control; (D) 
NUSPIO (3.0 µmol/mL); (E) NUSPIO (0.3 µmol/mL); and (F) NUSPIO (0.03 µmol/mL). 
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Figure 2.2.5. Cytotoxicity of NUSPIO (H-acid) was evaluated using TUNEL assay and trypan blue staining.  
TUNEL assay was performed by incubating RPMI8226 cells for 3 h with NUSPIO (A); and Trypan blue 
staining was performed for RPMI8226 incubated with NUSPIO (3 h) (B) respectively. Data presented as mean ± 
SD (n=3). 
 
 
The relative cell viability of RPMI8226 cells (0.5 x 10
6
 cells) after treatment with 
NUSPIO (3h) were calculated relative to the total viable cells available in the medium control 
(treated as 100% cell viability). The assay was performed in triplicates. With increase in 
NUSPIO concentration from 0.03 µmol Fe/mL to 3.0 µmol Fe/mL, the cells did not show any 
relevant loss in cell viability and they also well tolerated the high dosage of NUSPIO (3.0 
µmol Fe/mL) (Figure 2.2.5A). The high viability exhibited by cells incubated with 3.0 µmol 
Fe/mL of NUSPIO compared to the control (medium) could be attributed to the error 
associated with cell counting under the fluorescence microscope.  
Cytotoxicity results from trypan blue staining of RPMI8226 cells (2 x 10
6
 cells) 
incubated with NUSPIO (3 h) revealed only a slight decrease in cell viability. The 
cytotoxicity results also indicated a direct correlation that prevailed between the cell viability 
and the NUSPIO concentration in the growth medium. With 3.0 µmol Fe/mL of NUSPIO 
there was a slight decrease in the cell viability compared to the control cells (medium) 
respectively (Figure 2.2.5B).  
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Figure 2.2.6. Cytotoxicity of NUSPIO (H-acid) evaluated using LDH assay in which RPMI8226 cells were 
incubated with NUSPIO for 6 hand 24 h in three different concentration (3.0, 0.3, 0.03 µmol Fe/mL) 
respectively.  
 
Additionally, the cytotoxicity induced by NUSPIO on RPMI8226 cells was studied 
using LDH assay. Here, RPMI8226 cells were incubated (6 h, 24 h) with NUSPIO (H-acid) 
purified by dialysis against water and neutralized by HEPES/PBS buffers in triplicates and at 
three different iron concentrations (3.0, 0.3, 0.03 µmol Fe/mL). The positive control was 
generated by lysing the cells using a lysis buffer. The cells without NUSPIO treatment served 
as a negative control.  The LDH assay indicated decreased cell viability with 3 µmol Fe/mL 
of NUSPIO after 6 h and 24 h incubation (Figure 2.2.6). Further, the decrease in viability of 
cells incubated with NUSPIO stabilized in HEPES buffer (3 µmol Fe/mL) compared to 
NUSPIO stabilized in PBS buffer could be attributed to low toxicity induced by HEPES in 
specific cell types (reported) or due to the error associated with the measurements that 
originated due to the interaction of NUSPIO in the medium and LDH at high concentrations. 
However, in the case of other NUSPIO concentration (0.3, 0.03 µmol Fe/mL) at different 
incubation times, there was no relevant loss in cell viability.  
The intracellular uptake of NUSPIO (ANDS) in PC-3 (prostate cancer) and MDA-
MB-231(breast cancer) was evaluated using fluorescence microscopy. Both cell types were 
incubated (3 h) in triplicates with medium (Figure 2.2.7A, 2.2.7D), ANDS (3 µmol/mL; 
Figure 2.2.7B, 2.2.7E) and NUSPIO (3 µmol Fe/mL; Figure 2.2.7C, 2.2.7F) respectively. The 
cells highly internalized ANDS which was shown by their blue fluorescence inside the two 
different cell types (2.2.7B and 2.2.7E) respectively. However, the cells did not show 
fluorescence (blue) from the NUSPIO (ANDS) which  could be attributed to quenching of 
ANDS fluorescence (ANDS excited state tautomerization and paramagnetic USPIO). 
Furthermore, the internalization of NUSPIO could be observed from Figure 2.2.7C and 
2.2.7F (images (bright field) without fluorescence overlay), which should be further 
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supported and validated using Prussian blue staining for internalized NUSPIO nanoparticles 
respectively.  
 
 
 
Figure 2.2.7. Cellular uptake studies of NUSPIO (ANDS) by PC-3 and MDA-MB-231 cells after 3 h studied 
using fluorescence microscopy. Bright field image of PC-3 cells incubated with medium (A); fluorescence 
image of PC-3 incubated with ANDS (3.0 µmol/mL) B-C: fluorescence image of PC-3 incubated with ANDS 
(3.0 µmol/mL) (B) and NUSPIO (3.0 µmol Fe/mL). Bright field image of MDA-MB-231 incubated with 
medium (D); E-F: fluorescence image of MDA-MB-231 incubated with ANDS (3.0 µmol/mL) (D) and 
NUSPIO (3.0 µmol/mL) (E) respectively. 
 
2.9. USPIO coated with different naphthalene sulfonates  
USPIO (2 mg/mL) were coated with different naphthalene sulfonates (30,40,50 
mmol/mL) like sodium 4-hydroxy-5-oleamido-7-sulfonaphthalene-2-sulfonate (compound 
10), potassium 7-oleamido-3-sulfonaphthalene-1-sulfonate (compound 11), potassium (s)-7-
(2-amino-3-(1H-indol-3-yl)propanamido)-3-sulfonaphthalene-1-sulfonate (compound 9), 1-
(6-hydroxy-2-naphthoyloxy)ethane-1,1-diyldiphosphonic acid (compound 8), sodium 3,3-
(1´Z)-(4,4´-((E)-ethene-1,2-diyl)bis(4,1-phenylene))bis(diazene-2,1-diyl)bis(5-amino-4-
hydroxynaphthalene-2,7-disulfonate) (compound 5), sodium 3,3´-(1´Z)-(4,4´-((E)-ethene-1,2-
diyl)bis(3-sulfonato-4,1-phenylene))bis(diazene-2,1-diyl)bis(5-amino-4-hydroxynaphthalene-
2,7-disulfonate) (compound 6) by incubation for 1 h at ambient temperature. After 
incubation, the naphthalene sulfonates coated nanoparticles were purified by washing several 
times with water aided by a permanent magnet. NUSPIO synthesized using compound 10 and 
11 displayed a reasonable blue fluorescence, and exhibited a low degree of agglomeration 
respectively.  
However, NUSPIO synthesized by using compounds 5,6,8 and 9 for coating at 
different concentration did not show any fluorescence (because of the quenching that 
occurred due to the interaction of hybrid H-acid/ANDS moiety with the paramagnetic 
 82 
USPIO) and some of them were highly unstable due to strong agglomeration which 
originated from insufficient surface coverage of iron oxide nanoparticles.  
 
2.9.1. USPIO coated with new non-polymeric ligands  
In line with the previous non-polymeric coating strategy, USPIO were coated with 
some new ligands like 2-(6-hydroxy-2-napthamido)ethylphosphonic acid (compound 7), 4-
(4-((R)-hydroxy((2S,4S,8R)-8-vinylquinuclidin-2-yl)methyl-6-methoxyquinolinium-1-
yl)butane-1-sulfonate (compound 4), 4-(9-aminoacridinium-10-yl)butane-1-sulfonate 
(compound 3), thiamine monophosphonic acid (TMP), sodium 8-hydroxy-3,6-dihydropyrene-
1,3,6-trisulfonate by 1 h incubation at ambient temperature. After incubation, the 
nanoparticles were purified by removing the unreacted ligands via water washing guided by a 
permanent magnet. The sulfonates based non-polymeric ligand system did not provide 
nanoparticles with better coating and often resulted in quenching and agglomeration. 
Therefore, phosphonic acid based ligand system such as TMP was employed to achieve the 
coating for USPIO, which displayed sufficient fluorescence and reasonable stability under 
physiological conditions for few days (~3 days).  However, with increase in the storage time 
TMP coated USPIO resulted in agglomeration.  
In conclusion, NUSPIO prepared using ANDS displayed low fluorescence emission 
compared to NUSPIO prepared via H-acid (quenched fluorescence), which makes them 
unsuitable for MR and optical imaging. In spite of the enormous experimental work in 
generating NUSPIO with blue fluorescence, we were unable to develop a formulation which 
could ideally serve as an appropriate candidate for both imaging techniques. Therefore, the 
search for biocompatible ligands, which could be used for generating fluorescent, non-
polymeric coated monodispersed USPIO, was performed. 
 
2.10. Synthesis of FLUSPIO nanoparticles 
The first two synthesis strategies i.e. Ln-USPIO and NUSPIO, failed in generating 
magnetofluorescent nanoparticles suitable for cellular labeling and MR in vivo imaging. 
Therefore, the flavins received much attention as the coating molecules due to their 
characteristics such as biocompatibility, inherent fluorescence, phosphate groups and 
targeting ability respectively. These flavin (FMN) decorated USPIO were utilized as versatile 
MR contrast agent via more pronounced RCP targeting and designated as fluorescent USPIO 
(FLUSPIO) respectively. 
USPIO nanoparticles prepared by co-precipitation were coated with non-polymeric 
fluorescent FMN, which strongly binds to the iron oxide core via phosphate groups (Figure 
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2.2.8a). The FMN coating was achieved in aqueous solutions of USPIO and FMN (at pH 4) 
under sonication at ambient temperature. The coating of USPIO with FMN alone did not lead 
to an efficient and stable coverage of the entire nanoparticle surface, which might be due to 
steric hindrance caused by the isoalloxazine ring of FMN. Consequently, by visual inspection 
nanoparticle sediments were found indicating nanoparticle agglomeration. In addition, the 
nanoparticle surface should not be covered entirely with FMN due to the quenching of green 
fluorescence that occurs at high concentrations. GMP is less bulky and contains a phosphate 
group (similar to that of FMN), which strongly chemisorbs to the iron oxide surface during 
the non-polymeric coating. Both, FMN and GMP are negatively charged molecules and their 
binding to USPIO results in a negative surface charge of FLUSPIO at pH 7.0, thus providing 
colloidal stabilization. Therefore, the addition of GMP was necessary to stabilize the colloidal 
suspension and to complete the surface coverage. Furthermore, GMP also allows for further 
functionalization with biomolecules (peptides, antibodies etc.) using standard conjugation 
techniques via the amine group available in the guanine moiety. 
 
2.10.1. Physico-chemical characterization results of FLUSPIO 
 The physical and chemical characteristics of generated FLUSPIO were evaluated 
using different techniques such as transmission electron microscopy (TEM), scanning 
electron microscopy (SEM), atomic force microscopy (AFM), dynamic light scattering 
(DLS), powder X-ray diffraction (XRD), superconducting quantum interface device 
(SQUID), thermogravimetric analysis (TGA), energy dispersive X-ray absorption (EDX), 
fluorescence spectroscopy, fourier transform infrared spectroscopy (FT-IR), magnetic 
resonance imaging (MRI), time of flight secondary ion mass spectrometry (TOF-SIMS), X-
ray photoelectron spectroscopy (XPS), fluorescence quantum yield. Characterization results 
from AFM. XPS, quantum yield, TOF-SIMS, powder XRD are presented in the appendices 
section. 
Transmission electron microscopy (TEM), dynamic light scattering (DLS) and 
scanning electron microscopy (SEM) were used to characterize the FLUSPIO. TEM analysis 
of USPIO, and FLUSPIO showed nanoparticles with an average iron core diameter of 5 ± 1 
nm (Table 2.1.5 and Figure 2.2.8b-c). SEM was used to study the surface morphology of the 
nanoparticles. SEM images of USPIO and FLUSPIO confirmed the spherical surface 
morphology, with an average particle diameter of 23.19 ± 4.62 nm (USPIO) and 27.76 ± 4.76 
nm (FLUSPIO) (Figure 2.2.8d-e). The increase in size observed in SEM could be attributed 
to the clustering of the nanoparticles that occurs due to drying and/or to the conductive layer 
of sputtered gold on the nanoparticles surface. The thin layer of non-polymeric coating yields 
nanoparticles with a low hydrodynamic diameter (Dh) which enhances the uptake of 
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nanoparticles into tissues
[226]
. The FLUSPIO in HEPES buffer showed an average (Dh) of 97 
± 3 nm with a low polydispersity index (PDI) of 0.16. The broad average Dh, which can be 
observed in Figure 2.3.2a-b, is an average of several runs, which displayed similar Dh with 
comparable PDI values. The increase in average Dh of FLUSPIO in HEPES buffer may 
derive from the hydration shell and could be further increased by minor agglomeration which 
arises from the tendency of smaller iron cores to form clusters, which are not sterically 
stabilized by FMN and GMP. However, these DLS results of FLUSPIO are in line with the 
characteristics of clinically approved/used MR contrast agent Resovist (4 nm core size), 
which displayed Dh around ~60 nm. In comparison to FLUSPIO, USPIO, show stability only 
at pH 2 without any surface coverage with coating molecules, and displayed a large Dh with a 
broad size distribution at pH 7 (252 ± 66 nm), due to aggregation between the iron cores at 
increasing pH (Table 2.1.5 and Figure 2.3.2a-b).  
 
 
 
Figure 2.2.8. Preparation of FLUSPIO. a: Schematic diagram showing the mode of binding of FMN and GMP 
to the iron oxide cores in FLUSPIO. b-c: TEM images of USPIO (b) and FLUSPIO (c). Quantitative analysis of 
the images reveals that both types of nanoparticles have a core diameter of 5±1 nm and a narrow size 
distribution. d-e: SEM images of USPIO (d) and (e) FLUSPIO, displayed spherical morphology. Quantitative 
analysis indicated an average diameter of 23±4 nm (USPIO) and 27±4 nm (FLUSPIO) respectively.   
 
 Zeta potential measurements were performed to determine the surface charge, 
electrophoretic mobility and colloidal stability of the USPIO and FLUSPIO particles at pH 2, 
7 and 13 (Table 2.1.5). Under acidic conditions, USPIO had a positive zeta potential due to 
their highly protonated surface hydroxyl and oxygen groups. USPIO agglomerated 
immediately in PBS buffer and saline solution (0.9% NaCl). A negative zeta potential was 
observed for FLUSPIO, which fosters for colloidal stability of the nanoparticles at neutral pH 
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and usually leads to better pharmacokinetic properties. FLUSPIO were stable in physiological 
pH in water, HEPES buffer and in 5% glucose solution. However, after 15 min, aggregation 
was observed in PBS buffer and saline solution (0.9% NaCl) by visual inspection, likely 
because of the high ion concentrations and electrostatic interactions. No aggregation was 
found in cell culture media, most probably due to colloidal stabilization of FLUSPIO by 
serum proteins (Figure 2.2.9). 
 
Table 2.1.5.  Physico-chemical characterization results of USPIO and FLUSPIO 
 
 [a]   Size of polycrystalline iron oxide with multiple single crystals and its reported relaxivity values
[205]
 [b]  
Hydrodynamic diameter of Resovist in water and its approximate zeta potential at pH 7 [c]  Relaxivity of 
USPIO at pH 7 could not be determined because of aggregation and susceptibility artefacts. 
 
The stability of FLUSPIO in different cell culture media and physiological solutions 
(HEPES, saline, PBS) were evaluated merely by visual inspection. To this end, FLUSPIO 
were diluted in RPMI (Figure 2.2.9A) and McCoy‟s cell culture media (Figure 2.2.9B), both 
supplemented with 10% FBS, 5% glucose solution (Figure 2.2.9C), 25 mM HEPES buffer 
pH 7.2 (Figure 2.2.9D), saline solution (0.9%) (Figure 2.2.9E), and PBS buffer (Figure 
2.2.9F) to reach a final concentration of 3.0 µmol Fe/mL, respectively. Photographs were 
taken after filling the suspensions into cuvettes at 0 min, 15 min, 1 h. In contrary to the 
agglomeration of FLUSPIO after 15 min in PBS buffer and saline (0.9% NaCl) solution, no 
visible aggregation was found within 1 h if FLUSPIO were incubated with one of the FBS 
enriched cell culture media. Similarly, FLUSPIO displayed reasonable stability in HEPES 
buffer without any visible agglomeration respectively.  
 
Sample 
TEM 
diameter 
[nm] 
Hydrodynamic 
diameter [nm] 
Zeta potential in different pH solutions [mV] MR Relaxivities at 3T in 
water  
HEPES buffer pH 2 pH 7 pH 13 r2[s-1mM-1] r1[s-1mM-1] 
USPIO 5.5 ± 1.1 252 ± 66 32.83 ± 1.53 18.93 ± 2.46  –0.01 ± 0.03 n.d[c]. n.d[c]. 
FLUSPIO 5.6 ± 1.7 97 ± 3 4.59 ± 2.48  –31.13 ± 1.70  –31.70 ± 2.76 202.64 ± 0.48 2.13 ± 0.04 
Resovist 4.2[a] 45.87 ± 0.09[b]  n.d.   -34.36 ± 2.30   n.d. 221.11 ± 0.61 5.21 ± 1.40 
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Figure 2.2.9. Photographs of FLUSPIO in RPMI cell culture medium (A), McCoy‟s cell culture medium (B), 
5% glucose solution (C), HEPES buffer (D), saline solution (E), and PBS buffer (F) after 0 min, 15 min, 1 h 
respectively. 
 
X-ray powder diffraction (XRD) analysis was used to determine the chemical 
composition and crystalline of the FLUSPIO.  The XRD patterns of FLUSPIO could be 
assigned to (220), (311), (400), (422), (511), and (440) reflections of the spinal structure of 
magnetite (JCPDS No. 19-0629) (Figure 2.3.0). The observed diffraction peaks of generated 
USPIO are consistent with the expected diffraction patterns of Fe3O4. These peaks are also 
present in FLUSPIO, together with three other diffraction peaks. The additional peaks in 
FLUSPIO diffract gram at approximately 23.4 and 27.6° (2θ) are broad and are thus due to a 
material with low crystallite size, whereas the third additional peak at approximately 31.8° 
(2θ is sharp which is due to a material with larger crystallite size). The crystalline nature of 
their iron cores explains the high relaxivities of FLUSPIO found in MRI experiments. 
Fourier-transform infrared  (FTIR) spectroscopy confirmed the binding of FMN and GMP 
phosphate groups to nanoparticles, and this was validated by comparing the spectra of free 
FMN and GMP and unmodified USPIO (Figure 2.3.2c). The chemical composition of the 
surface (concentration of FMN, GMP) was analyzed by energy-dispersive X-ray 
spectroscopy (EDX), Vaskovsky phosphate determination, elemental analysis and 
thermogravimetry (TGA).  As expected from the theoretically calculated ratio of phosphate to 
iron, the Fe:P ratio of the fluorescent nanoparticles determined by EDX was 1:0.231. This 
was further supported by the Vaskovsky phosphate determination (Table 2.1.6) and elemental 
analysis. Elemental analysis (C/H/N) revealed C 14.80%, H 2.65% and N 4.47% by weight 
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(expected C 13.45%, H 1.43% and N 4.55%) for FLUSPIO. TGA of the FLUSPIO showed a 
weight loss of 24% when heated to 600 ºC (Figure 2.3.1). This account for the decomposition 
of the surface coating (FMN and GMP), as well as for the dehydration of the inorganic matrix 
(theoretically calculated weight loss: 23 %).  
 
 
 
Figure 2.3.0. X-ray diffraction patterns of (a) USPIO and (b) fluorescent USPIO nanoparticles (FLUSPIO) 
 
 
Table 2.1.6. Total phosphate content deriving from the non-polymeric molecules (FMN and GMP) on the 
surface of FLUSPIO. 
 
 
 
 
 
 
Sample Iron amount (µg) 
Phosphorous amount  
(µg) 
Fe:P ratio 
FLUSPIO 223.38 45.28 1:0.203 
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Figure 2.3.1. TGA curves of (a) FMN (b) FLUSPIO respectively. 
 
Fourier-transform infrared  (FTIR) spectroscopy confirmed the binding of FMN and 
GMP phosphate groups to the nanoparticles, which was validated by comparing the spectra of 
free FMN,GMP and unmodified USPIO (Figure 2.3.2c). Functional groups in FMN, GMP 
and USPIO were characterized by FT-IR spectroscopy (with 4 cm
-1 
resolution) of the KBr 
pellets.  USPIO showed ν(Fe-O) bands at 562 and 627 cm-1.  FMN displayed unbound 
ν(P=O) band at 1181 cm-1 and ν(P-OR) bands at 927, 983 and 1045 cm-1.  For GMP free 
ν(P=O) bands occur at 1120 and 1180 cm-1 and ν(P-OR) bands occur at 905, 937 and 974  
cm
-1. The ν(P=O) band disappeared due to binding of FMN and GMP in FLUSPIO which 
indicates binding of the phosphate groups to the nanoparticles. The ν(P-OR) band of FMN in 
FLUSPIO shifted to 994 and 1090 cm
-1
. 
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Figure 2.3.2.  Physico-chemical characterization of FLUSPIO. DLS analysis of (a) USPIO and (b) FLUSPIO. 
(c). FT-IR spectra of FLUSPIO with reference to free FMN, GMP and uncoated USPIO. (d). T2-weighted MR 
images of FLUSPIO (50 – 0.005 µg) in comparison to Resovist in water. (e) Fluorescence emission spectrum of 
FLUSPIO at different concentration in water (0.5 x 10
-6
 M to 0.5 x 10
-10
 M Fe).  
 
2.10.1.1. Magnetic Properties of FLUSPIO 
The superparamagnetic behavior of the FLUSPIO was studied by SQUID 
magnetometry, at a constant temperature of 290 K and a field of ± 5 T. The magnetization vs 
field curve was compared to that of unmodified USPIO and showed the expected regular 
progression for superparamagnetic substances (Figure 2.3.3)
[177]
. The MR relaxivity of the 
FLUSPIO in de-ionized water at ambient temperature and at 3 T was found to be similar to 
that of the clinically used MR contrast agent Resovist (FLUSPIO: r2 = 202.64±0.48 s
-1
mM
-1
, 
Resovist: r2 = 221.11±0.61 s
-1
mM
-1
; Table 2.1.5 and Figure 2.3.2d), thereby confirming their 
excellent MR contrast enhancement properties.  
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Figure 2.3.3.  Magnetization versus applied field of FLUSPIO measured at T = 290 K (± 5 T) 
 
2.10.1.2. Fluorescence Properties of FLUSPIO 
Fluorescence spectroscopy and microscopy of the FLUSPIO revealed a high 
fluorescence intensity due to the photoluminescence of the FMN fluorophore associated with 
the nanoparticle surface
[206]
. The fluorescent nanoparticles can be excited in a wide 
wavelength range (250-500 nm), resulting in an intense green emission at 530 nm 
respectively (Figure 2.3.2e, 2.3.4 and 2.3.5). The absolute quantum yield without referring to 
a standard fluorophore was determined to elucidate the difference in quantum yield between 
free FMN and FMN on the FLUSPIO. Importantly, it was found that the association of FMN 
to the surface of the FLUSPIO did not affect the quantum efficiency of the dye (see 
appendices section). 
The absorbance spectrum of USPIO, FMN, FMN with GMP and FLUSPIO was 
recorded in water and various buffer solutions (data not shown) using TECAN Infinite M200 
(Tecan Austria GmbH) plate reader. The absorbance spectrum of FMN, FMN with GMP and 
FLUSPIO showed absorption peaks at 376 nm and 450 nm, respectively (Figure 2.3.4). After 
exposing them for 3 days to daylight, the absorption spectrum showed a peak maximum at 
358 nm and a shoulder at 468 nm without any significant change in the absorption intensity 
(Figure 2.3.4). 
The fluorescence of FLUSPIO was recorded in water and various buffer solutions 
(TRIS, TES, HEPES, sodium phosphate)(data not shown) at RT using the TECAN Infinite 
M200 (Tecan Austria GmbH) plate reader (iron concentration range: 10
-6
 M to 10
-12
 M). No 
change in the emission intensity of FMN was observed when mixed with GMP.  FMN was 
excited at 452 nm and 468 nm and its intense emission occurred at 530 nm. The FLUSPIO 
showed more intense fluorescence due to presence of huge amount of luminescent centres per 
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nanoparticle (fluorescence spectroscopy and microscopy). FMN and FLUSPIO were exposed 
to daylight for three days in order to study the effect of daylight on their emission intensity. 
After three days, only a moderate decrease of 40% in their emission intensity was found, 
which proves that FLUSPIO are sufficiently stable enough without photobleaching (Figure 
2.3.5).  
 
 
 
Figure 2.3.4. Absorption spectra of (a) FMN (no daylight exposure), (b) FMN (daylight exposure, three days), 
(c) FLUSPIO measured in water.  
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Figure 2.3.5. Fluorescence spectra of FMN in water with (a) no daylight exposure (b) daylight exposure (3 
days). Emission spectra of FLUSPIO in water with (c) daylight exposure (3 days) respectively. 
 
2.10.2. In vitro evaluation of FLUSPIO 
 After successful physico-chemical characterization, the biocompatibility of FLUSPIO 
was evaluated using different cytotoxicity assays and staining (staining: Trypan blue and 7-
AAD, assays: TUNEL and MTT, and direct cell counting). Further, the cellular labeling 
efficacy of FLUSPIO was studied using MRI, TEM, fluorescence microscopy and ICP-MS 
respectively. 
 
2.10.2.1. Cytotoxicity Assay 
The biocompatibility of the FLUSPIO was investigated using PC-3 cells (human 
prostate cancer cells) and HUVEC (as an example of activated endothelial cells). As shown 
in Figure 2.3.6 and 2.3.7, neither trypan blue staining nor TUNEL staining (common assays 
used for determining the cytotoxicity of iron oxide nanoparticles)
[207]
 indicated any 
significant change in cell viability at relevant cell labeling concentrations (i.e. up to 0.3 µmol 
Fe/mL). This observation was further confirmed by flow cytometry, in which 7-AAD (7-
amino actinomycin D) was used to label dead cells, suggesting that the FLUSPIO are highly 
biocompatible (Figure 2.3.8).  
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Figure 2.3.6. Relative viability of PC-3 cells determined by trypan blue staining after 24 h incubation with 
USPIO and FLUSPIO (0.3, 0.03 µmol Fe/mL) in the cell growth medium, respectively. 
 
 
 
 
Figure 2.3.7. Data from the TUNEL assay showing the percentage of viable cells after 3 h incubation: (a) PC-3 
cells, (b) HUVEC respectively. 
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Figure 2.3.8. Flow cytometry analysis of PC-3 cell viability after incubation with FLUSPIO (S1) in which dead 
cells were stained with the 7-AAD dye (FL3 (APC channel)). Negative controls (dot plot), on which gating was 
performed, were incubated with medium for 3h (a) and 24h (c). PC-3 cells incubated with different iron 
concentrations (3.0, 0.3, 0.03 µmol Fe/mL) of  FLUSPIO for 3h (b) and 24h (d) did not show any change in 
viability at cell labeling concentrations up to 0.3 µmol Fe/mL. In Figure (d) the peak from the positive control 
was shifted to the right respectively. 
 
2.10.2.2. Cellular Labeling and Competition (MRI and ICP-MS) 
Subsequently, the cellular labeling efficiency and the uptake of FLUSPIO were 
investigated by MRI (at 3.0 T). The cells were labeled with FLUSPIO, re-suspended in 10% 
gelatin (9 x 10
6
 cells/0.3 mL; 0.3 µmol Fe/mL, 30 min and 1 h) and the R2 relaxation rates 
were determined. PC-3 cells in gelatin showed a significantly higher R2 relaxation rate after 
1 h of incubation with FLUSPIO (5.08±1.44 s
-1
, p<0.001) than with USPIO (2.28±0.19 s
-1
), 
indicating a higher cellular uptake of FLUSPIO (similar R2 values for FLUSPIO were 
obtained after 30 min incubation). Furthermore, the specificity of FLUSPIO uptake was 
investigated via competitive blocking of RCP with free FMN
[208-210]
.  After the addition of 
free FMN to PC-3 cells and subsequent incubation with FLUSPIO for 30 min, the R2 
relaxation rate was significantly reduced (10-fold FMN competition; 4.33±0.70 s
-1
, p<0.05; 
100-fold FMN competition: 3.19±0.58 s
-1
, p<0.001; FLUSPIO incubation alone:  5.08±1.44 
s
-1
). Similar results were obtained when blocking RCP with free FMN for 1 h. In this case, 
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the corresponding R2 relaxation rates were 3.84±0.81 s
-1
 (10-fold FMN competition) and 
3.87±0.69 s
-1 
(100-fold FMN competition), respectively (Figure 2.3.9a-b).  The higher 
cellular uptake of FLUSPIO compared to USPIO and the capability of free FMN to block 
FLUSPIO internalization in PC-3 cells was confirmed by the quantification of the 
intracellular iron contents using inductively coupled plasma mass spectrometry (ICP-MS, 
Figure 2.3.9e, Table 2.1.7).  
In line with this, also HUVEC showed a significantly higher uptake of FLUSPIO (30 
min: 3.69±0.45 s
-1
, 1 h: 7.23±0.64 s
-1
) than of USPIO (30 min: 1.98±0.17 s
-1
,
 
1 h: 2.03±0.06 
s
-1
; Figure 2.3.9c-d). Competition experiments with free FMN confirmed the specificity of 
the RCP-mediated uptake of FLUSPIO in HUVEC. After RCP blocking by free FMN for 30 
min, the R2 relaxation rate of HUVEC was decreased with respect to FLUSPIO alone (100-
fold FMN competition: 1.73±0.07 s
-1
; 10-fold FMN competition: 1.95±0.18 s
-1
). Even after 1 
h of FLUSPIO incubation, the uptake was still significantly lower in presence of 10- 
(2.54±0.53 s
-1
) and 100-fold excess (1.60±0.12 s
-1
) of free FMN (Figure 2.3.9c-d). Together, 
these findings convincingly show that the RCP-mediated uptake of FLUSPIO by human 
prostate cancer cells (PC-3) and HUVEC is significantly higher than that of USPIO. 
The less pronounced reduction of the relaxation rates (R2) by 10-fold FMN 
competition in PC-3 cells in comparison to HUVEC is most probably related to the higher 
unspecific nanoparticle uptake in these cells in comparison to RCP-mediated FLUSPIO 
internalization (Figure 2.3.9f). To the best of our knowledge, the regulation of RCP 
expression is still unclear. However, with increase in metabolic activity, cells are expected to 
have a higher demand for Rf. The Rf uptake in cells is facilitated by RCP. The increased 
uptake of Rf (FLUSPIO) by metabolically active cells points to an up regulation of RCP 
expression. Thus, we hypothesize that the RCP expression level is linked to the metabolic 
activity of the cell. Unfortunately, the expression levels of RCP on the PC-3 and HUVEC cell 
surface could not be determined (and correlated to the MR findings) due to lack of a human 
RCP-binding antibody. 
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Figure 2.3.9. FLUSPIO uptake analyzed by means of MR and ICP-MS. a: R2 relaxation rates of PC-3 cells in 
gelatin (9.0 x10
6
 cells/0.3 mL) incubated with 0.3 µmol Fe/mL of USPIO, FLUSPIO and FLUSPIO plus free 
FMN (10- and 100-fold excess, for competition purposes) for different time intervals, i.e. 30 min (a) and 1 h (b). 
c: R2 relaxation rates of HUVEC in gelatin (1.0 x10
6
 cells/0.3 mL) incubated with 0.3 µmol Fe/mL of USPIO, 
FLUSPIO and FLUSPIO plus free FMN (10- and 100-fold excess) for 30 min (c) and 1 h (d). e: ICP-MS 
determination of intracellular iron content in  PC-3 cells after a 1 h incubation with USPIO, FLUSPIO and 
FLUSPIO in the presence of excess FMN (100-fold excess). (f). R2 relaxation rates of three different prostate 
cancer cell lines and HUVEC (2 x 10
6
 cells/0.3 mL for each; in gelatin) incubated with 0.3 µmol Fe/mL of 
FLUSPIO for 1 h and 3 h. In all cases, two-sided student t-tests were performed to address statistical 
significance.  ***: p<0.001. 
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Table 2.1.7. Uptake of USPIO, FLUSPIO and FLUSPIO under competition with FMN in PC-3 cells (2 x 10
6 
cells/0.3 mL) after 1h incubation (ICP-MS) 
 
ICP-MS iron content 
[pg Fe/cell] 
USPIO 
(0.3 µmol 
Fe/mL) 
FLUSPIO 
(0.3 µmol 
Fe/mL) 
FMN 
(100 fold) 
0.097 ± 0.003 0.675 ± 0.31 0.274 ± 0.04 
 
Interestingly, FLUSPIO were found to be taken up much more efficiently by HUVEC 
than by PC-3 cells, which may be due to cell type-specific characteristics of activated 
endothelial cells. To investigate this interesting phenomenon in more detail, and to confirm 
FLUSPIO uptake in different cancer cells, a comparative MR relaxometry study was 
performed using PC-3, LnCap and DU-145 cells. All of these three prostate cancer cell lines 
are known to express RCP,
[151]
 and all three showed a high uptake of FLUSPIO. Remarkably 
however, in all cases, the R2 relaxation rate of HUVEC was found to be more than twice as 
high as that of the prostate cancer cell lines (Figure 2.3.9f). Together, these findings suggest 
that FLUSPIO are highly suitable for targeting and labeling (angiogenic) endothelial cells 
[208-210]
.
    
 
 
Figure 2.4.0. FLUSPIO uptake analyzed by MRI.  R2 relaxation rates of PC-3, LnCap, myofibroblast cells  and 
HUVEC in gelatin (2.0 x10
6
 cells/0.3 mL) incubated with 0.3 µmol Fe/mL of FLUSPIO for different time 
intervals, i.e. 1 h and 3 h (A). R2 relaxation rates of PC-3, LnCap, myofibroblast cells and HUVEC in gelatin 
(2.0 x10
6
 cells/0.3 mL) incubated with 0.3 µmol Fe/mL of double coated FMN USPIO for 1 h (B).  R2 relaxtion 
rates of PC-3 cells in gelatin (2.0 x 10
6
 cells/0.3 mL) incubated for 3 h with USPIO, FLUSPIO in McCoy´s 
medium with and without FBS supplements (C) respectively.  
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Further, the cellular labeling efficiency and the uptake of FLUSPIO in four different 
cells (PC-3, LnCap, HUVEC, and myofibroblasts) were investigated by MRI (at 3.0 T). The 
cells were labeled with FLUSPIO, re-suspended in 10% gelatin (2.0 x 10
6
 cells/0.3 mL; 0.3 
µmol Fe/mL, 1 h and 3 h) and the R2 relaxation rates were determined. R2 relaxation rates 
after 1 h incubation (Figure 2.4.0A) are 3.12±0.27 s
-1 
(PC-3), 3.11±0.51 s
-1
 (LnCap), 
2.76±0.65 s
-1
 (HUVEC), 4.84±0.18 s
-1
 (Myofibroblasts) and after 3 h incubation (Figure 
2.4.0A) are 3.62±0.24 s
-1 
(PC-3), 2.64±0.24 s
-1 
(LnCap), 5.04±0.98 s
-1
 (HUVEC) and 
6.19±0.35 s
-1
 (Myofibroblasts) respectively. These results clearly show the increase in 
FLUSPIO uptake in HUVEC and myofibroblast cells with increase in incubation time, which 
could be related to cell-type specific characteristics of fibroblast cells. To validate the specific 
uptake of FLUSPIO is due to the RCP specific ligand, four different cells were incubated for 
1 h with double coated FMN USPIO and relaxation rates were measured. The relaxation rates 
after 1 h incubation are 24.15±1.93 s
-1
 (PC-3), 5.14±0.50 s
-1
 (LnCaP), 12.18±1.38 s
-1 
(HUVEC), 17.23±1.24 s
-1
(myofibroblasts) which confirmed the RCP-mediated specific 
uptake in different cell types (Figure 2.4.0B). The inhibitory effect of FBS on USPIO, 
FLUSPIO uptake by PC-3 cells was evaluated using MR relaxometry (Figure 2.4.0C). The 
FLUSPIO and USPIO (0.3 µmol Fe/mL) diluted in the PC-3 cell growth medium without 
FBS enrichment displayed high R2 relaxation rate (FLUSPIO: 78.58±15.41 s
-1
 and USPIO: 
31.63±1.30 s
-1
) compared to the medium enriched with FBS (FLUSPIO: 11.45±0.80 s
-1 
and  
 
USPIO: 2.86±0.23 s
-1
) respectively.  The high uptake of FLUSPIO and USPIO in the absence 
of FBS clearly demonstrates the unspecific interaction between the nanoparticles and serum 
proteins of the FBS enriched medium thereby inhibiting the cellular uptake of the 
nanoparticles. 
 
2.10.2.3. Fluorescence Microscopy and TEM 
In vitro experiments on PC-3 cells and HUVEC were also performed to evaluate the 
cellular labeling efficiency of FLUSPIO. The TEM images in Figure 2.4.1a-d show that after 
3 h and 6 h, FLUSPIO strongly accumulated inside endosomes, while USPIO were not taken 
up effectively. The high uptake of FLUSPIO by PC-3 cells was confirmed by fluorescence 
microscopy (Figure 2.4.2a-f) and flow cytometry (Figure 2.4.3). A strong green fluorescence 
of the cells was observed after FLUSPIO incubation (Figure 2.4.2a-f). The perinuclear 
fluorescence pattern strongly suggests (likely) endosomal localization of the FLUSPIO and 
supports the results observed from the TEM studies. 
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Figure 2.4.1. FLUSPIO uptake analyzed by TEM. a-d: TEM images of PC-3 cells incubated with USPIO and 
FLUSPIO at an iron concentration of 3.0 µmol Fe/mL. After 3 h (a and b) and 6 h (c and d) of incubation, PC-3 
cells have internalized only a small amount of uncoated USPIO (a and c; see arrows), while there is strong 
uptake for FLUSPIO (b and d). 
 
 
 
 
Figure 2.4.2. FLUSPIO uptake analyzed by means of fluorescence microscopy. a-f: Fluorescence microscopy 
images of PC-3 cells incubated for 3 h with FLUSPIO (0.5 µmol Fe/mL). Nuclei are counterstained with DAPI. 
a: Blank medium. b: FMN. c: GMP. d: USPIO. e: FLUSPIO without DAPI. f: FLUSPIO plus DAPI. The images 
clearly show the vesicular (likely endosomal) localization of the FLUSPIO. 
 
PC-3 cells on glass cover slips were incubated for 3 h with FLUSPIO and controls 
(see above) at 37 °C, 5% CO2 and 95% relative humidity. Medium was removed and cells 
were washed three times with 1 mL PBS. Further, cells were fixed on cover slips using 0.5 
mL of 100% ethanol and dried at RT. Nuclei of cells were stained with DAPI (Figure 2.4.2 a-
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f). The green fluorescence of FLUSPIO was analyzed in the FITC channel (FL1 channel) and 
the high cell labeling efficiency with fluorescence microscopy and flow cytometry was 
demonstrated.  
 
Figure 2.4.3. Flow cytometry of PC-3 cells after incubation with FLUSPIO (S1). (a): negative control cells (dot 
plot) incubated for 3 h on which gating was performed; (b): PC-3 cells incubated with FLUSPIO (3 h) show an 
increase in fluorescence intensity with increasing FLUSPIO iron concentration
 
 
 
Furthermore, the dose- and time-dependency of nanoparticle uptake was investigated 
by incubating PC-3 and HUVEC cells with FLUSPIO of different iron concentrations (3.0, 
0.3, 0.03 µmol Fe/mL) in the respective cell culture media for different incubation periods. 
As shown in Figure 2.4.4 and 2.4.5, MR relaxometry of these cells showed increased R2 
relaxation rates of FLUSPIO with increasing dose and incubation time.  
 
 
Figure 2.4.4. R2 relaxation rate of gelatin gels containing (a) PC-3 cells and (b) HUVEC (2 x 10
6
/0.3 mL) after 
1 h incubation.  
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Figure 2.4.5. R2 relaxation rate of gelatin gels containing (a) PC-3 cells and (b) HUVEC (2 x 10
6
/0.3 mL) after 
3 h incubation.  
 
In summary, we here introduce RCP targeting as an effective way to specifically 
transport (iron oxide-based) nanomaterials into metabolically active tumor and endothelial 
cells. In this context, USPIO with an adsorptive fluorescent coating of FMN and GMP 
(FLUSPIO) were synthesized, which are stable at physiological pH and show an intense 
fluorescence as well as high R2 relaxation rate in MRI. The high RCP-mediated uptake of 
FLUSPIO by activated endothelial and cancer cells suggest them as promising tools for 
molecular MRI and cell tracking experiments. As a follow up application (in vivo) study for 
FLUSPIO, we will investigate whether FLUSPIO specifically accumulate in tumors and/or 
tumor endothelial cells after intravenous injection. We assume that in vivo, FLUSPIO will 
mostly target activated endothelial cells, thereby enabling molecular MR and optical imaging 
of tumor angiogenesis respectively. 
 
2.11. Synthesis of FAD USPIO nanoparticles 
After having achieved the traits essential for imaging, such as successful coating, 
stability under physiological conditions and high cellular labeling efficacy for FLUSPIO, we 
tried to extend this promising fluorescent flavin based coating to USPIO by using FAD 
(flavin analogues) in order to generate nanoparticles with a very high MR-cellular labeling 
profile and for highly specific in vivo targeting of the riboflavin carrier protein (RCP) 
respectively.  In this aspect, FAD USPIO nanoparticles were generated by adapting similar 
synthesis protocol as pursued for FLUSPIO. Here, also a mixed coating for USPIO of 
fluorescent FAD and non-polymeric GMP was achieved in two simple steps at ambient 
temperature (Figure 2.4.6A). The reasons for including GMP in this coating were congruent 
to that of FLUSPIO as explained in section 2.10 respectively.  
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2.11.1. Physico-chemical characterization results of FAD USPIO 
 The physico-chemical properties of FAD USPIO were evaluated using TEM, SEM, 
DLS, Zeta potential, TGA, FT-IR, powder XRD, EDX, MRI, fluorescence spectroscopy and 
microscopy respectively. The characterization results obtained from above techniques will be 
discussed in this section. 
TEM analysis of USPIO, and FAD USPIO showed nanoparticles with an average iron 
core diameter of 5.8 ± 1 nm (Table 2.1.8 and Figure 2.4.6B-C) similar to that of FLUSPIO 
diameters. SEM images of USPIO and FAD USPIO confirmed the spherical surface 
morphology, with an average particle diameter of 23.19 ± 4.62 nm (USPIO) and 35.83 ± 5.69 
nm (FAD USPIO) (Figure 2.4.6D-E). There was an increase in size of FAD USPIO observed 
in SEM compared to FLUSPIO which could be attributed to the nanoparticles prone to 
clustering upon drying. The FAD USPIO in HEPES buffer showed an average hydrodynamic 
diameter (Dh) of 265 ± 2.48 nm with a low polydispersity index (PDI) of 0.23 (2.4.8A-B) 
higher than FLUSPIO Dh values. The discrepancies observed in the Dh values between the 
flavin coated nanoparticles could be attributed to the lack of centrifugation for FAD USPIO 
compared to FLUSPIO. The average Dh of FAD USPIO in 10% glycine, 5% glycine, saline, 
PBS are 272.90 ± 28.63 nm (PDI = 0.35); 256.46 ± 3.91 nm (PDI = 0.26); 872.76 ± 75.69 nm 
(PDI = 0.25); 707.93 ± 66.33 nm (PDI = 0.22) respectively. The increase in average Dh of 
FAD USPIO in saline and PBS clearly indicates agglomeration due to high electrostatic 
interaction between USPIO and different anions respectively. USPIO showed stability only at 
pH 2 and displayed an increase in Dh at pH 7 (393 ± 35.37 nm) with PDI equal to 0.84, due to 
agglomeration that occurred at increasing pH (Table 2.1.8 and Figure. 2.4.8A-B).  
 
 
Figure 2.4.6. Preparation of FAD USPIO. A: Schematic diagram showing the mode of binding of FAD and 
GMP to the iron oxide cores in FAD USPIO. B-C: TEM images of USPIO (B) and FAD USPIO (C). 
Quantitative analysis of the images reveals that both types of nanoparticles have a core diameter of 5.8±1 nm 
and a narrow size distribution. D-E: SEM images of USPIO (D) and (E) FAD USPIO, displayed spherical 
morphology. Quantitative analysis indicated average diameters of 23±4 nm (USPIO) and 35.83±5.69 nm (FAD 
USPIO) respectively.   
 103 
Zeta potential measurements were performed to determine the surface charge, 
electrophoretic mobility and colloidal stability of the USPIO and FAD USPIO particles at pH 
2, 7 and 9 (Table 2.1.8). Under acidic and physiological conditions USPIO displayed a 
positive zeta potential due to their highly protonated surface hydroxyl and oxygen groups. 
Further, under basic conditions USPIO displayed a negative zeta potential which could be 
attributed to the deprotonation of surface groups respectively. FAD USPIO displayed a 
negative zeta potential under physiological and basic conditions which facilitates their in vivo 
application and bolster better pharmacokinetic properties. Under acidic conditions, FAD 
USPIO displayed a positive zeta potential as anticipated due to prominent protonation at this 
pH.  FAD USPIO was stable at physiological pH in water, HEPES buffer and in 5% glucose 
solution. No aggregation was found in cell culture media, most probably due to the colloidal 
stabilization of FAD USPIO by serum proteins.  
X-ray powder diffraction (XRD) analysis was used to determine the chemical 
composition and crystallinity of the FAD USPIO. The majority of the nanoparticles were 
crystalline in nature, with low amounts of amorphous constituents which was validated by 
comparing with magnetite diffraction patterns (Figure 2.4.7). The crystalline nature of their 
iron cores explains the high relaxivities of FAD USPIO found in the MRI experiments.  
 
Table 2.1.8.  Physico-chemical characterization results of USPIO and FAD USPIO (PDI = polydispersity index) 
Samples 
TEM 
size 
(nm) 
Hydrodynamic size (nm) Zeta potential (mV) 
pH 2 (PDI) pH 7 (PDI) pH 9 (PDI) pH 2 pH 7 pH 9 
USPIO 
5.97 ± 
1.18 
18.50 ± 0.22 
(0.26) 
393.43 ± 
35.57 (0.84) 
575.30 ± 86.26 
(0.73) 
27.03 ± 3.74 33.80 ± 5.02 -27.36 ± 1.14 
FAD 
USPIO 
5.83 ± 
1.05 
327.50 ± 25.63 
(0.49) 
265.23 ± 2.48 
(0.23) 
382.70 ± 15.59 
(0.42) 
24.50 ± 1.61 -27.96 ± 0.11 -25.83 ± 2.06 
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Figure 2.4.7. X-ray diffraction patterns of generated (a) USPIO and (b) fluorescent nanoparticles (FAD USPIO) 
respectively. 
 
Fourier-transform infrared  (FTIR) spectroscopy confirmed the binding of FAD and 
GMP phosphate groups to nanoparticles, and this was validated in comparison to free FAD 
and GMP and unmodified USPIO spectra (Figure 2.4.8C). Functional groups in FAD, GMP 
and USPIO were characterized by FT-IR spectroscopy (with 4 cm
-1 
resolution) of KBr 
pellets.  USPIO showed ν(Fe-O) bands at 583 and 629 cm-1. FAD displayed unbound ν(P=O) 
bands at 1116 cm
-1
 and ν(P-OR) bands at 949 and 1078 cm-1. For GMP free ν(P=O) bands 
occured at 1121 and 1190 cm
-1
 and ν(P-OR) bands occur at 905, 935, 979, 1006 and 1021 
cm
-1
. The ν(P=O) band disappeared due to the binding of FAD and GMP in FAD USPIO 
which indicated the binding of the phosphate groups to nanoparticles. The ν(P-OR) band of 
FAD in FAD USPIO shifted to 992 and 1050 cm
-1
. 
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Figure 2.4.8. Physico-chemical characterization of FAD USPIO. DLS size measurements of USPIO (A) and 
FAD USPIO (B) in water. USPIO displayed agglomeration at pH 7 in water due to lack of surface coating. FT-
IR spectra of FAD, GMP, USPIO, and FAD USPIO (C) indicated that binding of FAD/GMP occurs via 
phosphate groups. EDX spectrum of FAD USPIO (D) displayed the peaks (Kcounts) for phosphorous and iron 
respectively. 
 
The chemical composition of the surface (concentration of FAD, GMP) was analyzed 
by energy-dispersive X-ray spectroscopy (EDX), Vaskovsky phosphate estimation, elemental 
analysis and thermogravimetry (TGA). As expected from theoretically calculated ratios, the 
Fe:P ratio of the fluorescent nanoparticles determined by EDX was 1:0.145 (Figure 2.4.8D). 
This was further supported by the Vaskovsky phosphate estimation (Table 2.1.9) and 
elemental analysis.  
Table 2.1.9. Total phosphate content deriving from the non-polymeric molecules (FAD and GMP) on the 
surface of FLUSPIO (Vaskovsky phosphate determination). 
 
Sample Iron amount (µg) 
Phosphorous amount  
(µg) 
Fe:P ratio 
FAD USPIO 223.38 5.807 1:0.026 
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The elementary analysis of FAD USPIO revealed C 16.21%, H 2.58% and N 8.20% 
by weight (expected C 15.45%, H 2.2% and N 7.25%) for FAD USPIO.  TGA of the FAD 
USPIO showed a weight loss of 26% when heated to 600 ºC (Figure 2.4.9). This accounts for 
the decomposition of the surface coating (FAD and GMP), as well as for the dehydration of 
the inorganic matrix (expected theoretical weight loss: 27 %).  
 
 
Figure 2.4.9. TGA curves of (A) FAD (B) GMP and (C) FAD USPIO respectively. 
 
2.11.1.1. Magnetic Properties of FAD USPIO 
The MR relaxivity of the FAD USPIO in de-ionized water (slightly basic) at RT at 3 
T was found to be similar to that of the clinically used MR contrast agent Resovist (FAD 
USPIO: r2 = 136.22±0.46 s
-1
mM
-1
, Resovist: r2 = 144.36±0.92 s
-1
mM
-1
; thereby confirming 
their excellent contrast enhancement properties.  
 
2.11.1.2. Fluorescence Properties of FAD USPIO 
Fluorescence spectroscopy and microscopy of the FAD USPIO revealed a high 
fluorescence intensity due to the photoluminescence of the FAD fluorophore associated with 
the nanoparticle surface
[206]
. The fluorescent nanoparticles can be excited in a wide 
wavelength range (250-500 nm), resulting in an intense green emission at 530 nm. The 
absorbance spectrum of FAD and FAD USPIO was recorded in water using a TECAN 
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Infinite M200 (Tecan Austria GmbH) plate reader. The absorbance spectrum of FAD and 
FAD USPIO showed absorption peaks at 378 nm and 450 nm, respectively (Figure 2.5.0A 
and 2.5.0B). The fluorescence of FAD USPIO was recorded in water at RT (iron 
concentration range: 10
-6
 M to 10
-12
 M). FAD was excited at 452 nm and 468 nm and its 
intense emission occurred at 530 nm. The FAD USPIO showed more intense fluorescence 
due to the presence of a huge amount of luminescent FAD centres per nanoparticle 
(fluorescence spectroscopy and microscopy)(Figure 2.5.0C, 2.5.0D and 2.5.1).  
 
 
 
Figure 2.5.0.Absorption spectra of (A) FAD (B) FAD USPIO and fluorescence spectra of (C) FAD and (D) 
FAD USPIO recorded in water respectively. 
 
 
 
 
Figure 2.5.1. Fluorescence microscopy images of (A) FLUSPIO and (B) FAD USPIO recorded with 20X 
magnification respectively. 
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2.11.2. In vitro evaluation of FAD USPIO 
 The biocompatibility of the generated FAD USPIO was checked using cytotoxicity 
assays and staining (staining: Trypan blue and 7-AAD, assay: MTT) respectively. Further, 
the cellular labeling efficacy of FAD USPIO was evaluated using MRI and fluorescence 
microscopy. 
 
2.11.2.1. Cytotoxicity Assay 
The biocompatibility of the FAD USPIO was investigated using LnCap cells (human 
prostate cancer cells). As shown in Figure 2.5.2, neither trypan blue staining nor MTT assay 
indicated any significant change in cell viability at relevant cell labeling concentrations (i.e.  
up to 0.3 µmol Fe/mL). This observation was further confirmed by flow cytometry, in which 
7-AAD (7-amino actinomycin D) was used to label dead cells, suggesting that the FAD 
USPIO is highly biocompatible (Figure 2.5.3).  
 
 
Figure 2.5.2. Relative viability of LnCap cells determined by trypan blue staining after (a) 3 h; (b) 24 h 
incubation of USPIO, FAD USPIO with 3.0, 0.3, 0.03 µmol Fe/mL in the cell growth media; (c) Rf (10- and 
100- fold competition) for 1 h and 3 h and (D) MTT assay of LnCap cells incubated with FAD USPIO and 
controls for 4 h. The trypan blue staining and MTT assay results didn‟t show any relevant loss in LnCap cell 
viability respectively. 
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The viability of the LnCap cells after incubation with FAD USPIO at three different 
labeling concentrations (3.0, 0.3, 0.03 µmol Fe/mL) were evaluated using trypan blue 
staining and MTT assay. Cells were cultured, incubated for two different time points (3 h and 
24 h), stained with trypan blue and dead cells (stained blue) were counted analogous to 
FLUSPIO. Trypan blue staining results did not show any loss in viability at relevant cell 
labeling concentrations (0.3 µmol Fe/mL). These viability results were further confirmed by 
MTT assay. Additionally, the effect of excess Rf (10- and 100-fold) used for competition 
purposes on cell viability was also evaluated using trypan blue staining. The trypan blue 
results indicated that there was no cytotoxicity exhibited by excess of Rf on LnCap cells. 
 
 
Figure 2.5.3. Flow cytometry analysis of LnCap cell viability after incubation with FAD USPIO in which dead 
cells were stained with the 7-AAD dye (FL3 (APC channel)). Negative controls (dot plot), on which gating was 
performed, were incubated with medium for 3 h (A) and 24 h (D). LnCap cells incubated with different iron 
concentrations (3.0, 0.3, 0.03 µmol Fe/mL) of  FAD USPIO for 3 h (C) and 24 h (F) show no relevant loss of 
viability at cell labeling concentrations (0.3 µmol Fe/mL). The increase in green fluorescence could be detected 
in FL1(FITC channel) after 3 h (B) and 24 h (diminished fluorescence) (E) incubation with increase in FAD 
USPIO concentration respectively.   
 
2.11.2.2. Cellular Labeling and Competition (MRI) 
The cellular labeling efficiency and the uptake of FAD USPIO were investigated by 
MRI (at 3.0 T). Triplicates were used per condition. The cells were labeled with FAD 
USPIO, re-suspended in 10% gelatin (2 x 10
6
 cells/0.3 mL; 0.3 µmol Fe/mL, 30 min and 1 h) 
and the R2 relaxation rates were determined. LnCap cells in gelatin showed a significantly 
 110 
higher R2 relaxation rate after 1 h incubation with FAD USPIO (135.56±36.78 s
-1
, p<0.001) 
than with USPIO (2.76±0.43 s
-1
), indicating a significant higher cellular uptake of FAD 
USPIO (similar R2 values for FAD USPIO were obtained after 30 min incubation).  
Furthermore, the specificity of FAD USPIO uptake was investigated via competitive blocking 
of RCP with free Rf
[208-210]
. After the addition of free Rf to LnCap cells and subsequent 
incubation with FAD USPIO for 30 min, the R2 relaxation rate was significantly reduced 
(10-fold Rf competition; 8.51±0.42 s
-1
, p<0.001; 100-fold Rf competition: 3.46±0.94 s
-1
, 
p<0.001; FAD USPIO incubation alone:  69.91±27.43 s
-1
). Similar results were obtained 
when blocking RCP with free Rf for 1 h. In this case, the corresponding R2 relaxation rates 
were 7.76±1.42 s
-1
 (10-fold Rf competition) and 2.22±0.15 s
-1 
(100-fold Rf competition), 
respectively (Figure 2.5.5A-B).   
Similarly, the LnCap cells in the FAD based competition experiments also showed a 
significantly higher uptake of FAD USPIO (30 min: 57.63±9.15 s
-1
, 1 h: 82.93±14.49 s
-1
) 
than of USPIO (30 min: 4.59±0.25 s
-1
,
 
1 h: 4.75±0.64 s
-1
; Figure 2.5.5C-D). Competition 
experiments with free FAD confirmed the specificity of the RCP-mediated uptake of FAD 
USPIO in LnCap cells. After RCP blocking by free FAD for 30 min, the R2 relaxation rate of 
LnCap cells was lower compared to the ones incubated with FAD USPIO alone (100-fold 
FAD competition: 22.41±2.01 s
-1
). Even after 1 h of FAD USPIO incubation, the uptake was 
still significantly lower in the presence of 100-fold excess (47.48±6.57 s
-1
) of free FAD 
(Figure 2.5.5C-D). Together, these experimental insights adequately show that the RCP-
mediated uptake of FAD USPIO by LnCap cells is intensely higher than that of plain USPIO. 
Furthermore, the uptake of FAD USPIO in PC-3 cells displayed under competition (100 fold 
Rf and FMN) was enormously higher than that of USPIO (the relaxation rates are shown in 
Table 2.2.0). 
The LnCap cells and HUVEC were labeled with FAD USPIO, re-suspended in 10% 
gelatin (2 x 10
6
 cells/0.3 mL; 0.3, 0.03 µmol Fe/mL, 1 h) and the R2 relaxation rates were 
determined. HUVEC in gelatin showed a significantly higher R2 relaxation rate compared to 
LnCap after 1 h of incubation with FAD USPIO (0.3 µmol Fe/mL, 58.34±6.74 s
-1
, p<0.001) 
than with USPIO (3.74±0.35 s
-1
), indicating a higher cellular uptake of FAD USPIO.  
Similarly, the LnCap cells also displayed a significant higher R2 relaxation rate after 1 h 
incubation with FAD USPIO (0.3 µmol Fe/mL, 28.83±12.18 s
-1
, p<0.005) than with USPIO 
(2.85±0.06 s
-1
), respectively (Figure 2.5.5F). The higher uptake of FAD USPIO in HUVEC 
compared to LnCap cells could be attributed to cell type specific characteristics of activated 
endothelial cells. Remarkably, the R2 relaxation rate of HUVEC was found to be twice as 
high as that of the prostate cancer cell lines (Figure 2.5.5F). Together, these MR findings 
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suggest that FAD USPIO is highly suitable for targeting and labeling (angiogenic) endothelial 
cells. 
 Table 2.2.0. Uptake of USPIO, FAD USPIO and FAD USPIO under competition with FMN and Rf in PC-3 
cells (2 x 10
6 
 cells/0.3 mL) after 1 h incubation (MRI) 
 
 
Furthermore, the time-dependency of nanoparticle uptake was investigated by 
incubating three different prostate cancer cells (PC-3, DU-145, and LnCap) with FAD USPIO 
(0.3 µmol Fe/mL) which are known to express RCP,  in the respective cell culture media for 
two different incubation periods (1 h and 3 h) respectively. As shown in Figure 2.5.4, MR 
relaxometry of these cells showed high R2 relaxation rates for FAD USPIO compared to 
USPIO with increase in the incubation times. LnCap displayed the highest uptake (shown by 
R2 relaxation rates) for the FAD USPIO nanoparticles among the three prostate cancer cells.
   
 
 
 
 
Figure 2.5.4. R2 relaxation rates of three prostate cancer cells (PC-3, DU-145 and LnCap) incubated with FAD 
USPIO and USPIO for 1 h and 3 h respectively. 
 
 
 
R2 relaxation rate 
[1/s] 
USPIO 
(0.3 µmol 
Fe/mL) 
FAD USPIO 
(0.3 µmol 
Fe/mL) 
FMN 
(100 fold) 
 
Rf  
(100 fold) 
3.351 ± 0.239 67.56 ± 9.49 46.74 ± 4.21 
 
2.45 ± 0.21 
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Figure 2.5.5. FAD USPIO uptake analyzed by MRI A-D: R2 relaxation rates of LnCap cells in gelatin (2.0 x10
6
 
cells/0.3 mL) incubated with 0.3 µmol Fe/mL of USPIO, FAD USPIO, FAD USPIO plus free Rf (10- and 100-
fold excess) (30 min (A), 1 h (B)), and FAD USPIO plus free FAD (100-fold excess for competition 
purposes)(30 min (C), 1 h ( D)). (E): R2 relaxation rates of PC-3 in gelatin (2.0 x10
6
 cells/0.3 mL) incubated 
with 0.3 µmol Fe/mL of USPIO, FAD USPIO and FAD USPIO plus free FMN and Rf (100-fold excess) for 1 h. 
(F): R2 relaxation rates of LnCap and HUVEC (2 x 10
6
 cells/0.3 mL for each; in gelatin) incubated with 0.3 and 
0.03 µmol Fe/mL of USPIO, FAD USPIO for 1 h.  In all cases, two-sided student t-tests were performed to 
address statistical significance.  ***: p<0.001; **:p<0.005; *:p<0.01. 
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Figure 2.5.6. Rf-USPIO, FLUSPIO, and FAD USPIO cellular uptake analyzed by MRI. R2 relaxation rates of 
PC-3 cells in gelatin (2.0 x 10
6
 cells/0.3 mL) incubated for 3 h with 0.3 µmol Fe/mL of double coated (twice 
coated with Rf and metabolic analogues) Rf USPIO, FMN USPIO, and FAD USPIO (A). The controls 
(medium, Rf, FMN, FAD) from (A) were not shown for better clarity.  R2 relaxation rates of PC-3 (2.0 x 10
6
 
cells/0.3 mL)(B) and DU-145(2.0 x 10
6
 cells/0.3 mL) (C) in gelatin incubated for 3 h with Rf-USPIO, FLUSPIO 
and FAD USPIO. The controls (medium, GMP, Rf, FMN, FAD) from (B) and (C) are not shown for better 
clarity.  
 
 
The cellular uptake of Rf and its metabolic analogues coated USPIO by different 
prostate cancer cells was evaluated using MR relaxometry measurements.  In this regard, the 
USPIO double coated with Rf, FMN, FAD i.e. Rf USPIO, FMN USPIO, and FAD USPIO 
cellular uptake in PC-3 cells after 3 h incubation displayed high R2 relaxation rates for 
double coated FAD USPIO compared to plain USPIO. R2 relaxation rates of the 
nanoparticles double coated with endogenous RCP ligand are 7.47±0.83 s
-1 
(Rf-USPIO), 
2.51±0.08 s
-1 
(FMN USPIO), 30.72±6.90 s
-1
(FAD USPIO) compared to USPIO (3.47±0.16  
s
-1
) (Figure 2.5.6A) respectively. The cellular uptake of three different flavin based 
nanoparticles (Rf-USPIO, FLUSPIO, and FAD USPIO coated with GMP for stabilization) 
was studied in PC-3 (Figure 2.5.6B) and DU-145 cells (Figure 2.5.6C). Among the 
fluorescent nanoparticles generated by flavin coating i.e. Rf-USPIO, FLUSPIO, and FAD 
USPIO, high R2 relaxation rates were displayed by FAD USPIO in gelatin after 3 h 
incubation (PC-3: 2.92±0.17 s
-1
; DU-145: 3.19±0.32 s
-1
 for Rf-USPIO), FLUSPIO (PC-3: 
3.67±0.16 s
-1
; DU-145: 4.59±0.33 s
-1
 ) and FAD USPIO (PC-3: 49.87±11.33 s
-1
; DU-145: 
14.92±0.86 s
-1
 ) than that of USPIO alone (PC-3: 2.60±0.12 s
-1
; DU-145: 2.84±0.28 s
-1
) 
respectively. 
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2.11.2.3. Fluorescence Microscopy (Cell uptake and competition) 
In vitro experiments on LnCap cells were also performed to evaluate the cellular 
labeling profile of FAD USPIO. The high uptake of FAD USPIO by LnCap cells was 
confirmed by fluorescence microscopy (Figure 2.5.7A-F) and flow cytometry (Figure 2.5.3B 
and 2.5.3E). A strong green fluorescence from the cells was observed after FAD USPIO 
incubation (3 h) (Figure 2.5.7A-F). The perinuclear fluorescence pattern strongly suggests the 
endosomal localization of the FAD USPIO. In addition, the specificity of FAD USPIO for 
RCP was confirmed using fluorescence microscopy by competitively blocking their uptake 
by free Rf (10- and 100- fold excess). In Figure 2.5.7G and 2.5.7H, FAD USPIO uptake by 
LnCap cells is competitively blocked using free Rf, which could be clearly visualized by 
reduction in the green fluorescence of FAD USPIO respectively. 
 
 
 
Figure 2.5.7. FAD USPIO uptake and Rf competition (10- and 100-fold excess) in LnCap cells analyzed by 
means of fluorescence microscopy. A-F: Fluorescence microscopy images of LnCap cells incubated for 3 h with 
FAD USPIO (3.0 µmol Fe/mL). Nuclei are counterstained with DAPI. A: Blank medium. B: FAD. C: GMP. D: 
USPIO. E: FAD USPIO without DAPI. F: FAD USPIO plus DAPI. The images clearly show the vesicular 
(likely endosomal) localization of the FAD USPIO. G-H: FAD USPIO (0.3 µmol Fe/mL) uptake by LnCap cells 
was competitively blocked by Rf (10- and 100-fold competition) after 1 h incubation. The competition effect 
clearly indicates the RCP-mediated uptake of FAD USPIO by LnCap cells. 
 
 
2.11.3. In vivo evaluation of FAD USPIO 
 The FAD USPIO displayed intense cell labeling efficacy for metabolically active cells 
(prostate and activated endothelial cells) compared to their antecedent FLUSPIO. RCP-
mediated uptake of FAD USPIO (in vitro) profile was further advanced to in vivo targeting 
investigations. Prior to the intended in vivo studies the pharmacokinetic profile of FAD 
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USPIO was checked by blood half life studies. Additionally, in vivo MR findings of FAD 
USPIO were validated using histology and supported by Prussian blue staining respectively.  
 
2.11.3.1. Blood half life of FAD USPIO 
 
 
Figure 2.5.8. Blood half life of FAD USPIO as determined using fluorescence spectroscopy. Male nude (CD1) 
mouse (n=1) was intravenously injected with FAD USPIO (900 µmol Fe/Kg) and fluorescence from FAD 
USPIO (emission at 530 nm) in blood at different time points (0, 3, 10, 30 and 60 min) was measured using 
fluorescence spectroscopy respectively.  
 
The blood half life of FAD USPIO was determined using CD1 male nude mouse 
(n=1), which was administered with 900 µmol Fe/Kg of FAD USPIO (130 µL) and their 
circulation time in the blood was followed using fluorescence spectroscopy. The FAD on 
FAD USPIO was excited using either 450 or 468 nm as the excitation wavelength and the 
emission intensity was measured at 530 nm in the blood.  The auto fluorescence from blood 
was subtracted by including the blood collected prior to i.v. injection of the nanoparticles 
which is used as the control. The blood samples (FAD USPIO in blood), withdrawn from the 
mouse at different time points, were diluted in 5% glucose solution prior to the fluorescence 
measurements. The FAD USPIO displayed a reasonable blood half life of 10 min (Figure 
2.5.8A and 2.5.8B). The increase in blood half life after 60 min could be attributed to the 
error associated with the measurements and fluorescence originating from the remnant 
nanoparticles (may be agglomerates) in blood.  As a follow up study, more number of mice 
will be used for determining the half life of FAD USPIO in blood in order to draw statistical 
conclusions.  
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2.11.3.2. In vivo MR imaging of FAD USPIO 
The in vivo specificity of FAD USPIO for RCP was evaluated in CD1 male nude mice 
bearing LnCap tumor xenografts. Resovist was used as a control group for the in vivo study. 
The specific uptake of FAD USPIO was shown by the increase in R2 relaxation rates after 1 
h and 3 h incubation in comparison to the Resovist. R2 relaxation rates of FAD 
USPIO/Resovist (n=3) after 1 h and 3 h incubation are 21.86±3.85 s
-1
/6.43±3.88 s
-1
 and 
13.97±4.91 s
-1
/3.24±4.16 s
-1
 respectively (Figure 2.6.0E).  Additionally, visual inspection of 
the T2*-weighted images of LnCap tumors after 1 h and 3 h of injection of FAD USPIO 
showed clearly the accumulation of the specific probe in the centre and periphery of the 
tumor compartment due to the decrease in T2* signal intensity (indicated by arrows in Figure 
2.5.9E-F).  Contrarily, T2*-weighted images of LnCap tumors after 1 h and 3 h of injection of 
Resovist showed less or no signal intensity reduction in the tumor borders (Figure. 2.5.9A-C). 
Furthermore, the color coded R2 relaxation pixel map supported the visual observations from 
T2*-weighted images and confirmed the specificity of FAD USPIO for RCP compared to 
Resovist in LnCap tumor xenografts (Figure 2.5.9G-L). 
To verify the observed FAD USPIO specificity (MR findings), histology and Prussian 
blue staining was performed.  Histological sections of LnCap tumors previously injected with 
Resovist and FAD USPIO were stained for blood vessel density using CD-31 (red) and nuclei 
were stained  with DAPI (blue)(Figure 2.6.0A-B). LnCap tumor sections displayed a high 
vascularity with many mature vessels facilitating the accumulation of the specific probe 
(FAD USPIO) in the endothelial cells of the tumor xenografts. Further, to confirm the high 
intratumor accumulation of the probe Prussian blue staining was performed. The Prussian 
blue images clearly show the accumulation of the RCP-specific probe (FAD USPIO) after 3 h 
incubation as indicated by arrows in Figure 2.6.0D respectively. In contrast, the Prussian blue 
images of the control LnCap tumors after 3 h incubation, did not show any accumulation of 
Resovist (Figure 2.6.0C).  
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Figure 2.5.9. T2*-weighted MR images (transversal slice) of CD1 male nude mice bearing s.c. LnCap tumors 
before and after 1 h and 3 h i.v. injection of Resovist (A-C) and FAD USPIO (D-F) respectively. The focal areas 
with strong and heterogeneous signal intensity (SI) decrease are observed in the tumor center and periphery after 
1 h of injection of FAD USPIO (arrows in E) and less intense heterogeneous SI decrease are observed in tumor 
periphery after 3 h incubation (arrows in F). Only few spots with high susceptibility are found at the margin of 
the control tumor after injection of the Resovist (A). No decrease in signal was observed in control tumors by 
visual inspection after 1 h and 3 h incubation (B-C). The color coded R2 relaxation pixel map was overlayed on 
T2*-weighted MR images of Resovist (G-I) and FAD USPIO (J-L) respectively. The increase in R2 relaxation 
rate after 1 h of injection of FAD USPIO are observed in tumor center and periphery (displayed as organisch red 
color pixel map in K) and similarly after 3 h incubation the increase in relaxation rate (R2) is shown in L. In 
contrast, the control tumor didn‟t show any change in the R2 relaxation rates (1 h and 3 h) after injection of the 
Resovist (H and I) respectively. 
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Figure 2.6.0. Immunofluorescence and Prussian blue staining images of LnCap tumors and prostate gland. 
Histological sections of LnCap tumors previously injected with Resovist (A), FAD USPIO (B) in which (blood 
vessel-)density were studied by staining with CD-31(red) and nuclei with DAPI (blue). Both control and FAD 
USPIO tumor sections displayed CD-31-positive vessels. In addition, Prussian blue staining of tumors showed 
considerable accumulation of FAD USPIO (arrows in D) while control tumors (C) displayed less or no 
accumulation of the Resovist respectively. E, change of R2 relaxation rates in LnCap tumors (n=3) after 
injection of FAD USPIO and Resovsit respectively. The specificity of the FAD USPIO probe for RCP in LnCap 
tumors after 1 h and 3 h incubation was clearly indicated by increase in R2 values compared to the Resovist. 
Two sided student ttest was performed to address the statistical significance *: p<0.01 respectively. 
 
In summary, FAD coating of iron oxide nanoparticles rendered them fluorescent and 
highly specific for targeting the RCP in vivo.  Further, FAD decorated USPIO proved itself as 
a better candidate for MR-cellular labeling than FLUSPIO and displayed intense 
accumulation in the prostate cancer tumors via targeting RCP.  Hence, these FAD USPIO 
could be used as a tool for in vivo MR imaging and subsequently the MR findings could be 
validated by histology.  As a follow up study, blood half life of FAD USPIO will be 
increased by conjugation of long circulating ligands (PEG spacer) and further, optimization 
of its imaging properties (magnetism and fluorescence) will be carried out in order to 
generate nanoparticles with even better in vivo targeting ability respectively.   
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Chapter 3. 
Conclusion and Outlook 
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In this thesis three different synthesis attempts were made to generate the 
magnetofluorescent nanoparticles under aqueous reaction conditions by using simple and 
straightforward formulation techniques.  Initially, lanthanide incorporation into the magnetic 
nanoparticles was tested and evaluated, followed by naphthalene sulfonates-coated 
nanoparticles, and finally non-polymeric flavin-coated magnetofluorescent nanoparticles 
were developed.  
Firstly, lanthanides were incorporated into iron oxide nanoparticles (via doping) for 
the attempted generation of magnetofluorescent nanoparticles.  The synthesis of lanthanide-
doped iron oxide nanoparticles (Ln-USPIO) was achieved by replacing molar percentages of 
iron(III) by lanthanide (Eu(III), Tb(III), Yb(III)) metal ions under aqueous reaction condition. 
However, the Ln-USPIO synthesis only leads to a low level of lanthanides inside the iron 
oxide crystal lattice, due to size-based difference between the lanthanide and iron cations. As 
a consequence, the fluorescent properties of the particles were not satisfying. Furthermore, 
Ln-USPIO storage under highly acidic conditions might lead to leaching of the lanthanides 
inclusion from the iron oxide crystal structure. As further trials, the lanthanide inclusion in 
USPIO may be increased by a protective coating of (bio-)polymers (dextran, chitosan, PEG, 
PVA, PVP, PEO) thus preventing its leaching from Ln-USPIO.  
Secondly, NUSPIO were generated by incubating naphthalene disulfonic acids (H-
acid and ANDS) with iron oxide nanoparticles under aqueous acidic conditions at ambient 
temperature. The final nanoparticles were purified using dialysis or resin exchange 
techniques, and neutralized using ideal buffers (HEPES, PBS, MOPS, etc.). However, 
NUSPIO failed to display any fluorescence under the fluorescence microscope, which could 
be explained based on quenching of naphthalene sulfonates fluorescence by the paramagnetic 
species (magnetic nanoparticles), via the static and dynamic electron transfer reactions.  As 
further investigations, sonication and mixed coating with small molecules (AMP, GMP) to 
avoid steric hindrance should be tested for generating fluorescent NUSPIO.   
Finally, the first fluorescent and non-polymeric coating of iron oxide nanoparticles 
was achieved based on the endogenous flavin analogues such as flavin mononucleotide 
(FMN) and flavin adenine dinucleotide (FAD). Additionally, the importance of the riboflavin 
carrier protein (RCP) and its role in mediating the uptake of the fluorescent nanoparticles by 
prostate cancer cells and activated endothelial cells was demonstrated. The 
magnetofluorescent nanoparticles (FLUSPIO/FAD USPIO) were generated in aqueous 
reaction conditions at ambient temperature, by first sonicating FMN or FAD with magnetic 
nanoparticles followed by a coating with GMP in order to avoid steric hindrance between the 
bulky isoalloxazine rings of FMN or FAD respectively. The FLUSPIO and FAD USPIO were 
stable under physiological conditions and displayed an intense green fluorescence. FLUSPIO 
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and FAD USPIO showed high relaxivity values similar to Resovist (clinical MR contrast 
agent) in water and HEPES buffer, respectively. The biocompatibility of FLUSPIO and FAD 
USPIO was confirmed using different cytotoxicity assays and staining (assays: TUNEL and 
7-AAD labeling; staining: trypan blue). The high cellular uptake of FLUSPIO/FAD USPIO 
by activated endothelial and cancer cells is anticipated to be mediated by RCP, since 
blocking/saturating this carrier protein with free FMN/FAD/Rf attenuated nanoparticle 
uptake. Using activated endothelial cells and different prostate cancer cell lines, the 
suitability of FLUSPIO/FAD USPIO for MR- and fluorescent cell tracking purposes was 
demonstrated. The in vivo specificity of FAD USPIO was confirmed by MRI and further 
validated through histology studies (immunohistochemistry and Prussian blue staining).  
However, the mechanistic aspects of FLUSPIO and FAD USPIO uptake (i.e. RCP mediated 
uptake) in metabolically active (cancer and activated endothelial) cells have to be dealt 
critically in future by performing rigorous experimental investigations. 
In follow-up analyses, we aim to investigate the fluorescence and target specificity of 
USPIO with different core diameters by employing flavin and its derivatives (Rf, FMN, 
FAD) as an adsorptive, fluorescent and non-polymeric coating.  In addition, we will 
investigate the accumulation and target specificity of FLUSPIO in tumors and/or tumor 
endothelial cells. We presume that in vivo, FLUSPIO will mostly target activated tumor 
endothelial cells, thereby enabling molecular MR and optical imaging of tumor angiogenesis. 
Nevertheless, the concept of targeting RCP is not only limited to USPIO.  FMN could also 
serve as a versatile building block in generating contrast agents for other imaging modalities. 
For instance, small FMN-containing molecular probes could be synthesized for nuclear 
imaging techniques such as PET and SPECT, and they could serve as a platform to develop 
novel diagnostic tools for monitoring tumor metabolism and progression.  
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Chapter 4. 
Experimental Section 
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4.1. Materials  
4.1.1. List of chemicals  
Sigma Aldrich Chemie GmbH, Steinheim, Germany 
Iron (III) chloride (FeCl3, >97%), Iron (II) chloride tetrahydrate (FeCl2.4H2O, >99%), 
Sodium hydroxide (NaOH, 98%), 5-sulfosalicylic acid dehydrate ( ≥ 99% for metal titration), 
IDRANAL III standard solution (EDTA-Na2, reagent for metal titration,0.1 M), N-
[Tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid sodium salt (TES, ≥99%), 
Potassium bromide (KBr, ≥99%), 3-aminopropyltrimethoxy silane (APTMS, 97%), 
Tetraethyl orthosilicate (TEOS, 98%), Europium (III) chloride hexahydrate (EuCl3.6H2O, 
99.9% trace metal basis),  Gadolinium (III) chloride hexahydrate (GdCl3.6H2O, 99% 
titration), Terbium (III) chloride hexahydrate (TbCl3.6H2O, 99.9% trace metal basis), 
Riboflavin-5`-monophosphate sodium salt dihydrate (Flavin mononucleotide, FMN, 73-79% 
fluorimetric grade), Oleic acid (Ph Eur), Glutaraldehyde solution (25% wt in H2O), Thiamine 
monophosphate chloride dihydrate (TMP, ≥ 99%), D-(+)-Glucose (≥99.5%), 7-amino-1,3-
naphthalene disulfonic acid monopotassium salt (≥98%; ANDS, fluorescent grade), 4-amino-
5-hydroxy-2,7-naphthalene disulfonic acid disodium salt (H-acid, 85%), Etidronic acid 
monohydrate (≥95% (T)),  Fluorescein-5(6)- isothiocyanate (FITC, 90% (HPLC)), Quinine 
hydrochloride dihydrate (≥99% (NT); suitable for fluorescence), 9-aminoacridine 
hydrochloride monohydrate (≥96% (AT), purum for fluorescence), DL-Tryptophan (≥99%), 
N-hydroxysuccinimide (NHS, 98%), Bromotrimethyl silane (TMBS, 97%), Diethyl vinyl 
phosphate (97%), N,N`-dicyclohexylcarbodiimide (DCC, 99%),  N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, commercial grade), 
DOWEX 50WX8 (20/50 Mesh, strongly acidic, H
+
 form), Amberlite IRA 95 resin (weakly 
basic), 1,4-butane sultone (≥99 (GC)), 2-pyrrolidinone (99%), Silicagel for column 
chromatography (60 Ǻ pore size, mesh (230 to 400)), Iron (III) acetylacetonate (Fe(C5H7O2)3, 
97%), Tetramethyl ammonium hydroxide solution (TMAOH, ACS reagent,1M solution),  
Iron (II) sulfate heptahydrate (FeSO4.7H2O, reagent plus, ≥99%), N,N`-
diisopropylcarbodiimide (DIC, ≥98% (GC)), N-ethyldiisopropylamine (DIPEA,≥98% (GC)), 
1-hydroxybenzotriazole hydrate (HOBt, ≥97% (T)), 2-aminoethyl dihydrogen phosphate 
(AEP, 98%), Diethylazodicarboxylate (DEAD, puriss, ~40%  in toluene), 
(Diacetoxyiodo)benzene (purum, ≥98% (AT)), Triphenylphosphine (purum, ≥95% (GC)), (4-
dimethylamino)pyridine (DMAP, reagent plus, 99%), Sephadex G25 (medium), Disodium 
Molybdenum oxalate (puriss, p.a) 
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Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ammonia solution (NH3, ≥25%), Hydrochloric acid (HCl, 37%), Ammonium 
peroxodisulfate (NH4S2O8, ≥98%), Sodium acetate (CH3COONa, ≥99%), N-(2-
Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES, ≥99.5%), N,N-
dimethylformamide (DMF, ≥99.8% for synthesis), spectrum dialysis membrane (Molecular 
weight cut off 10,000 and 5,000), visking membrane (Molecular weight cut off 14,000).  
 
Applichem GmbH, Darmstadt, Germany 
Zinc sulphate heptahydrate (ZnSO4.7H2O, p.a), Eriochrome Black T (analytical grade 
for metal titration), PBS buffer (10X Dulbecco`s powder), Riboflavin (Rf, 98-100% 
analytical grade), Riboflavin-5`-adenosine diphosphate disodium salt dihydrate (Flavin 
adenine dinucleotide, FAD, 95-98% analytical grade), Guanosine-5`-monophosphate 
disodium salt hydrate (GMP, 98%), Adenosine-5`-monophosphate disodium salt dihydrate 
(AMP, 99%), Gelatin (ph. Eur, powder), Pyridine for analysis. 
 
MercK KGaA/VWR, Darmstadt, Germany 
TLC Silicagel 60F254 25 Al sheets 20X20cm, hydrazine hydrochloride (puriss), 
perchloric acid (70-72%)). 
 
4.2. Methods  
4.2.0. Different physico-chemical characterization techniques  
4.2.1. Transmission electron microscopy (TEM) 
The morphology, size, and size distribution of the generated nanoparticles were 
characterized by TEM (EM 400 T (Philips, Eindhoven, The Netherlands) with an accelerating 
voltage of 60 kV (TEM accelerating range 30 – 120 kV). USPIO, FLUSPIO, FAD USPIO 
were embedded in 2 % agarose, rinsed with distilled water and dehydrated with ethanol (30 
%, 50%, 70%, 90%, 100 %). Subsequently, they were embedded in Epon, polymerized 8 h at 
37 °C, 56 h at 60 °C, and then cut into 70 – 100 nm thick slices using Leica EM UC6, 
Reichert Ultracut S loaded with LKB knife maker 7801 Type A. TEM micrographs were 
recorded using SIS Morada (11 Mpix) digital camera. The particle size and size distributions 
were calculated using an image analysis program (iTEM software, Olympus, Germany) and 
by measuring the diameter of at least 200 particles. TEM measurements of the cellular uptake 
of the USPIO and FLUSPIO by prostate cancer cells were performed similar to the above 
described procedure. The uranyl acetate and lead citrate contrast of the cells for different cell 
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organelles embedded in the Epon polymer was performed using LKB ultrastainer. The 
morphology, size and size distribution of NUSPIO, Ln-USPIO were characterized by TEM 
(Jeol 2100F, Japan). These nanoparticle suspensions were directly deposited onto a carbon-
coated copper grid and air dried at RT and further examined using TEM respectively. Dr. 
Jörg Bornemann, Pathology Institute, University Clinics RWTH Aachen University 
performed TEM measurements. 
 
4.2.2. Scanning electron microscopy (SEM) 
The surface morphology of the nanoparticles was characterized by SEM [FEI 
(PHILIPS) ESEM XL 30 FEG; EDAX Falcon genesis, resolution 2 nm, sample chamber 
pressure 3.0 nbar – 7.5 mbar] with an accelerating voltage of 20 kV (SEM accelerating range 
200 V – 30 kV). USPIO, FLUSPIO, and FAD USPIO in water were dried by dehydrating 
them with different percentages of ethanol (25%, 50%, 70-75%, 90-95%, 100%). Finally, 
trace amounts of water were removed by treating them with propylene oxide. Further, 
samples were dried and mounted on the glass cover slip, which is kept over the specimen 
stub, and a conductive glue (silver paste or graphite) was applied between them in order to 
have connectivity as well as conductivity between them.  Mr. Manfred Bovi, Pathology 
Institute, University Clinics RWTH Aachen University performed SEM measurements. 
 
4.2.3. Atomic force microscopy (AFM) 
A drop (5 μL) of the sample (USPIO, FLUSPIO) solutions was deposited onto a 
polymer membrane providing a very flat surface for visualizing nanoparticles (Nucleopore 
0.1μm, Whatman). These samples were left to dry in a fume hood for 1.5 h. A circular shaped 
deposit was formed. Structurally the circular deposit consists of a tidemark which is a high 
concentration of the particle aggregates formed on the edge of the dried droplet, and the 
central region enclosed where a low concentration of the particle aggregates is evident. 
Tapping mode imaging was subsequently performed on both of these regions. 
All AFM images were taken in the Tapping Mode on a Multimode Nanoscope IIIa 
instrument (Veeco, USA) using Budget Sensors Tap300 probes. Imaging parameters were 
continually adjusted to provide the best resolution and phase contrast. Images are shown with 
topography on the left and phase images on the right. Both images are recorded 
simultaneously from the same area of sample. Phase images can highlight features not shown 
clearly in the topography, and present contrast based on variations in mechanical or surface 
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chemical material properties. Dr. Matt Bunker, Molecular Profiles Ltd, Nottingham, UK 
performed AFM measurements. 
 
4.2.4. Dynamic light scattering (DLS)  
Dynamic light scattering (DLS) measures Brownian motion and relates this to the size 
of the nanoparticles. Brownian motion is the random movement of particles due to the 
bombardment by the solvent molecules that surround them. DLS is concerned with 
measurement of particles suspended within a liquid. The larger the particle, the slower will be 
the Brownian motion. Smaller particles are “kicked” further by the solvent molecules and 
move more rapidly. The temperature also needs to be maintained as constant; otherwise 
convection currents in the sample will cause the non-random movements that will ruin the 
correct interpretation of size. The velocity of the Brownian motion is defined by a property 
known as the translational diffusion coefficient (D). DLS measurements were conducted with 
glass cuvette with square aperture (PCS1115) by using a Nanosizer ZS (Malvern Instruments, 
Malvern, United Kingdom). DLS of USPIO, FLUSPIO, and FAD USPIO were measured 
using Nanosizer ZS in different physiological solutions in addition to acidic and basic 
solutions respectively. The NUSPIO particle size prepared by different purification methods 
were measured in water at 23.6 °C using MICROTRAC-UPA 150 using polystyrene cuvettes 
and 386 mV as reflected power respectively. DLS measurements were performed at the DWI, 
RWTH Aachen University. 
 
4.2.5. Zeta potential 
The liquid layer surrounding the nanoparticle consists of two parts (regions); an inner 
region (stern layer) where the ions are strongly bound and an outer (diffuse) region where 
they are less firmly associated. Within the diffuse layer there is a notional boundary, inside 
which the ions and particles form a stable entity. When a particle moves (e.g., due to gravity), 
ions within the boundary move it. Those ions beyond the boundary stay with the bulk 
dispersant. The potential at this boundary (surface of hydrodynamic shear) is the zeta 
potential. The surface charge of USPIO, FLUSPIO and FAD USPIO nanoparticles was 
determined by measuring the zeta potential as a function of the pH value of USPIO and FAD 
USPIO suspensions with clear disposable zeta cell (DTS1060C) by using a zetasizer (Nano 
sizer, Malvern Instruments). Zeta potential measurements were performed at the DWI, 
RWTH Aachen University. 
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4.2.6. X-ray powder diffraction (XRD) 
The crystal structures of the USPIO, FLUSPIO, and FAD USPIO particles were 
characterized by using the powder diffractometer STOE STADI P equipped with an IP-PSD 
detector and CuKα1 –radiation (1.54059Å; STOE & Cie, Darmstadt, Germany) source. The 
diffraction pattern of the nanoparticles was compared with STOE STADIMP diffractometer 
equipped with a PSD detector and MoKα1 –radiation (0.70932Å) source where the 
fluorescence from iron is eliminated. The crystal structure of Ln-USPIO and NUSPIO 
nanoparticles were characterized by using the powder diffractometer equipped with a 
monochromatic x-ray source (CuKα1 1.5406 A) and calibrated against NIST1976 Corundum 
standard reference material. Scans were recorded from 10 to 140° (2θ), with a 0.10° (2θ) step 
and a counting rate of 1.2 s per step at RT. Dr. Paul Müller, Inorganic Chemistry Institute, 
RWTH Aachen University and Dr. Matt Bunker, Molecular Profiles Ltd, Nottingham, UK 
performed powder XRD measurements. 
 
4.2.7. Fourier-Transform Infra Red (FT-IR) 
Functional groups in FMN, GMP, FAD, Naphthalene sulfonates, USPIO, FLUSPIO, 
NUSPIO, and FAD USPIO were characterized by using FT-IR spectroscopy [Perkin Elmer - 
Spectrum 100 FT-IR Spectrometer] using the KBr pellet technique with a resolution of  
4 cm
-1
. Mr. Maik Jacob, from Prof. Peter Comba´s group, Inorganic Chemistry Institutes, 
University of Heidelberg performed FT-IR measurements. 
 
4.2.8. Elemental analysis (C,H,N analysis) 
The organic elementary analysis of FLUSPIO and FAD USPIO was performed in the 
analytical laboratories of the Chemical Institutes at the University of Heidelberg on a Vario 
EL analysis instrument with a thermal conductivity detector (Elementar, Germany).  
 
4.2.9. Thermo gravimetric analysis (TGA) 
Thermo gravimetric analysis of fluorescent FMN, GMP, FAD, FLUSPIO, and FAD 
USPIO was performed using a Shimadzu TGA-50H device, by heating the samples in an 
alumina crucible in presence of inert nitrogen atmosphere at a heating rate 20 °C/min from 0 
to 600 °C. Mr. Friedrich Haulena, DWI, RWTH Aachen University performed TGA 
measurements. 
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4.2.10. SQUID magnetometry 
The magnetic susceptibility of the fluorescent nanoparticles (FLUSPIO) and USPIO 
was determined using SQUID magnetometry (Quantum Design MPMS-5XL) in the field 
range of B = 5.0 to – 5.0 T and at RT (T = 290.0 K). The data were corrected for the sample 
holder (Teflon capsules) and the diamagnetic contribution of the compound. Mr. Manfred 
Spieldrich, Inorganic Chemistry Institute, RWTH Aachen University performed the SQUID 
measurements. 
 
4.2.11. MR relaxometry 
Nuclear MR relaxometry of FLUSPIO and FAD USPIO nanoparticles was performed 
in a clinical 3T whole-body MR scanner (PHILIPS Achieva, The Netherlands) using a knee 
coil (SENSE-flex-M, PHILIPS, The Netherlands) at RT in University Clinics RWTH Aachen 
University. FLUSPIO and FAD USPIO were diluted in deionized water at concentrations 
ranging from 0.001 to 100 µg of Fe/0.3 mL. For MR measurements 0.3 mL/well of diluted 
FLUSPIO/FAD USPIO solution was filled in custom made phantoms (Greiner 96 well Flat 
Transparent Polystyrol microplate, Germany). Transverse relaxation times (T2) were 
measured in 2 D scan mode using a multi-slice, multi shot spin echo sequences with 90° 
excitation pulses followed by a train of  equally spaced 180° refocusing pulses  [TR = 1500 
ms, mTR = 1189 ms, TE = 8.1 ms (shortest), number of echoes = 20, inter-echo spacing = 8.1 
ms, FOV = 130 x 162.5,  reconstruction matrix = 64 x 81, voxel size = 2 x 2, slice thickness = 
3 mm, slice orientation = coronal, scan mode = multishot (MS)]. Transverse relaxation times 
(T2) were measured in 3 D scan mode using a multi-slice, multi shot spin echo sequences 
with 90° excitation pulse followed by a train of equally spaced 180° refocusing pulses [TR = 
1500 ms, mTR = 716 ms, TE = 11.8 ms (shortest), number of echoes = 20, inter-echo spacing 
= 12 ms, FOV =  130 x 162.5  x 18 mm, reconstruction matrix = 64 x 81, voxel size = 2 x 2 x 
3, slice orientation = coronal, scan mode = 3 D, TSE turbo direction = Y].  T2 relaxation 
times were calculated by a linear fit of logarithmic region of interest (ROI) signal amplitudes 
versus echo time (TE).  Longitudinal relaxation times (T1) were determined using a multi 
shot spin echo sequences with 10° excitation pulse without refocusing pulse [TR = 6.8 ms, 
TE = 3.3 ms (shortest), number of echoes = 1, FOV = 170 x 148.75 mm, reconstruction 
matrix = 152 x 130, voxel size = 1.12 x 1.11, slice thickness = 5 mm, slice orientation = 
coronal, scan mode = 2 D, cardiac synchronization = ECG trigger, cardiac frequency = 30]. 
Relaxivities r1 and r2 were determined by a linear fit of the inverse relaxation times as a 
function of the iron concentrations. Nuclear MR relaxometry of the NUSPIO nanoparticles 
was performed using a clinical 1.5 T whole-body MR system (Siemens Symphony, Erlangen, 
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Germany) in combination with a custom-made radio frequency coil for excitation and signal 
reception. The radio frequency coil was designed as a cylindrical volume resonator with an 
inner diameter of 83 mm and a usable length of 120 mm. To optimize the available signal-to-
noise ratio, manual tuning and matching of the coil‟s resonance circuitry was performed for 
each measurement. NUSPIO nanoparticles were diluted in distilled water at concentrations 
between 0.001 and 100 µg of Fe/mL. For MR measurements 0.5 mL NUSPIO dilutions were 
filled in 1 mL Eppendorf vials each. T2 relaxation times were measured using a standard 
Carr-Purcell-Meiboom-Gill pulse sequence (TR = 2000 ms, TE range 30-960 ms, 32 echoes, 
FOV = 134 x 67 mm, matrix 128 x 64, slice thickness 10 mm, BW = 40, NEX = 3). T1 
relaxation times were determined using a T1w saturation recovery turbo FLASH sequence, 
thereby varying the inversion time, TI(TR = 7160 ms, TE = 1.67 ms, TI = 900-4000 ms, FOV 
= 200 x 150 mm, matrix 52 x 128, slice thickness 2 mm), respectively. 
 
4.2.12. Fluorescence Spectroscopy and Microscopy 
The absorbance spectra of USPIO, FMN, FMN with GMP, and FLUSPIO were 
recorded in water and various buffer solutions using the TECAN Infinite M200 (Tecan 
Austria GmbH) plate reader at RT (iron concentration range: 10
-6
 M to 10
-12
 M). FAD, FAD 
USPIO absorbance spectra were only recorded in water. The absorbance measurements were 
performed on a 96-well plate (Greiner Bio-one 96 well flat transparent polystyrol microplate, 
Germany). Additionally, the absorbance spectra of the moieties (i.e. FMN, FLUSPIO) in 
water were recorded after 3 d exposure to daylight.  The fluorescence spectra of FMN and 
FLUSPIO were recorded in water and various buffer solutions (TRIS, TES, HEPES, sodium 
phosphate) at RT using the TECAN Infinite M200 (Tecan Austria GmbH) plate reader (iron 
concentration range: 10
-6
 M to 10
-12
 M). FAD, FAD USPIO fluorescence spectra were only 
recorded in water respectively. The fluorescence measurements were performed using a 96-
well plate (Greiner Bio-one 96 well, F-bottom (chimney well), fluorotrac 600 black 
polystyrene microplate, Germany). Further, we exposed FMN and FLUSPIO to daylight for 3 
days in order to study the effect of daylight on their emission intensity. 
The fluorescence spectra of organic dyes (naphthalene sulfonates, FITC, RITC) and 
NUSPIO was measured in water and different buffer solutions using aminco-bowman series 2 
fluorescence spectrophotometer (Thermo electron corporation, Germany).  
The fluorescence intensity of FLUSPIO and FAD USPIO nanoparticles was checked 
using a fluorescence microscope (Axio Imager M2, Carl Zeiss, Germany). Additionally, 
fluorescence intensity of Ln-USPIO, NUSPIO was evaluated using an epifluorescence 
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microscope (Olympus, Model BX50, Germany) with an added fluorescence device 
respectively. In brief, 3 to 5 µL of the fluorescent nanoparticles in water was placed in the 
microscopic observation slides (75 x 26 mm, R. Langenbrinck, Emmendingen, Germany) and 
they were fixed with a cover slip (round, 12 mm, Carl Roth GmbH, Karlsruhe, Germany). 
Further, the samples were directly examined under the fluorescence microscope for their 
fluorescence intensity and for visualizing the surface morphology and shape (spherical 
morphology and degree of agglomeration) of the nanoparticles. These preliminary 
microscopic examinations were carried out for all batch preparations and their fluorescence 
ability was validated prior to their intended in vitro experiment. 
 
4.2.13. Energy dispersive X-ray (EDX) analysis 
The chemical composition of the FLUSPIO and FAD USPIO nanoparticles was 
determined by SEM [FEI (PHILIPS) ESEM XL 30 FEG; EDAX Falcon genesis]. FLUSPIO 
and FAD USPIO in water were dried under high vacuum conditions. Further, the dry samples 
were mounted on specimen stub with silver paste or graphite and EDX spectrometric analysis 
was measured by employing 20 kV as the EDX accelerating voltage. 
 
4.2.14. NMR spectroscopy 
            NMR spectra were recorded at 199.92 MHz (
1
H) and (
13
C) on a Bruker DRX200 
instrument. For 
1
H and 
13
C spectra, the respective solvent peak was used as reference for the 
chemical shift δ. In case of the TMS added deutrated solvent, the peak from TMS was used as 
the reference for the chemical shift δ. For the chemical investigation using NMR, deutrated 
chloroform, water, methanol and DMSO was used respectively. The following abbreviations 
are used for signal multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, br = broad 
singlet or broad multiplet, m = multiplet. The measurements were performed at Inorganic 
Chemistry Institute, Heidelberg University. 
 
4.2.15. Mass spectrometry 
4.2.15.1. ESI Mass spectrometry 
              Electrospray ionization (ESI) mass spectrometry is a “soft” (i.e. fragmentation free) 
method for the analysis of charged molecules and supramolecular compounds present in the 
solution. Analysis of small organic molecules, metal complexes, biomolecules (peptides), 
nucleic acids, spacers (polyethylene glycol and derivatives) and phospholipids can be carried 
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out using ESI Mass spectrometry. ESI mass spectra of the samples were measured in 
methanol on an ICR Apex-Qe instrument using ESI pos HPmix 550-2800 m/z and ESI neg 
Arginin 100-900/150-1300 m/z methods. The measurements were performed at the Institute 
of Organic Chemistry, Heidelberg University.   
 
4.2.15.2. TOF-SIMS Spectrometry 
              Time-of-Flight Secondary Ion Mass Spectrometry (TOF-SIMS) uses a pulsed 
primary ion beam to desorb and ionize species from a sample surface. The resulting 
secondary ions are accelerated into a mass spectrometer, where they are mass analyzed by 
measuring their time-of-flight from the sample surface to the detector. There are three 
different modes of analysis in TOF-SIMS; 1) mass spectra are acquired to determine the 
elemental and molecular species on a surface; 2) images are acquired to visualize the 
distribution of individual species on the surface; and 3) depth profiles are used to determine 
the distribution of different chemical species as a function of depth from the surface.  
                An image is generated by rastering a finely focused beam across the sample 
surface. Due to the parallel detection nature of TOF-SIMS, the entire mass spectrum is 
acquired from every pixel in the image. The mass spectrum and the secondary ion images are 
then used to determine the composition and distribution of sample surface constituents. 
                TOF-SIMS provides spectroscopy for characterization of chemical composition, 
imaging for determining the distribution of chemical species, and depth profiling for thin film 
characterization. TOF-SIMS analysis of FMN, GMP, and FLUSPIO were carried out in order 
to evaluate the chemical composition of the fluorescent nanoparticles. Dr. Matt Bunker, 
Molecular Profiles Ltd, Nottingham, UK performed TOF-SIMS measurements. 
 
4.2.15.3. ICP-MS Spectrometry 
The amount of iron present in nanoparticles (USPIO, APTMS-USPIO and FLUSPIO) 
was determined by high-resolution sector field ICP-MS (Element 2, Thermo Electron, 
Bremen, Germany) equipped with an autosampler (ASX-100, CETAC, Omaha, NE). Data 
were acquired at medium resolution (4000) using rhodium (5 ppb) as an internal standard. A 
PFA spray chamber equipped with a PFA 100 microflow nebulizer (CETAC) was used for 
sample introduction. The instrument was tuned and calibrated via infusion of a 1 ng/mL multi 
element standard solution (Merck, Darmstadt, Germany). Digestion of the USPIO, APTMS-
USPIO and FLUSPIO was performed in a closed vessel microwave reaction system (CEM, 
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Kamp-Linfort, Germany) after addition of 53% nitric acid (60%) at 3 bar and 600 Wfor 50 
min. Samples were diluted 1:200 in H2O. Calibration was linear between 2 and 150 ng/mL 
iron (r>0.999). The iron content was expressed in nanograms of iron per mL. Mr. Sven 
Thöree, Hygiene department, University Clinics RWTH Aachen University performed ICP-
MS measurements. 
 
4.2.16. pH meter 
pH values were adjusted at 25 ºC with a Mettler Toledo pH meter equipped with a 
KCl electrode and calibrated with pH standard solutions at pH 4.01,7.00 and 9.21 
respectively. 
 
4.2.17. X-ray photon electron spectroscopy 
X-ray photoelectron spectroscopy (XPS) is a surface chemical analysis technique with 
the capability of determining elemental composition, oxidation state, empirical formula and 
impurities present in a sample. XPS takes advantage of the photoelectric effect. It measures 
the kinetic energy of the electrons that are ejected from a sample after irradiation by x-rays. 
The kinetic energy of an ejected electron is related to the binding energy of that electron for a 
certain atom. In this way, binding energies can be used to assign peaks to atoms in a typical 
spectrum. XPS of USPIO and FLUSPIO were measured in order to evaluate the coating 
efficiency of FMN, GMP through their binding energy to the surface of iron oxide 
nanoparticles. Dr. Matt Bunker, Molecular Profiles Ltd, Nottingham, UK performed XPS 
measurements. 
 
4.2.18. Absolute quantum yield and fluorescence lifetime measurements 
Absolute quantum yield measurements of FLUSPIO was measured using a custom 
made fluorescence set up (integrated sphere set up) without using any fluorophore standard 
which is often used in determining the relative quantum yield. Fluorescence lifetime of 
FLUSPIO was measured in order to evaluate the lifetime of FMN on the USPIO surface and 
to check their photostability. Dr. Ute Resch, BAM Federal Research Institute, Berlin 
performed absolute quantum yield and fluorescence lifetime measurements. 
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Formulation techniques 
4.3. Ligand synthesis 
Column chromatography was performed using 230 – 400 mesh silica gel. Thin-layer 
chromatography (TLC) was performed using TLC Silicagel 60F254 25 Al sheets 20X20 cm 
(Merck KGaA, Darmstadt, Germany). Solvents for organic synthesis were of standard quality 
( p.a. grade) and used without further purification. Dry solvents were purchased form Sigma-
Aldrich, stored over molecular sieves and used without further purification. All chemicals 
were used without further purification. The hydrochloride from 9-aminoacridine and quinine 
hydrochlorides was removed by washing it with the saturated K2CO3 and further they were 
extracted with ethyl acetate. The separated organic layer was dried over Na2SO4 and rotatory 
evaporated to generate 9-amino acridine and quinine respectively. 
 
4.3.1. Synthesis of (2-([2-(Diethoxy-phosphoryl)ethyl]-naphthalen-1-ylmethyl-amino)-
ethyl)-phosphonic acid diethyl ester 
 
 
In a typical synthesis, a mixture of aminomethylnaphthalene (0.5 g, 3.18 mmol) and 
diethyl vinylphosphonate (3.13 g, 19.08 mmol, 6 equiv) in 10 mL of dry methanol was 
refluxed for 5 days
[211]
. The solvent was evaporated and the crude product was purified by 
column chromatography using silica gel as the solid phase and a mixture of CH2Cl2-methanol 
(20:1=v:v) as the mobile phase. The product was separated as a colourless gummy liquid 
(Yield 50%). 
Molecular Formula:  C23H37NO6P2      Molecular weight :  485.59 
1
H-NMR (400 MHz, CDCl3): δ = 8.05 (m, 2H, CH), 7.67 – 7.80 (m, 4H, CH), 7.33 – 7.46 (m, 
8H), 4.18 (m, 8H, CH2), 2.96 (m, 4H, N-CH2), 1.89 – 2.05 (m, 4H, CH2-P), 1.19 (m, 12 H, 
CH3) 
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13
C-NMR (400 MHz, CDCl3): δ = 133.8, 132.8, 127.7, 126.9, 125.2, 124.6, 122.5 (CH), 
60.72 (PO-C), 49.97, 42.09 (N-C), 26.6, 23.8 (P-H2C), 15.4 (H3C)  
 
4.3.2. Synthesis of [2-naphthalen-1-ylmethyl-(2-phosphono-ethyl)amino]ethyl]-
phosphonic acid  
 
 
 
To a solution of (2-([2-(diethoxy-phosphoryl)ethyl]-naphthalen-1-ylmethyl-amino)-
ethyl)-phosphonic acid diethyl ester (0.08 g, 0.16 mmol), in dry CH2Cl2 (5 mL), 
bromotrimethylsilane (0.4 g, 2.6 mmol, 16 equiv) was added in three different portions at 15 
min intervals. The mixture was stirred for 60 min after the addition of the last portion. 
Evaporation of the solvent along with excess bromotrimethylsilane under reduced pressure 
afforded the crude product which was washed and triturated with hexane (3 X 15 mL) to get 
the pure product as a white solid (Yield 50%). 
Molecular Formula: C15H21NO6P2        Molecular weight:    373.28 
1
H-NMR (400 MHz, CD3OD): δ = 8.24 (d, 1H), 8.03 (t, 2H), 7.52 – 7.77 (m, 4H), 4.09 (m, 
2H), 2.21 – 2.43 (m, 4H), 1.33 (m, 4H)  
13
C-NMR (400 MHz, CD3OD): δ = 135.4, 132.6, 131.7, 130.5, 130.1, 128.6, 128.3, 127.6, 
126.5, 124.0 (CH), 64.08 (C-C), 43.0. 43.8 (N-CH2), 25.8, 25.0, 23.0, 22.2 (P-C) 
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4.3.3. Synthesis of 4-(9-aminoacridinium-10-yl)butane-1-sulfonate  
 
 
In brief, toluene (30 mL), 9-aminoacridine (0.68 g, 3.5 mmol) and 1,4-butane sultone 
(0.54 mL, 5.25 mmol) were heated under reflux for 3 days
[212]
.  Further, the reaction mixture 
was allowed to cool to RT. The resulting orange solid was filtered and washed with acetone. 
Furthermore, they were re-crystallized with methanol and ethanol mixture (1:2) by gentle 
warming and cooling them to RT and then at 4°C. The crystals were collected and dried in 
vacuum (Yield 45%). 
Molecular Formula:    C17H18N2O3S      Molecular Weight:      330.40 
1
H-NMR (400 MHz, DMSO d6): δ = 8.65 (m, 2H, CH), 8.47 (m, 2H, CH), 8.24 (m, 2H, CH), 
8.10 (m, 2H, CH), 7.52 – 7.68 (m, 2H, CH), 4.65, 4.79 (m, 2H, N-CH2), 2.50 (m, 2H, S-CH2), 
1.67 (m, 2H, S-CH2-CH2), 1.94 (m, 2H, N-CH2-CH2) 
 
4.3.4. Synthesis of 4-(4-((R)-hydroxy((2S,4S,8R)-8-vinylquinuclidin-2-yl)methyl)-6-
methoxyquinolinium-1-yl)butane-1-sulfonate  
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The mixture of 1,4-butane sultone (0.16 mL, 1.57 mmol) and quinine (0.34 g, 1.04 
mmol) in 10 mL of toluene was heated under reflux for 21 h. The reaction mixture was 
allowed to cool to RT. The resulting pink solid was filtered and washed with toluene and 
acetone. Further, the crude product was re-crystallized with methanol and ethanol mixture 
(1:2).  The crystalline solid was collected and dried in vacuum (Yield 97%). 
Molecular Formula:   C24H32N2O5S      Molecular weight:      460.59 
1
H-NMR (400 MHz, D2O): δ = 8.65 (m, 1H, CH), 7.72 – 7.86 (m, 2H, CH), 7.63 (br, 1H, 
CH), 7.32 (m, 1H, CH), 7.19 (m, 1H, CH), 7.07 (m, 1H, CH), 5.87 (s, 1H, C=CH), 5.08 (br, 
2H, C=CH2), 4.86 (m, 3H, N
+
-CH2, C-CH), 3.98 (m, 3H, O-CH3), 3.58 (br, 1H, C-OH), 2.86 
(br, 1H), 2.19 – 2.29 (m, 5H), 1.99 (br, 5H), 1.26 (m, 2H) 
 
4.3.5. Synthesis of  sodium 3,3’-(1’Z)-(4,4’-((E)-ethene-1,2-diyl)bis(4,1-
phenylene))bis(diazene-2,1-diyl)bis(5-amino-4-hydroxynaphthalene-2,7-disulfonate)  
 
 
 
A mixture of 4,4‟-diaminostilbene dihydrochloride (0.25g, 0.88 mmol), 5 mL of water 
and 0.37 mL of 37% HCl was heated until the solution was clear. After cooling the above 
solution down to 0 – 5 °C, NaNO2 (0.122g, 1.76 mmol) in a minimum amount of water was 
added dropwise to the solution and the diazotization was continued for 2 h (colour of the 
solution changed from light brown to reddish brown). The as-prepared diazonium salt was 
added into the coupling solution having H-acid (0.663 g, 1.94 mmol) dissolved in 50 mL of 
water at pH 7 and further to facilitate the coupling reaction, the pH of the solution was 
maintained between 8 and 9 (color of H-acid changed from brown  into dark violet colour).  
Further, the solution was stirred for 2 h and 25 mL of NaCl solution (3 wt%) was added to the 
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final solution
[213;214]
. The precipitate formed was filtered, washed with water and dried in a 
vacuum oven. The crude product was purified by refluxing in ethanol for 2 h, which was 
filtered and washed with hot ethanol and subsequently dried in oven (Yield 50%). 
Molecular Formula:    C34H22N6Na4O14S4       Molecular weight   :     958.79 
 
1
H-NMR (400 MHz, D2O): δ = 7.48 -7.59 (br, 3H, CH), 7.09 – 7.29 (br, 8H, CH), 6.93 (br, 
2H, C=CH) 
 
4.3.6. Synthesis of sodium 3,3’-(1’Z)-(4,4’-((E)-ethene-1,2-diyl)bis(3-sulfonato-4,1-
phenylene))bis(diazene-2,1-diyl)bis(5-amino-4-hydroxynaphthalene-2,7-disulfonate)  
 
 
 
A mixture of 4,4‟-diamino-2,2‟-disulfonato stilbene dihydrochloride (0.25g, 0.67 
mmol), 5 mL of water and 0.37 mL of 37% HCl was heated until the solution became clear. 
After cooling the above solution to 0 – 5 °C, aqueous solution of NaNO2 (0.093g, 1.35 mmol) 
was added dropwise to the above acidified solution and the diazotization was continued for 2 
h (colour of the solution changed from light brown to reddish brown). Then, H-acid (0.506g, 
1.48 mmol) was dissolved in 50 mL of water at pH 7. Without further purification the 
diazonium salt liquor was added into the coupling solution and pH of the solution was 
maintained between 8 and 9 (color of H-acid changed from ivory (cream) into dark violet 
colour). The reaction mixture was stirred further for 2 h and 25 mL of NaCl solution (3 wt%) 
was added in order to quench the reaction. The resulting crude product was refluxed in 
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ethanol for 2 h, filtered and washed with hot ethanol and subsequently dried in oven (Yield 
50%). 
Molecular Formula:  C34H20N6Na6O20S6         Molecular weight   :  1162.88 
1
H-NMR (400 MHz, D2O): δ = 8.09 (br, 4H, CH), 7.94 (br, 2H, CH), 7.80 (br, 2H, CH), 7.60 
(br, 2H, CH), 7.36 (br, 2H, CH), 7.17 (br, 2H, CH), 7.04 (br, 2H, HC=CH) 
 
4.3.7. Synthesis of 2-(6-hydroxy-2-naphthamido)ethyl phosphonic acid  
 
 
 
The carboxylic acid group of 6-hydroxy-2-naphthoic acid (0.20g, 1.06 mmol) was 
activated in dry DMF (15 mL) by adding 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) (0.24g, 1.27 mmol) at 0 ºC for 10 min.  To further enhance the activation of 
carboxylic group and to increase the reaction yield, 1-hydroxybenzotriazole (HOBt) (0.17g, 
1.27 mmol) and N,N-diisopropylethylamine (DIPEA) (0.58 mL, 3.40 mmol) were added
[215]
. 
2-aminoethyl phosphonic acid (0.22 g, 1.59 mmol) was added to the above solution at 0 ºC.  
The reaction mixture was stirred at 0 ºC for 2 – 5 h. Further, the reaction was allowed to 
proceed overnight at RT. The completion of the reaction was checked and monitored using 
TLC (70% chloroform and 30% methanol). The reaction mixture was filtered and DMF was 
removed and dried. Final residue after drying was dissolved in minimum amount of water 
and extracted twice with diethyl ether. The final product is recrystallized from water (Yield 
55%). 
Molecular Formula:  C13H14NO5P          Molecular weight   :  295.23 
1
H-NMR (400 MHz, CD3OD): δ =  7.83 – 7.88 (m, 2H, CH), 7.70 – 7.75 (m, 2H, CH), 7.42 – 
7.57 (m, 2H, CH), 3.28 – 3.31 (m, 2H, NH-CH2), 2.14 (br, 2H, P-CH2) 
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4.3.8. Synthesis of 1-(6-hydroxy-2-naphthoyloxy)ethane-1,1-diyldiphosphonic acid by 
Mitsunobu reaction  
 
 
6-hydroxy-2-naphthoic acid (0.185 g, 0.98 mmol) and 1-hydroxyethane-1,1-
diyldiphosponic acid (0.20 g, 0.89 mmol) was dissolved in anhydrous DMF (7.5 mL). To the 
DMF solution, triphenylphosphine (0.468 g, 1.78 mmol), diethyl azodicarboxylate 
(DEAD)(0.041 mL, 0.089 mmol) and iodosobenzene diacetate (0.575 g, 1.78 mmol) were 
added
[216]
. The reaction mixture was stirred at RT for 16 – 24 h and the completion of the 
reaction was checked using TLC. After completion of the reaction, the DMF was removed by 
rotatory evaporation and the final residue was diluted in minimum amount of water and 
solubility was facilitated by sonication followed by washing twice with diethyl ether for 
removal of organic impurities. The final product was recrystallized from water (Yield 45%) 
Molecular Formula:  C13H14N9O2     Molecular weight   : 376.19 
1
H-NMR (400 MHz, D2O): δ = 8.80 – 8.84 (br, 1H, CH), 8.61 – 8.69 (br, 1H, CH), 8.10 – 
8.14 (br, 2H, CH), 7.95 (br, 1H, CH), 7.76 – 7.80 (br, 1H, CH), 1.55 – 1.71 (m, 3H, CH3)   
 
4.3.9. Synthesis of potassium (S)-7-(2-amino-3-(1Hindol-3-yl)propanamido)-3-
sulfonaphthalene-1-sulfonate 
 
 
 
The carboxylic acid group of tryptophan (0.20g, 0.97 mmol) was activated in dry 
methanol (15mL) by adding 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (0.23g, 
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1.17 mmol) at 0 ºC for 10 min. To further promote the activation of carboxylic group, 1-
hydroxybenzotriazole (HOBt) (0.16g, 1.17 mmol) and N,N-diisopropylethylamine (DIPEA) 
(0.54 mL, 3.13 mmol) were added. ANDS (0.53 g, 1.47 mmol) was added to the above 
solution at 0 ºC. The reaction mixture was stirred at 0 ºC for 2 – 3 h and further allowed to 
proceed overnight at RT. The completion of the reaction was monitored using TLC (60% 
chloroform and 40% methanol). The methanol from reaction mixture was rotatory 
evaporatored. The residue obtained was washed with chloroform and hexane in order to 
remove the impurities. Further, the residue was dissolved in methanol and the solution was 
filtered and triturated with diethyl ether to extract the pure product. (Yield 45%) 
Molecular Formula: C21H18KN3O7S2           Molecular weight   : 527.61 
1
H-NMR (400 MHz, D2O): δ = 8.30 – 8.48 (m, 1H, CH), 7.73 (m, 1H, CH), 7.67 -7.68 (m, 
2H, CH), 7.08 – 7.16 (m, 2H, CH), 7.33 – 7.36 (m, 1H, CH), 7.00 (br, 1H, CH), 3.46, 3.17 
(m, 2H, C-CH2) 
 
4.3.10. Synthesis of sodium 4-hydroxy-5-oleamido-7-sulfonaphthalene-2-sulfonate 
 
 
 
 
The carboxylic acid group of oleic acid (0.20g, 0.71 mmol) was activated in dry 
methanol (10 mL) by adding 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (0.16g, 
0.85 mmol) at 0 ºC for 10 min. The activation of carboxylic group was promoted and to 
increase the reaction yield, HOBt (0.11g, 0.85 mmol) and DIPEA (0.38 mL, 3.2 mmol) were 
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added. H-acid (0.36 g, 1.06 mmol) was added to the above solution at 0 ºC. The reaction 
mixture was stirred at 0 ºC for 5 h
[217]
 and further reacted overnight at RT. The reaction 
mixture in methanol was neutralized with drops of acetic acid in methanol to pH 7.  The 
methanol was rotatory evaporated and the residue obtained was washed with chloroform and 
hexane. Further, the residues were dissolved in methanol and filtered followed by trituration 
with diethyl ether to generate the pure product. (Yield 50%) 
Molecular Formula : C28H40NNaO8S2                  Molecular weight    : 605.74 
1
H-NMR (400 MHz, D2O): δ = 7.07 – 7.36 (m, 4H, CH), 7.26 (br, 1H, OC-NH), 5.35 (m, 2H, 
HC=CH), 2.37 (m, 2H, OC-CH2), 2.05 (m, 4H, H2C-CH=CH-CH2), 1.64 (m, 2H, OC-CH2-
CH2), 1.27 (m, 20H, CH2), 0.91(m, 3H,CH3) 
 
4.3.11. Synthesis of potassium 7-oleamido-3-sulfonaphthalene-1-sulfonate  
 
 
 
ANDS (0.25g, 0.69 mmol) and oleoyl chloride (2.06 mL, 6.23 mmol) were heated to 
120 – 125 °C followed by addition of dry pyridine (20 mL) which was further heated under 
reflux for 4 h. Excess pyridine was removed by distillation and the solid mass thus obtained 
was dissolved in chloroform. Further, they were washed twice with methanol and filtered. 
The filtrate was triturated with diethyl ether and the separated solid was filtered to yield the 
product (Yield 40%) 
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Molecular Formula: C28H40KNO7S2          Molecular weight   : 605.85 
1
H-NMR (400 MHz, D2O): 11.08 (s, 1H, exchangeable with D2O), 9.13 (s, 1H, CH), 8.66 (s, 
1H, CH), 8.18 (s, 1H, CH), 7.88 (br,1H, CH), 7.65(br, 1H, CH), 5.45 (m, 2H, HC=CH), 2.42 
(m, 2H, OC-CH2), 2.14 (m, 4H, H2C-CH=CH-CH2), 1.72 (m, 2H, OC-CH2-CH2), 1.40 (s, 18 
H, CH2), 1.00 (s, 3H, CH3). 
 
4.3.12. Synthesis of (S)-2-(2-amino-3-(1H-indol-3-yl)propanamido)ethyl phosphonic acid  
 
 
 
The carboxylic acid group of tryptophan (0.20g, 0.98 mmol) was activated in dry 
DMF (15 mL) by adding 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (0.23g, 
1.17 mmol) at 0 ºC. The activation was facilitated by HOBt (0.16g, 1.17 mmol) and DIPEA 
(0.53 mL, 3.13 mmol) addition. 2-aminoethyl phosphonic acid (0.21 g, 1.46 mmol) was 
added to the above solution and the reaction mixture was stirred at 0 ºC for 2 – 5 h. Then, the 
reaction was allowed to react at RT for 24 h. The completion of the reaction was often 
checked using TLC (85% chloroform and 15% methanol). Excess DMF from the reaction 
mixture was removed under high vacuum. Then it was washed with chloroform, filtered and 
filterate was evaporated. The residue after drying was dissolved in methanol and extracted 
twice with diethyl ether. The final product could not be recovered from the above solvents. 
Methanolic solution of the final product was heated and allowed to crystallize at 4°C. 
Unfortunately, the product didn‟t crystallize out of the methanolic solution.  
Molecular Formula:  C13H18N3O4P          Molecular weight  : 311.27 
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4.4. Iron oxide nanoparticles synthesis (USPIO) 
The iron oxide nanoparticles were prepared either in aqueous or in organic phase. In 
aqueous solution, they were prepared by co-precipitation of ferric and ferrous salts by using a 
base. In organic phase, nanoparticles were prepared under thermal decomposition of iron 
precursors and the solvent used itself acts as a capping agent that stabilizes the generated iron 
oxide nanoparticles.   
4.4.1. Synthesis of iron oxide nanoparticles (10-12 nm)  
Ultrasmall superparamagnetic iron oxide nanoparticles (USPIO), were prepared as 
described below
[172]
. An aqueous solution of sodium hydroxide (250 mL, 0.5 M) was 
maintained at 80 ºC in a three necked reaction flask with mechanical stirring and further it 
was degassed using inert nitrogen as the cover gas.  Aqueous  solutions of FeCl3 (25mL, 1 M 
in 0.2M HCl) and FeCl2 (25 mL, 0.5M in 0.2M HCl) were added to a mechanically stirred 
solution of NaOH within 5 min under an inert nitrogen atmosphere at 80 °C. On addition a 
black precipitate of magnetite is formed immediately. The nanoparticle formation was 
allowed to proceed for 20 min at 80 °C. After the reaction time, subsequently the 
nanoparticles formed were cooled to ambient temperature. The nanoparticles were separated 
from the parent solution by using an external magnetic field, and washed three times with de-
ionized water, and dispersed into 100 mL of aqueous hydrochloric acid (0.01 M). The size of 
the magnetic cores was tuned by varying the concentration of the basic solution used for the 
nanoparticle synthesis (1.0, 1.5 M NaOH).  
4.4.2. Synthesis of iron oxide nanoparticles (10 nm)  
Ultrasmall SuperParamagnetic Iron Oxides (USPIO) nanoparticles were synthesized 
by co-precipitation of ferrous (Fe
2+
) and ferric (Fe
3+
) salts in aqueous alkaline conditions by a 
modified one-part synthesis protocol
[178]
. We used stoichiometric ratio of 2Fe
3+
:Fe
2+
, 16 
mmol (2.66 g) of FeCl3 and 8 mmol (1.63 g) of FeCl2.4H2O which was dissolved in 190 mL 
de-ionized water at RT by magnetic stirring for 10 min.  Under vigorous stirring, 10 mL of 
25% NH3 were poured down the vortex of the iron solution. Immediately, magnetite was 
formed as a black precipitate. After stirring for 10 min, the nanoparticles were washed thrice 
with water and finally magnetic fluids were dispersed in 100 mL of aqueous hydrochloric 
acid (0.1 M) and stored at pH 2 for further investigations. 
4.4.3. Synthesis of iron oxide nanoparticles (5-6 nm)
 
 
USPIO were synthesized by co-precipitation of ferrous (Fe
2+
) and ferric (Fe
3+
) salts in 
aqueous alkaline conditions by a modified one-part synthesis protocol
[178]
.  Stoichiometric 
ratio of 2Fe
3+
:Fe
2+
, 16 mmol (2.66 g) of FeCl3 and 8 mmol (1.63 g) of FeCl2.4H2O was 
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dissolved in 190 mL de-ionized water at RT by magnetic stirring for 10 min.  Under vigorous 
stirring, 10 mL of 25% NH3 was poured down the vortex of the iron solution. The magnetite 
was formed as a black precipitate. After stirring for 20 min, the nanoparticles were washed 
thrice with water and cationic ferrofluid was prepared by washing two times with 0.1 M HCl 
solution under the influence of external magnetic field using a rare-earth magnet. Magnetic 
fluids were dispersed in 100 mL of aqueous hydrochloric acid (0.1 M). The USPIO were 
further sonicated for 20 min with ultrasonic cleaner (Ultrasonic cleaner, 30 W, VWR GmbH, 
Germany) at ambient temperature. Consequently, the sonicated nanoparticles were filtered 
through 0.22 µm filter units in order to get rid of the agglomerates. Additionally, USPIO 
were centrifuged at 20,000g for 20 min at ambient temperature in order to remove big 
aggregates. The final ferrofluid was collected and stored at 4 ºC at pH 2 for further use. The 
colloidal dispersion is stable for 2-3 months at ambient temperature. 
 
4.4.4. Synthesis of 2-pyrrolidione stabilized iron oxide nanoparticles (5 nm)  
Iron oxide nanoparticles with small core diameter (5 nm) were synthesized by the 
thermal decomposition of iron acetylacetonate in the presence of 2-pyrrolidione at high 
temperatures (250-270ºC)
[181;182]
.  A typical synthesis yielding iron oxide nanoparticles with 
5-nm particle diameter is described below. 20-mL of 2-pyrrolidione solution containing 2.0 
mmol Fe(acac)3 was first purged with nitrogen to remove the oxygen and then heated. After 
being refluxed at high temperature (250 -300 °C) for 10 min, the reaction system was cooled 
to RT. The iron oxide nanoparticles were precipitated from the black solution by addition of 
methanol into the 2-pyrrolidione solution which resulted in a dark-brown precipitate. The 
precipitate was washed with acetone for several times in order to remove the excess 2-
pyrrolidione and then dried in air. The final black powder was found to be soluble in water 
and 2-pyrrolidione. The weak interaction between 2-pyrrolidione and USPIO could be 
exploited and further functionalized with different coating molecules (Figure 4.1.1). The 
nanoparticles obtained indicated an average diameter of 5±1.2 nm as reported in the 
literature. 
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Figure 4.1.1. The schematic figure shows the iron oxide nanoparticles (5 nm) stabilized with the capping ligand 
(2-pyrrolidione) synthesized via thermal decomposition technique respectively. 
 
4.4.5. Synthesis of oleic acid stabilized iron oxide nanoparticles (7 nm)  
Oleic acid stabilized iron oxide nanoparticles (7 nm) were synthesized by a modified 
thermal decomposition protocol. In a typical synthesis, Fe(acac)3(2 mmol), 1,2-
hexadecanediol (10 mmol), benzyl ether (20 mL, 105 mmol), oleic acid (6 mmol) and oleyl 
amine (6 mmol) were mixed together and stirred magnetically under nitrogen flow. The 
temperature of the mixture was raised to 200 ºC. Initially, the color of the reaction mixture 
was blood red and with increase in temperature the color changed to yellow. The mixture was 
heated at 200 ºC for 30 min under a blanket of nitrogen. Further, the mixture was refluxed at 
200-250 ºC for 7-8 h which resulted in the brownish black solution which was cooled to RT. 
The iron oxide nanoparticles were retrieved from the above solution by addition of 75 mL of 
ethanol, followed by centrifugation at 900 rpm for 15 min. The resulting blackish brown 
precipitate was dried and used for further characterization
[218]
. Iron oxide nanoparticles with 
increased size can be synthesized by using the above nanoparticles with 7 nm diameter as 
seeds to grow in the iron precursor solution (Fe(acac)3).  
4.4.6. Synthesis of oleic acid stabilized iron oxide nanoparticles (8 nm)  
USPIO cores were synthesized and stabilized with oleic acid by a modified synthesis 
protocol. In a typical synthesis, to a solution of (NH4)2Fe(SO4)2.6H2O (2.04g, 5 mmol) in 50 
mL of de-ionized water were added KOH (1.14g, 20 mmol) in 20 mL water followed by 
dropwise addition of (NH4)2S2O8 (0.38 g,1.6 mmol) in 10 mL water. Subsequently, 1.5 mL 
(4.7 mmol) of oleic acid in 30 mL toluene was added and the mixture was heated (95 ºC) at 
reflux for 30 min. After cooling the reaction mixture to RT, the organic layer was extracted 
by using toluene for three to four times. The aqueous layer was collected and discarded. The 
organic layer was dried over anhydrous sodium sulphate to remove trace amounts of water. 
Then the solution was poured slowly into acetone and further centrifuged at 900 rpm for 10 
min. The precipitated iron oxide nanoparticles were collected and washed three times with 
acetone, air dried and used for further characterization
[219]
.  The ligand exchange reactions 
could be performed in order to bring the oleic acid stabilized iron oxide nanoparticles into 
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water. This could be achieved by exchanging them with either betaine- or carboxyethylsilane 
triol in ethanol and stirring for 24 h at RT followed by centrifugation and washing with 
ethanol and dried. The resulting solid is easily dispersible in water affording clear hydrosols 
of high concentration. 
4.4.7. Commercial iron oxide nanoparticles (EMG 911)  
Iron oxide nanoparticles were extracted from a commercial available ferrofluid as 
reported. In a typical process, 20 mL of acetone was added to 1 mL of ferrofluid EMG 911 
(Ferrotec, Nashua, NH) and shaken vigorously to extract iron oxide nanoparticles from the 
dispersion medium (light mineral oil). The nanoparticles were then collected with the aid of a 
permanent magnet. This extraction procedure was repeated 5 times. These extracted iron 
oxide nanoparticles were dried in oven at 60 ºC for 1 h and finally re-dispersed in 20 mL of 
toluene by sonication for 1 h
[220]
. These magnetic nanoparticles can be coated with silane 
molecules in the organic phase. The magnetic characteristics and stability of these 
nanoparticles (control nanoparticles) were compared with iron oxide nanoparticles generated 
in our laboratory. 
4.4.8. Synthesis of lanthanide-doped iron oxide nanoparticles (10-12 nm)  
Lanthanide doped USPIO were prepared using the Massart method with a small 
modification
[210]
.  An aqueous solution of sodium hydroxide (250 mL, 0.5 M) was maintained 
at 80 ºC in a three necked reaction flask with mechanical stirring and further it was degassed 
using inert nitrogen as the cover gas. Iron (III) chloride was partly replaced by lanthanide 
(III) chloride (Eu, Gd, Tb) in different molar percentages (2%, 5%, 15%, 20%).  Aqueous 
solutions of FeCl3 and LnCl3(Eu,Gd, Tb) (25mL, 1 M in 0.2M HCl) and FeCl2 (25 mL, 0.5M 
in 0.2M HCl) was added to a mechanically stirred solution of NaOH within 5 min under an 
inert nitrogen atmosphere at 80 °C. On addition a black precipitate of magnetite is formed 
immediately. The nanoparticle growth (nanoparticle formation) proceeds for 20 min at 80 °C. 
After the reaction time, subsequently the nanoparticle formed was cooled to ambient 
temperature. The nanoparticle was separated from the parent solution by using an external 
magnetic field, and further washed three times with de-ionized water, and dispersed into 100 
mL of aqueous hydrochloric acid (0.01 M).  
4.4.9. Synthesis of iron nanoparticles with TMAOH  
USPIO were also synthesized by co-precipitation using tetramethyl ammonium 
hydroxide (TMAOH) as the base for precipitation of iron salts. For magnetite synthesis, 1 M 
ferric chloride (FeCl3 >99%) and 2 M ferrous chloride tetrahydrate (FeCl2. 4H2O >99%) were 
prepared by dissolving iron salts in 2 M HCl solutions, respectively
[221]
. In a typical 
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experimental procedure, 10 mL of 1 M FeCl3 solution was mixed with 2.5 mL of 2 M FeCl2 
solution in a flask. This solution was stirred, followed by the slow addition of 21 mL of 25% 
(w/w) N(CH3)4OH, until a pH 13 was reached. Vigorous stirring was continued for 20 min. 
The solution color could be seen to alter from orange to black, leading to a black precipitate. 
The precipitated nanoparticles were isolated via using a permanent magnet. The supernatant 
was discarded by decantation. The precipitate was washed three times in order to remove 
excess ions and tetramethyl ammonium salt in the suspension. Finally, the washed 
precipitates were dispersed in de-ionized water for further investigation. 
4.5. Estimation of total iron concentration in nanoparticles  
 The total iron concentration of the magnetic fluids was determined by using either one 
of the following methods/techniques such as titration, colorimetry and ICP-MS respectively. 
4.5.1. Titration of iron oxide nanoparticles 
Total iron content of the nanoparticles was estimated by performing the titration for 
iron against an EDTA standard solution. The EDTA solution was first standardized using 
standard zinc solution prior to its use in iron estimation. 
4.5.1.1. Standardization of the EDTA solution 
A standard zinc solution (0.01 M) was prepared as a stock solution. A 10 mL aliquot 
from the stock of 0.01 M standard zinc solution was transferred into a 250 mL Erlenmeyer 
flask and the pH of the solution was adjusted by addition of 20 mL of the bicarbonate-
carbonate buffer solution (pH 10.0 ± 0.1) which was prepared by using Na2CO3 (30g/L and 
pH adjusted using 6 M HCl). To this solution three drops of Eriochrome Black T indicator 
(0.25 g in 50 mL of absolute ethanol) were added and mixed well. The color of the solution 
changed into pink color. The solution was titrated with 0.01 M EDTA solution until the color 
changed to pure blue at the end point. The titration was repeated to get concordant titre 
values. The exact concentration of the EDTA solution was calculated from the 
standardization (titration) with standard zinc solution. 
4.5.1.2. Estimation of the iron(III) content with standardized EDTA  
 The determination of the total iron content of USPIO suspensions by titration is based 
on complexation of Fe
3+
 with sulfosalicylic acid. Briefly, 0.5 mL of the USPIO solution was 
added into Erlenmeyer flasks (250 mL) followed by addition of 10 mL of 0.5 N HCl to 
dissolve the iron oxide nanoparticles. The solution was heated (100 °C) until it turned yellow. 
To the boiling solution small amounts of (NH4)2S2O8 were added in order to completely 
oxidize the remaining Fe(II) to Fe(III). Then, the solution was diluted with 40 mL of de-
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ionized water to get a colorless or pale yellow colored solution. The solution pH was adjusted 
to ~ 2.5 using 1M Na(OOCCH3) and pH change was monitored with the pH meter. Then, 0.1 
mL of sulfosalicylic acid indicator was added and the color of the solution changed from 
yellow to pink due to complexation with Fe
3+
.  Further, the solution was heated to 40-50 °C 
and titrated immediately against the standard 0.01M EDTA solution. The end point was the 
appearance of  the yellow color
[222]
. The titration was repeated to get concordant titre values. 
The iron concentration of NUSPIO, FLUSPIO, FAD USPIO (0.5 mL) was determined by 
using the above described protocol. 
4.5.2. Colorimetric estimation of the iron concentration  
The determination of USPIO total iron content with Tiron is based on the 
complexation of Fe
3+
 with Tiron
[223;224]
.  The Fe
2+ 
in the USPIO suspension was oxidized to 
Fe
3+
 by adding 300 µL of a mixture containing 37% HCl/65 % HNO3 in a volume ratio (3:1). 
The required volume of deionized water was added to the sample in order to obtain the 
respective dilution factor (solution A) as shown in Table 4.1.1 and Table 4.1.2. Then, the 
procedure for the colorimetric iron determination was performed. To 500 µL of solution A, 
100 µL of iron complexing reagent i.e. aqueous solution of 0.25 M Tiron (4,5-Dihydroxy-
1,3-benzenedisulfonic acid) was added. Further, 500 µL of 4 M  KOH solution, and 1000 µL 
of phosphate buffer pH 9.5 ( prepared by using 0.2 mole (71.6g) Na2HPO4.12H2O and 4 mL 
of 1 M KOH in 600 mL de-ionized water and made up to 1L ) were added to the solution 
containing Tiron. Further, the absorption of the solution was measured at  = 480 nm. Each 
sample was analysed in threefolds. To obtain a linear calibration curve, the same procedure 
was followed with aqueous Fe
3+
 solutions with known iron concentrations (10 - 100 µg/mL). 
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Table 4.1.1.  Preparation of standard iron solutions for calibration (iron standard stock solution: 1 mg Fe/mL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1.2.  Dilution series for the probe 
Dilution 
factor 
probe (mL) 
37% HCl 
(mL) 
65% HNO3 
(mL) 
De-ionized 
water (mL) 
2 1.0 0.24 0.08 0.68 
5 0.4 0.24 0.08 1.28 
10 0.2 0.24 0.08 1.48 
15 0.133 0.24 0.08 1.547 
20 0.1 0.24 0.08 1.58 
25 0.08 0.24 0.08 1.60 
30 0.0667 0.24 0.08 1.613 
40 0.05 0.24 0.08 1.63 
50 0.04 0.24 0.08 1.64 
75 0.0267 0.24 0.08 1.6533 
100 0.025 0.3 0.1 2.075 
 
4.5.3. Total iron concentration determination by ICP-MS 
The amount of iron present in the nanoparticles was determined by high-resolution 
sector field ICP-MS (Element 2, Thermo Electron, Bremen, Germany) equipped with an 
autosampler (ASX-100, CETAC, Omaha, NE). Data were acquired at medium resolution 
 
 
Nr. 
 
 
µg Fe/mL 
 
Iron 
standard 
solution 
(µL) 
 
37% HCl 
(mL) 
 
 
65% HNO3 
(mL) 
 
De-ionized 
water(mL) 
0 0 0 0.3 0.1 2.1 
1 10 25 0.3 0.1 2.075 
2 20 50 0.3 0.1 2.05 
3 30 75 0.3 0.1 2.025 
4 50 125 0.3 0.1 1.975 
5 70 175 0.3 0.1 1.875 
6 100 250 0.3 0.1 1.85 
7 150 375 0.3 0.1 1.725 
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(4000) using rhodium (5 ppb) as an internal standard. A PFA spray chamber equipped with a 
PFA 100 microflow nebulizer (CETAC) was used for sample introduction. The instrument 
was tuned and calibrated via infusion of a 1 ng/mL multi element standard solution (Merck, 
Darmstadt, Germany). Digestion of the USPIO, APTMS-USPIO, FLUSPIO was performed 
in a closed vessel microwave reaction system (CEM, Kamp-Linfort, Germany) after addition 
of 53% nitric acid (60%) at 3 bar and 600W for 50 min. Samples were diluted 1:200 in H2O. 
Calibration was linear between 2 and 150 ng/mL iron (r>0.999). The iron content was 
expressed in nanograms of iron per mL. 
4.6. Different coating strategies for iron oxide nanoparticles. 
  Iron oxide nanoparticles generated in this thesis, were synthesized by the co-
precipitation method. The stability of the iron oxide nanoparticles decreased if there was no 
surface coverage (coating) which resulted in agglomeration. The ferrofluid is stable by 
changing their negative surface charge to positive by protonating their surface with addition 
of an acid. To further increase the stability, the surface was covered with either polymer or 
bio-compatible organic molecules (non-polymer) in order to make them stable at 
physiological pH and suitable for in vitro and in vivo bio-medical applications. 
4.6.1. Silane coating of iron oxide nanoparticles (10 nm) 
Iron oxide nanoparticles (10 nm) prepared by modified co-precipitation method were 
coated with a protective thin layer of silane by using 3-aminopropyltrimethoxy silane 
(APTMS)
[210]
 as the coating molecule. In brief, USPIO cores (100 mL, 10 mg/mL) stored 
under acidic conditions were washed three times with methanol by retrieving the 
nanoparticles with the aid of a permanent magnet. The nanoparticles were isolated from the 
methanol washings by centrifugation at 20,000 g for 10 min respectively. The ferrofluid was 
suspended in 30 mL of dry methanol under inert nitrogen atmosphere. The methanolic 
solution of the nanoparticles was added to 70 mL of dry toluene placed in 250 mL reaction 
flask, which was equipped with a condenser, and maintained under inert nitrogen atmosphere. 
At 110 °C, an aliquot of APTMS (0.1 mL, 0.573 mmol) was added quickly to the ferrofluid 
in the reaction mixture followed by a 10 h reflux at 110 °C under nitrogen purging 
respectively. After reflux, the reaction mixture was cooled to RT. Further, the reaction 
mixture was suspended in methanol (50 mL) and sonicated for 10 min in order to disperse the 
agglomerated nanoparticles that originated due to the frequent exchange of solvents. The 
nanoparticles were recovered from methanol by using a permanent magnet, followed by 
washing with water. Furthermore, the silane coated nanoparticles were washed two times 
simultaneously with methanol (50 mL) to remove toluene and two times with water (50 mL) 
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to remove methanol. The nanoparticles lost during different washing steps were recovered by 
centrifuging them at 20,000 g for 10 min. Finally, the silane coated nanoparticles were 
suspended in 100 mL of water and stored at 4°C for further use. A similar coating protocol 
was followed for coating the iron oxide nanoparticles with 5 nm as the average core diameter 
respectively. 
4.6.2. Mixed silane coating of iron oxide nanoparticles (10 nm) 
10 nm USPIO and Ln-USPIO (Ln = Eu,Gd,Tb) were prepared by co-precipitation 
using aqueous alkaline solution (0.5 M NaOH). The nanoparticles were coated 
simultaneously with two different silanes namely APTMS and TEOS. In a typical coating 
procedure, USPIO (100 mL, 10 mg/mL) at pH 2 were washed three times with methanol by 
retrieving the nanoparticles with a permanent magnet. The nanoparticles were recovered from 
the methanol washings by centrifugation at 20,000 g for 10 min. The ferrofluid was 
suspended in 30 mL of dry methanol and added to dry toluene (70 mL) in a three necked 
round bottom flask (250 mL), which was equipped with a condenser and maintained under 
inert atmosphere. At 110 °C, APTMS (0.05 mL, 0.286 mmol) and TEOS (0.043 mL, 0.192 
mmol) were added to the reaction mixture either simultaneously or after 5 h of reaction 
completion by sequential addition of APTMS followed by TEOS and vice versa respectively. 
The reaction mixture was refluxed with stirring for 10 h at 110 °C under nitrogen purging. 
After reflux, the reaction mixture was cooled to RT. Then, the nanoparticles were transferred 
into the methanol (50 mL) and sonicated for 10 min. Further; the mixed silane coated 
nanoparticels were washed for three times simultaneously with methanol (50 mL) and water 
(50 mL). The nanoparticles from different washing steps were recovered by centrifugation at 
20,000 g for 10 min. Finally, the mixed silane coated nanoparticles were suspended in 100 
mL water and stored at 4°C for further use. 
In addition, the nanoparticles (USPIO and Ln-USPIO (Ln = Gd, Eu, Tb))  prepared by 
a modified co-precipitation method were coated with a thin layer of protective silane by using 
TEOS (0.1 mL, 0.478 mmol) 
[225]
.  Further, the procedure followed for silane coating was 
similar to the one described above. The TEOS coated nanoparticles were suspended in 100 
mL water and stored at 4°C for further investigations.  
 
4.6.3. Synthesis of NUSPIO  
The USPIO were coated with the following non-polymeric molecules to yield 
fluorescent naphthalene coated USPIO (NUSPIO): 7-amino-1,3-naphthalene disulfonic acid 
monopotassium salt (ANDS), 4-amino-5-hydroxy-2,7-naphthalene disulfonic acid 
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monosodium salt (H-acid), Naphthol blue black (Naph 3),  1-hydroxy-3,6-naphthalene 
disulfonic acid monosodium salt (Naph 4), 3-hydroxy-2,7-naphthalene disulfonic acid 
monosodium salt (Naph 5), Sodium 5-acetamido-4-hydroxy-3-(phenyldiazenyl) naphthalene-
2,7-disulfonate (Naph 6), 2,2´-(naphthalene-1-ylmethylazanediyl)bis(ethane-2,1-diyl) 
diphosphonic acid (Naph 7). The coating strategy was followed by slight modification of the 
reported procedure. In brief, different concentrations of the above non-polymeric molecules 
(30, 40, 50, 60, 70 and 80 mmol/L) were added to the suspension of iron oxide nanoparticles 
(Fe = 10 g/L). After 1 h incubation at 20 °C, the nanoparticles were dialyzed against water for 
2 days and neutralized by dialysing for 3 days against buffers or NaCl solution (0.15 mol/L) 
at different temperatures (4 °C and RT). The purification methods (dialysis and resin 
exchange), performed after non-polymeric coating, will be discussed in detail under the 
section (4.7.1 and 4.7.2).  The incubation time and dialysis temperature were varied in order 
to study their influence/effect on the stability of the non-polymeric coated iron oxide 
nanoparticles
[226]
.  
 
4.6.3.1. Synthesis of USPIO coated with different naphthalene sulfonates
  
The USPIO were coated with the following non-polymeric molecules (synthesized): 
sodium 4-hydroxy-5-oleamido-7-sulfonaphthalene-2-sulfonate, potassium 7-oleamido-3-
sulfonaphthalene-1-sulfonate, potassium (s)-7-(2-amino-3-(1H-indol-3-yl)propanamido)-3-
sulfonaphthalene-1-sulfonate, 1-(6-hydroxy-2-naphthoyloxy)ethane-1,1-diyldiphosphonic 
acid, sodium 3,3-(1´Z)-(4,4´-((E)-ethene-1,2-diyl)bis(4,1-phenylene))bis(diazene-2,1-
diyl)bis(5-amino-4-hydroxynaphthalene-2,7-disulfonate), sodium 3,3´-(1´Z)-(4,4´-((E)-
ethene-1,2-diyl)bis(3-sulfonato-4,1-phenylene))bis(diazene-2,1-diyl)bis(5-amino-4-
hydroxynaphthalene-2,7-disulfonate) which were anticipated to display fluorescence that 
might aid MR cellular labeling studies and further facilitate the co-validation of the results 
obtained via MRI.  
To this end, the non-polymeric coating of USPIO (2g/L) was achieved using different 
concentration of the above naphthalene sulfonates (30, 40, 50 mmol/L) respectively. After 1 h 
incubation at 20 °C, the nanoparticles were washed several times with water via the aid of a 
permanent magnet. The fluorescence efficiency of final nanoparticles synthesized was 
evaluated using fluorescence spectroscopy and microscopy techniques. 
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4.6.3.2. Synthesis of USPIO coated with sulfonates and phosphates 
The stability and fluorescence efficiency of the USPIO coated with different 
sulphonates was compared to the nanoparticles coated with phosphonic acids in the 
physiological solutions merely by visual inspection and validated through fluorescence 
spectroscopy and microscopy respectively. The different sulphonates and phosphates which 
were employed as non-polymeric coating molecules are  2-(6-hydroxy-2-
napthamido)ethylphosphonic acid, 4-(4-((R)-hydroxy((2S,4S,8R)-8-vinylquinuclidin-2-
yl)methyl-6-methoxyquinolinium-1-yl)butane-1-sulfonate, 4-(9-aminoacridinium-10-
yl)butane-1-sulfonate, thiamine monophosphonic acid (TMP), sodium 8-hydroxy-3,6-
dihydropyrene-1,3,6-trisulfonate respectively. The coating strategy followed was a 
modification from the reported procedure
[226]
. The concentrations of USPIO and non-
polymeric molecules (sulfonates and phosphates) used were similar to the previously 
described procedure (section 4.6.3.1). After incubation (1 h), excess non-polymeric ligands 
were removed by washing several times with water (permanent magnet) respectively.  
 
4.6.4. Synthesis of FLUSPIO  
The fluorescent ultrasmall superParamagnetic iron oxides (FLUSPIO) nanoparticles 
were synthesized by sonication of fluorescent, non-polymeric flavin mononucleotide (FMN) 
and non-polymeric guanosine monophosphate (GMP) with USPIO in different 
concentrations. In brief, 5-6 nm iron oxide nanoparticles (8 mg/mL, 143 mmol) suspensions 
at pH 2 were sonicated with FMN (35 and 50 mmol) using an ultrasonic cleaner (30 W, VWR 
GmbH, Germany)  for 1 h at ambient temperature. On FMN addition to USPIO the pH of the 
solution reached 4.0. After sonication, the FMN modified nanoparticles were purified by 
washing several times with water aided via the high gradient magnetophoresis. Further, FMN 
modified USPIO were treated with GMP (43, 50 and 64 mmol) and sonicated for 1 h at 
ambient temperature. Excess GMP was removed by washing the nanoparticles several times 
with water (high gradient magnetophoresis). The FLUSPIO were stored at low temperature 
for further use. FLUSPIO were also generated by performing the FMN coating in 
combination with adenosine monophosphate (AMP) or with thiamine monophosphate (TMP). 
In addition, double FMN coating of USPIO was achieved by following similar 
protocol as described above. For this type of coating, iron oxide nanoparticles were coated 
twice with the FMN (35 mmol) and excess FMN was removed by washing them with water 
(high gradient magnetophoresis).  The double FMN coated USPIO were stable and stored at 4 
ºC for further investigations. 
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4.6.5. Synthesis of FAD USPIO 
  The flavin adenine dinucleotide USPIO (FAD USPIO) were synthesized by sonication 
(1 h) of USPIO with FAD and GMP and further synthesis steps were followed analogues to 
the FLUSPIO synthesis (section 4.6.4).  After sonication, purification of the FAD modified 
nanoparticles was achieved via high gradient magnetophoresis. After GMP coating, excess 
non-polymeric ligands was removed by washing with water to yield the fluorescent FAD 
USPIO nanoparticles.  
In addition, USPIO coated two times with FAD was prepared by incorporating the 
above protocol. FAD (35 mmol) was coated twice over USPIO and further purified by 
employing high gradient magnetophoresis.  Similarly, USPIO were also coated two times 
with riboflavin (35 mmol) for generating double coated riboflavin-USPIO respectively. 
 
4.6.5.1. In situ coating of USPIO with non-polymeric molecules  
Iron oxide nanoparticles synthesized by thermal decomposition of iron precursors at 
high temperatures were coated in situ using H-acid by employing a slight modification in the 
reported procedure
[181]
. 10 mL of 2-pyrrolidinone solution containing Fe(acac)3 (0.35 g, 1 
mmol) and H-acid (0.34 g, 1 mmol) were sonicated for 12 min. Then, the reaction mixture 
was purged with nitrogen to remove the dissolved oxygen and heated to reflux under nitrogen 
for 10 min at 250 ºC. The reaction system was cooled to RT. Further, methanol was added 
into 2-pyrrolidinone which resulted in dark brown precipitate which was washed several 
times with acetone and then dried. The modified nanoparticles were dialyzed against water at 
4 ºC for two days in order to remove excess H-acid from the sample.  The fluorescence of the 
nanoparticles was checked with fluorescence spectroscopy and microscopy techniques. 
 
4.7. Different purification techniques used for magnetofluorescent nanoparticles 
 The purification of the non-polymeric coated iron oxide nanoparticles was achieved 
by employing three different techniques/methods such as dialysis, resin exchange and high 
gradient magnetophoresis respectively. 
4.7.1. Dialysis 
Excess non-polymeric molecules on iron oxide nanoparticles was removed by dialysis 
using the cellulose ester (CE) membrane spectra/por FloatALyzer G2 (MWCO 10, 100 
kD)(SPECTRUM). The dimension of the CE membrane used are: length (10 cm), membrane 
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diameter (10 mm), top piece diameter (23 mm), flotation ring (38 mm), volume (5 mL) 
respectively. The features of the FloatALyzer G2 are screw-on cap (color coded for MWCO, 
polypropylene), silicon O-ring (leak proof and resealable), floatation ring (center to maintain 
buoyancy, polyethylene), top/bottom piece (polycarbonate), potting (polyurethane) 
respectively (Figure 4.1.2). The glycerol which was used to dry the CE membrane was 
removed from the membrane by washing it with water prior to the sample dialysis. The non-
polymeric modified nanoparticles were loaded in the dialysis membrane and dialysed against 
water at 4 ºC for two days in order to remove excess non-polymeric molecules. The dialysed 
water was removed every 4 h and exchanged with fresh water to continue the sample dialysis. 
Further, the samples were dialysed against various buffers and solutions for neutralization 
(0.15 mol/L (NaCl, glucose, citric acid), PBS (1X), HEPES (25 mM), MOPS (20 mM), MES 
(20 mM), oxalate (20 mM), and tris buffer) at 4 ºC for 1-2 days. 
 
 
Figure 4.1.2. The figure shows different parts of the cellulose ester membrane dialyser and displays different 
steps involved from the sample addition to the color coded membrane dialyser, dialysis technique and sample 
recovery after dialysis respectively. 
Dialysis of the non-polymeric modified USPIO was also performed using visking 
membranes with different molecular weights. The glycerine from visking membrane was 
cleaned by washing either with warm water or by heating the membrane in 2% sodium 
bicarbonate and 1mM EDTA at 80 ºC for 30 min and rinsing it with distilled water. After 
cleaning, the membranes should be stored, fully immersed in one of the following solutions; 
1% formaldehyde, 1% sodium benzoate or 0.1% sodium azide at 4 ºC. The dialysis technique 
followed for purification of non-polymeric modified nanoparticles with visking membrane 
was similar to the protocol described above. 
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4.7.2. Resin exchange method 
Non-polymeric coated USPIO can be purified by employing a resin exchange method, 
in which the acidic and basic resin was used for better separation and purification of the 
sample. Dowex fine mesh resins are based on a microporous copolymer of styrene and 
divinylbenzene (DVB) that results in maximum resistance to oxidation, reduction, 
mechanical wear and breakage (Figure 4.1.3). This co-polymeric structure of dowex is 
insoluble in common solvents, thus facilitating the ionic exchange. The DOWEX 50 WX8 
20/50 is a strong acid cation resin containing 8% DVB and X being the number describing 
the degree of resin cross linkage. The Dowex resin is activated by stirring them in water 
overnight and further washed with 1 M HCl and excess acid cations was removed by washing 
simultaneously with water until the resin pH reached 2. 
 
 
 
 
 
Figure 4.1.3. The schematic diagram shows the steps involved in synthesis of strong acidic cationic resin 
(DOWEX 50WX8) respectively. 
Amberlite IRA 95 is a weakly basic anion exchanger with exceptional resistance to 
organic fouling. This resin is used for de-acidification, de-ionization of water where removal 
of strong mineral and organic acids is desired and for removal of heavy metals. The resin 
matrix consist of styrene divinylbenzene (macroreticular matrix) with active polyamine 
functional groups and particle size (16-50 mesh) which has working pH range (0 – 7). The 
amberlite resin is activated by stirring it in water overnight and further washing with 1 M 
NaOH. Excess base anions were removed by washing with water until the resin pH reached 
8.0. 
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The non-polymeric modified nanoparticles were first acidified over 1 mL of an H
+
 
exchange resin (DOWEX 50WX8-20/50 Mesh) per mL of iron nanoparticle suspension. 
After 10 min of incubation at pH 4, the suspension was passed over 2 mL of a weakly basic 
OH
-
 resin (Amberlite IRA 95) for pH neutralization. After resin exchange, the nanoparticles 
were stored at low temperature. 
 
4.7.3. High gradient magnetophoresis  
High gradient magnetophoresis was performed using a MiniMacs separator (Miltenyi 
Biotech, Bergisch Gladbach, Germany) (Figure 4.1.4).  To increase the separator efficiency, 
regions of high magnetic field gradient were produced to capture the magnetic nanoparticles 
as they flow by in their aqueous medium
[227]
. This efficiency can be achieved by loosely 
packing a flow column with a magnetizable matrix of wire (e.g., steel wool) and facilitating 
the magnetic fluid flow through the column under the influence of applied magnetic field. 
The steel wool is packed inside a 100 µL pipette tip and placed in a 3 mm gap between the 
two pole faces of a permanent magnet thus generating high gradient magnetic field which 
aids magnetic separation of the nanoparticles. Non-polymeric modified nanoparticles were 
passed through the steel wool and after separation each retentate was thoroughly washed with 
water to remove any non-adsorbed non-polymeric molecules (sulfonates, phosphate groups) 
remaining in the steel wool.  Further, the pipette tip (holding the steel wool) was removed 
from the pole of the permanent magnet and the magnetic nanoparticle retentates were 
recovered and re-suspended from the filter matrix by washing with water. 
 
 
 
Figure 4.1.4 The figure shows the set up which was used for high gradient magnetophoresis separation of 
coated magnetic nanoparticles. A high gradient magnetic field was generated by using steel wool in a pipette tip 
and by placing it between the poles of a permanent magnet. Excess coating molecules (FMN) was removed by 
washing the coated nanoparticles several times with water which results in the green solution respectively. 
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4.8. Total phosphate determination of FLUSPIO and FAD USPIO  
4.8.1. Vaskovsky phosphate determination  
Vaskovsky phosphate determination is based on the oxidative decomposition of the 
phospholipids and further, this phosphate determination could be applied to the iron oxide 
cores coated/functionalized with ligands containing phosphate groups respectively. The 
determination is based on the complexation of the inorganic phosphate with partially reduced 
molybdate metal ions under acidic conditions
[228]
. The stock solution for phosphate 
determination was prepared as follows, 3.81 mmol (0.40 g) NH2NH2
.
2HCl (Riedel-de Haën) 
and 41.33 mmol (10 g) Na2MoO4
.
2H2O (Merck) were dissolved in 14 mL and 60 mL of 4 M 
HCl respectively.  Both solutions were mixed and the mixture was heated to 80 ºC for 20 min 
on a water bath. The mixture was cooled to 25 °C and then 14 mL of concentrated H2SO4 was 
added with vigorously stirring. Then, de-mineralised water was added to a total volume of 
100 mL(standard flask). The final stock solution can be stored in the dark for at least six 
months. The working solution was prepared by using 5.5 mL of the above-mentioned stock 
solution and 26 mL of 0.5 M H2SO4 which were made up to 100 mL using the de-mineralised 
water. The following procedure was performed for the actual phosphate determination: a 
mixture of 100 L of a properly diluted sample and 100 L of 70-72 % HClO4 were 
introduced into a pyrex reagent tube and heated to 200-240 ºC for 45 min. The mixture was 
cooled to 25 °C and 1000 L of working solution was added to it.  Subsequently, the mixture 
was heated to 100 °C on a water bath for 20 min. After cooling to 25 °C, 1500 µL of 0.5 M 
H2SO4 are added and the absorbance was measured at 820 nm. The total phosphate 
concentration was determined on the basis of calibration curve. For this purpose solutions 
with a known phosphate concentration between 0.1 und 1.0 mol/mL were treated in the 
similar way as the samples. For accuracy all samples were analysed threefold. 
 
4.9. Conjugation of dyes/biomolecules to APTMS coated nanoparticles 
 Fluorescent iron oxide nanoparticles were generated by coupling different organic 
dyes such as 5-carboxyfluorescein diacetate-N-succinimidyl ester, fluorescein isothiocyanate 
(FITC), tetramethyl rhodamine isothiocyanate (TRITC) to the silane (APTMS) coated iron 
oxide nanoparticles via the free amino groups accessible from the APTMS coating 
respectively. 
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4.9.1. Coupling of 5-carboxyfluorescein diacetate-N-succinimidyl ester with APTMS 
USPIO 
Coupling of 5-carboxyfluorescein diacetate-N-succinimidyl ester (dye) with APTMS 
USPIO was performed by following a slight modification in the reported protocol
[229]
. The 
APTMS coated USPIO (10 mg/mL) were retrieved from water using a permanent magnet and 
suspended in acetate buffer (pH 8.5). The stock solution of 5-carboxyfluorescein diacetate-N-
succinimidyl ester (λex = 492 nm, λem = 517 nm) was prepared by dissolving 0.5 mg in 0.5 
mL of DMSO and protected from light for further use. The dye solution in DMSO (50 – 100 
µL) was added slowly to the silica coated USPIO suspension (pH = 8.5) in dark and the 
reaction vessel was covered with aluminium foil and allowed to react for 2 h at 4 ºC in the 
dark. Excess of activated fluorescein dye was removed from the reaction mixture by 
performing the dialysis against water at 4 ºC for 2 days. 
4.9.2. Coupling of fluorescein isothiocyanate (FITC) with APTMS USPIO 
APTMS coated USPIO was funtionalized with FITC by following a modified 
protocol
[230]
. The APTMS coated USPIO (10 mg/mL) were retrieved from water by using a 
permanent magnet and suspended in a buffer with pH 9. The dye stock solution of 1 mg/mL 
of FITC (λex = 494 nm, λem = 520 nm) was prepared using DMSO which was stored in the 
dark. The dye solution in DMSO (50 – 100 µL) was added slowly to each mL of silica coated 
nanoparticle (2 mg/mL) at pH 9 in dark and the reaction vessel was covered with aluminium 
foil and  allowed to react for 8 h at 4 ºC in the dark. The reaction was quenched by addition 
of NH4Cl (50 mM) and reacted for further 2 h to block the remaining isothiocyanate groups. 
Excess of activated fluorescein dye was removed from the reaction mixture by performing 
the dialysis against water at 4 ºC for 2 days. 
4.9.3. Coupling of rhodamine isothiocyanate (TRITC) with APTMS USPIO 
TRITC was conjugated with APTMS USPIO by superseding the reported coupling 
protocol with a slight modification
[231]
. The APTMS coated USPIO (2 mg/mL) were retrieved 
from water by using a permanent magnet and suspended in 0.1 M Na2CO3 solution with pH 
9.0. The dye stock solution of 1 mg/mL of TRITC (λex = 544 nm, λem = 570 nm) was 
prepared using DMSO and protected from light respectively. The dye solution in DMSO (50 
µL) was added slowly to each mL of silica coated nanoparticle (2 mg/mL) at pH 9 in dark 
and allowed to react for 8 h at 4 ºC in the dark. The reaction was quenched by addition of 50 
µL of NH4Cl (50 mM) and reacted for 2 h to block the remaining isothiocyanate groups. 
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Excess of activated rhodamine dye was removed from the reaction mixture by performing the 
dialysis against water at 4 ºC for 2 days. 
4.9.4 Coupling of biotin-FITC to APTMS USPIO 
Coupling of streptavidin to APTMS USPIO and further interaction with FITC labelled 
biotin was carried out by a modification in the reported protocol
[232]
. The APTMS coated 
USPIO were retrieved from water using a permanent magnet. The silica coated USPIO (10 
mg/mL) were washed three times with 500 µL of PBS buffer. The amine groups present in 
the APTMS USPIO were activated using 200 µL of glutaraldehyde (5% aqueous solution) 
and 800 µL of PBS buffer by vacillating them for 4 h at RT. After vacillation, nanoparticles 
were recovered using a permanent magnet and washed thrice with PBS buffer and further 
0.25 mg streptavidin was added. The reaction was allowed to proceed for 24 h by vacillation 
at RT. Excess streptavidin from the nanoparticles was removed by washing thrice with PBS 
buffer by retrieving nanoparticles with a permanent magnet. The stock solution of 1 mg of 
FITC labelled biotin (λex = 494 nm, λem = 520 nm) was prepared by dissolving it in 1 mL of 
PBS. The dye stock solution (30 µL) was added slowly to silica coated nanoparticle in dark 
and allowed to react for 10 min in the dark. Excess of FITC labelled biotin was removed 
either by dialysis against water at 4 °C or by high gradient magnetophoresis respectively. 
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4.10  In vitro experiments 
4.10.1. List of equipments and accessories 
Instrument Model Manufacturer 
Laminar air flow cabinet MSC-Advantage Thermo Scientific Inc., Waltham, 
MA, USA 
Waterbath (37 ºC) Lauda AL12 Aqualine GmbH & Co. KG, 
Lauda-Königshofen, Germany 
Suction pump  AA04 HLC, Bovenden, Germany 
Incubator (37ºC, 5% CO2, 95% 
relative humidity 
C150 Binder Inc., Great River, NY, USA 
Centrifuge Multifuge 1L Thermo Scientific Inc., Waltham, 
MA, USA 
Microscope (Bright field) Axiovert Carl Zeiss MicroImaging GmbH, 
Germany 
Fluorescence Microscope - AxioObserver Z1 
- Imager M2 
- Olympus BX50 
Carl Zeiss MicroImaging GmbH, 
Germany. Olympus, Germany. 
Eppendorf pipette (10 µL, 100 µL, 
200 µL and 1000 µL) 
Transferpette S Brand GmbH & Co. KG, 
Wertheim, Germany 
Cryovial Cryo S Greiner Bio-one GmbH, 
Frickenhausen, Germany 
Centrifuge  Fresco 21 Heraeus Germany 
Image based cell analyser Cedex XS Innovatis AG, Bielefeld, Germany 
Hemocytometer, Neubauer 0.100 mm depth 
0.0025 mm
2
 
Brand, Wertheim, Germany 
Autoclave VE-40 Systec GmbH, Wettenberg, 
Germany 
Cryocan (cell freezing)  Isotherm, Germany 
Cryotom  CM 3050 S Leica GmbH, Germany 
Flow cytometer FACS Calibur BD Bioscience, Heidelberg, 
Germany 
 
4.10.1.2. List of reagents 
Reagent Composition Manufacturer 
DPBS Phosphate buffered saline without 
CaCl2 and MgCl2 
GIBCO Invitrogen, Grand Island, 
NY, USA 
RPMI 1640 Without L-Glutamine GIBCO Invitrogen, Grand Island, 
NY, USA 
RPMI 1640 With L-Glutamine GIBCO Invitrogen, Grand Island, 
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NY, USA 
McCoy`s 5A With Glutamax GIBCO Invitrogen, Grand Island, 
NY, USA 
DMEM  High glucose with Glutamax GIBCO Invitrogen, Grand Island, 
NY, USA 
Vasculife VEGF Endothelial 
cell culture medium 
VascuLife Basal medium, 
VascuLife VEGF Lifefactors kit, rh 
FGF basic, Ascorbic acid, 
Hydrocortisone sulphate, FBS, L-
Glutamine, rh IGF-1, rh EGF, rh 
VEGF, Heparin sulphate Life 
Factors  
Cellsystems Biotechnologie 
Vertrieb GmbH, Troisdorf, 
Germany 
Eagle`s minimum essential 
medium (MEM) 
Modified to contain Earles 
Balanced Salt Solution, non-
essential amino acids, 2 mM L-
glutamine, 1 mM sodium pyruvate, 
and 1500 mg/L sodium bicarbonate 
LGC Standards GmbH, Wesel, 
Germany 
Fetal bovine serum (FBS) South American origin  GIBCO Invitrogen, Grand Island, 
NY, USA 
Pen/Strep 10,000 units/mL Penicillin 
10,000 µg/mL Streptomycin 
GIBCO Invitrogen, Grand Island, 
NY, USA 
EDTA 0.05% in PBS Merck KGaA. Darmstadt, 
Germany 
Trypsin/EDTA 0.25% Trypsin; 0.05% EDTA in 
PBS buffer 
GIBCO Invitrogen, Grand Island, 
NY, USA 
DMSO 100% DMSO SIGMA-ALDRICH Chemie 
GmbH, Steinheim, Germany 
DAPI 100% DAPI Merck KGaA, Darmstadt, 
Germany 
Trypan blue Microscopy grade SIGMA-ALDRICH Chemie 
GmbH, Steinheim, Germany 
7-amino actinomycin D  7-AAD viability staining solution 
in PBS and contains 0.09% NaN3 
NatuTec GmbH, 
an eBioscience Company, 
Frankfurt, Germany 
In situ Cell Death Detection Kit, 
TMR red (TUNEL kit) 
Enzyme solution (Terminal 
deoxynucleotidyl transferase 
from calf thymus recombinant in E. 
Coli, in storage buffer)  and Label 
solution (Nucleotide mixture in 
reaction buffer) 
Roche Diagnostics Deutschland 
GmbH, Mannheim, Germany 
DNase I recombinant RNase free Qiagen GmbH, Hilden, Germany 
Cell Proliferation kit I (MTT) MTT labeling reagent and 
solubilization solution 
Roche Diagnostics Deutschland 
GmbH, Mannheim, Germany 
Cytotoxicity test kit (LDH) Catalyst and dye solution Roche Diagnostics Deutschland 
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GmbH, Mannheim, Germany 
Paraformaldehyde 4% paraformaldehyde SIGMA ALDRICH Chemie 
GmbH, Steinheim, Germany 
Triton X-100 0.1% Triton X-100 SIGMA ALDRICH Chemie 
GmbH, Steinheim, Germany 
Sodium citrate 0.1 % Sodium citrate Carl Roth GmbH & Co. KG; 
Karlsruhe, Germany 
Permafluor mounting medium  Thermo Scientific Inc., Waltham, 
MA, USA 
 
 
 4.10.1.3. List of laboratory products  
Product Manufacturer 
50 mL Falcon tubes BD, Franklin Lakes, NJ, USA 
Disposable pipettes (5mL, 10 mL, 25 mL, 50 mL) Costar Stripettes, Corning, NY, USA 
Pipette tips (10 µL,200 µL and 1000 µL) TipOne by USA Scientific Inc., Ocala, FL, USA 
Sterile glass Pasteur pipettes Brand GmbH & CO. KG, Wertheim, Germany 
T-25/T-75 cell culture flasks Greiner Bio-one GmbH, Frickenhausen, Germany 
Latex powder free gloves MaiMed GmbH & CO. KG, Neuenkirchen, Germany 
6-well plate BD Falcon, Germany 
24-well plate BD Falcon, Germany 
96-Flat transparent microplate Greiner Bio-one, Frickenhausen,Germany 
Petri dish (200 x 20 mm) Greiner Bio-one, Frickenhausen,Germany 
Cover slips, round (12 mm) Carl Roth GmbH & Co. KG; Karlsruhe, Germany 
Glass slides (76 x 26 mm) R. Langenbrinck, Emmendingen, Germany 
quadri PERM Greiner Bio-one GmbH, Frickenhausen, Germany 
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4.11. Cell culture 
4.11.1. PC-3 cell line  
PC-3 cells initiated from a bone metastasis of a grade IV prostatic adenocarcinoma 
from a 62-year-old male Caucasian (Figure 4.1.5).  Prostate cancer cells (PC-3 cell line) were 
purchased from ATCC (CRL-1435) and cultured by the reported procedure respectively. 
 
Figure 4.1.5. The figure shows PC-3 cell population grown in low and high density respectively.  
 
4.11.2. DU-145 cell line 
The DU-145 cells were established from the tumor tissue removed from the metastatic 
central nervous system lesion of a 69-year-old man with prostate carcinoma in 1975 (Figure 
4.1.6).  DU-145 cell lines were purchased from ATCC (HTB-81) respectively. 
 
Figure 4.1.6. The figure shows DU-145 cell population grown in high density respectively 
 
4.11.3. LnCap cell line 
The LnCap cells were established from the left supraclavicular lymph node metastasis 
from a 50-year-old man with prostate carcinoma in 1977; cells were described to be 
androgen-sensitive (Figure 4.1.7).  LnCap cell line was purchased from DSMZ (ACC.256) 
and was further expanded according to the following procedures. 
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Figure  4.1.7. The figure shows LnCap cell population grown in low and high density respectively. 
 
4.11.4. Human Umblical Vein Endothelial cells (HUVEC)  
The endothelium is composed of a thin layer of endothelial cells (EC), which line the 
interior surface of blood and lymphatic vessels from the aorta to the smallest capillary. 
Endothelial cells vary in morphology and functions according to the type and size of the 
associated vessel. The cells were isolated from normal human adult tissues from different 
locations e.g., umbilical vein. Human Umbilical Vein Endothelial Cells (HUVEC) (Figure 
4.1.8) were purchased from Promocell (C-12203, HUVEC pooled) and expanded according 
to the reported procedures. 
 
Figure 4.1.8.  The figure shows HUVEC cell population grown in low and high density respectively. 
 
4.11.5. Myofibroblasts  
Myofibroblasts are thought to be derived from local resident mesenchymal cells, 
particularly fibroblasts, and further from smooth muscle cells, pericytes and endothelial cells. 
However, cellular origin of myofibroblasts was also reported to be emerged from bone-
marrow-derived circulating fibrocytes (BMDCF) and epithelial-to-mesenchymal 
transformation (EMT) respectively. The process that involves the homing to local tissue sites 
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of BMDCF, under the influence of the local micro-environment appears to become 
myofibroblasts.  
Myofibroblasts in granulation tissue and tumor stroma exhibit similarities in structure, 
immunophenotype and molecular activities. Wound healing myofibroblasts have the primary 
role of producing local concentration of matrix, a process supported by collagen synthesis 
and secretion. The myofibroblast has the same synthetic machinery as the fibroblast (rough 
endoplasmic reticulum, Golgi apparatus and collagen secretion granules). The myofibroblast 
has the same kind of myofilaments as in the smooth muscle cells but in reduced numbers and 
at the cell periphery: it also has the fibronexus which is not a distinctive feature of fibroblasts, 
smooth muscle cells and it lacks a lamina. The cellular machinery of the myofibroblasts and 
fibroblasts as shown in the Figure 4.1.9 are RER, rough endoplasmic reticulum, C, collagen 
secretion granules, G, Golgi apparatus, FA, focal adhesion, FF, fibronectin fibril, FNX, 
fibronexus, M, myofilaments respectively.  
The myofibroblasts cells were kindly provided by Prof. Stefan Jockenhoevel, AME, 
Helmholtz Institute Aachen and further they were expanded according to the recommended 
cell culture protocols.  
 
 
Figure 4.1.9. The figure shows the differences between fibroblast and myofibroblast cells respectively. 
 
4.11.6. RPMI-8226 cell line 
The RPMI-8226 cells were established from the peripheral blood of a 61-year-old 
man with multiple myeloma (IgG lambda-type) at diagnosis in 1966; described to produce 
and secrete only lambda light chains (but not heavy chains) (Figure 4.2.0).  Human multiple 
myeloma cells (RPMI-8226 cell line) were purchased from DSMZ (ACC-402) and expanded 
further according to the suggested protocols. 
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Figure 4.2.0. The figure shows RPMI-8226 cell population in low and high magnification (bright field 
microscope) respectively. 
 
4.11.7. U87MG cell line 
The U87MG cells were established from 44-year-old Caucasian woman with 
malignant glioma.  This is one of a number of cell lines derived from malignant gliomas by J. 
Ponten and associates from 1966 to 1969(Figure 4.2.1). Human malignant glioma cells 
(U87MG cell line) were purchased from ATCC (HTB-14) and expanded according to the 
reported procedures. 
 
Figure 4.2.1. The figure shows U87MG cell population grown in low and high density respectively. 
 
4.11.8. Cell culture media cocktails 
The following cell culture media cocktail´s were used for culturing different cell types. 
PC-3 cell line: 
McCoy´s 5A with glutamax medium supplemented with 10% FBS and 1% 
Penicillin/Streptomycin.  
DU-145 cell line: 
RPMI 1640 without glutamine medium supplemented with 10% FBS and 1% 
Penicillin/Streptomycin. 
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LnCap cell line: 
RPMI 1640 with glutamine medium supplemented with 20% FBS and 1% 
Penicillin/Streptomycin. 
HUVEC: 
DMEM with glutamax medium with high glucose content supplemented with 10% FBS and 
1% Penicillin/Streptomycin. 
Vasculife endothelial cell growth medium supplemented with endothelial cell growth factors. 
Myofibroblasts: 
DMEM with glutamax medium with high glucose content supplemented with 10% FBS and 
1% Penicillin/Streptomycin 
RPMI-8226 cell line: 
RPMI 1640 without glutamine medium supplemented with 10% FBS and 1% 
Penicillin/Streptomycin 
U87MG cell line: 
Eagle´s minimum essential medium supplemented with 10% FBS and 1% 
Penicillin/Streptomycin. 
 
4.11.9. General procedures for culturing different cell types 
4.11.9.1. Cell thawing 
Frozen cell suspensions were transferred from the cryovial into a 50 mL falcon tube 
with respective cell culture media (including supplements) and the cell suspensions were 
centrifuged at 1000 rpm for 5 min to remove the DMSO from the freezing medium. The 
supernatant medium was discarded and the cell pellet was resuspended in 10 mL of 
respective cell culture media with supplements. The cell suspension was transferred into the 
T25 cell culture flasks (Greiner bio-one, Germany) and incubated at 37 ºC, 5% CO2 and 95% 
relative humidity. 
4.11.9.2. Cell growth (cell propagation) 
Once the cells reached 80-90% confluency in T25 cell culture flask (Greiner bio-one, 
Germany), the following protocol was followed: The old medium above the cells was 
removed and cells were washed with 10 mL PBS.  Further, cells were trypsinized using 2 mL 
of Trypsin/EDTA (0.25%/0.5%) by 3 min incubation in the incubator. The trypsinization was 
stopped by addition of 8 mL of respective cell growth media. Then, 10 mL of cell suspension 
were transferred to a T75 cell culture flask (Greiner bio-one, Germany) which is further 
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diluted with 10 mL of respective cell growth media and grown in the incubator. Medium was 
renewed routinely (two to three times per week). After every medium change, confluency of 
the cells was examined under the bright field microscope. 
4.11.9.3. Cell splitting (sub cultivation) 
The cells were frequently passaged in order to avoid spontaneous differentiation and 
sub cultivated until they reach 90% confluency. Cells were split according to the following 
protocol. After removing the old medium, cells in T75 cell culture flask were washed with 10 
mL PBS to remove traces of serum that contains trypsin inhibitor. Cells were trypsinized with 
4 mL of trypsin/EDTA(0.25%/0.5%). The trypsinization was stopped by adding 16 mL of the 
cell growth media. Further, the amount of medium added depends on the splitting ratio 
attempted (Table 4.1.3). The following volumes were added to account for the desired 
splitting ratio. 
Table 4.1.3.  List of cell splitting ratios and volume added 
 
4.11.9.4. Freezing cells 
The cells were washed, trypsinated and the cell pellet was collected according to the 
above described procedure. Required amount of cells were frozen with 70% cell culture 
media, supplemented with 20% FBS, 10% DMSO and 1% Penicillin/Streptomycin and 
further stored at vapour phase liquid nitrogen temperature. 
 
4.12. Mycoplasm test 
Cell culture contamination by mycoplasms occur due to the contamination from 
individuals or contaminated cell culture media or cell culture supplements.  Mycoplasma is a 
kind of bacteria that lacks a cell wall (Ryan, et al., 2004)
[233]
. It can induce cellular changes, 
including chromosome aberrations, metabolism changes and slow cell growth. Several 
techniques have been developed to detect mycoplasms such as polymerase chain reaction 
(PCR), plating on sensitive agar and staining with a DNA stain (e.g., Hoechst or DAPI). The 
Splitting ratio 
Trypsin/EDTA 
(mL) 
Medium (mL) Total volume (mL) 
1:2 4 4 8 
1:3 4 8 12 
1:4 4 12 16 
1:5 4 16 20 
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prostate cancer cells, myofibroblasts, myeloma cells and glioma cells were tested for 
mycoplasma contamination with DAPI DNA staining. The mycoplasma test was performed 
by following the below described protocol. 
The cells were cultured in antibiotic-free (Streptomycin/Penicillin) cell growth media 
for 14 days and seeded onto sterile glass microscope slides. The cells were rinsed with PBS 
and placed in Carnoy`s fixative solution (75% methanol and 25% glacial acetic acid) for 15 
min then they were air dried. Carnoy fixative is normally used to fix tissues that will be 
embedded in the paraffin. The regions of interest were marked using super PAP PEN IM3580 
(Immunotech, Beckmann coulter company, France) into different squares (e.g., divide the 
region of interest into 4 x 2 squares) and UV fluorescent DNA stain (DAPI, 4`,6-diamidino-
2-phenylindole) was added on each squares in drops until the square was filled. The 
concentrations used for DAPI staining were 2 µg/mL and 5 µg/mL. The cells were left in the 
dark in a humid metal chamber for 30 min. 
This incubation time allows the infusion of the DAPI and its intercalation into the 
DNA between the bases and therefore allows the detection of DNA (nucleus) under 
ultraviolet light. The cells were then rinsed three times with PBS, mounted in mounting 
medium and covered by a cover slip. The samples were stored for long time at 4 ºC. The cells 
were viewed under the UV-Epifluorescent microscope (Imager M2, Carl Zeiss 
Microimaging, Germany) for extranuclear DNA-staining in the cytoplasm as an indicator of 
mycoplasma contamination. No cell contamination should be detected under the microscope 
prior to their in vitro investigations.  
 
4.13. Cell viability assays 
4.13.1. Trypan blue stain  
The toxicity of the nanoparticles (FLUSPIO, FAD USPIO, NUSPIO) on prostate 
cancer cells (PC-3, LnCap), RPMI-8226 cells and HUVEC was investigated using trypan 
blue staining (trypan blue stain, Sigma-aldrich, Steinheim, Germany).  Cell population of 2 x 
10
6
 cells were seeded in the 6-well plates (BD Falcon, Germany) and incubated for 24 h in 
the incubator. Medium was removed, and each well was washed with 2 mL of PBS buffer. 
Nanoparticles (FLUSPIO, FAD USPIO, NUSPIO) and controls were diluted in respective 
cell growth media, in order to have iron concentrations of 0.03, 0.3, 3.0 µmol Fe/mL, 
respectively. 1 mL of cell growth media comprising nanoparticles with different iron 
concentrations and respective controls were added to each well (6-well plate). Cells were 
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incubated for 3, 12 and 24 h. After incubation, medium was removed and transferred to 15 
mL falcon tubes. Cells were washed once with PBS and subsequently trypsinized using 0.5 
mL of trypsin/EDTA (0.25%/0.5%). The cell suspension was centrifuged at 1000 rpm 
(Multifuge, Thermo scientific, Germany) for 5 min and the supernatant medium was 
removed. The cell pellet was dissolved in 0.5 mL of respective fresh cell growth media. 50 
µL of the cell suspension were mixed with 50 µL of the trypan blue staining solution (1:2).  
Trypan blue positive cells (dead cells) were counted using a Cedex XS (Innovatis AG, 
Germany) cell counter.  The percentage of trypan blue positive cells as a function of the total 
cell number was calculated in order to determine the relative cell viability. Three samples per 
condition were analysed.  
 4.13.2. TUNEL assay 
Toxicity of the nanoparticles (FLUSPIO and NUSPIO) on PC-3, HUVEC and RPMI-
8226 cells was additionally evaluated using the In situ Cell Death Detection Kit, TMR red, 
(Roche Diagnostics GmbH, Mannheim, Germany).  The cells (1x10
5 
cells/mL) were grown 
on cover slips (12 mm, Carl Roth, Germany) inside the 24 well plates (Cell star, Greiner bio-
one, Germany). Nanoparticles diluted in respective cell growth media (3.0, 0.3, 0.03 µmol 
Fe/mL) were added to the cells and incubated for 3 h. Duplicates were used (FLUSPIO). 
Triplicates were performed for NUSPIO toxicity investigation. After incubation, medium was 
removed and cells were washed three times with PBS buffer. Further, cells were fixed with 
4% paraformaldehyde at RT for 15 min. Again, cells were washed three times with PBS 
buffer. After fixation, cells were permeabilised for 2 min using the permeabilisation solution 
[(0.1% Triton X-100 (Sigma Aldrich, Steinheim, Germany) and 0.1 % sodium citrate (Carl 
Roth, Germany)].  Cells were washed three times with PBS buffer and further dried at RT. 
Negative control cells were treated only with 50 µL of the labeling solution (without active 
enzyme). Positive control cells were generated by incubation with recombinant DNase I for 
10 min in order to induce DNA strand break. 50 µL of TUNEL reaction mixture (label 
solution + active enzyme solution) were added to the positive control cells and to the cells, 
which were previously treated with controls and nanoparticles for 3 h. The TUNEL reaction 
mixture was incubated for 1 h at 37 °C in a humidified atmosphere in dark. After incubation, 
cells were washed three times with PBS for 10 min. Nuclei were counterstained with 4´,6´-
diamino-2-phenylindole (DAPI, 5 µg/mL, Merck, Darmstadt, Germany). Viable and 
apoptotic cells were counted in five different fields of view/slide using a fluorescence 
microscope (AxioObserver Z1; Carl Zeiss GmbH, Germany).  Images were acquired using a 
digital camera (AxioCam MRm; Carl Zeiss GmbH, Germany) with 10X magnification 
respectively. 
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4.13.3. MTT proliferation assay 
MTT cell proliferation assay was used as the third method used to assess the cell 
viability. The Cell Proliferation Kit I (Roche Diagnostics GmbH, Mannheim, Germany) was 
designed to be used for the non-radioactive, spectrophotometric quantification of cell 
proliferation and viability in cell populations using the 96-well-plate format. The cleavage of 
the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
into a blue colored product (formazan) by the mitochondrial enzyme succinate-
dehydrogenase takes place only in living cells and amount of formazan produced is 
proportional to the number of cells (Figure 4.2.2). 
 
Figure 4.2.2.  The figure shows the conversion of the tetrazolium salt (MTT) into formazan by mitchondrial 
reductase enzyme respectively. 
Cells were grown in 96 well microplates by suspending them in 100 µL of respective 
cell growth media per well (8x10
3
 cells/well). Incubation of the cells was carried out at 37 °C 
and 5% CO2 for 24 h in the incubator. After incubation, cells were washed with warm cell 
culture medium without phenol red. Negative controls are the cells which was incubated with 
medium and 1 % FBS. Positive control is generated by adding 100 µL of triton X (0.5 %) and 
100 µL of DMSO served as the blank control. Serial dilutions of the nanoparticles 
(FLUSPIO, FAD USPIO) were added to the cells in triplicates with final iron concentrations 
of  3.0, 0.3, and 0.03 µmol Fe\mL. 100 µL of samples (FLUSPIO, FAD USPIO and controls) 
in the cell growth media was introduced to the cells and further incubated for 3 h. The 
medium was removed after the incubation. Further, 100 µL of cell growth media were added 
to each well and trace amount of remnant nanoparticles and controls were removed. 20 µL of 
MTT solution (5 mg /mL of tetrazolium salt in PBS) were added to the each well, which were 
subsequently incubated for 4 h. Excess MTT-solution was removed after the incubation. The 
converted dye (formazan crystals) was solubilized with 150 μL of DMSO and stored at RT 
overnight to enhance the solubility of the samples. Further, trituration was performed in order 
to dissolve the converted dye completely. Absorbance of the converted dye was measured at 
570 nm with background subtraction at 690 nm. Relative viability of the cells was calculated 
with reference to the negative control cells which were presumed to be 100% viabile. 
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4.13.4. LDH cytotoxicity assay 
Cytotoxicity of the nanoparticles (NUSPIO) on PC-3 cells was also tested using LDH 
kit (Roche Diagnostics GmbH, Mannheim, Germany). The Cytotoxicity Detection Kit (LDH) 
was designed to be used as a precise, fast and simple colorimetric alternative to quantitative 
cytotoxicity/cytolysis based on the measurement of LDH activity released from the damaged 
cells into the supernatant of the incubated cell growth medium. The culture supernatant was 
collected cell-free and incubated with the reaction mixture from the kit. The LDH activity is 
determined in an enzymatic test: In the first step NAD
+
 is reduced to NADH/H
+
 by the LDH-
catalyzed conversion of lactate to pyruvate. In the second step the catalyst (diaphorase) 
transfers H/H
+
 from NADH/H
+
 to the Iodotetrazolium chloride (INT) which is reduced to 
formazan (Figure 4.2.3, Table 4.1.4). 
 
Figure 4.2.3.  The schematic figure shows the different conversion steps related to LDH activity. The first step 
involves LDH mediated conversion of lactate into pyruvate and second step involves catalytic conversion of the 
tetrazolium salt into formazan salt respectively. 
Table 4.1.4. Contents of LDH assay. 
 
 
 
 
 
PC-3 cells (2 x 10
4
 cells/well) were grown by suspending them in 100 µL of cell 
growth medium (DMEM/McCoy`s 5A with glutamax medium and 1-2% BSA (bovine serum 
albumin)) in 96 well microplates (Greiner bio-one, Germany). Cells were incubated at 37 °C 
and 5% CO2 for 24 h in the incubator for the cells to adhere on the surface of the plate. After 
incubation, cells were washed with warm (37 °C) PC-3 growth medium. The assay medium 
Label Contents/function 
Catalyst 
Diaphorase/NAD+ mixture, lyophilizate, 
stabilized 
Dye solution 
Iodotetrazolium chloride (INT) and sodium 
lactate 
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from the adherent cells was removed (to avoid LDH activity released from the cells during 
the overnight incubation step) and 100 µL of fresh cell growth medium was added to each 
well. 100 µL of the nanoparticle diluted in the PC-3 cell culture medium (3.0, 0.3, 0.03 µmol 
Fe/mL) was transferred into wells with PC-3 cells. 200 µL of cell growth medium without 
nanoparticles was used in triplicates as a background control for the medium. Negative 
control was generated by incubating the cells with culture medium (100 µL) in triplicates.  
Positive controls were generated by addition of 100 µL Triton X-100 (0.5%) to the cells. The 
background control for the nanoparticles (without cells) was used in order to avoid 
interference from nanoparticle absorption on LDH assay, which was achieved by using 100 
µL of the nanoparticles (3.0 µmol Fe/mL) in 100 µL of the cell culture medium. Triplicates 
were used. Cells were incubated with nanoparticles (3.0, 0.3, 0.03 µmol Fe/mL) for 6 and 24 
h respectively. After incubation, 100 µL of supernatant was removed carefully (the cells at 
the bottom was not disturbed) and transferred into wells of an optically clear 96-well flat 
bottom microplate (Greiner bio-one, Germany).  The LDH activity in these supernatants was 
determined by treating each well with 100 µL of the reaction mixture (freshly prepared: mix 
250 µL of bottle 1 (catalyst) with 11.25 mL of bottle 2 (dye solution)) and incubating them 
for 30 min between 15 and 25 °C in the dark. The absorbance of the samples was measured at 
490/492 nm in addition to a reference for the background subtraction (above 600 nm) using 
an ELISA microplate reader. Cell viability (%) was calculated by the following 
relation/formula (experimental value-negative control/positive control-negative control) x 
100.  
 
4.13.5. Flow cytometry analysis 
7-amino actinomycin D (7-AAD) viability staining (eBioscience GmbH, Frankfurt, 
Germany) was used to determine the effect of the nanoparticles (FLUSPIO and FAD USPIO) 
on the viable cells by flow cytometry (FACS Calibur, BD Bioscience). Cells (PC-3, LnCap 
cells and HUVEC) were grown in petridishes (200 X 20 mm; Greiner bio-one, Germany) 
until they reached 80% confluency.  For the FACS analysis 4x10
5
 cells (PC-3, LnCap) and 
2x10
5
 cells (HUVEC) in 300 µL were used.  Positive controls were generated by exposing 
the cells to 2 mL of triton X-100 (0.5%) for 10 min in the incubator. Nanoparticles 
(FLUSPIO and FAD USPIO) were diluted in the respective cell growth media of PC-3, 
LnCap and HUVEC with the different iron concentrations (3.0, 0.3, 0.03 µmol Fe/mL). 10 
mL of medium containing the nanoparticles were added to the cells and incubated at different 
time periods (3 h, 24 h). After incubation, medium was removed and cells were washed three 
times with PBS supplemented with 2% FBS. Cells were trypsinized by adding 2 mL of 
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trypsin/EDTA (0.25%/0.5%) and by 3 min incubation in the incubator. Trypsinization was 
stopped by adding 8 mL of the respective cell growth media to the cells. Further, they were 
centrifuged at 1000 rpm for 5 min in order to bring down the cells in the suspension. The cell 
pellet was re-suspended in 300 µL PBS supplemented with 2% fetal calf serum. The cell 
suspension (245 µL) was stained with 5 µL of 7-AAD viability staining solution by 
incubating them in the dark at RT for 20 min prior to the FACS measurement.  The 
fluorescence intensity of 7-AAD was determined in the FL3 (7-AAD) channel of the flow 
cytometer for the nanoparticles (at three different concentrations) inside the cells and for the 
controls (positive, negative) respectively. 
 
4.13.6. Direct cell viability counting method 
The direct cell viability counting method was applied to assess the viability of the PC-
3 cells after incubation with different iron concentrations of FLUSPIO nanoparticles.  The 
PC-3 cells (1x10
5
 cells/mL) were seeded into a 24 well plate (BD Falcon, Germany) and then 
incubated overnight to adhere onto the surface (24 well plate). Subsequently, the medium was 
removed and cells were washed once with PBS buffer. Negative controls were generated by 
incubating the cells with PC-3 cell growth medium. FLUSPIO nanoparticles were diluted in 
the growth medium to reach a final iron concentration of 3.0, 0.3, 0.03 µmol Fe/mL and 
further incubated for 3 h, 6 h, 12 h, 24 h, 48 h and 72 h respectively. After incubation, the 
medium containing the nanoparticles was removed and cells were washed three times with 
PBS. Cells were trypsinized. Finally, the cells were suspended in the medium and counted 
with the aid of a bright field microscope/cedex cell counter. The viability of the cells 
incubated with different FLUSPIO concentration were calculated relatively (drop in cell 
viability) in comparison to the total viable cell population of the negative control which was 
treated as 100% viable cells respectively. 
 
4.14. Fluorescence microscopy 
4.14.1. Fluorescence cell labeling by FLUSPIO/FAD USPIO nanoparticles 
         The fluorescence efficiency of the FLUSPIO nanoparticles in labeling the prostate 
cancer cells (PC-3) was evaluated by fluorescence microscopy. PC-3 cells (0.5 x 10
6 
cells) 
were seeded into the wells of 24-well plates (BD Falcon, Germany) which were already 
loaded with cover slips (12 mm, Carl Roth, Germany). Cells were incubated for 24 h to 
adhere on the cover slips respectively.  Subsequently, the medium was removed and cells 
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were washed once with PBS.  FLUSPIO nanoparticles (0.5 – 1.0 µmol Fe/mL) and controls 
(USPIO, FMN: 3.0 µmol/mL, GMP: 7.0 µmol/mL), diluted in the PC-3 cell growth medium, 
were added (1 mL) to the cells and incubated for 3 h. After incubation, the medium was 
removed and cells were washed three times with 1 mL of PBS buffer. Then, the cells on the 
cover slips were fixed with 0.5 mL of 100% ethanol by incubating them for 10 min in RT. 
Furthermore, ethanol was removed and the coverslips were dried in RT. The cover slips were 
removed from the 24-well plates and the cell nuclei were stained with 500 µL of DAPI (10 
µg/mL) by 30 min incubation in the dark. Excess DAPI was removed by washing with 
copious amount of water. Finally, the cover slips were fixed on the glass slides using the 
permafluor mounting medium and air dried prior to the fluorescence microscopic 
(AxioObserver Z1, Carl Zeiss Microimaging GmbH, Germany) evaluation. Triplicates were 
used for all conditions. 
 The fluorescence efficiency of FAD USPIO nanoparticles was evaluated in LnCap 
cells (0.5 x 10
6
 cells) using fluorescence microscopy. The LnCap cells were seeded and 
further incubation procedure was followed analogous to that of FLUSPIO labeling. The FAD 
USPIO nanoparticles (3.0 µmol Fe/mL) and controls (USPIO, FAD: 3.0 µmol/mL, GMP: 7.0 
µmol/mL) diluted in RPMI 1640 with glutamax medium supplemented with 10% FBS and 
1% Pen/Strep were added (1 mL) in triplicates and incubated for 3 h respectively. Further, the 
cells were washed, trypsinized, fixed, stained with DAPI, and mounted on cover slips for 
analysis by fluorescence microscopy (analogous to FLUSPIO) respectively. 
4.14.2. Competition experiments (Fluorescence Microscopy) 
The fluorescence efficiency of the FAD USPIO nanoparticles for labeling the prostate 
cancer cells was mediated by riboflavin carrier protein (RCP) and their strong intracellular 
uptake was evaluated by fluorescence microscopy. The RCP dependant FAD USPIO uptake 
was proved by performing in vitro fluorescence competition experiments where RCP was 
blocked by free Rf in 10 and 100 fold excess. LnCap cells were seeded on the glass slides (76 
x 26 mm) placed inside the quadriPERM chamber and incubated for 24 h. 2 mL of the LnCap 
cells suspension (0.5 – 1.0 million cells) in the RPMI 1640 with glutamax medium 
supplemented with 20% FBS and 1% Pen/Strep and 3 mL of LnCap cell growth medium was 
added to the quadriPERM chamber. The cells were incubated at 5% CO2 and 37 °C for 48 h, 
until the cells reached 70-80% confluency. After incubation, the medium was removed from 
the wells and cells were washed once with PBS buffer. The FAD USPIO nanoparticles (0.3 
µmol Fe/mL) were diluted in the LnCap cell growth medium. LnCap cells on the glass slides 
were pre-incubated with free Rf (10 and 100 fold in comparison to the concentration of FAD 
(Rf analogue) on the nanoparticles) in order to block the RCP that is responsible for the high 
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uptake of FAD USPIO. After 10 min incubation, medium with FAD USPIO was added and 
subsequently incubated for 1 h. After incubation, the medium was removed and cells were 
washed three times with PBS. Then, the cells were fixed with 5 mL of 100% ethanol for 10 
min in RT. Excess ethanol was removed and the glass slides were dried at RT.  Cell nuclei 
were stained with DAPI and processed as described before (section 4.14.1) prior to the 
fluorescence analysis.  
 
 4.14.3. Flow cytometry analysis of cells labelled with FLUSPIO and FAD USPIO  
The fluorescence intensity of nanoparticles (FLUSPIO and FAD USPIO) inside the 
viable cells was determined by using flow cytometry (FACS Calibur, BD Biosciencs, 
Germany). Cells (PC-3 and LnCap cells) were grown in petridishes (200 X 20 mm; Greiner 
bio-one, Germany) until they reach 80% confluency.  Flow cytometry analysis was 
performed with 4x10
5
 cells (PC-3, LnCap) in 300 µL. Positive controls were generated by 
exposing the cells to 2 mL of triton X-100 (0.5%) in the PBS buffer at 37°C. Nanoparticles 
(FLUSPIO and FAD USPIO) were diluted in respective cell growth media with different iron 
concentrations (3.0, 0.3, 0.03 µmol Fe/mL). 10 mL of the medium with the nanoparticles 
were added to the cells (incubation time: 3 h, 24 h). After incubation, medium was removed 
and cells were washed three times with PBS supplemented with 2% FBS. Cells were 
trypsinized. Trypsinization reaction was stopped by adding 8 mL of the respective cell 
growth media to the cells. Further, they were centrifuged at 1000 rpm for 5 min in order to 
bring down the cells in the suspension. The cell pellet was resuspended in 300 µL PBS with 
2% fetal calf serum. The cell suspension (245 µL) was measured in the FL1 (FITC) channel 
in order to visualize the green fluorescence of FLUSPIO and FAD USPIO.   
 
4.14.4. FLUSPIO uptake in prostate cancer cells (Bright field microscopy) 
Additionally, the uptake of FLUSPIO by prostate cancer cells (PC-3 and DU-145) 
was evaluated using bright field microscopy. PC-3 and DU-145 cells were used at 80% 
confluency.  The supernatant medium above the cells was removed and cells were washed 
with PBS.  Then, the cells were trypsinized. Trypsinization was stopped by adding 16 mL of 
the respective cell growth media and cells were seeded on glass slides (76 x 26 mm) which 
were kept inside a quadriPERM chamber and incubated for 24 h. The supernatant medium 
was removed and the cells were washed once with PBS buffer. Cells were incubated with 
FLUSPIO for 3 h in different iron concentrations (3.0, 0.3, 0.03 µmol Fe/mL) in triplicates. 
After incubation, medium was removed and cells were washed three times with PBS buffer. 
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Then, the cells were fixed on the glass slides using 100% ethanol by 10 min incubation in 
RT. Ethanol was removed and the glass slides were dried in RT. The glass slides was 
removed from the quadriPERM chamber and cover slips were fixed on the glass slides using 
the permafluor mounting medium and dried prior to the analysis with the bright field 
microscope (AxioImagerD1, Carl Zeiss Microimaging GmbH, Germany). 
 
4.15. TEM - FLUSPIO uptake by prostate cancer cells  
The high competency of FLUSPIO in labeling prostate cancer cells (PC-3) was 
visualized using transmission electron microscopy (TEM). USPIO and FLUSPIO (3.0 µmol 
Fe/mL) were diluted in PC-3 cell growth medium. 11mL of medium containing either USPIO 
or FLUSPIO were added to the cells and incubated for 3 h and 6 h. After incubation, medium 
was removed and cells were washed thrice with PBS. Subsequently, cells were fixed in 3 % 
glutaraldehyde (in 0.1 M Soerensen‟s phosphate buffer [pH 7.4; 13 mM NaH2PO4 x H2O; 87 
mM Na2HPO4 x 2H2O]) by incubation for 22 h, and subsequently washed with 0.1 M 
Soerensen‟s phosphate buffer. Fixed cells were embedded in 2 % agarose, rinsed with 
distilled water and dehydrated with ethanol (80 % - 100 %). Finally cells were processed for 
embedding in Epon, by polymerizing 8 h at 37 °C and 56 hours at 60 °C, and then cut into 70 
– 100 nm thick slices. After polymerization, cells were contrasted with uranyl acetate and 
lead citrate. The samples were analyzed with a PHILIPS EM 400 T microscope at 60 kV and 
micrographs were taken by an OLYMPUS CCD-Camera (MORADA) 
 
4.16. Quantification of FLUSPIO intracellular uptake (ICP-MS) 
4.16.1. In vitro FMN competition experiments  
The increased FLUSPIO uptake by PC-3 cells mediated via RCP was also studied 
using ICP-MS technique by effectively blocking the RCP receptors with 10 and 100 fold 
excess of FMN respectively. PC-3 cells were cultured in respective cell growth medium and 
processed for FLUSPIO uptake analogous to the competition experiments performed for 
LnCap cells (as in  section 4.14.2) respectively. FLUSPIO (0.3 µmol Fe/mL) and respective 
10 and 100 fold excess of FMN was added to the PC-3 cells and incubated for 30 and 60 min. 
Triplicates of all conditions was performed. Further, after incubation the cells were washed, 
trypsinized, and centrifuged. The supernatant medium was discarded and the cell pellet (2 x 
10
6
 cells) was measured for the total iron content of the FLUSPIO internalized inside the PC-
3 cells.  Digestion of the cells was performed in a closed vessel microwave reaction system 
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(MLS ethos plus, MPV-100/HAT) by addition of 1.5 mL nitric acid (65%) to 1.5 mL 
hydrogen peroxide and 1 mL of internal standard (rhodium) using 1000 W for 45 min and by 
raising the temperature from RT to 210 ºC (left constant at 210 ºC for another 15 min). 
Samples were diluted in 1:100 in water. 
The amount of the intracellular iron was determined using a high-resolution sector 
field inductively coupled plasma mass spectrometer [ICP-MS (Elan-DRCII, Perkin-Elmer)] 
equipped with an injector (2.0 mm i.d. Quartz, Part No.: WE02-3916). Data were acquired at 
medium resolution using rhodium as an internal standard. A Quartz Cyclonic spray chamber 
(Part No.: WE02-52222) equipped with a Meinhard Type A quartz nebulizer was used for the 
sample introduction. The instrument was tuned and calibrated via infusion of a 1 µg/mL 
rhodium standard solution. The iron content was expressed in picograms of iron per cell. 
 
4.17. In vitro MR relaxometry 
4.17.1. Phantom generation for FLUSPIO and FAD USPIO cellular uptake by different 
cell types  
The intracellular uptake of the nanoparticles (FLUSPIO, FAD USPIO) by prostate 
cancer cells (PC-3, DU-145, LnCap) and endothelial cells (HUVEC) were investigated by 
determining the R2 relaxation rates using a clinical 3T MR scanner (PHILIPS Achieva, The 
Netherlands) in combination with a knee coil (SENSE-flex-M, PHILIPS, The Netherlands) at 
RT. The prostate cancer and endothelial cells were cultured according to the protocol 
described in section 4.11 respectively. Further, these cells were labelled using different 
concentration of FLUSPIO and FAD USPIO (3.0, 0.3, 0.03 µmol Fe/mL) by incubating them 
at different time periods respectively. Subsequently, the cells were washed and trypsinized as 
described in the previous sections. Furthermore, the incubated cells were centrifuged at 1000 
rpm (Multifuge, Thermo scientific, Germany) for 5 min and supernatant medium was 
discarded. The cell pellet was re-suspended in 50 mL of PBS buffer and washed three times 
by performing the centrifugation as described above. The total cell number in the cell 
suspension was counted using a hemocytometer and cell pellet after PBS washing was 
dissolved in required volume of 10% gelatin solution to have 2 x 10
6 
cells/0.3 mL as the final 
cell concentration. For MR measurements 0.3 mL/well of cell suspension in 10% gelatin was 
filled in the custom made phantoms (Greiner 96 well Flat Transparent Polystyrol microplate, 
Germany).  The relaxation times T1 and T2 are measured according to the sequences 
parameters mentioned in section 4.2.11 respectively. 
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4.17.2. Comparison of FLUSPIO and FAD USPIO cellular uptake by different cell types  
FLUSPIO efficiency in labeling prostate cancer cells, fibroblasts and endothelial cells 
were compared as these cells are kown to express different RCP levels. We believe that the 
high uptake of FLUSPIO is RCP dependant in above cells. The intracellular uptake of 
FLUSPIO nanoparticles in prostate cancer cells (PC-3, LnCap, DU-145), myofibroblasts and 
HUVEC was compared using MR tomography (R2 relaxation rates).  
FLUSPIO nanoparticles were diluted in the respective cell growth media, to have a 
final iron concentration of 0.3 µmol Fe/mL for cellular labeling. 11 mL of cell culture 
medium with nanoparticles were added to each T75 flask with respective cells. Three samples 
per condition were analysed. Cells were incubated for 1 h and 3 h at 37 ºC, 5% CO2 and 95% 
relative humidity.  Cells were trypsinized and dissolved in 10% gelatin to have 2 x 10
6 
cells/0.3 mL as the final cell concentration. R2 relaxation rates of the samples were 
determined as described before. 
Similarly, the cellular uptake of FAD USPIO by prostate cancer cells (PC-3, DU-145, 
LnCap) mediated via RCP was studied in comparison to USPIO using MR relaxometry based 
on the R2 relaxation rates respectively. The three different prostate cancer cells were cultured 
according to the previously described protocols (section 4.11). FAD USPIO and USPIO (0.3 
µmol Fe/mL) were diluted in the respective cell culture media and cells were labelled with 11 
mL of medium containing nanoparticles. Triplicates of all conditions were performed. The 
cells with nanoparticles were incubated for 1 h and 3 h in the incubator. After incubation, 
cells were washed, trypsinized, centrifuged, and suspended in 10 % gelatin in order to have a 
total cell concentration of 2 x 10
6
 cells/0.3 mL respectively. Further, the FAD USPIO cellular 
uptake was analyzed by measuring the R2 relaxation rates of the cells as described before. In 
line with the above described experiment (under identical experimental conditions), Rf-
USPIO, FLUSPIO, and FAD USPIO cellular uptake by PC-3 and DU-145 cells were studied 
via the R2 relaxation rates (MR relaxometry) in order to determine the specific uptake of the 
probes mediated by different RCP ligands respectively. 
In addition, the RCP mediated specific uptake of flavin coated nanoparticles by 
prostate cancer cells, fibroblasts and endothelial cells was studied by employing double FMN 
coated USPIO using MR relaxometry. The double FMN coated USPIO was diluted in the 
respective cell growth media to 0.3 µmol Fe/mL and 11 mL of this medium was used for 
labeling the cells by incubating them for 1 h respectively. Triplicates of the samples were 
analyzed.  After incubation, cells were washed, trypsinized, centrifuged analogous to the in 
vitro phantom generation protocols. The cell pellet was diluted in 10% gelatine to have a cell 
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concentration of 2 x 10
6
 cells/0.3 mL respectively. Further, the R2 relaxation rates of the 
labelled cells and controls were determined as described prior to MRI measurements. In line 
with the above described experimental conditions, double Rf coated USPIO, double FMN 
coated USPIO and double FAD coated USPIO cellular uptake by PC-3 cells were evaluated 
using MR relaxometry (R2 relaxation rates) in order to prove that the uptake is highly 
regulated via RCP.  
4.17.3. Inhibition of FLUSPIO uptake by FBS in prostate cancer cells  
The uptake of FLUSPIO by PC-3 cells in the absence of FBS was almost two to three 
folds in comparison to cells incubated with FLUSPIO in the presence of FBS. FLUSPIO and 
USPIO nanoparticles were diluted in McCoy`s 5A with glutamax medium supplemented only 
with 1% penicillin/streptomycin with and without FBS supplementation, to have a final iron 
concentration of 3.0, 0.3, 0.03 µmol Fe/mL to facilitate cellular labeling. 11 mL of medium 
with nanoparticles (USPIO and FLUSPIO) was added to each T75 flask. Cells were 
incubated for 3 h at 37 ºC, 5% CO2 and 95% relative humidity. Cells were embedded in 
gelatin and measured by R2- relaxometry by using MR-sequences as described before. Three 
samples per condition were analysed. 
 
4.18. In vitro competitive blocking of FLUSPIO/FAD USPIO uptake by different cells  
Flavin (Rf, FMN, FAD) based competition experiments were performed in order to 
validate the uptake of FLUSPIO and FAD USPIO mediated via RCP respectively. The high 
intracellular uptake of FAD USPIO and FLUSPIO nanoparticles by prostate cancer cells (PC-
3, LnCap, DU-145) and HUVEC was determined using MR tomography (R2 relaxation 
rates). For labeling cells, FAD USPIO, FLUSPIO nanoparticles and control (USPIO) were 
diluted in the respective cell growth media, in order to have a final iron concentration of 0.3 
µmol Fe/mL. Cells were pre-incubated for 10 min with 10 mL of cell growth media 
containing 10 and 100 fold excess of one of the following RCP specific ligand (Rf, FMN, 
FAD) in order to block the highly expressed RCP. Subsequently, 10 mL of FLUSPIO and 
FAD USPIO (0.3 µmol Fe/mL) in respective cell growth media were added and further, cells 
were incubated for 30 or 60 min at 37 ºC, 5% CO2 and 95 % relative humidity.  Three 
samples per condition were analysed. After incubation, cells incubated with nanoparticles and 
excess RCP ligand (flavins) were washed, trypsinized and centrifuged. Finally, the cell pellet 
was diluted in 10 % gelatin to yield a final cell concentration of 2 x 10
6
 cells/0.3 mL 
respectively. The R2 relaxation rates of the above cells in gelatin were determined using MR 
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relaxometry as described above to evaluate the flavin coated USPIO uptake by different cells 
mediated via the RCP.  
 
 4.19. Fluorescence imaging (Fluorvivo300 Indec imaging system) 
Fluorvivo Model 300 Indec imaging system offers multicolor, simultaneous, GFP-
RFP imaging with two additional excitation and emission filter sets, thus allowing at least 
three alternative probes to be imaged (see Table 4.1.4). Real time multicolor imaging and live 
video imaging and recording can be achieved with this system. The system finds its 
applications in basic research that include studies of gene expression and apoptosis, tumor 
growth and angiogenesis, and metastasis and invasion. Pre-clinical applications include drug 
screenings, drug targeting, and further validation of the animal models can also be achieved 
using this imaging system respectively.  
The MR gelatin phantom`s from different experiments i.e FLUSPIO and FAD USPIO 
in prostate cancer cells, endothelial cells were scanned using FluorVivo300 Indec system 
before and after MR scan in order to co-validate the results obtained from MR relaxometry 
via fluorescence.  Further, the fluorescence image`s (intensity) of these phantoms were 
compared with the relaxation rate`s (R2) from MR measurements which can be related to 
very high specific uptake of FLUSPIO, FAD USPIO nanoparticles in different cells. 
Table 4.1.4. Table shows different channels available in the FluorVivo imaging system respectively. 
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4.20. In vivo experiments with FAD USPIO  
Ten CD1 male nude mice (Charles River Laboratories International, Inc., 
Wilmington, MA, USA) were used for the in vivo evaluation of FAD USPIO and Resovist. 
The male nude mice were generated from the transfer of the nude gene through a series of 
crosses and backcrosses. All animal experiments were approved by the governmental review 
committee on animal care.  
4.20.1.1 Tumor Xenograft model: subcutaneous injection (s.c. injection) 
For xenotransplantation, 4 x 10
6
 LnCap cells in 100 µL matrigel (with small amount 
of medium) were subcutaneously injected into the right hind limb of each male nude mouse 
(n = 10). The tumors were left for 6-8 weeks to grow. 
4.20.1.2. Assessment of tumor growth 
Assuming that the tumor has an ellipsoid shape, the diameters were measured using a 
calliper and the tumor volume was calculated according to the volume formula of ellipsoid V 
= ab
2Π/6, where a & b being the longest and shortest diameters of the ellipsoid along 2 axes 
respectively. 
4.20.1.3. MRI of tumor bearing mice 
The nude mice bearing LnCap tumor were scanned using a solenoid sense-receive 
mouse coil manufactured by Philips in the clinical 3T MRI system under isoflurane 
anesthesia before and after i.v. injection of FAD USPIO and Resovist (1 h and 3 h).  The 
tumor was non-invasively imaged using T2w, T2*w, T1w image sequences. In addition, T2 
and T2* relaxometry sequences was applied as described below. 
Transverse relaxation times (T2) were measured using a multi-slice, multi shot spin 
echo sequences with 90° excitation pulses followed by a train of equally spaced 180° 
refocusing pulses [TR = 1500 ms, TE = 18 ms (shortest), number of echoes = 20, FOV = 30 
mm, matrix scan = 80, reconstruction matrix = 112, slice thickness = 1 mm, slice orientation 
= sagittal, scan mode = multishot (MS), scan technique = SE]. T2 relaxation times were 
calculated by a linear fit of logarithmic region of interest (ROI) signal amplitudes versus echo 
time (TE). T2 star relaxation times (T2*) were measured using a multi-slice, multi shot spin 
echo sequences with 30º excitation pulse without refocusing pulse [TR = 1330 ms, TE 1= 10 
ms, TE = 7.9 ms, number of echoes = 15, FOV = 30 mm, matrix scan = 80, reconstruction 
matrix = 112, slice thickness = 1 mm, slice orientation = sagittal, scan mode = multishot 
(MS), scan technique = FFE].  T2 weighted (T2w) images were acquired by measuring a 
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multi-slice, single shot spin echo sequences with 30º excitation pulse without refocusing 
pulse [TR = 800 ms, TE = 26 ms, number of echoes = 1, FOV =25 mm, matrix scan = 96, 
reconstruction matrix = 96, slice thickness = 1mm, slice orientation = sagittal, scan mode = 
M2D, scan technique = FFE]. T2star weighted (T2*w) images were acquired by measuring a 
multi-slice, multi shot spin echo sequences with 90º excitation pulses followed by a train of 
equally spaced 120º refocusing pulses [TR = 2391 ms, TE = 100 ms, number of echoes = 1, 
FOV = 25 mm, matrix scan = 128, reconstruction matrix = 144, slice thickness = 1mm, slice 
orientation = sagittal, scan mode = multishot (MS), scan technique = SE]. T1weighted (T1w) 
images were acquired by measuring a multi-slice, multi shot spin echo sequences with 90º 
excitation pulses followed by a train of equally spaced 115º refocusing pulses [TR = 500 ms, 
TE = 20 ms, number of echoes = 1, FOV = 150 mm, matrix scan = 304, reconstruction matrix 
= 512, slice thickness = 5mm, slice orientation = sagittal, scan mode = multishot (MS), scan 
technique = SE] respectively. 
4.20.1.4. Injection of contrast agent (FAD USPIO) 
The animals were randomly divided into two groups: Resovist (control, n=5), and 
FAD USPIO (n=5). The animals were injected with 130 µL of respective agents in 5% 
glucose solution with a total iron concentration of 900 µmol Fe/Kg. The injection process 
was performed under the FluorVivo 300 imaging system (GFP channel) in order to visualize 
the fluorescence of the FAD USPIO nanoparticles. 
4.20.2. Prussian blue staining  
Prussian blue staining was performed to localize USPIO, and FAD USPIO in the 
prostate cancers. The tumors were frozen in tissue tek (O.C.T. Compound, Sakura Finetek 
Europe B.V., Germany) and stored at -80°C. Thin sections (8 µm) of the tumor tissues were 
cut using a cryotom. Tumor tissues were first incubated with an aqueous solution of 
K4Fe(CN)6 (10%) for 5 min, then with a 1:1 mixture of K4Fe(CN)6 (10%) and hydrochloric 
acid (20%) for 30 min. Tissues were counterstained with Nuclear Fast Red (Carl Roth, 
Karlsruhe, Germany) for 10 min. After staining, tumor tissues were washed with water, dried 
with ethanol (70%, 80%, and 100% respectively), rinsed with xylene and embedded with 
coverslips for microscopic analysis (Imager M2, Carl Zeiss Microimaging GmbH, Germany). 
4.20.3. (Immuno-)histological Staining of Tumors  
The tumor slices on microscopic slides were stained for vascularization using a 
primary rat anti-mouse CD31 antibody (BD Biosciences, San Jose, CA) for 2 h (RT) in 
combination with a Cy3-labeled anti-rat IgG secondary antibody (Dianova GmbH, 
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Hamburg,) which was incubated for 30 min at RT, respectively.  Nuclei in the tumor sections 
were counterstained with DAPI for 30 min. The slides were visualized using fluorescence 
microscope (Imager M2, Carl Zeiss GmbH, Germany) with different magnification (10X, 
20X and 40X) and fields of view, respectively.  
4.20.4. Pharmacokinetic profile of FAD USPIO in mouse blood (Blood half life) 
Small volumes of blood (30 µL – 50 µL) were withdrawn intravenously from a male 
nude mouse (CD1) before injecting them with specific nanoparticles under the isoflurane 
anesthesia. The blood was diluted with 50 µL of 5% glucose solution which acts as a blank 
(5% glucose solution) and control (blood without nanoparticles). The FAD USPIO 
nanoparticles (900 µmol/Kg) in 5% glucose solution were injected in one mouse which was 
visualized under the FluorViVo 300 imaging system. After the injection, 30 – 50 µL of the 
blood were withdrawn at different time points (3-5,10, 30 and 60 min) and mixed with 50 µL 
of the 5% glucose solution. Blood half life of the FAD USPIO was determined by analysing 
the fluorescence (using TECAN microplate reader) in the blood at 530 nm for various time 
points.   
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Appendices 
Appendix 1: NMR spectra of different ligands 
1
H NMR spectrum of compound 1 recorded in CDCl3 
13
C  NMR spectrum of compound1 recorded in CDCl3 
 202 
1
H NMR spectrum of  compound 2 in CD3OD 
13
C  NMR spectrum of compound 2 in CD3OD 
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1
H NMR spectrum of compound 3 in DMSO d6 
 
1
H NMR spectrum of compound 4 in D2O 
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1
H NMR spectrum of compound 5 in D2O 
 
1
H NMR spectrum of compound 6 in D2O 
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1
H NMR spectrum of compound 7 in CD3OD  
1
H NMR spectrum of compound 8 in D2O  
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1
H NMR spectrum of compound 9 in D2O 
 
1
H NMR spectrum of compound 10 in D2O 
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1
H-NMR spectrum of compound 11 in D2O 
 
 
Appendix 2: Fluorescence microscopy of USPIO coated/conjugated with dye 
Fluorescence microscopy of RITC and FITC conjugated/coated USPIO 
 
 
Figure A1. Fluorescence microscopy of dye conjugated USPIO. (A) RITC conjugated to APTMS-USPIO; (B) 
FITC conjugated to APTMS-USPIO and (C) FITC coated USPIO respectively. 
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Appendix 3: NUSPIO (Naphthalene USPIO) characterization results 
 
 
 
 
Figure A2. ESI mass spectra of (A) ANDS coupled to oleic acid in pyridine at high temperature (B) H-acid and 
(C) H-acid coupled to oleic acid respectively. 
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Figure A3. Fluorescence spectra recorded in water for (A) NUSPIO (H-acid) purified by dialysis against water 
and by exchange through basic resin, (B) NUSPIO (ANDS), (C) Napthol blue black and (D) ANDS were 
recorded in water. Absorption spectra recorded in water for (E) ANDS, (F) Napthol blue black, (G) NUSPIO 
(ANDS), (H) NUSPIO (H-acid, 40mmol/mL) purified by dialysis against water, (I) NUSPIO (H-acid, 40 
mmol/mL) purified by resin exchange, (J) H-acid, (K) 4-(9-aminoacridinium-10-yl)butane-1-sulfonate and (L) 
NUSPIO (H-acid) purified by dialysis against water and PBS buffer respectively.  
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Figure A4. Fluorescence spectra recorded in water for (A) pyrene trisulfonic acid excited at 328 nm, (B) pyrene 
trisulfonic acid excited at 460 nm, (C) NUSPIO (H-acid) purified by dialysis against water and HEPES buffer, 
(D) NUSPIO (H-acid) purified by dialysis against water and PBS buffer, (E) 4-(9-aminoacridinium-10-yl) 
butane-1-sulfonate, (F) NUSPIO (H-acid) purified by dialysis against water and 0.15 M NaCl solution, (G) 
NUSPIO (H-acid) purified by dialysis against water and 0.15 M glucose solution, (H) H-acid excited at 300 nm, 
(I) H-acid excited at 340 nm, (J) H-acid excited at 360 nm, (K) NUSPIO (H-acid, 40 mmol/mL) purified by 
resin exchange method  and (L) NUSPIO (H-acid, 40 mmol/mL) purified by dialysis against water respectively. 
 
 
 
 
 
Figure A5. Bright field image of USPIO coated with ANDS (A); fluorescence image of USPIO coated with 
ANDS (B); fluorescence image of NUSPIO (H-acid) purified by dialysis against water and PBS buffer (C); 
fluorescence image of NUSPIO (H-acid) and dialysed against water and HEPES buffer respectively.  
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Appendix 4: FLUSPIO characterization results 
 
 
 
Figure A6. AFM images and size distribution of USPIO (A and B) and FLUSPIO (C and D). The size of the 
nanoparticles is close to the size of the AFM probe (near the resolution limit) which limits the accuracy of the 
size measurements of the individual nanoparticles. The particle size of USPIO is within the range 10-50 nm (B) 
and coincides well with TEM images. The particle size of FLUSPIO (with more defined particulate 
morphology) was approximately 20-40 nm respectively.   
 
 
 
 
 
 
Figure A7. X-ray photoelectron spectroscopy (XPS) results of USPIO, FLUSPIO 1 (35 mM FMN) and 
FLUSPIO 2 (50 mM FMN). A higher percentage of iron was observed on uncoated sample (USPIO) and 
interestingly there is some iron still visible on the coated samples at about 1 atomic weight percentage for 
FLUSPIO. Carbon and chlorine are detected on uncoated samples respectively. 
 
 212 
 
 
 
 
 
 
 
Figure A8. TOF-SIMS measurements displayed specific secondary ions for GMP and FMN from FLUSPIO (A 
and B) compared to the uncoated USPIO. Further, FLUSPIO displayed peaks for phosphate groups and some 
higher mass fragments appearing at slightly different strengths on two different coated samples (FLUSPIO I (35 
mM FMN) and FLUSPIO II (50 mM FMN)). In close agreement with XPS, the uncoated USPIO showed a 
much stronger FeO peak respectively. 
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Figure A9. Experimental XRD patterns of USPIO (black, A) and FLUSPIO (black, B) with a calculated XRD 
of observed peaks (red) respectively. 
 
 
 
 
 
Figure A10. DLS size distribution by number for USPIO, FLUSPIO I (35 mM FMN), FLUSPIO II (50 mM 
FMN) at different pH (2.0, 6.1 and 7.4) respectively. 
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Figure A11. Absorption, fluorescence and fluorescence lifetime measurements of USPIO, FMN, FLUSPIO 
respectively. Absorbance of USPIO (A), absorbance and fluorescence of FMN (B), absorbance and fluorescence 
of FLUSPIO (C) and fluorescence lifetime measurements of FLUSPIO (D) respectively. The absolute quantum 
yield of free FMN and FMN on FLUSPIO is about 21% and the fluorescence lifetime of FMN and FMN on 
FLUSPIO is about 4.8 ns respectively. 
 
 
 
Figure A12. Trypan blue staining results for FLUSPIO 1 (35 mM FMN) and FLUSPIO 2 (50 mM FMN) 
incubated with HUVEC in two different time points respectively. Trypan blue staining did not show any 
relevant loss in cell viability after (A) 3 h incubation and (B) 24 h incubation with FLUSPIO at the respective 
cell labeling concentrations (0.3 µmol Fe/mL).  
 215 
 
 
 
Figure A13. Results from direct cell viability counting experiments did not display any relevant loss in cell 
viability of PC-3 cells after incubation with FLUSPIO 1 (35 mM FMN) and FLUSPIO 2 (50 mM FMN) at 
different time points respectively.  PC-3 cells (10
5 
cells) were incubated for (A) 3 h (B) 12 h (C) 24 h (D) 48 h 
and (E) 72 h respectively with three different concentrations of FLUSPIO (3.0, 0.3. 0.03 µmol Fe/mL) 
respectively. 
 
 
 
 
 
 
Figure A14. Bright field images of PC-3 and DU-145 incubated (3 h) with FLUSPIO (3.0 µmol Fe/mL) 
respectively. Bright field images of PC-3 incubated (A) growth medium (B) FLUSPIO. Bright field images of 
DU-145 incubated with (C) growth medium (D) FLUSPIO. The bright field images clearly show the high 
uptake of FLUSPIO in both prostate cancer cell types respectively. 
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Figure A15. Fluorvivo Indec system (optical imaging) images of (A) FAD USPIO in 5% glucose solution and 
(B) FLUSPIO cellular uptake (incubated for 1 h and 3 h) in three different prostate cancer cells (PC-3, LnCap, 
DU-145) and activated endothelial cell line (HUVEC) suspended in 10% gelatin after MRI measurements 
respectively. 
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a b s t r a c t
Riboﬂavin is an essential vitamin for cellular metabolism and is highly upregulated in metabolically
active cells. Consequently, targeting the riboﬂavin carrier protein (RCP) may be a promising strategy for
labeling cancer and activated endothelial cells. Therefore, Ultrasmall SuperParamagnetic Iron Oxide
nanoparticles (USPIO) were adsorptively coated with the endogenous RCP ligand ﬂavin mononucleotide
(FMN), which renders them target-speciﬁc and ﬂuorescent. The core diameter, surface morphology and
surface coverage of the resulting FMN-coated USPIO (FLUSPIO) were evaluated using a variety of physico-
chemical characterization techniques (TEM, DLS, MRI and ﬂuorescence spectroscopy). The biocompati-
bility of FLUSPIO was conﬁrmed using three different cell viability assays (Trypan blue staining, 7-AAD
staining and TUNEL). In vitro evaluation of FLUSPIO using MRI and ﬂuorescence microscopy demon-
strated high labeling efﬁciency of cancer cells (PC-3, DU-145, LnCap) and activated endothelial cells
(HUVEC). Competition experiments (using MRI and ICP-MS) with a 10- and 100-fold excess of free FMN
conﬁrmed RCP-speciﬁc uptake of the FLUSPIO by PC-3 cells and HUVEC. Hence, RCP-targeting via FMN
may be an elegant way to render nanoparticles ﬂuorescent and to increase the labeling efﬁcacy of cancer
and activated endothelial cells. This was shown for FLUSPIO, which due to their high T2-relaxivity, are
favorably suited for MR cell tracking experiments and cancer detection in vivo.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
The vast majority of (pre-)clinically used MR contrast agents
based on iron oxide nanoparticles are functionalized with (bio-)
polymers like dextran, carboxydextran and polyethylene glycol.
However, with few exceptions [1], polymeric coated magnetic
nanoparticles are known to display relatively large hydrodynamic
diameters and therefore display limitations in tissue penetration,
diffusion, bio-distribution and metabolic clearance and might even
induce side effects [2,3]. To overcome the afore-mentioned
setbacks of polymer coatings, a thin layer of non-polymeric
coating using organic biocompatible molecules was introduced in
a simple, and straightforward synthetic method [4e6]. Based on
the advantages of non-polymeric coatings, we here report for the
ﬁrst time ﬂuorescent and non-polymeric ﬂavin mononucleotide
(FMN)-decorated iron oxide nanoparticles as versatile MR contrast
agents. FMN and its precursor riboﬂavin (Rf) mediate various redox
reactions that regulate the metabolism of carbohydrates, amino
acids and lipids [7]. The cellular uptake of Rf is mediated by
a membrane protein known as the riboﬂavin carrier protein (RCP),
which strongly binds and transports Rf into the cell [8,9]. RCP is
upregulated in cells with high metabolic activity like tumor cells
[10,11] and activated endothelial cells. The current state of the art is
that ﬂuoro-2-deoxy-D-glucose (18F-FDG) used for positron emission
tomography (PET) imaging is the only clinically approved diag-
nostic agent for labeling cells with high metabolic activity [12e14].
On that basis, it was reasoned that besides 18F-FDG-uptake, also the
uptake of FMN-functionalized probes by RCP could serve as effec-
tive metabolic marker for diagnostic (and therapeutic) interven-
tions using non-invasive imaging modalities.
Molecular imaging and cell tracking with magnetic resonance
imaging (MRI) are frequently achieved using Ultrasmall Super-
Paramagnetic Iron Oxide nanoparticles (USPIO) [15e25]. In this
context, a ﬂuorescent label incorporated into the nanoparticles is
extremely helpful in detecting the labeled cells and tissues using
optical imaging, as well as in histology [26e33]. The spectral
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characteristics of the FMN (display emission at 530 nm) are
suboptimal for in vivo ﬂuorescence imaging due to the green
autoﬂuorescence, high scattering and low penetration of photons
into tissues that is prevalent in this spectral range. However, FMN
conjugated USPIO could be evidently used for co-validation of the
MR ﬁndings through histology. Therefore, the aim of this study was
to develop a hybrid optical (for invasive clinical interventions) and
MR probe targeting RCP, based on FMN-functionalized USPIOwhich
speciﬁcally accumulates in cells with high metabolic activity.
To this end, USPIO cores were prepared by co-precipitation of
iron salts in aqueous base at ambient temperature [34]. USPIO
nanoparticles were adsorptively coated with non-polymeric ﬂuo-
rescent FMN in two steps, to yield FLUSPIO (Fluorescent Ultrasmall
SuperParamagnetic Iron Oxides). FLUSPIO were puriﬁed by high-
gradient magnetophoresis to generate a stable colloidal suspen-
sion which showed intense green ﬂuorescence under ultraviolet
irradiation. This versatile and simple synthetic strategy yields very
stable magnetic nanoparticles with an intense ﬂuorescence and
does not require the use of colloidal stabilizers, such as citric acid,
surfactants or polyethylene glycol (PEG). FLUSPIO were evaluated
for their efﬁciency in MR cell labeling, and their speciﬁcity for RCP
was studied in metabolically active cancer and endothelial cells by
competitively blocking the upregulated RCP receptors.
2. Materials and methods
2.1. Materials
Ferric chloride (FeCl3 >97 %), ferrous chloride tetrahydrate (FeCl2.4H2O >99%),
Riboﬂavin-50-monophosphate sodium salt dihydrate (Flavin mononucleotide FMN,
73e79% (ﬂuorimetric)), Trypan blue solution for microscopy, IDRANAL III standard
solution ((EDTA-Na2), reagent for metal titration, 0.1 M), 5-sulfo salicylic acid
dehydrate (99% for metal titration), N-[Tris(hydroxymethyl)methyl]-2-amino-
ethanesulfonic acid sodium salt (TES, 99%), potassium bromide (KBr for IR spec-
troscopy) were purchased from Sigma Aldrich (Steinheim, Germany). Ammonia
(NH3 25%), 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-Hydrox-
yethyl)piperazine-N0-(2-ethanesulfonic acid) (HEPES, 99.5 %), tris(hydroxymethyl)
aminomethane (Tris HCl,99.3%), hydrochloric acid (HCl, 37%) were purchased from
Carl Roth (Karlsruhe, Germany). Guanosine-50-monophosphate disodium salt
hydrate (GMP, 98%) was purchased from AppliChem (Darmstadt, Germany). All
chemicals were used without further puriﬁcation.
2.2. Synthesis of iron oxide nanoparticles(Fe3O4)
Ultrasmall SuperParamagnetic Iron Oxide nanoparticles (USPIO) were synthe-
sized by co-precipitation of ferrous (Fe2þ) and ferric (Fe3þ) salts in aqueous alkaline
conditions. A modiﬁed one-pot synthesis protocol was followed [33]. We used
a stoichiometric ratio of 2Fe3þ:Fe2þ, 16 mmol (2.66 g) of FeCl3 and 8mmol (1.63 g) of
FeCl2.4H2O which was dissolved in 190 mL de-ionized water at RT by magnetic
stirring for 10 min. Under vigorous stirring, 10 mL of 25% NH3 were poured down
the vortex of the iron solution. Immediately, magnetite formed a black precipitate.
After stirring for 20 min, the particles were washed thrice with water and two
times with 0.1 M HCl solution by magnetic separation using a rare-earth magnet.
Magnetic ﬂuids were dispersed in 100 mL of aqueous hydrochloric acid (0.1 M). The
USPIO were sonicated for 20 min at RT. Subsequently, USPIO were centrifuged
at 20,000 g for 15 min at RT in order to remove aggregates. Iron content of USPIO
was determined by a titration method, in which magnetic particles were dissolved
in 0.5 M HCl solution and oxidized using (NH4)S2O8 to Fe3þ. The dissolved Fe3þ
metal ions form a red complex with sulfo salicylic acid which is titrated with EDTA
(Idranal III standard solution) to give yellow color as end point. The total iron
concentration of USPIO determined by titrimetry [35] and colorimetry (tiron
method) [36] was 161 mM. A colorimetric method was used to conﬁrm the results
from titrimetry.
2.3. Synthesis of FLUSPIO nanoparticles
Fluorescent Ultrasmall Superparamagnetic Iron Oxide nanoparticles (FLUSPIO)
were synthesized by coating a thin layer of organic biocompatible molecules around
the iron oxide core in a non-polymeric way [3]. We used ﬂavin mononucleotide
(FMN) as ﬂuorescent and guanosine monophosphate (GMP) as non-polymeric
coating molecules. Non-polymeric coating was performed by sonication (Ultra-
sonic cleaner, 30 W, VWR GmbH, Germany) of 143 mM USPIO with 35 mM FMN for
1 h at ambient temperature. Excess FMN was removed by high-gradient magneto-
phoresis. FMNmodiﬁed particles were sonicatedwith 50mMGMP for another 1 h at
ambient temperature. Excess of GMP was removed by high-gradient magneto-
phoresis to yield the ﬁnal ﬂuorescent FLUSPIO nanoparticles.
2.4. General characterization - Transmission electron microscopy (TEM)
Themorphology, size, andsizedistributionof thenanoparticleswerecharacterized
by TEM (EM 400 T (Philips, Eindhoven, The Netherlands). USPIO and FLUSPIO were
embedded in2%agarose, rinsedwithdistilledwateranddehydratedwithethanol (30%,
50%, 70%, 90%,100%). Subsequently, they were embedded in Epon, polymerized 8 h at
37 C, 56 h at 60 C, and then cut into 70e100 nm thick slices. The particle size and size
distributions were calculated using an image analysis program (iTEM software,
Olympus, Germany) and by measuring the diameter of at least 100 particles.
2.4.1. Scanning electron microscopy (SEM)
The surface morphology of the nanoparticles was characterized by SEM [FEI
(PHILIPS) ESEM XL 30 FEG; EDAX Falcon genesis]. USPIO and FLUSPIO in water were
dried by dehydrating themwith different percentages of ethanol (25%, 50%, 70e75%,
90e95%, 100%). Finally, trace amounts of water were removed by treating themwith
propylene oxide. Further, samples were dried and mounted on specimen stub with
silver paste or graphite.
2.4.2. X-ray powder diffraction (XRD)
The crystal structures of the USPIO and FLUSPIO particles were characterized by
using the Bruker D8 Advance x-ray powder diffractometer equipped with a mono-
chromatic x-ray source (CuKa11.5406 Å) and calibrated against NIST1976 Corundum
Standard Reference Material. Scans were recorded from 2 to 85 (2q), with a 0.02
(2q) step and a counting time of 0.5 s per step, and also from 22 to 68 (2q), with
a 0.02 (2q) step and a counting time of 4 s per step.
2.4.3. SQUID magnetometry
The magnetic susceptibility of the ﬂuorescent nanoparticles (FLUSPIO) was
determined using SQUID magnetometry (Quantum Design MPMS-5XL) in the ﬁeld
range of B¼ 5.0 toe 5.0 T and at T¼ 290.0 K. The data were corrected for the sample
holder (Teﬂon capsules) and the diamagnetic contribution of the compound.
2.4.4. MR relaxometry
Nuclear MR relaxometry of FLUSPIO nanoparticles was performed in a clinical 3T
whole-body MR scanner (PHILIPS Achieva, The Netherlands) using a knee coil
(SENSE-ﬂex-M, PHILIPS, The Netherlands) at RT. FLUSPIO were diluted in de-ionized
water at concentrations ranging from 0.005 to 50 mg of Fe/0.3 mL. For MR measure-
ments 0.3 mL/well of diluted FLUSPIO solution was ﬁlled in custommade phantoms
(Greiner 96 well Flat Transparent Polystyrol microplate, Germany). Transverse
relaxation times (T2) were measured in 2 D scanmode using amulti-slice, multi shot
spin echo sequences with 90 excitation pulse followed by a train of equally spaced
180 refocusing pulses [TR ¼ 1500 ms, mTR ¼ 1189 ms, TE ¼ 8.1 ms (shortest),
number of echoes ¼ 20, inter-echo spacing ¼ 8.1 ms, FOV ¼ 130  162.5 mm,
reconstruction matrix ¼ 64  81, voxel size ¼ 2  2, slice thickness ¼ 3 mm, slice
orientation¼ coronal, scanmode¼multi shot (MS)]. Transverse relaxation times (T2)
were measured in 3 D scan mode using a multi-slice, multi shot spin echo sequences
with 90 excitation pulse followed by a train of equally spaced 180 refocusing pulses
[TR¼ 1500ms, mTR¼ 716ms, TE¼ 11.8ms (shortest), number of echoes¼ 20, inter-
echo spacing¼ 12ms, FOV¼ 130 162.518mm, reconstructionmatrix¼ 64 81,
voxel size ¼ 2  2  3, slice orientation ¼ coronal, scan mode ¼ 3 D, TSE turbo
direction¼Y]. T2 relaxation timeswere calculatedbya linearﬁt of logarithmic region
of interest (ROI) signal amplitudes versus echo time (TE). Longitudinal relaxation
times (T1) were determined using a multi shot spin echo sequences with 10 exci-
tationpulsewithout refocusingpulses [TR¼6.8ms, TE¼3.3ms (shortest), number of
echoes ¼ 1, FOV ¼ 170  148.75 mm, reconstruction matrix ¼ 152  130, voxel
size ¼ 1.12  1.11, slice thickness ¼ 5 mm, slice orientation ¼ coronal, scan
mode ¼ 2 D]. Relaxivities r1 and r2 were determined by a linear ﬁt of the inverse
relaxation times as a function of the iron concentrations.
2.5. Cell culture
PC-3 cells were cultured using McCoy‘s (Gibco, Invitrogen, Germany) cell culture
medium supplemented with 10% fetal calf serum (Invitrogen, Germany) and 1% Pen/
strep (10,000 U/mL penicillin; 10,000 mg/mL streptomycin, Invitrogen, Germany).
LnCap cells were cultured using RPMI medium without glutamine (Gibco, Invi-
trogen, Germany), 10% fetal calf serum (Invitrogen, Germany), 1% non-essential
amino acid (MEM), 0.5% sodium pyruvate and 1% Pen/strep (10,000 U/mL peni-
cillin; 10,000 mg/mL streptomycin, Invitrogen, Germany). DU-145 cells were cultured
using RPMI medium without glutamine (Gibco, Invitrogen, Germany), 10% fetal calf
serum (Invitrogen, Germany) and 1% Pen/strep (10,000 U/mL penicillin; 10,000 mg/
mL streptomycin, Invitrogen, Germany). HUVEC were cultured using human endo-
thelial cell growth medium (Promocell, Germany) containing 2% growth supple-
ments, 3% fetal calf serum (Invitrogen, Germany) and 1% Pen/Strep (10,000 U/mL
penicillin; 10,000 mg/mL streptomycin, Invitrogen, Germany). Cells were cultured in
T75 cell culture ﬂasks (Cell star, Greiner, Germany) and incubated at 37 C, 5% CO2
and 95% relative humidity.
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2.5.1. Trypan blue staining
The toxicity of the FLUSPIO on prostate cancer cells (PC-3) and HUVEC was
investigated using trypan blue staining (trypan blue stain, SigmaeAldrich, Stein-
heim, Germany). PC-3 cells and HUVEC (2  106 cells) were seeded in 6-well plates
(BD Falcon, Germany). Mediumwas removed, and each well was washed with 2 mL
PBS (phosphate buffered saline). Cells incubated with regular growth medium
served as negative controls. The amount of free FMN and GMP, used as controls was
determined according to their concentration in the FLUSPIO. FLUSPIO and USPIO
were diluted in respective media, in order to have iron concentrations of 0.03,
0.3 mmol Fe/mL. 1 mL of medium containing nanoparticles, FMN or GMP was added
to each well. 3 samples per condition were analyzed. Cells were incubated for 3, 12
and 24 h. After incubation, medium was removed and transferred to 15 mL falcon
tubes. Cells were washed once with PBS and subsequently trypsinized. The cell
suspensionwas centrifuged at 1000 rpm (Multifuge, Thermo scientiﬁc, Germany) for
5 min and the supernatant was removed. The cell pellet was dissolved in 0.5 mL of
respective fresh cell medium. 50 ml of the cell suspension were mixed with 50 ml of
the trypan blue staining solution (1:2). Trypan blue positive cells (dead cells) were
counted using a Cedex XS (Innovatis AG, Germany) cell counter. The percentage of
positive cells as a function of the total cell number was calculated.
2.5.2. TUNEL assay
Toxicity of the FLUSPIO on PC-3 cells and HUVEC was additionally evaluated
using the In situ Cell Death Detection Kit, TMR red, (Roche Diagnostics GmbH,
Mannheim, Germany). The cells (1x105 cells/mL) were grown on cover slips (12mm,
Carl Roth, Germany) inside 24 well plates (Cell star, Greiner bio-one, Germany).
FLUSPIO diluted in cell culture medium (3.0, 0.3 mmol Fe/mL) were added to cells for
3 h. Duplicates were used. After incubation, medium was removed and cells were
washed three times with PBS. Further, cells were ﬁxed with 4% paraformaldehyde at
RT for 15 min. Again, cells were washed three times with PBS. After ﬁxation, cells
were permeabilised for 2 min using the permeabilisation solution [(0.1% Triton
X-100 (Sigma Aldrich, Steinheim, Germany) and 0.1% sodium citrate (Carl Roth,
Germany)]. Cells were washed three times with PBS and then dried at RT. Negative
control cells were treated only with 50 mL label solution (without active enzyme).
Positive control cells were generated by incubation with recombinant DNase I for
10 min in order to induce DNA strand break. 50 mL of TUNEL reaction mixture (label
solution þ active enzyme solution) were added to the positive control cells and to
the cells, which were previously treated with FMN, GMP, USPIO and FLUSPIO for 3 h.
The TUNEL reaction mixture was incubated for 1 h at 37 C in a humidiﬁed atmo-
sphere in dark. After incubation, cells were washed three times with PBS for 10 min.
Nuclei were counterstained with 40 ,60-diamino-2-phenylindole (DAPI, 5 mg/mL,
Merck, Darmstadt, Germany). Viable and apoptotic cells were counted in ﬁve
different ﬁelds of view/slide using a ﬂuorescence microscope (AxioObserver Z1; Carl
Zeiss GmbH, Germany). Images were acquired using a digital camera (AxioCam
MRm; Carl Zeiss GmbH, Germany) with 10 magniﬁcation.
2.5.3. Flow cytometry analysis
7-amino actinomycin D (7-AAD) viability staining (eBioscience GmbH, Frankfurt,
Germany) was used to determine the number of viable cells by ﬂow cytometry (FACS
Calibur, BD Bioscience). Both, PC-3 cells and HUVEC were grown in petridishes (200
X 20 mm; Greiner bio-one, Germany). Positive controls were generated by exposing
the cells to a temperature of 60 C for 18 min. We used 4x105 cells (PC-3) and 2x105
cells (HUVEC) in 300 mL for ﬂow cytometry analysis. FLUSPIO were diluted in
respective media of PC-3 and HUVEC with 3.0, 0.3, 0.03 mmol Fe/mL. After incuba-
tion, mediumwas removed and cells were washed three times with PBS. Cells were
trypsinized as described above, and centrifuged. The cell pellet was suspended in
300 mL PBS with 2% fetal calf serum (Invitrogen, Germany). The cells were stained
with 6 mL of 7-AAD viability staining solution by incubating them in dark at RT for
10 min before measurement.
2.6. Cellular uptake of FLUSPIO nanoparticles (MRI)
The intracellular uptake of FLUSPIO in prostate cancer cells (PC-3) and endo-
thelial cells (HUVEC) was investigated usingMRI. FLUSPIO and USPIOwere diluted in
the respective cell culture media, to have ﬁnal iron concentration of 0.03, 0.3 and
3.0 mmol Fe/mL. FMN (0.03, 0.3, 3.0 mmol/mL) and GMP (0.07, 0.7, 7.0 mmol/mL)
controls were also diluted in the respective cell culture media. The supernatant
medium was removed when 80% conﬂuency was reached and cells were washed
once with PBS buffer. Subsequently, cells were labelled with 11 mL of mediumwith
nanoparticles and controls. Three samples per condition were analyzed. Cells were
incubated for 1 h at 37 C, 5% CO2 and 95% relative humidity. After incubation, cells
were washed once with PBS and subsequently trypsinized using 4 mL of trypsin/
EDTA (0.25%/0.5%). Trypsinization was stopped by adding cell culture medium and
the cell suspension was centrifuged at 1000 rpm (Multifuge, Thermo scientiﬁc,
Germany) for 5 min. The cell pellet was re-suspended in 50 mL of PBS buffer and
washed three times by performing the centrifugation as described above. The total
cell numbers in the suspension were counted and after washing the cell pellet with
PBS, it was dissolved in 10% gelatin to have 2  106 cells/0.3 mL as ﬁnal cell
concentration. MR-relaxometry of cells was performed at 3 T using the
MR-sequences described in section 2.4.4.
2.7. In vitro competition of FLUSPIO cellular uptake using excess FMN (MRI)
FMN competition experiments were performed in order to validate that the
uptake of FLUSPIO is mediated by the riboﬂavin carrier protein (RCP). Cells were pre-
incubated for 10 min with FMN in 10- and 100- fold excess (with respect to FMN on
FLUSPIO) to block RCP. Subsequently, FLUSPIO were added (0.3 mmol Fe/mL) and
cells were incubated for 30 and 60 min, respectively. After incubation, cells were
trypsinized and prepared for MRI analysis as described above. Three samples per
condition were analyzed.
2.8. Cellular uptake of FLUSPIO nanoparticles (TEM)
USPIO and FLUSPIO were diluted in PC-3 cell culture medium to 3 mmol Fe/mL.
Cells were labelled using 11 mL of medium containing USPIO or FLUSPIO for 3 h and
6 h. After incubation, mediumwas removed and cells were washed thrice with PBS.
Subsequently, cells were ﬁxed in 3% glutaraldehyde (in 0.1 M Soerensen’s phosphate
buffer [pH 7.4; 13 mM NaH2PO4 .H2O; 87 mM Na2HPO4 .2H2O]) by incubation for
22 h, and subsequently washed with 0.1 M Soerensen’s phosphate buffer. Fixed cells
were embedded in 2% agarose, rinsed with distilled water and dehydrated with
ethanol (80%e100%). Finally cells were processed for embedding in Epon, by poly-
merizing 8 h at 37 C and 56 h at 60 C, and then cut into 70e100 nm thick slices.
After polymerization, cells were contrasted with uranyl acetate and lead citrate. The
samples were analyzed with a PHILIPS EM 400 T microscope at 60 kV and micro-
graphs were taken by an OLYMPUS CCD-Camera (MORADA).
2.9. Cellular uptake of FLUSPIO nanoparticles (ICP-MS)
Digestionofcellswasperformed inaclosedvesselmicrowave reactionsystem(MLS
ethos plus, MPV-100/HAT) after addition of 1.5mL nitric acid (65%) to 1.5mL hydrogen
peroxide and 1mL of internal standard (rhodium) using 1000W for 45min by raising
the temperature from RT to 210 C and left constant at 210 C for another 15 min.
Samples were diluted in 1:100 in water. The amount of intracellular iron was deter-
mined using a high-resolution sector ﬁeld inductively coupled plasma mass spec-
trometer [ICP-MS (Elan-DRCII, PerkineElmer)] equipped with an injector (2.0 mm i.d.
Quartz, PartNo.:WE02-3916).Datawere acquiredatmediumresolutionusing rhodium
as an internal standard. A Quartz Cyclonic spray chamber (Part No.: WE02-52222)
equipped with a Meinhard Type A quartz nebulizer was used for sample introduc-
tion. The instrument was tuned and calibrated via infusion of a 1 mg/mL rhodium
standard solution. The iron content was expressed in picograms of iron per cell.
3. Results and discussion
3.1. FLUSPIO synthesis
USPIO nanoparticles prepared by co-precipitation were coated
with non-polymeric ﬂuorescent FMN, which strongly binds to the
iron oxide cores via phosphate groups (Fig.1a). The FMNcoatingwas
achieved in aqueous solutions of USPIO and FMN (at pH 4) under
sonication at ambient temperature. The coating of USPIO with FMN
alone did not lead to an efﬁcient and stable coverage of the entire
nanoparticle surface,whichmight be due to steric hindrance caused
by the isoalloxazine ring of FMN. Consequently, by visual inspection
nanoparticle sediments were found indicating particle agglomera-
tion. In addition, the nanoparticle surface should not be covered
entirely with FMN due to the quenching of green ﬂuorescence that
occurs at high concentrations. GMP is less bulky and contains
a phosphate group (similar to that of FMN), which strongly chemi-
sorbs to the iron oxide surface during the non-polymeric coating.
Both, FMN and GMP are negatively charged molecules and their
binding to USPIO results in a negative surface charge of FLUSPIO at
pH7.0, thus providing colloidal stabilization. Therefore, the addition
of GMP was necessary to stabilize the colloidal suspension and to
complete the surface coverage. Furthermore, GMP also allows for
further functionalization with biomolecules (peptides, antibodies
etc.,) using standard conjugation techniques via the amine group
available in the guanine moiety.
3.2. FLUSPIO characterization
Transmission electron microscopy (TEM), dynamic light scat-
tering (DLS) and scanning electron microscopy (SEM) were used to
characterize the FLUSPIO. TEM analysis of USPIO, and FLUSPIO
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showed nanoparticles with an average iron core size of 5  1 nm
(see Table 1 and Fig. 1b,c). SEM was used to study the surface
morphology of the nanoparticles. SEM images of USPIO and FLUS-
PIO conﬁrmed the spherical surface morphology, with an average
particle size of 23.19  4.62 nm (USPIO) and 27.76  4.76 nm
(FLUSPIO) (see Fig. 1d,e). The increase in size observed in SEM could
be attributed to clustering of the nanoparticles that occurs due to
drying and/or to the conductive layer of sputtered gold on the
nanoparticles surface. The thin layer of non-polymeric coating
yields nanoparticles with a low hydrodynamic diameter which
enhances the uptake of nanoparticles into tissues [3]. The hydro-
dynamic diameter (DLS) of the FLUSPIO in HEPES buffer showed an
average hydrodynamic diameter of 97  3 nmwith a relatively low
polydispersity index of 0.16. The broad average hydrodynamic
diameter, which can be observed in Fig. 2a,b is an average of several
runs, which displayed similar hydrodynamic diameter with
comparable polydispersity index values. The increase in average
hydrodynamic particle diameter of FLUSPIO in HEPES buffer may
derive from the hydration shell and could be further increased by
minor agglomeration which arises from the tendency of smaller
iron cores to form clusters, which are not sterically stabilized by
FMN and GMP. However, these DLS results of FLUSPIO are in line
with the characteristics of clinically approved/used MR contrast
agent Resovist (4 nm core size), which displayed hydrodynamic size
distribution around w60 nm. In comparison to FLUSPIO, USPIO,
show stability only at pH 2 without any surface coverage with
coating molecules, and displayed a large hydrodynamic diameter
with a broad size distribution at pH 7 (252  66 nm), due to
aggregation between the iron cores at increasing pH (see Table 1
and Fig. 2a,b).
Zeta potential measurements were performed to determine the
surface charge, electrophoretic mobility and colloidal stability of
the USPIO and FLUSPIO particles at pH 2, 7 and 13 (Table 1). Under
acidic conditions USPIO had a positive zeta potential due to their
highly protonated surface hydroxyl and oxygen groups. USPIO
agglomerated immediately in PBS buffer and saline solution (0.9%
NaCl). A negative zeta potential was observed for FLUSPIO, which
fosters for colloidal stability of the nanoparticles at neutral pH and
usually leads to better pharmacokinetic properties. FLUSPIO were
stable in physiological pH in water, HEPES buffer and in 5% glucose
solution. However, after 15 min, aggregation was observed in PBS
buffer and saline solution (0.9% NaCl) by visual inspection, likely
because of the high ion concentrations and electrostatic interac-
tions. No aggregation was found in cell culture medium, most
probably due to colloidal stabilization of FLUSPIO by serum proteins
(see Fig. S12 in the Supporting Information).
Table 1
Physico-chemical characterization of USPIO and FLUSPIO.
Sample TEM diameter
[nm]
Hydrodynamic diameter [nm] Zeta potential in different pH solutions [mV] MR Relaxivities at 3T in water
HEPES buffer (PDI) pH 2 pH 7 pH 13 r2[s1mM1] r1[s1mM1]
USPIO 5.5  1.1 252  66 (0.35) 32.83  1.53 18.93  2.46 0.01  0.03 n.dc. n.dc.
FLUSPIO 5.6  1.7 97  3 (0.16) 4.59  2.48 31.13  1.70 31.70  2.76 202.64  0.48 2.13  0.04
Resovist 4.2a 45.87  0.09b(0.30) n.d. 34.36  2.30 n.d. 221.11  0.61 5.21  1.40
a Size of polycrystalline iron oxide with multiple single crystals and its reported relaxivity values [42].
b Hydrodynamic diameter of Resovist in water and its approximate zeta potential at pH 7.
c Relaxivity of USPIO at pH 7 could not be determined because of aggregation and susceptibility artefacts.
Fig. 1. Preparation of FLUSPIO. a: Schematic diagram showing the mode of binding of FMN and GMP to the iron oxide cores in FLUSPIO. bec: TEM images of USPIO (b) and FLUSPIO
(c). Quantitative analysis of the images reveals that both types of nanoparticles have a core diameter of 5  1 nm and a narrow size distribution. dee: SEM images of USPIO (d) and
(e) FLUSPIO, displayed spherical morphology. Quantitative analysis indicated average sizes of 23  4 nm (USPIO) and 27  4 nm (FLUSPIO) respectively.
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X-ray powder diffraction (XRD) analysis was used to determine
the chemical composition and crystallinity of the FLUSPIO. The XRD
patterns of FLUSPIO could be assigned to (220), (311), (400), (422),
(511), and (440) reﬂections of the spinel structure of magnetite
(JCPDS No.19-0629) (see Fig. S1, in the Supporting Information). The
observed diffraction peaks of USPIO are consistentwith the expected
diffraction peaks of Fe3O4. These peaks are also present in FLUSPIO,
together with three other diffraction peaks. The additional peaks in
FLUSPIOdiffractogramatapproximately 23.4 and27.6 (2q) are broad
and are thus due to a material with low crystallite size, whereas the
third additional peak at approximately 31.8 (2q is sharpwhich is due
to a material with larger crystallite size). The crystalline nature of
their iron cores explains thehigh relaxivities of FLUSPIO found inMRI
experiments. Fourier-transform infrared (FT-IR) spectroscopy
conﬁrmed the binding of FMN and GMP phosphate groups to nano-
particles, and thiswasvalidatedbycomparing the spectraof freeFMN
and GMP and unmodiﬁed USPIO (see Fig. 2c). The chemical compo-
sition of the surface (concentration of FMN, GMP) was analyzed by
energy-dispersive X-ray spectroscopy (EDX), Vaskovsky phosphate
determination, elemental analysis and thermogravimetry (TGA). As
expected from the theoretically calculated ratio of phosphate to iron,
the Fe:P ratio of the ﬂuorescent nanoparticles determined by EDX
was 1:0.231. Thiswas further supported by the Vaskovsky phosphate
determination (see Table S1 in the Supporting Information) and
elemental analysis. TGA of the FLUSPIO showed a weight loss of 24%
when heated to 600 C (see Fig. S2, in the Supporting Information).
This accounts for the decomposition of the surface coating (FMN and
GMP), as well as for the dehydration of the inorganic matrix (theo-
retically calculated weight loss: 23%).
3.3. Magnetic properties of FLUSPIO
The superparamagnetic behavior of the FLUSPIO was studied by
SQUID magnetometry, at a constant temperature of 290 K and
a ﬁeld of 5 T. The magnetization vs ﬁeld curve was compared to
that of unmodiﬁed USPIO and showed the expected regular
Fig. 2. Physico-chemical characterization of FLUSPIO. DLS analysis of (a) USPIO and (b) FLUSPIO. (c). FT-IR spectra of FLUSPIO with reference to free FMN, GMP and uncoated USPIO.
(d). T2-weighted MR images of FLUSPIO (50e0.005 mg) in comparison to Resovist in water. (e) Fluorescence emission spectrum of FLUSPIO at different concentration in water.
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progression for superparamagnetic substances (see Fig. S3, in the
Supporting Information) [33]. The MR relaxivity of the FLUSPIO in
de-ionized water at RT at 3 T was found to be similar to that of the
clinically used MR contrast agent Resovist (FLUSPIO:
r2¼ 202.64 0.48 s1mM1, Resovist: r2¼ 221.110.61 s1mM1;
see Table 1 and Fig. 2d), thereby conﬁrming their contrast
enhancement properties.
3.4. Fluorescence properties of FLUSPIO
Fluorescence spectroscopy and microscopy of the FLUSPIO
revealed a high ﬂuorescence intensity due to the photo-
luminescence of the FMN ﬂuorophore associated with the nano-
particle surface [37]. The ﬂuorescent nanoparticles can be excited in
a wide wavelength range (250e500 nm), resulting in an intense
Fig. 3. FLUSPIO uptake analyzed by means of MR and ICP-MS. a: R2 relaxation rates of PC-3 cells in gelatin (9.0 x106 cells/0.3 mL) incubated with 0.3 mmol Fe/mL of USPIO, FLUSPIO
and FLUSPIO plus free FMN (10- and 100-fold excess, for competition purposes) for different time intervals, i.e. 30 min (a) and 1 h (b). c: R2 relaxation rates of HUVEC in gelatin (1.0
x106 cells/0.3 mL) incubated with 0.3 mmol Fe/mL of USPIO, FLUSPIO and FLUSPIO plus free FMN (10- and 100-fold excess) for 30 min (c) and 1 h (d). e: ICP-MS determination of
intracellular iron content in PC-3 cells after a 1 h incubation with USPIO, FLUSPIO and FLUSPIO in the presence of excess FMN (100-fold excess). (f). R2 relaxation rates of three
different prostate cancer cell lines and HUVEC (2  106 cells/0.3 mL for each; in gelatin) incubated with 0.3 mmol Fe/mL of FLUSPIO for 1 h and 3 h. In all cases, two-sided student
t-tests were performed to address statistical signiﬁcance. ***: p < 0.001.
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green emission at 530 nm with a moderate drop of about 40% in
emission intensity after prolonged exposure to daylight (see Fig. 2e,
Fig. S4 and Fig. S5, in the Supporting Information).
3.5. Cytotoxicity assay
The biocompatibility of the FLUSPIOwas investigated using PC-3
cells (human prostate cancer cells) and HUVEC (as an example of
activated endothelial cells). As shown in Fig. S6 and S7 (in the
Supporting Information), neither trypan blue staining nor TUNEL
staining (common assays used for determining the cytotoxicity of
iron oxide nanoparticles) [38] indicated any signiﬁcant change in
cell viability at relevant cell labeling concentrations (i.e. up to
0.3 mmol Fe/mL). This observation was further conﬁrmed by ﬂow
cytometry, in which 7-AAD (7-amino actinomycin D) was used to
label dead cells, suggesting that the FLUSPIO are highly biocom-
patible (see Fig. S8, in the Supporting Information).
3.6. Cellular labeling and competition (MRI and ICP-MS)
Subsequently, the cellular labeling efﬁciency and the uptake of
FLUSPIO were investigated by MRI (at 3 T). The cells were labeled
with FLUSPIO, re-suspended in 10% gelatin (9  106 cells/0.3 mL;
0.3 mmol Fe/mL, 30 min and 1 h) and the R2 relaxation rates were
determined. Three samples per condition were analyzed, and the
cellular labeling and competition experiments were performed in
triplicates. PC-3 cells in gelatin showed a signiﬁcantly higher R2
relaxation rate after 1 h of incubationwith FLUSPIO (5.08 1.44 s1,
p < 0.001) than with USPIO (2.28  0.19 s1), indicating a higher
cellular uptake of FLUSPIO (similar R2 values for FLUSPIO were
obtained after 30 min incubation). Furthermore, the speciﬁcity of
FLUSPIO uptake was investigated via competitive blocking of RCP
with free FMN [39e41]. After the addition of free FMN to PC-3 cells
and subsequent incubation with FLUSPIO for 30 min, the R2
relaxation rate was signiﬁcantly reduced (10-fold FMN competi-
tion; 4.33  0.70 s1, p < 0.05; 100-fold FMN competition:
3.19  0.58 s1, p < 0.001; FLUSPIO incubation alone:
5.08  1.44 s1). Similar results were obtained when blocking RCP
with free FMN for 1 h. In this case, the corresponding R2 relaxation
rates were 3.84  0.81 s1 (10-fold FMN competition) and
3.87 0.69 s1 (100-fold FMN competition), respectively (Fig. 3a,b).
The higher cellular uptake of FLUSPIO compared to USPIO and the
capability of free FMN to block FLUSPIO internalization in PC-3 cells
was conﬁrmed by the quantiﬁcation of the intracellular iron
contents using inductively coupled plasmamass spectrometry (ICP-
MS, Fig. 3e, Table 2).
In line with this, also HUVEC showed a signiﬁcantly higher
uptake of FLUSPIO (30 min: 3.69  0.45 s1, 1 h: 7.23  0.64 s1)
than of USPIO (30 min: 1.98  0.17 s1, 1 h: 2.03  0.06 s1; see
Fig. 3c,d). Competition experiments with free FMN conﬁrmed the
speciﬁcity of the RCP-mediated uptake of FLUSPIO in HUVEC. After
RCP blocking by free FMN for 30 min, the R2 relaxation rate of
HUVEC was decreased with respect to FLUSPIO alone (100-fold
FMN competition: 1.73  0.07 s1; 10-fold FMN competition:
1.95  0.18 s1). Even after 1 h of FLUSPIO incubation, the uptake
Table 2
Uptake of USPIO, FLUSPIO and FLUSPIO under competition with FMN in PC-3 cells
(2  106 cells/0.3 mL) after 1 h incubation (ICP-MS).
ICP-MS iron content [pg Fe/cell]
USPIO
(0.3 mmol Fe/mL)
FLUSPIO
(0.3 mmol Fe/mL)
FMN
(100 fold)
0.097  0.003 0.675  0.31 0.274  0.04
Fig. 4. FLUSPIO uptake analyzed by means of TEM. aed: TEM images of PC-3 cells incubated with USPIO and FLUSPIO at an iron concentration of 3.0 mmol Fe/mL. After 3 h (a and b)
and 6 h (c and d) of incubation, PC-3 cells have internalized only a small amount of uncoated USPIO (a and c; see arrows), while there is strong uptake for FLUSPIO (b and d).
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was still signiﬁcantly lower in presence of 10- (2.54  0.53 s1) and
100-fold excess (1.60  0.12 s1) of free FMN (Fig. 3c,d). Together,
these ﬁndings convincingly show that the RCP-mediated uptake of
FLUSPIO by human prostate cancer cells (PC-3) and HUVEC is
signiﬁcantly higher than that of USPIO.
The less pronounced reduction of the relaxation rates (R2) by
10-fold FMN competition in PC-3 cells in comparison to HUVEC is
most probably related to the higher unspeciﬁc particle uptake in
these cells in comparison to RCP-mediated FLUSPIO internalization
(see Fig. 3f). To the best of our knowledge, the regulation of RCP
expression is still unclear. However, with increase in metabolic
activity, cells are expected to have a higher demand for Rf. The Rf
uptake in cells is facilitated by RCP. The increased uptake of Rf
(FLUSPIO) by metabolically active cells points to an upregulation of
RCP expression. Thus we hypothesize that the RCP expression level
is linked to the metabolic activity of the cell. Unfortunately, the
expression levels of RCP on the PC-3 and HUVEC cell surface could
not be determined (and correlated to the MR ﬁndings) due to lack
of a human RCP-binding antibody.
3.7. Fluorescence microscopy and TEM
In vitro experiments on PC-3 cells and HUVEC were also per-
formed to evaluate the cellular labeling efﬁciency of FLUSPIO. The
TEM images in Fig. 4aed show that after 3 and 6 h, FLUSPIO
strongly accumulated inside endosomes, while USPIO were not
taken up effectively [39e41]. The high uptake of FLUSPIO by PC-3
cells was conﬁrmed by ﬂuorescence microscopy (Fig. 5aef) and
ﬂow cytometry (see Fig. S9, in the Supporting Information).
A strong green ﬂuorescence of the cells was observed after FLUSPIO
incubation (see Fig. 5aef). The perinuclear ﬂuorescence pattern
strongly suggests endosomal localization of the FLUSPIO and
supports the results from the TEM studies.
Furthermore, the dose- and time-dependency of nanoparticle
uptake was investigated by incubating PC-3 and HUVEC cells with
FLUSPIO of different iron concentrations (3.0, 0.3, 0.03 mmol Fe/mL)
in the respective cell culture media for different incubation periods.
As shown in Fig. S10 and S11 (in the Supporting Information), MR
relaxometry of these cells showed increased R2 relaxation rates of
FLUSPIO with increasing dose and incubation time. Interestingly,
FLUSPIO were found to be taken up much more effectively by
HUVEC than by PC-3 cells, which may be due to cell type-speciﬁc
characteristics of activated endothelial cells. To investigate this
interesting phenomenon in more detail, and to conﬁrm FLUSPIO
uptake in different cancer cells, a comparative MR relaxometry
study was performed using PC-3, LnCap and DU-145 cells. All of
these three prostate cancer cell lines are known to express RCP [10],
and all three showed a high uptake of FLUSPIO. Remarkably
however, in all cases, the R2 relaxation rate of HUVEC was found to
be more than twice as high as that of the prostate cancer cell lines
(Fig. 3f). Together, these ﬁndings suggest that FLUSPIO are highly
suitable for targeting and labeling (angiogenic) endothelial cells
[39e41].
In follow-up analyses, we aim to investigate the ﬂuorescence
and target speciﬁcity of USPIO with different core diameter by
employing ﬂavin and its derivatives (riboﬂavin, FMN, FAD) as an
adsorptive, ﬂuorescent and non-polymeric coating. In addition, we
will investigate whether FLUSPIO also speciﬁcally accumulate in
tumors and/or tumor endothelial cells after intravenous injection.
We assume that in vivo, FLUSPIO will mostly target activated
endothelial cells, thereby enabling molecular MR and optical
imaging of tumor angiogenesis. Moreover, the concept of targeting
RCP is not limited to USPIO, and FMN could serve as a versatile
building block in generating contrast agents for other imaging
modalities.
4. Conclusions
In summary, we here introduce RCP targeting as an effective way
to speciﬁcally transport (iron oxide-based) nanomaterials into
metabolically active tumor and endothelial cells. In this context,
USPIO with an adsorptive ﬂuorescent coating of FMN and GMP
Fig. 5. FLUSPIO uptake analyzed by means of ﬂuorescence microscopy. aef: Fluorescence microscopy images of PC-3 cells incubated for 3 h with FLUSPIO (0.5 mmol Fe/mL). Nuclei
are counterstained with DAPI. a: Blank medium. b: FMN. c: GMP. d: USPIO. e: FLUSPIO without DAPI. f: FLUSPIO plus DAPI. The images clearly show the vesicular (likely endosomal)
localization of the FLUSPIO.
J. Jayapaul et al. / Biomaterials 32 (2011) 5863e58715870
(FLUSPIO)were synthesized,which are stable atphysiological pHand
show an intense ﬂuorescence as well as high R2 relaxation rate in
MRI. The high RCP-mediated uptake of FLUSPIO by activated endo-
thelial andcancer cells suggest themaspromising tools formolecular
MRI and cell tracking experiments.
Acknowledgements
This work was supported by the DFG grant KI 1072/1-3 “Dual
modal contrast agents for MRI and Optical Imaging techniques” by
the InnoMeT grant z0909im008a “Entwicklung und Bildgebung
patientenoptimierter Implantate” and by the EC (FP6: MediTrans).
The authors would like to thank Mrs. Natascha Mertens for MRI
measurements, Ms. Anne Rix for cell experiments, Dr. Matt Bunker
(Molecular Proﬁles, Nottingham) for size determinations and for
powder XRD measurements.
Appendix. Supplementary material
Supplementary data associated with this article can be found in
the online version, at doi:10.1016/j.biomaterials.2011.04.056.
References
[1] Lee HY, Lee SH, Xu C, Xie J, Lee JH, Wu B, et al. Synthesis and characterization
of PVP-coated large core iron oxide nanoparticles as an MRI contrast agent.
Nanotechnology 2008;19:165101.
[2] Du L, Chen J, Qi Y, Li D, Yuan C, Lin MC, et al. Preparation and biomedical
application of a non-polymer coated superparamagnetic nanoparticle. Int J
Nanomedicine 2007;2:805e12.
[3] Zhang Y, Kohler N, Zhang M. Surface modiﬁcation of superparamagnetic
magnetite nanoparticles and their intracellular uptake. Biomaterials 2002;23:
1553e61.
[4] Portet D, Denizot B, Rump E, Lejeune JJ, Jallet P. Nonpolymeric coatings of iron
oxide colloids for biological use as magnetic resonance imaging contrast
agents. J Colloid Interface Sci 2001;238:37e42.
[5] Mowat P, Franconi F, Chapon C, Lemaire L, Dorat J, Hindri F, et al. Evaluating
SPIO-labelled cell MR efﬁciency by three-dimensional quantitative T2* MRI.
NMR Biomed 2007;20:21e7.
[6] Cheng FY, Shieh DB, Yeh CS. Non-polymer coated Fe3O4 aqueous dispersion
with NH3-surface modiﬁcation as new magnetite nanoparticles and their
biomedical applications. Proceedings of 2005 5th IEEE Conference on Nano-
technology Nagoya, Japan 2005.
[7] Huang SN, Swaan PW. Involvement of a receptor-mediated component in
cellular translocation of riboﬂavin. J Pharmacol Exp Ther 2000;294:117e25.
[8] Mason CW, D’Souza VM, Bareford LM, Phelps MA, Ray A, Swaan PW. Recog-
nition, cointernalization, and recycling of an avian riboﬂavin carrier protein in
human placental trophoblasts. J Pharmacol Exp Ther 2006;317:465e72.
[9] Foraker AB, Khantwal CM, Swaan PW. Current perspectives on the cellular
uptake and trafﬁcking of riboﬂavin. Adv Drug Deliv Rev 2003;55:1467e83.
[10] Johnson T, Ouhtit A, Gaur R, Fernando A, Schwarzenberger P, Su J, et al.
Biochemical characterization of riboﬂavin carrier protein (RCP) in prostate
cancer. Front Biosci 2009;14:3634e40.
[11] Karande AA, Sridhar L, Gopinath KS, Adiga PR. Riboﬂavin carrier protein:
a serum and tissue marker for breast carcinoma. Int J Cancer 2001;95:277e81.
[12] Brock CS, Meikle SR, Price P. Does ﬂuorine-18 ﬂuorodeoxyglucose metabolic
imaging of tumours beneﬁt oncology? Eur J Nucl Med Mol Imaging 1997;24:
691e705.
[13] Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K. Clinical
implication of glucose transport and metabolism evaluated by 18F-FDG PET in
hepatocellular carcinoma. Int J Oncol 2008;33:1047e54.
[14] Pracchia LF, Chaves AAR, Cerci JJ, Soares Junior J, Meneghetti JC, Buccheri V.
Metabolic test with ﬂuorine-18-ﬂuorodeoxyglucose in staging and detection
of residual tumor or recurrence in Hodgkin lymphoma. Clinics 2007;62:
121e6.
[15] Tong S, Hou S, Zheng Z, Zhou J, Bao G. Coating optimization of super-
paramagnetic iron oxide nanoparticles for high T2 relaxivity. Nano Lett 2010;
10:4607e13.
[16] Schellenberger E, Schnorr JÃ, Reutelingsperger C, Ungethum L, Meyer W,
Taupitz M, et al. Linking proteins with anionic nanoparticles via protamine:
ultrasmall protein-coupled probes for magnetic resonance imaging of
apoptosis. Small 2008;4:225e30.
[17] Golovko DM, Henning T, Bauer JS, Settles M, Frenzel T, Mayerhofer A, et al.
Accelerated stem cell labeling with ferucarbotran and protamine. Eur Radiol
2010;20:640e8.
[18] Kluza E, van der Schaft DWJ, Hautvast PAI, Mulder WJM, Mayo KH,
Grifﬁoen AW, et al. Synergistic targeting of alphaVbeta3 integrin and galectin-
1 with heteromultivalent paramagnetic liposomes for combined MR imaging
and treatment of angiogenesis. Nano Lett 2010;10:52e8.
[19] Meier R, Henning TD, Boddington S, Tavri S, Arora S, Piontek G, et al. Breast
cancers: MR imaging of folate-receptor expression with the folate-speciﬁc
nanoparticle P11331. Radiology 2010;255:527e35.
[20] Henning TD, Wendland MF, Golovko D, Sutton EJ, Sennino B, Malek F, et al.
Relaxation effects of ferucarbotran-labeled mesenchymal stem cells at 1.5T
and 3T: discrimination of viable from lysed cells. Magn Reson Med 2009;62:
325e32.
[21] Bulte JWM, Kraitchman DL. Iron oxide MR contrast agents for molecular and
cellular imaging. NMR Biomed 2004;17:484e99.
[22] Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, et al. Clinically
applicable labeling of mammalian and stem cells by combining super-
paramagnetic iron oxides and transfection agents. Radiology 2003;228:480e7.
[23] Bulte JWM, Kraitchman DL. Monitoring cell therapy using iron oxide MR
contrast agents. Curr Pharm Biotechnol 2004;5:567e84.
[24] Bulte JWM, Kraitchman DL, Mackay AM, Pittenger MF, Arbab AS, Yocum GT,
et al. Chondrogenic differentiation of mesenchymal stem cells is inhibited
after magnetic labeling with ferumoxides. Blood 2004;104:3410e3.
[25] Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dye-loaded, multifunctional
iron oxide nanoparticles for combined targeted cancer therapy and dual
optical/magnetic resonance imaging. Small 2009;5:1862e8.
[26] Kircher MF, Grimm J, Swirski FK, Libby P, Gerszten RE, Allport JR, et al.
Noninvasive in vivo imaging of monocyte trafﬁcking to atherosclerotic
lesions. Circulation 2008;117:388e95.
[27] Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, et al. Optical and MRI
multifunctional nanoprobe for targeting gliomas. Nano Lett 2005;5:1003e8.
[28] Lu CW, Hung Y, Hsiao JK, Yao M, Chung TH, Lin YS, et al. Bifunctional magnetic
silica nanoparticles for highly efﬁcient human stem cell labeling. Nano Lett
2007;7:149e54.
[29] Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G,
et al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel
magneto-optical nanoparticle. Magn Reson Med 2005;54:718e24.
[30] Aime S, Castelli DD, Crich SG, Gianolio E, Terreno E. Pushing the sensitivity
envelope of lanthanide-based magnetic resonance imaging (MRI) contrast
agents for molecular imaging applications. Acc Chem Res 2009;42:822e31.
[31] Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, et al. PET/NIRF/MRI triple func-
tional iron oxide nanoparticles. Biomaterials 2010;31:3016e22.
[32] Jarzyna PA, Skajaa T, Gianella A, Cormode DP, Samber DD, Dickson SD, et al.
Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle
platform for tumor targeting and imaging. Biomaterials 2009;30:6947e54.
[33] Skajaa T, Cormode DP, Jarzyna PA, Delshad A, Blachford C, Barazza A, et al. The
biological properties of iron oxide core high-density lipoprotein in experi-
mental atherosclerosis. Biomaterials 2011;32:206e13.
[34] Bumb A, Brechbiel MW, Choyke PL, Fugger L, Eggeman A, Prabhakaran D, et al.
Synthesis and characterization of ultra-small superparamagnetic iron oxide
nanoparticles thinly coated with silica. Nanotechnology 2008;19:335601.
[35] Jander G, Jahr K. Massanalyse. 17 ed; 2009. 219e221.
[36] Bashir WA. Photometric determination of iron (III). Microchem J 1981;26:
477e80.
[37] Roming M, Lunsdorf H, Dittmar KEJ, Feldmann C. ZrO(HPO4)1-x(FMN)x: Quick
and easy synthesis of a nanoscale luminescent biomarker. Angew Chem Int
Ed; 2009:632e7.
[38] Soenen SJH, De Cuyper M. Assessing cytotoxicity of (iron oxide-based)
nanoparticles: an overview of different methods exempliﬁed with cationic
magnetoliposomes. Contrast Media Mol Imaging 2009;4:207e19.
[39] Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, et al.
Speciﬁc targeting of tumor angiogenesis by RGD-conjugated ultrasmall
superparamagnetic iron oxide particles using a clinical 1.5-T magnetic reso-
nance scanner. Cancer Res 2007;67:1555e62.
[40] Kiessling F, Huppert J, Zhang C, Jayapaul J, Zwick S, Woenne EC, et al. RGD-
labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-
integrin-expressing glioma cells and only accumulates in the vascular
tumor compartment. Radiology 2009;253:462e9.
[41] Zhang C, Waengler B, Morgenstern B, Zentgraf H, Eisenhut M, Untenecker H,
et al. Silica- and alkoxysilane-coated ultrasmall superparamagnetic iron oxide
particles: a promising tool to label cells for magnetic resonance imaging.
Langmuir 2007;23:1427e34.
[42] Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-
speciﬁc contrast agent for contrast-enhanced MRI of the liver: properties,
clinical development, and applications. Eur Radiol 2003;13:1266e76.
J. Jayapaul et al. / Biomaterials 32 (2011) 5863e5871 5871
­­­­­­­­­­­ ­­­­­ ­­­­­­­­
§­­­­­§­ ­­­ §­­§§§­§­­§ §§­­§­­§
§º § í­­­­­¹¹­­¹­¹¹¹­­­­­¹
­­­§§­ §­­­­ ­­­ ­­­§
§§§®§®­­­­­ ­­ ­­­ ®­­§®­­¹
¬®§§¹ §§§¹­¹­§­­­ï
ÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜÜÜ
ÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜ ÜÜÜ
ÜÜÜÜÜÜ ÜÜÜÜÜÜ ÜÜÜ
ÜÜÜÜÍÜÜÜÜ ÜÜÍÜÜÜÜÜÜ ÜÍ
ÍÜÜÜÜÜ ÜÜÜÜÜÜ ÜÜÜ
ÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜÜ
ÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜ
ÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜÜ
ÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜÜ
ÜÜÜÜÜÜ ÜÍÍÜÍÜÜÜÜ
ÜÜÜÜÜÜ ÜÜÜÜÜÜÜ ÜÜÜ
ÜÜÜÜÜÜÜÍ ÍÜÜÜÜÜÜÜÜÜÜ ÜÜÜ
ææææææææ óó óóóóóóóóóóó óóó óóóóóóóó óóóóóó óó óóóóóóóóóóóóóóóóóóóóóóó
óóó óóó² ²²²²²²óóóóóó² ²óóóóó²óóó ó²óóóóóóó²óóóóóóó óóóó
ó²ó²ó ²²²²²²² ²óóóóóóó² óó óó ²²²ó²²²²²² óó ó²²óó
²²óóóóóóó óóóó óó²óóóóóóóó óóóóó ²ó²óóóó²ó óóóóóóó óóóóóó
óó²ó ²²²²² óóóóóó óó² óóóóóóóóóó²ó ²²²²²²² óóóóó óó² óó
²²²²² ²óóóóóóóóó óó óóóóò
¼¼¼ææ¼¼¼æ ¼¼¼
¼æ¼ææ¼ææ
óóó ó²óóóó²óóóó óóóó óóóóóóó² óó óóó óóóóóó²óóóóó óóó
óóóó óó²²óóóóó óó óóó²óó óóóóò ²²²²²ó óóóó óóóóó² óóóó
óóóóóóóóóóóóóóóó ²²²²² óó ²óóóóóóóó ²óóóóóóóóóóóóóóóóóóóó
óóóóóó óóó² ô²ó²ô² óóóóó²óóò ²²²²² ²óóóôó óó ó²óóóóó
²²² óóóóóó óó² ²²²²² óóóóó óó² óó ²²²²² ó²²óó ²óóóó
óóóóóó óóó ²óóóó²óóó² óóóó ó÷ ²óóóóóóó óóóóóóóóó ²²²²
óóóó²ó²óóóó óó óó ó²²ó ²óóóò óóóóó óó² ó²²óóó óóóó óóóóó
óóóóóóòó² óó ²óóóó ó²²²óóò²óóóóóóóóó ²óóóóóóóóóò
óóóóóó óó²ó óóóóóóóó óó² óóóóóóó ²óóó²óóóóóóóó óóóóó
óóóó ²óó² óó óóóóóó óóóóóó²óóóóóò ²óóóóóóóóóó óóóó²óóóóó óóó
óóóóóó²ó² óó ²óóóó ó ²óóóó¼óóóóóó óóóó óó ó óóóóóó ²ó²ó²
²ó²óó óóóó óóó²ó² óóóóóóóóó óóó óóó óó²óóóóóóó óó ²óóó
óóó² ²óóóóóóóó ó²óóóó²óóóóò ²óóó óóó óóóóóóóó óó²óóóóó
óóóó óóóó ó²ò²óóó² óóóóó²óóó óó ó ó²ôóó óóóóò
ææææ¼¼ææ ó²óóóó óó² ²²² óóóóó óóóóóóóóóòó² ²²²ó²²²²²ó óóóóóóó
óóóóóó ²óóó óóóó ²óóóóóóóó óóóóóóò óóóóóóóóóóóóóóóó ²²²²²
óóóóó óóó²²²óóóó² ²²²ó²²²²²ó óó ó óóóóóó ó²óóóó óóóó
²²²²²ò ¼²óóóóó²óóóó óóóó óó ²²²²² óóóóóó óóóó ²²² óó²
ó í óóóóóóóó²óóóóôóóó óóóóóó²óóó óóóóóóóó óó²²óó² óó²óóóó
óóóóó óó óóóóóóóóóó ²²²²²óò óóóó óóó óóóó²óóóóó² óó ó óóóó
óó óó²óóóóóó²óóóó²óóó óóóóóóóóó²óóó óóóóóóóóó óóóóó óó²ó²
óóó óó óóóóóó²óó² óó óóóó ²ó²óóóò ²ó ²²²²² ó²²óóóó ²²²ó
²²²²² óóó²²²óóóó² ó²óó²óóóóóó óó óóó óóóóóóó²óóó²óó ó²ó óóó
óóóóóó ó²²óó óóóóóò óóó óóóó²óóó óóó²²²óóóóóó óó ²²²ó
²²²²² óó²óó² óóóóóóóóóóóó óóóóóó óóóóóóó óó óóó ²÷ óóóó²ó
óóóóó óóóó óó ó²²óóó óóóó óóóóóóó² óóó ²²²²²ò
ææ¼æ¼ææ¼æ¼æ ²ó óóóó²ó óóóóó óóóó ²óóóóóóó óóóóóóóóó²óóó óóóóóóóóó óóóóóóó
óóóó óó ó í óóóóóóóóó óó óóóóóó²óóó óó² ²²² óó² ²²²ó
²²²²² ²óóóóóóóóóóó² óóóóóóóóó²óóó óóóóóóóó óó² óó²²óó²
óó²óóóóóóóó óóóóóóóóó óóó²óóóóóóóó óóó óóóô óó óó²²óóóó óóóó
óóóóó óóóóóóó óó ²óóóó ²óóóó²óóó ²² óóóóóóò
²²çóó ÷ççç
²²óóóó²óóóóó ²óóóóóóóæ °°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°°
°°°°°°°°°°°ïï°ïïïï°°°°°°°°ïïïïïïïïïï°ï°ïïï
ï óóóó óóó óóóóóóóóóó óó óóóóóó óóóóó óóóóóóóóó ó óóó
óóóó óóóóóó óóóóóó óóóóóóóó óóóóóóó óóóó óóóóóó óóóó
§óóóóó§ó §óó§óóóóóóóóóó §§ó §§§§§ óóóóóóó óóóóóó§
óóóóóó óóóóóó óóóóó óóóóóóóó óóóóóóóóóó óóóó óóóó óóó§óóó
óóó§ó ´óóóóóóóó óóóóó óóó´óóó óóóóóóóóóó óó ´óóóóóóóóó
óóóóóóóóóóó óóóôóóóó óóóóóóóóóó óóóó§óóó óóóóóó óóóôóó
ôóóóóó óóóóóóóóóó óó óóóóóóó §ó§óóóó óó óóóóóóóó§ óóóóóó
óóóóó óóóóó ´ó´óó óóóó óó óó´óóó óóóóó óóó óóóóóóó§óóóóó
óóóó óóóóó óóóóóóóóó óóóóóóóóóó óó óóóóóóó óóóóó óóóóóó
óó§ óóó´óóó óóó óóóóóóóóóó óó óóóóóóóóóóóóóóóóóóó
óóóóóóóó§ óóóóóóó óóóóóó óóóóóó óóóóóóóó óóóóóóó óóóó
óóó²óóóó óóóóóó§ó óóóóó§óó ²óóó²óó ²²ó §§§²ó óó§óóóóó
óóôóóóóóó óóóóó²óó ²²ó óó§óóóóó óóóóó§óó óó²óóóó§ ²²ó
§§§òó óóóóóóóó óóóóó ²²ó òóóó §óóóóóó óóóóóóóó óó§ ²²ó
´óóóóóóóó ²§ óóó óóóóóóóó óóóóóóóóóóóóóóóóóóóóóó
óóóóóó óóó óó²§§§ó²ó²ó óóó ²§ óóó óóó´óó²´ó óóóóóóóó
óóóóóó óóóóóóóó ±±±±±±± ±±±±±±±±±±±±±± ±± óóóó óóóóóóóæ
»»»»»»»»»»»»»»»»»»»»»» óó
ó´ôóó §§§ò
îîî ¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹ ææææææææææ çÜÜÜÜÜ çççç ÜÜÜÜÜÜ ççÜÜÜÜÜÜÜÜ çççç
                                                                                         
                                                                     òòòòòòòòòòòòòòòòòòòòòòòò
æ
óóó ó²óóóóóó ²óóóó²óóó ó²óó óó
ó í óóóóóóóó óóó óóóóó²óóóóóó²
óó óóóóóóóó² óó²óóóóóóóó óóóóó óó²
óóó óó óóóóóóó² óóóó óóóóó²ó óóóóó²ó óó
óóó²óóóòó óó² óóóóóóó ó²²óó óóóóóóóóóó
óóó ²ó²ó²ò óóóóóóóóóóóóóóóóóóóóóóóóó
óóó² ²²²²² óóóóó²óó óóó óóó óó óóó
²óóó óóó²óóó óóóóó²ó óóóó óóóóóó ó í
óóóóóóóóò ²²² óóóóó²óó óóóóóóó óóóóóó
óóóó²óóóó óó² óó²ó óóóó óóóóóóóóó ²óó²
óóó óóóóóóóóóóóóóó óóóóóóó ²÷ó²ó²²ò
¼óóó óóóò²óóóó² óó ²óóóóó²óóóóó
²çóóç²ó ò²óóóóóóóó ²óóôóóó ²ôóóó²ó
²óóóóóóó óóóóóóóóóóóóó ²óóó÷²ó óó óóó
²óóóóóóóóó ²óí²óó²ó ²²² óóóóóó óóó
²óóóóóóóó óó óóóóóóóóóóóóò ó²²óó óóóóó
óóó² óóóó²óó ²óôóóó²ó óóóóóóó óóóóóó
óó²óó ²ó²óó²²ó óóóóóó óóóóóóó²óó
²óç²ó óó² óóóóó ó²²óóó ²óç²÷÷² óóóó
ó²óóóóó ó í óóóóóóóóóò óóóóóóóó óóóó
óóó ó²óóóóóóó óó ²²²óóó²óóó² óó²óóó
óóóóóóó ²óí²óó²ó óó ²óóó óóóóóó²ó ó²ó
óóóóó óó²²óóóó ²²² óóó óó²ó² óó óóóó
óóó ²óóóó²óóó óó óóóóóóóóó óóóó óóóó
óóó óóóóó óó ó²óóóóóóóóó ²óçó÷íó÷ô²
óó² óó²ó óóóó ó í óóóóóóóóó óó óóó
óóóó²óóó ó²²óó óóóó óóóóóóó²ò ²ó ²óóóó
óóóóóó ó í óóóóóóóó²óóóóóóóóó óóóóóó
óóó óóóóóóó óó ó²óóóóóóóóóóóó óóóóó
óó²ó² óó óóóóóóóó óóóóóóó óó ó²²óó
óóóóóò óóóó óóó²ó óóóóóó²óóóóó óó²ó óóó
²óóóóóóó óóóóóóóóó ²²²² ó²óóóóó óó
óóóóó ó óóóó óóóóóóóóóóóóó óó ²²²ó
óóóóóóóóóó óóóóóó ²²óó óóó²²²óóóó óó
óóóóóó²ó óóó óó²óóó² óóóóóóóóóóó óóó
óóó ²óóóóóóóó óó óóóóóóóó ²ó²óóò
óó²óó óóó ó²óóóóó óó óóóó óó²²ó
óóó óó óóóó²óóó óóó óóóóóóóó óóóóóó óó
²²²óóóóóóó² ²óóóóó²óóó ó²óóóóóóóó
²óóóóóóó óóóó ó²ó²ó ²²²²²²² ²óóó
óóóóó² óó óó ²²²ó²²²²²² óó ó²²óó
²²óóóóóóó óóóó óó²óóóóóóóó óóóóó
²ó²óóóó²ó óóóóóóó óóóóóóó²ó ²²²²²
óóóóóó óó² óóóóóóóóóó²ó ²²²²²²² óóóóó
óó² óó ²²²²² ²óóóóóóóóó óó óóóóò
¼¼¼ææ¼¼¼æ ¼¼¼ ¼æ¼ææ¼æ
óóó ó²óóóó²óóóó óóóó óóóóóóó² óó óóó
óóóóóó²óóóóó óóóóóó óó²²óóóóó óó óóóó
²óó óóóóò
¬¼æ¼¬ ¬¼æ¬ ææ¼æ¼
óóó óóóóóóóóó ó²óóóó²óóóó óóóó óóóó
óóó²ó² óó óóæ²óóóóæ
óò ²óóóóóóóó óó² óóóóóóóóóóòóóóóó
óó ²²²²²ó ²²²ó²²²²²ó óó² óóóóóóóóó
óóóóóóó¼óóóóóóóó óóó² ²²ó²²²óóóóóó²
²²²²² ²óóóóóóó² óó óó ²ó²ó²²²²²²
²óóóóó²ó² óó ôóóóóóóô²å
÷ò óóóóóóóóóóòóóóóó óó ó íó óó
óó² ó ó²óóóóóóóó óó ó²óóóóó
²²²²² óóóóóó óó² ²²² óóóóó óó ²óóóó
ò²óóóóóóóóóóóóóóóóóó² óóóó óóóóóóó
²óóóóó²ó² óó ôóóóóóóô²å
íò ²óó óó ²² óóóó²ó²óóóó óó óóóóóó
óóóóóó óóó óóóó²óóó ²óóóôó óó ²²²²²ó
²²²ó²²²²²ó óó² ²ó²ó²²²²² ²óóóó
ó²óóóó² óó² óóó óóóóóóó óó óóóó ²²²
óó óóóóô ²²²ó²²²²² óóóóóóóóóòóóóóó
²óóóóóóó² óó óó óó²óóóóóóóó óóó²óó
óóóó²å
ôò ²óóóóóóóóóóóó óó ²²²²² óó² ²²²ó
²²²²² óóóóóóóóóòóóóóó óó ²²²²² óóóóó óó²
óó ó²óóóó óó ²óóóó óóóóó²óóóóóó
óóóóóóóó ²óóóóóóóóó ²óóóóó²ó² óó ôóóó
óóóóô²å
óò ²óóóóóóóóóóóó óó óóóó óóóóóóóóó óóó
óóó ²²²²² óó² ²²²ó²²²²² óóó²óóóóóó
óó ²óóóó óóóóóó óó²ó ó²óó²óóóó óó² óóóó
óóóó ²óóó²óóóóóóóó óóóóó ²óóóóó²ó²
óó ôóóóóóóô²å
óò óóóóóó²óóó óó ²²² óóóóóóó óó
²óóóóóóóó ²²²²² ²óóóôó óó ó²óóóóó
²²²²² óóóóóó óó² ²²² óóóóó ²²² óóóó
ó²ó²óóóó²å
²ò ²óó²óóóóóó óó ²²²²² óóóóó óóóó
²²²²² óó² ²óóóóóóóóó óóóóóó²óóó
óóóóóóó ó íó óó óó² ó óó ó²óóóóó
óóóóóóó óóó óóóóóó óó óóóóóóóó óóóóôó²ó
óó ²²²²² óó²óóóóóóóó ²²² óóóó²ó²ó
óóóó²å
²ò ²²²²óóò²óóóóóóóóó óóóóóóóó óó
óó²óóóóó ó²óóóóóóóó óó ó²óóóó óó²
²²²²² óóóóó óóó²óóóó² óóóó ²²²²²
óó² ²²²ó²²²²²å
çò ²² ó²óóóóó óó² ²² óóóó²ó²ó
óóóó óó óó ó²²ó ²óóó óóóóóóó ²²²²²
ó²²óó ²óóóóóóóóó óóóóóó óó² óóóóó óóó
òóóóóóó óó ²²²²² óó² ²²²ó²²²²²å óó²
óçò ²²²²óóóóóóóóóóóó óóóó²óóóóó
óó ²²²²² ó²²óó ²óóóóóóóóóò
æ­­­­¬æ­­ ­æ¼¼­æ ­¬ ææ¼¼æ
ó²óóóóó ²²²²² óóóóóó óó² ²²² óóóóó
óóóó óóó²óóóó² óóóó ²²²óóóóóóó² óó²
²óóóóóóó² ²²²²² ²çòçí ²óó óó óóóó
óóó ²óóóóóóóóó óóóóóó ²ó²ó²²² óóó ó
óó²ó ²²ò²òó í óóóóó óó ó²óóóóóóóó óó
²² óóóóóóóå óò²òó ó óóóóó óó ó²óóóóó
óóóó óó óóóóóóóóóóóó óóó²óóóóóå ïòïòó ó
óóóó óó ó²óóóóóóóó óó óóóóóóóóóóóó
óóó²óóóóóå »òóòó í óóóóó óó ó²óóóóóóóó
óó ²óóóó²óóó óóóóóóó²ò óó²óóóóóóóó ó²ó
óóóó²óóóó óóóó óóóóóó²ó² óó óóó²óóóó
óóó ó²óóóó óó² ²²² óóóóó óóóó ²²²ó
²²²²²ó óó óóó óóóóóóóó óó óç çççóóóó²
ó²óóóó óó ²²²ò ²óó óóó²óóó²²óóó² ó²ó
óóóó óó ²²² óóó ²óó² óóó ²²²²² óóóóó
óóóó²óó óó ²óóóóóóó óóóó ²óóóóó²óóó óó
óóó óóóóóóóó óó óç çççóóóó² ó²óóóó óó
²²²ò
óó óóóóóóóóóóó óóóóóóó ²²² óóó
óóóóó óóóóóóóóóó óóóóóóóóóóóóó
ó²óóóó óó² ²²²²² óóóóó óóóó óóó²ó
óóóó² óóó ó óó²ó óóóó ²óóóóóóó² ²²ó
²²²ó ²çòçí ²óó óó óóóó óóó ²óóóóóóóóó²
óó óóó óóóóóóóó óó óç çççóóóó² ó²óóóó
óó ²²² óóó ó²óóóó óó óçççóóóó² ó²ó
óóóó óó ²²² óóó ²²²²² óóóóóò óóó ó²ó
¬¬¬¬¬±¬±± ±±¬¬±± ¬±¬±±± ±±¬±±
²§ó²²§²óóóóóóóó§§²§§²²²²§
åå±¬±¬±åå ååååå §§²æ§ç§ç§çò
±¬¬±±æ¬å±¬±±±æ
óóóóó óóóóó óó²óóóóóó §óóó óóóóóóóóóóó óóóó
óóó óóóóóóóóóóóóóóóóóóóóóóóóó óóóó
óóó óóóóóóóóóóó§óóóóóóóóóóóóó óóóó
ó²ó óóóóóó óó óóóóóóóó
ó´§ó² óóóóóóóóóó óóóóóóóóóóóóóóóóó óóóó óóóóó
±¬±¬±± ±±±±±¬¬¬±¬±±±æ
óóóóóóóóóó óó óóóóóóóó§ óó óóóóóó óóóó§ó óóóóó ´ó´óó óóóó óó
óó´óó óó´óó óóóó§ óóóóóóóóóóóóó§ óóóóóó óó óóóó óóôóóóóó
óóóó óó óóóó óóóó§óóóóóóóóóóóóóóóóóóó óóó óóóóóóóó óóóóó
óóóóóó óóóóóóóó óó óóóóóóóóóó óó§óóóóó óóó ó óóóóóóó óóóóóó
óóóóóóó óóóóóóóó óóó óóóóóóóó óóóóóóóóóó òóóó §óóóóóó óóó
óóó§óóó óóó óóóóóóóó óóóóóóóóóó óóóóóóóóó óóóóó óóóóó óó´óó
óóóóóóó óóóóóóó óó´óó óóóóó óóôóó óóóóóó óóóóó óóóóóóóó
óóóóó óóóóó óó´óó óóóóó ´ó´óó óóóó óó óóóóóóó óó´óó óóóóó
ôóóóó óóóóóóóóóóó óóóó§óóóó óóóóó óó´óó óóóóó óóóó óó óó´óó ôóóóó
óóôóó óóó óóóóóóóóóó óóóóóóóó óóóóó óóóóó ´ó´óó óóóó óó
óóóóóóó óó´óó óóóóó ôóóóó óóôóó óó´ó
óóóóóóó óóóóóó óó òóóóóóóó óóóóóóóóóóóó óó óóóóóóóóó
±±æå±±±± ¬± »±±»¬±±å±
óóóóóóóóóóóóóóóóóóóóóóóóó óóó²
²²²²²²²óóóóó²óóó ó²óóóóóóó²óóó
óóóóó óóóó ó²ó²óó ²²²²²²ó² óóó²ó
²²óóóó óó óóó ²óóóóóóóó²óóó²óó óó
²²²²² óóóó²óó ó²ó óóó óó ó í
óóóóóóóó²ó²óóóóóóóó ó²²óó óóóóóò
²ó ²²²²² óóó²ó óóóóóó ²²²ó
²²²²²ó óóóóóóó ó²óóóóóó óó² ó²óó
óóóóóóó óóóóóóóóò
²óóóóóóóó óóóó óóóóó óóóó óó óóóóó
óóóóóóóó óóóóóóóó óó ²²²ó²²²²²ò
æææææææ±å ææ±æææææ ÜÜÜÜÜÜ ÜÜ ´ÜÜÜÜÜÍ ´ÍÜ´´Ü ÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜ ÜÜ
ææææææææææ çÜÜÜÜÜ çççç ÜÜÜÜÜÜ ççÜÜÜÜÜÜÜÜ çççç ¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹ îîí
óóóó²óóóó ²óóóóóóó² óóóóó óóóó óóó
óóóóó² óóóóó óó²óóò
²²²²² óóóóó óóóó óóó²óóóó² óóóó
²²²²² óó óóó óóóóóóóó óó ²óóóóóóóóó
óóóóóó²óóó ²óóó²óóóó ²óóóóóóóóóóóóó
óó²óó²óóó óóóóó² óóóóóóóóóóó óóóóôóóó
ó í ²²óó²óóóóó óæôç²ó ó ²²óó²óóóóó
óæóó²ó óó² ó ²²óó²óóóóó óæóç²ò
óóó óóóóóóóó ²óóóôó óó óóóóó óóó
óóóóóóóóóóó² óóóó ²² óóóó²ó²óóóó
²²ò²ò² óóóó ó óòóóó óóóóóóóó²ó ²²
ó²óóóó ²²ó²óóóóóå ²óó²óóóó óóóóóó
óóóó ²óó²óóó² óó óó²óóóóóóóó óóóó ó
ó²óóó²ó²ó²ó óó²óóóóóæ²óóóó óóóó óóó
ó²óóóóóóóó óó² óóóóóó óóóóóóóóóò ó óóóóó
óó ó óç² óóóóó ó²óó²óó² óóóóóó óóóóó²ó
óóó²óóóóóó óóóó ²óóóóóóó² óóóó íçç ²
óó óóóóóóó ²óçó²ò óóó óóóó óóóó óóóó
óóòó² óó ²óóóó ó óóóóó²²óóóóóó²óóó
óóó²ó²óóó óóæ²óóóó ²óóóóóóóóóó óó²ó
²óóóîóóóó óó²ó ²óóóó ó÷ççî²²íóçå í÷
óóóóóóå óóó² óó óóóóó óóç ²²÷å ²óó
óóó²ó ó÷² íçå óóóóóóó óóóóôóóóóó ó
²²²ò ó÷ óóóó²óóóóó óó²ó óóó óóóó²ó
óóóó² óó ²óóóó ó óóóóóó óó óó óóó óóóóó
óóóó²óó óóóóóóóóóóóóóóóóóó ²²²²² óóóóóó
ó²óóóó²²óó óóóó²ó óóóó óó²óò óóó ²óó
óóó²óóó² óó óóóóóó óóóó óó óóó óó²ó
óóóóó óóó óóó óóóóóó óó² óóóóóóóóó
óóóó óóó óóóóó²óóó² óó óóó óóóóóóóóóóó
óóóóóóóóò ²÷ óóó ²óóóó²óóó² óó óîó÷ò
²ó óóó ²² óóóó²ó²óóóó ó²óóóó²óóóóó
²²²ó óóóó ²óóóó² óóó²ó²óó óó óóó
²óóóóóóóó óóóóóóóóó óó óóó óóóóóóó óóó óó
óóóóóóó²ó óó ó²óóóóó ²²ò²ò óò²òó ïòïòó
óó² »òóò²ò ²óóóó óó² ²óóó²óó²óóó
óóóóóó óóóó óóóó²óóóó²ò
²²²ææ¼ æ¼ ææ¼¼ ¼æææææ¼æ²¬ ¼¼¼ ²¼æææ¼æ¼
ó²óóóó óó² ²²²²² óóóóó óóóóó óó
óóóóó óóó²óó óóóó óóó²óóóó² óóó ó óó²ó
óóóó ²óóóóóóó² ²²²²²óó ²²²ó²²²²²óó
óó² ²ó²óó óó²óóóóóóóó óóó²óóóóóó óó
²óóóóóóó² óóóóóó²óóóò óóóó ²óóóóóóóóó
óóó óóóóóóóóóóó² óó ²óóóó ó óóóóóó
óóóóóóóó ²óóóóóóóóó ²¼ò¬òó óó²óóóóóóóó
óóóó ² óóóóó óó ó²óóóóóóóó óó ²óóóó²ó
óóó ó²óóóóóå ²ò²ò²òó óóóó óó óóóóó óó
ó²óóóóóóóó óó ²óóóó²óóó óóóóóóó²ò
óó²óóóóóó óóóó óóóóóó²ò óó²ó
óóóóóó óóó ²óòóó óó²óóóóóóó óó óóóóóó
óóóó²óóó óóóóóóóó óóôó ó²óóóóóó ò²óóó
óóóóóó óóóóóóó ó²óóóóóóóó óó² ²óó²óó
óó²óóò óóóóó²óóóóó óóó ó²óóóóóó² óó
ó²óóóóó óó² çóóó²óóóóó óóó ó²ó
óóóóóó² óó ²²²²² óóóóóò óóóóó óóóó
óóó²ó² óó óóóóó óóó²óó óó² ó²ó² óó
²óóóóóóó óó² óóóóóóóò ó²óóóó óóóó
óóóóóó² óóóó óóó²óóó óóóóóó óóóó²óóó
óó²óóóóó ²óóó²óó ²óóóóó²óóóóóó ²óó
²óóóóó óóóóó²ó óó² ²²²²² óóóóó óóóó
óóóóóó² óóóó ²ó²óó óóóó²çóóó²óóóóó
²²² óóóóó²²óóóóó ²óóóóóóóóóóóó ²óó
ïóóóó óóóóó²ò óó÷óóóóóóó² óóóóóóóóóóó
²ó² óó² óóóó²ó²óóó²ó² óóóóó²óóó óóó
óóóó²óóó ²²óóóóóóó óó²ó²óóó ²óóó
²óóó² óóóó ²óó²ó óóóóóóóóóóóóò ç²ó
óóóóó óó²óóóóóóóóóóóó óóó óóóóóó²ó²
óóóó ô óóó²óó²ó²óóóó÷óóóóóóóóó²óóó
²²óóóóó ²óóóóóóóóóóóóó ²óóôóóó²ó ²óó²
óó ó ²óó²óóóó óó óæóççò
­¼ ®¼®æ ²®æææ¼®æ¼¼ ¼¼ ­®®¼­ ®æ®ææ
­æ¼æ²æ¼²¼æ
ó²²óóó óóóó óó²²óó² óóóó ó²óó²óóóóó
ó²ó óóòóóóóóó óó ²²²²² ó²²óó óóóó²ó
óóóóó ²í óç²² óó óóó óóó² óóó óó óó
ó²²ó ²óóó ²óò²òó ¼ò¬òó ïòïò²ò ¼ó²ó
óóóôó óóóóó ó²²óó óóóó²óóóóóóó óóóóó
²óóó óóóóóóó² ²²²ó²²²²²óó óó² óóóóó
óóóóóóó² ²óóóóóóó² ²²²²²ó ²²óóóæ ççç
²óó óó óóóó óóó ôóóóóóó² óó óó²ó
óóóóóó²ò óóó²óóó ²ó²óóóóóó ²² ó²óóó
óóó óóóóóó óó² ó óó²óó óóóóó óóóóóóóó
ó²²óóóóóóóóóóó óó ²óóóó ó ó÷óó
óóóóóóó² óóó²óóóóóóóóó óóæ²óóóó
²÷óíîóçòçå óóó² óó óóóóó óíç óóòç
²²å ²óóóó²ó ÷óó ÷óóå óóóóóóó óóóóôó
óóóóó óòó ²²å òóó óóóóóó óç¿² óó² ó
óóóóó²²óóóóóó²óóóóó²ó²óóó óóæ²óóóó
²óííçî²òí²÷óóòóå í÷ óóóóóóå ó²²óóó
óó óóóóóóó óóæ²óóó²ó óóóå óóó² óó óóóóó
ó÷ç íôòô ²²å ²óóóó²ó ó÷² ííå
óóóóóóó óóóóôóóóóó ÷ ²²² óóó ó÷ óóóó²ó
ó²óóóóò ²÷ óóó ²óóóó²óóó² óóó ²²²ó
óóóó óóóóóó² óóó óóóóóó ó²²óóó óó ²ó²ó
ó²óó ó²óóóóóóóò ²²² ²óóóóóóóó óóó
óóóóóó²ó² óó ó²óóóóó ²¼ò¬òó ïòïòó óó²
óò²ò² óó óóóóóóó²óò ²óóó ²²² óóòó óóó
çòô÷ ó²÷ çò÷÷ò
­®®æ¼ææ¼æ¼æ¼æ²¼æ ¬¼¼¼¼¼¼² æ² ®æ®æææ
ó²²óóó óóóó ²óóóóóóó²ó ó²óó²²ó² óó
óóóó²ó óóô ²²óó²óóó ²óóóóóóó²²óó óóó
çóóóóóóóó²ó²ó óó² óóóòóó óó óóæ²ó² óóó
óóóóóó óó² ó²ó ²óòóò¼òó óóóóóóóóó óóóó
ô óóóóó óó ó²óóóóóóóóå ²ò²ò²ò²ò ²ó²ó
²óóóó²óóóó óóóó óóóòóó óóóóóó óóóó
ó²ó² óó óóóóóóó óó² ²óóóóóóó óó²
óóóó óóó ²óóó²ò ²óóóóó óóóó óóóóóó²
óóóó óóó²óóó óó²óóóó óóóó²ó²óó
ó²óó óó² óóóóó²²óó ó²óóîó²óó óóó
óóóó²óóó ²²² ²óóóóóóóóóóó ²óó ïóóóó
óóóóó² óó óó²óóóóóóóó óóóó ó óó÷ó
óóóóóó² óóóóóó²óóóóó²ó² óóóóó²óóó óóóóó
óó²óò óó²óóóóóóóóóóóó óó óó²óóóóóóóó óóóóó
óóó óóóóóó²ó² óó ²óóóó ó óóó óóóó²ó²óó
ó²íó óóóóóó²ó ²²² ²óóóóóóóóóó² óó óó²ó
óóóóóóóó óóóó ó óóóóóóóóóó² óóóóóóó ó²²²ó
óóóóóó²óóóó² óóóóó²óóó óóóóóó²ó ²ïóóôó
óóó ²²²²óó²óóóóóóó ²óóóóóóóóóó ¼óóó
²óóóóó ²ó²ò ç²óóóó óóóó óóóóóó² óóóó
ô óóó²óó²ó²óóóó÷óóóóóóóóó²óóóò ¼óó
²ó²óóóóó óó²ó óóóóóóóóó ó óóóó²óó²
óóóóóóóó ²óóóóóóó² óó óóóóó²ó² óó
²óóóóó²ó² óó ôóóóóóóô² óóó óóóóóóó²ò
¬¼¼¼¼æ¼¼æ¼¼ ²¼¼¼¬æ¼æ
óó óóóóóóóóóóóóó óó²óóóó óóó ²óóó óó
óóóóóóóó ²óóóôó óó óóóóó óóó² ²óóóóóóóó
ó²óóóó²óóóóó ó óóóóóó ²ó²ó² ²ó²óó
óóóó óóó²ó² óóóóóóóóó óóó ²óó²ò ²óóó
óóó óóóóóóóó óó²óóóóóóóó óóóó ó²ó
ò²óóó² óóóóó²óóó óó ó ó²ôóó óóóóò
óóóóó óó²óóó ²óó÷² óóóóóóó ²óóó óóó²
óóó óó óóóóó óóóóóóóóóóóóóó ó²óóóóó
²óóóóò ²ó óóóó óóóóó²óó óóó ²óóôó óó²óó
óóóóóó óóóóóóóóóóó óóóóóóóóóóó óóó óóó
óóóó² óó óóó óóóóóóóóóóó óóóóóóóó ²óó
óóóóóó² óóóóóò óóó æ²óóóóóóóóóó ²óóó
óóóó ó²óóóóóó² óó ²óóó ²óóó²óóó
²óóó óóóóóò
²÷ óó ²²²²² ó²²óóó óóóóó ó²²óóóóó
óóóóóóó óó ²²²ó²²²²² óó ²²²²² óó²
óóó ²óóó óó óóóóóóóó óó²óóóóó óóóó óó²ó
óóóó² óó ²óóóó ó ²óóóó¼óóóóóó óóóó
²óóóóóóóóó²²ò ²óóóóóóóóó ²óóóóóóóóóó
óóóó óóóóóóó² óó Ð óóó²óó óóóó óóóó òçóò
ææææ¼¼æ
²¼¼ææ¬¼ææ¼æ æ² ­¬æ­­ ¼¼¼ æ­­­­¬æ­­
²ó ó²óóó óó² ²²²²² óóóó ó²óóóóó
²óóóóó ó óóóóóóóóóó ²Ð òçççó² ó²ó²
óóóóóó óóó óó²ó² óóó óóó ²óóóôó óó
²²²²² óó² ²²²ó²²²²² óó² ²ó²óó
óó²óóóóóóóó óóó²óóóóóò ²ó ó²óóóóó
óó óó²ó² ó óóóóóó ²óóóôó óó ²²²ó
²²²²²ó óóóóóóóó óó ²ó²ó²²²²²ó óó²
²²²²²ó ²Ð òççó² óó² ó óóóóóóóóóó
²Ð òççó² óó²óóóóóóóó óóóóóóóóóó óó óóó
²óóóôó óó óóó ó²²óóóóó óó óóóó ²²²ò
²²²²² óóóó²ó óóóóó óóóóóó² ²óóó
óóóóóóóó ²¼óó ó²ò ²÷ óóóóóóóó² óó óóóó
óóóóóóóóó óóóóóó óóóóóó óóóóó óóó²óóó
óóóó óóóó ²óóóóóóó² ²²²²²ó óóóó óóóóó
óóó²óóóóóó óóóó ²²²ó²²²²²ó ²Ð
æææææææ±å ææ±æææææ ÜÜÜÜÜÜ ÜÜ ´ÜÜÜÜÜÍ ´ÍÜ´´Ü ÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜ ÜÜ
îîî ¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹ ææææææææææ çÜÜÜÜÜ çççç ÜÜÜÜÜÜ ççÜÜÜÜÜÜÜÜ çççç
òççó²ò óóó óóóóóó óóóóóóóó óó ²÷ ²Ð
òççóó óó²óóóó² óóóó ²²²²² óó² ²²²ó
²²²²² óóó²óóóóóó² óóó óóóóóóó²
óóóó óóó ²²²²² óóóóó óóóó ²óóóó
óóóóó² ²ó²óó óó²óóóóóóóó óóó²óóóóóò
²²² óóóóó óóóóó² ó óóóóóóóó ²óóóôó
óó²óóóó óó óóóó óó ó²óóóóò óóóóó ó óó²óó
óóó²óóóóóó ²÷ óóó óóóóóóóóóóóó ²Ð òçó²
óóóóóó óó óó²óóóó óóóó²²óóó ²²² óóóóó óóó
ó²óóóó² óóóó ²²²ó²²²²²ó óóóó óó óóóóó
óóóóóó² óóóó ²óóóóóóó² ²²²²²ó óó² ²ó²óó
óó²óóóóóóóó óóó²óóóóóò
æ¬¼æ¼æ®¼æ¼¼¬ ¬¼æ¼¼ææ
óóóó óóóóó ó²óóó²ó² óóó²óóóóóó óó²óó
óóóó ²óóóóóóó² ²²²²²óó ²²²ó²²²²²óó
óó² óóóó ²²²ó óóóóóóóóó óó ó²óóóóó
²²²²² óóóóóó óó² ²²² óóóóó óóóóóóó²
óóóó óóóóóó óó²ó óóóóóóóó óó² óóóóóóó
²óóó²óóóóóóóó óóóóó óóó óóó óóóóóóó
óóóóóó ²óóóóóóóó óóó² óóóóó óóó²óóóó²
óóóó óóó²óóó óóóóóó ²ó²ó²² ²¼óó óó
óó² óóóóó²ó² óó ôóóóóóóô²ò
­¼²ææ¼ææ æ² ­¼¼æ²æ¼¼ ­¼æ¼­¼¼¼æ¼ æ¼
ææ¼²ææ¬¼ææ¼æ æ² ­¬æ­­æ
²² óóóó²ó²óóóó óóó²óóó óó²óóóóó²
óóóóó óóóóó ó²²óóóóó óó ²²²ó óóó ²óó
óóôó óó óóóóó ²²²²² óóó óó²²óó² óó
ó²óóóó ²óóó óóóóóóóóóó² óó² ²²²²²
óóóóó ²Ð òçó²ó óóóóó óó²óóó óó óóóóóó
óóó óó²ó² óó ²²² óóóóóò ²ó óóóó óóóó
óó²óó óóó óóóóóóóóóó óó óóóóóóóó ²óóóôó
óóó ²²óó óóóóóóóó óó ²²²²² óóóóó
óóóó óó ó²óóóó ²¼óó ÷²ò ²óóóóóóóóó óó
ó íó óó óó² ó óó óóóóóó²óóó óóóó
óóóóóóóó² óóó ²óóóôó óó ²óóóóóóóó
²²²²² óó ²²²²² óóóóóò óóó óóóóóó óóó
²óóó óóóóó²óóó² óóóó óóóóóóóóóóó
óóóóôóóó ó óó²óóóó² óóóó ó í óó² ó
²¼óó ó÷ óó² óóóóó²ó² óó ôóóóóóóô²ò
²²²ææ¼ æ¼ ææ¼¼ ¼æææææ¼æ²¬ ¼¼¼ ²¼æææ¼æ¼
²ó ²óóóó óóóóóóóóóóóóóó ²óóóóóóóóóó
óó óóóóóóó óó ²óóóóóóóóó óó² ó²óóó
óóóó óó ó²óóóó óóóó óóóóóóó óóóóó ó
óóóó²ó óóó²óóóóóó óóóó ²óóóóóóó²
²²²²²ó óó óóóó ²²²ó²²²²²ó óó ²ó²óó
óó²óóóóóóóó óóó²óóóóóò ²ó²óóóóóóó óóó²ó
óóóóóó óó ²²²²² óóóóó óóó ó óó²ó óó
óóó óó²ó óóóó óóóóóóóóóóóóó óóóó ²óó
óóóóóó² ²²²²²ó óó² óó óóóóóó óó óóóó
²óóóóóóóóóò óóóóóóóó ²²²²² óóóóó
óóó²óóóó² óóóó ²²²ó²²²²²ó óó²ó²ó²
óóóó óóóóóóóó² óóó² óóóó óóóóóó óó² óó²ó
óóóó ²óóóóóó²ò óóóó óóóóóó óóó óóóó²óóó
óóóóó²óóó² óóóó óóó óóóóó óóóó óóó²ó
¬¼²æææ ï
æ­¹®¹­ ææ ¼ç ÜÜÜÜ¼ÜÜÜÜÜ ÜÜÜÜÜ ÜÜ Ü´çÜÜÜÜ ´¼¼Ü¼ ÜÜÜÜÜÜ ÜÜÍÜ´Í ÜÜÜÜÜ ÜÜÜÜÜÜÍÜÍ ÜÜ ÜÜÜÜÜÜÜ ÜÜÍ ÜÜÜÜÜÜÜÜÍ ÜÜÜ ï ÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜÜÜÍ ´ÍÜ´´ÜÜ ÜÜÜÜ ¼¼Ü¼´ÍÜ´´ÜÜ ÜÜÍ
ÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜ ÜÜÜ ÜÜÍÜÜÜÜÜÍÜ
ÜÜÜÜÜÜÜÜÍ ÜÜÜÜÜÜÜ ÷­÷ÜÜÜÜÜÜÜÍ ÜÜÜÜ ÜÜÜÜÜÜÜ ÜÜÜÜÜ ½ïÜçç ÜÜÜ ï çÜçï½Ü ¼ç ÜÜ Ü´çÜÜÜ ÜÜ ÜÜÜÜÜÜÜ ÜÜÜ ïçÜçç ÜÜÜ ï çÜç¼ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜÜÜÍ ´ÍÜ´´Ü ÜÜÍ
ÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÍ ÜÜ çïÜçç ÜÜÜ ï çÜ¼¼ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜ ¼¼Ü¼´ÍÜ´´ÜÜ ´ÜÍÜÜ ÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÍÜÜÜÜÜÜ ¼ç ÜÜÜÍ ÜÜÜÜÜÜÜÜÍ ÜÜ ï½Üç¼ ÜÜÜ ï ïÜç¼Ü ¼ç ÜÜ ¼ÜÜ¼
ï ïÜïç ÜÜÍÜ ÜÜÜÜÜÜ ÜÜÜ ÜÜ ÜÜÜ ÜÜÜÜ ÜÜÜÜÜ ÜÜ ÜÜÜÜÜÜÜÜÍ ÜÜÜÜÜÜÜÜÜÜ ÷­÷ ´Ü ´¼¼Ü¼ ÜÜÜÜÜÜ
¼¼Ü¼´ÍÜ´´ ÜÜÜÜÜÜ ½¼ç ï¼Üç¼ ÜÜÜ ï çÜçç½ ÜÜÜ ÜÜÍÜÜÜÍ ÜÜÜÜÜÜÜÍ ÜÜÜÜ ´ÍÜ´´ ½¼ç ï¼Üïç ÜÜÜ ï çÜïç½ ÜÜÍ ÜÜÜÜÜÜÜ ÍÜÜÜÜÜÜÜÍ ÜÜÍÜÜ ÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÍÜÜÜÜÜ
½¼ç ïïÜç¼ ÜÜÜ ï çÜçç½Ü ÷§÷¼ç ÜÜÜ´Í ÜÜÜÜÜ ÜÜ ÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÍÜÜÜÜ ÜÜÜÜÜ ¼¼Ü¼´ÍÜ´´ ½¼ç ½Üçç ÜÜÜ ï çÜç½½ ÜÜÜÜ ´ÍÜ´´ ½¼ç çÜïç ÜÜÜ ï çÜïç½ ÜÜÜÜÜÜ¼
ÜÜÜÜÜ ¼¼Ü¼´ÍÜ´´ ÜÜÜÜÜÜ ÜÜÜ ÜÜÍÜÜÜÍ ÜÜÍÜÜ ÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÍÜÜÜÜÜ ½¼ç çÜç¼ ÜÜÜ ï çÜï¼½Ü Ð Üççå Ð ÜçïÜ
¬¼²æææ î
æ­¹®¹­ ææ ´ÍÜ´´ ÜÜÜÜÜÜ ÜÜ ÜÜÜ ÜÜÜÜÜÜÜÜ ÜÜ ÜÜÜÜ ¼¼ÜÜ ÷­÷ ÜÜÜÜÜ ï¼ÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜÜÜÍ ´ÍÜ´´ÜÜ ¼ç ÜÜ Ü´çÜÜÜ ÜÜ ÜÜÜÜÜÜÜ ÜÜÜ ¼Üïç ÜÜÜ ï çÜçç ÜÜÍ ÍÜ¼
ÜÜÜÜÜÜÍ ÜÜ çÜçç ÜÜÜ ï çÜçç ÜÜÜÜ ÜÜÜÜÜÜÜÜÍ ÜÜÜÜ ïç ççç¼ÜÜÜÍ Ü¼ÜÜÜÜ ÜÜ ÜÜÜÜ ¼¼ÜÜ ÷­÷ ´Ü ´¼¼Ü¼ ÜÜÜÜÜÜ ÜÜÜ ÜÜÜÜÜÜÜÜÜÜ ÜÜ ÜÜÜ ÜÜÜÜÜÜ ÜÜ ÜÜÜÜÜÜÜÜÍ ´ÍÜ´´Ü ÜÍ ¼¼ÜÜÜÜ
ÜÜÜÜÜÜÜÜ ÜÜÜÜ ÜÜÜ ÜÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜ ÜÜÜÜÜ ï¼ÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜÜ ¼ç ÜÜÜ çÜ¼ç ÜÜÜ ï çÜ½¼ ÜÜÍ ÍÜÜÜÜÜÜÜÍ ÜÜ ¼Ü¼ç ÜÜÜ ï çÜ¼¼ ÜÜ ÜÜÜ ÜÜÜÜÜÜÜÜ ÜÜ ïççç¼ÜÜÜÍ Ü¼ÜÜÜÜ ÜÜ ÜÜÜÜ
¼¼ÜÜ ÷§÷ ´ÜÜ´Í ÜÜÜÜÜÜ ´ÍÜ´´ ÜÜÜÜÜÜ ÜÜ ÜÜÜÜÜÜÜÜÜÍ ÜÜÜÜ ÜÜ ÜÜÜÜÜÜÜÜ ÜÜÍ ÜÜÜÜÜÜÜ ÜÜ ¼¼ÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜ ´ÍÜ´´Ü ¼çÜÜÜ çÜ¼¼ ÜÜÜ ï çÜïç ÜÜÍÜÜÜ ¼Üç¼
ÜÜÜ ï çÜç¼ ÜÜÜÜ ÜÜÜÜ ¼¼ÜÜÜÜ ÜÍÍÜÍÜ Ð Üçç½ ÜÜÜÜÜÜÜÍ ÜÜÜÜ ¼¼Ü¼´ÍÜ´´ ÜÜÜÜÜÜÜÜÍ ÜÜÜÜÜÜÜ
æææææææ±å ææ±æææææ ÜÜÜÜÜÜ ÜÜ ´ÜÜÜÜÜÍ ´ÍÜ´´Ü ÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜ ÜÜ
ææææææææææ çÜÜÜÜÜ çççç ÜÜÜÜÜÜ ççÜÜÜÜÜÜÜÜ çççç ¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹ îîë
óóóó² óóóó ²²²ó²²²²²ó óó óóó óóóóóóóó
óó óçççóóóó² ó²óóóó óó ²²²ò
²²²ææ¼ æ² æ­­­­¬æ­­æ æ¼ æ¼¼æææ¼¼
²®æææææ¼æ¼
óóóóó²óóóóó óóó ó²óóóóóó² óó óóó óóóó
óóóó óóóó óóó²óóó óó ó²óóó óóóóó óóó
óóóóóóó ó²óóóóóóóó óóó óóóóóóòó²ó óó²
óóóóó óóó óó ²óóóóóóóóó óó óóóóóóóó óóó
óóóóóóó óó óóóóóóòóóóóó óóóó óóóóó óóóó
óóó²óóóó² óóóó ²ó²ó²² óó ²²²²²óò
óóóóóóóó óóóóó óóó²óóóóóó óóóó ²²²ó
²²²²²óó óó ó²²óóóóóóó óóóóó²óóóóó óóóóóó
óóó óó óóóóó²óóóóó óóó²óóó² ²¼óó í²ò ó
óó²óóóóóóó óóó²óó óóó óóóóóóó² óóó
²²² óóóóó ²óóó óóóóó óó ¼óó²óó í²ò
²ó óóóóóóóóó óóó óóóóóóóóó²óóó óóóó
óóóóó óó ²²²²² óóóóó ²ó² óóó óóóóó óóó
óóóóóó óóóóóóó óóóó ²ó²óóóóóó óó²
óóóó ²óóó ó²óóóóóóò çóóó²óóóóó ó²ó
óóóóóóóó óóó óóóó óó²ó² óó óóóóó
óóóó²ó ²ó²óóóóó óó²óóóó²óóóó óó²
óó óóó óóóóó²óóóóó óóóóóóóó²ò óóóóó
óóó óó ²óóóóóóóóó óó óó²óóóóó ²óóóóóó²ó
óóóó ²óóóó²óóó óó óóó²óóóóóó óóóó ²óó
óóóóóó² ²²²²² óó ²ó²ó²²ò óóóóóóóó
óóóóó óóó²óóóóóó óóóó ²²²ó²²²²²óó
²ó²óóóóóóóóóóóóóóó² óó²óóóóó óóóóóó
óóó óóó óóóóóóó óó²²óó² óóóóóóóó óóóó
ó óóóóóó óóóóóóó²óóó óó óóó óóóóóóóóó
²óó óóóóóóóóò óó óóó óó²ó óó²óó
²²²²² óóóóó óóóó ²óóó óó óóóóó óóóóóó
óóóó²óóó óóóóóóóóò
²óó²óóóóóó óó ²²²²² óóóóó óóóó
óóóóóó²óóó óóóóôóóó ó íó óó óó² ó
óóóóóóóó óóóó ²óóóóóóóóóóó² óó²óóóóóó
²óóóó²óóó óóóóóóóóó²óóó óóóóóóóó ²¼óó
óí óó² óóóóó²ó² óó ôóóóóóóô²ò
¼æ ­®¼²¼¼² ¼¼¼ ææ¼¼®æ®æ¼æ¬ æ² ­®®¼­
®æ®ææ ­æ¼æ²æ¼²¼æ ¼¼ »æ¼æ ¼¼ææ
²²óóóóóóóóóó óóóóóóóó óó óóó óóóóóóó óó
²÷ óóóó²óóóóó óóóóó ² ²÷ óóóóóó óóó
òóóóóóó óóóóó óóòóóóóóó² óó ó²²óóó
óóóóóóó² óóóóóóóóóóóó ²Ð òçó² óóóóóó
²÷ óóóóó ²²²ó²²²²² ²÷òô óóó ó óòó²
óóóó óóóóó ²²²²² ²çòí óóó ó çò÷²
ó²²óóóóóóóóóóóó óó²óóóóóóó ó óóóóóó ²óó
óóôó óó ²²²ó²²²²²óò ¼óó²óó ô óóóóó
óóó ó÷óóóóóóóóó² óóóóóóóóóóó óó
óóóóó óóó²óóò
®¼æ¼æ¼æ²¼æ ²®¼¼æ¼¼¼æ¼ æ² ­®®¼­ ®æ®ææ
­æ¼æ²æ¼²¼æ
²²²²² ó²²óóó óóóóó² ó ²óóóó óó²
óó²óóóóóó²ó óóóóóóô óó ó²óóó óóóóóóó
óóóóóóóóóóó²óóó ó²óóóóóóóó ó í óóóóó
óóóóóò ó í óóóóóóóó ó²óóóóóóóó óó
²²²²² ó²²óó óóóóó óóó óóóó óóóóóóóóó
óóó²ó óó² óóó²óóó² ²óóó óóóóóóóó óó
óóó óóóóó óóóó óóóóóóòó² óóóó óóóó²óóó
óóóóóóôó ²¼óó ó²ò
²ó²óóóóó óó²ó óóóóóóóó óóóóóóó²
óóóó²óóó óó² óóóóóóóó²óóó óóóóóóòóóóóó
óó ²²²ó²²²²²ó ó²ó óó ²óóóôó óó ó²ó
²óó óóóóó ²¼óó ó²ó ó²óóóóóóóó óóóó óóóóó
óóóóóóóó óó²óóó óó ²²²ó²²²²² óó óóóó
ó²óóó óóó²óó²óóó óó óóóóóóóóóóó óóó óóó
óóóóóó óó ²÷ò ²ó óóóóóóó ó²²óóóó óóóó ó
óóó ²óóóóóóó² ²²²²²ó óóóó óó²ó² óó
óó ²óóóóóóóó ²óóóóóó²óóóóò
­¼æææææ¼æ¼
²²²óóó²óóó² ó²óóóóó óó²óó²ó²ó óóó
óóóæ²óóóóó ²óó² óó ²óóóóó óóóóóóóóóó
ó²²óó óóóóóóó óó² óó óóóóó ó í óóóóó
óóóó²óóóóóóóó ó²²óó óóóóó ²÷óôóóóç²
óóó÷íó÷ô²ò ²ó ó²óóóóó ²ó²óóóóóó óó²óóó
óóóóóó² ²óóóóóóóóó ²²² óó²óó²ó²ó
²óí²óó² óóó ²óó² óó óóó ²óóóó ²óóóóó
²óóóó óóóóó² óó² óó²ó óóóóóóóó óóóóóóóó
óóóóóóó óóóó óóóóóóò ²² ó²óóóóó óóó ó
óóóóóóóóóóóó óóóóó óóóóóóóóóóó óóó ²²²ó
óóóóóó² óó²óó²ó²ó óóóó ó²óóóóó ²ó²ó
óóóóóò óó ó óóóóóæ²óóóóó ó óóóó óóóó
óóóóóóóóóó óó ²²²óóóóóóóóóóó ²óóóó²ó
óóó ²² óóóóóó ²²óó óó óóó²²²óóóó² óó
óóó óóóóóó óóóó óó óó²²óó ó óóóóóóóóóó
óóóóóó óóóóóó óó óóó óóóó²óò óó²óó óóóó
óóóóó óóóóóóó óó ²²²óóóóóóó² ²² ó²óóó
óóó óóóóóó óó óó²óóóóóóóó óó² ó²²óó
óóóóó óóó óó óóóó óóóóóóóóò
óó óóóóóóó² óóóóóó²óóó ²ó²ó
ó²óóóó óóóóóóóóóòó² ²²²ó²²²²²
²óóó óóóóóóóóó óóóó ²óóóóóóó² óó²
²ó²óóóóóóó² ²²²²²ó óó² ²²²ó²²²²²
²óóóôó óó²ó² óó ó²óóóóóóó² óó óó²óóó
¬¼²æææ í
æ­¹®¹­ íæ
ÜÜÜÜÜÜÜ çÜ¼ÜÜÍÜÜÜÜÜ ÷÷÷÷÷¹¹÷¹÷ ½Ü´çÜÜ½ ÜÜÍÜ¼ÜÜÍÜÜÜÜÜ ÷÷÷÷¹¹÷¹÷ ½´¼¼Ü¼½ ÜÜÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜÍ
ÜÜÜÜ ¼ Ü½¼ÍÜÜÜÜÍÜÜÜ¼ç¼ÜÜÜÜÍÜÜÜÍÜÜÜ ÷÷÷Ð÷÷ ½ÜÜÜÜ½Ü ´Ü Ü´çÜÜÜ ÜÜÜÜÜÜÜÜÍ ÜÜÜÜ ÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÍÜÜÜ ÜÜÜ¼
ÜÜÜÜÜÜÜ ´ÍÜ´´ ÜÜ ÜÜÜÜ çÜ¼ÜÜÍÜÜÜÜÜ ÜÜÜ ÜÜÜÜÜÜÍ ÜÜÜÜÜ ÜÜÜ ÜÜÜÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜ ÜÜ Ü ÜÜÜÜÜÜÜ ÜÜÜ¼
ÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜ ÜÜ ÜÜÜÜÜÜÜÍ ÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜÜ ´Ü ´¼¼Ü¼ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÍ ÜÜÜÜ ÜÜÜÜÜÜÜ
ÜÜÜÜÜÜÜÜÍÜÜÜ ÜÜ ÜÜÜÜÜÜÜÜ ÜÜ ´ÍÜ´´ ÜÜ ÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜ Ü¼ÜÜÍÜÜÜÜÜ ÜÜ
ÜÜÜÜ ÜÜÜÜÜÜÜÍ Ü¼ÜÜÜÜÜÜÍ ÜÜ ÜÜÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜ »ÜÜÜÜÜ ÜÜ ÜÜÜ ÜÜ ÜÜÜÜÜÜÍ ÜÜ ÜÜÜÜÜ ÜÜÜÜÜ ÜÜ ÜÜÜ ÜÜÜÜÜÜÜÜÜÜÜÜÜÜ
ÜÜÍ ÜÜÜÜÜÜÜÜÜÜÜÜÍÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜ ¼¼Ü¼´ÍÜ´´Ü ÜÜÜÜÜÜÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜ ÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ
ÜÜÜÜÍ ÜÜÜ ÜÜÍ ÜÜÜÜÜÜÜÜ ÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜ ®ÜÜ çç ¼ççÜ½
æææææææ±å ææ±æææææ ÜÜÜÜÜÜ ÜÜ ´ÜÜÜÜÜÍ ´ÍÜ´´Ü ÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜ ÜÜ
îîî ¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹ ææææææææææ çÜÜÜÜÜ çççç ÜÜÜÜÜÜ ççÜÜÜÜÜÜÜÜ çççç
óóóóóó óóóó ²²²ò óóóóóóóóóóóóóóóó
²²²²² óóóóó óóó²²²óóóó² ²²²²²
²óóó óóóóóóóó óóóó ²²²óóóóóóó² óóóóó
óó² óóó óóóóóó ²²²ó²²²²² ²óóóôó ó²óó
óóóó ²óóóóóóó² ²ó²óó óó²óóóóóóóó
óóó²óóóóóò ó²²óóóóóóóóóó óó ²²²²² ó²ó
²óó ²óóóóóóóóóó ²²²ó²²²²²ó óóóó óóó
ó²²²óóóó² óó óóó óóóó²óóó óó²óóóóó
²óóó ó²ó óóó óó ²²²²² ó²²óó óóóóóò
óóóóó óóó²óóó óóó óó óóóó óóóó ó óóó
óóóóóó ó²óóóóóó² óó²²ó óó óóó óó² óóó
óóóôóóó ²÷ó²ó óóó óóóóóóóóóóó² óóó
²óóóôó óó ²²²óóó²óóó² óóóó ó²ó²ó
óóóóóóóóóóóóó óó ²²²²² ó²²óóóò
¼²óóóóó²óóóó óó ²²²²² óóóóó óó²
ó²óóóóó óóó ²óóóôó óó ²óóóóóóóó
²²²²² óóó óó²²óó² óó óóó óóóóóóóó óó
²²²ò ²óóó²óó óó ²ó óóó óóó²²ó óóóó
²óóóóóóó² ²²²²² óóóó óóóóóóóóóòó²
óóóó²óó óó óóóóóóóóó²óóóó²óóó óóóóó
óóóó ²²²ó²²²²² óó² óóóó ²²²
óóó²ó² óó óóóóóóó ²óóóóóóóó óó²óóóóóó
óóó óó óóóóóóóò óóó óóóóóó óóó²²óóóóó óó
ó²óóóóóó² óó óóóóóó²ó óóóóóóóó ²÷óó÷²²
óó óóó óóóóóóóóóó óó óóóóóóóóóóóóóó
óóóóó² óóóóóóóóóóóóò óó²óóóó² óóóó
²²²²² óóóóóó óó ó²óóóóó óóó óóóóó
óóóóó²óóóó²óóó óóóóóóóóóó óó ²óóóóóóóó
²²²²² óóóóóóóóóóóó óóó óóóó óóóó
óó²óóó²ò
²óóó óóó ²óóóóóóóó óó² óóó óóóóóó
óóóó²ó²óóóó² óóóóóóó ²óóóôó óóóóóóóó
²óó óó óóó óóó²²²óóóóóó óó ²²²ó
²²²²² óó óóóóóò ²ó ó²óóóóó óóó óóóóóóó
óóóóóóó óóóóóó ²óóóôó óó ²²²ó²²²²²
óó²óóóó² óóóó ²²²²² ²óóó óóóóóóóó
óó óóóó²óó óó ó óóóóóó óóóóóóó ²óóóôó
ó²ó óóóó ó ²óóóó óóóóóóóóóó óó óóó ²óó
óóóóóóó óóóóóóóóóóóóò ²ó óóóóóóóóó óó
óóó²²ó óóóó óó ²²²²² óóóóó óóó óóóóó
óóóóóó óó ²óóóóóóóó óóó²²²óóóóóó óóó
ó²óóóóóó óó óóó óó²²óóóóó óó ó óóóóóó
óóóó²ó²óóóó² ²²²ó²²²²² ²óóóôóò ²ó
óóóó óóóóó óóóóóóóóóòó² ²²²ó²²²²²
óó²ó² ²óóóóó óó óóóóóóó² óó óóó óóóóó
óóóó óóóóóóóóó óóóóó óóó²ó² óó óóóóó
²óóó² óó ó²óóóóó ó²óóóó²óóóóò
óóó æ²óóóóóó óó óóó ²²²ó²²²²²ó
óóóóô óóóóóóóóóó óó²óóóóóóóó óó
óóóóó²ò ¼ó ó²óó²²ó² óó²óó óóóóóóó óó
óóó óóóóóóóóó óó óóó óóóóó óóóó²óó óóóóó
óóóóó óóóóó óóóó óó²²óó² óóóóóóóó ó²óóó
óóóóò ¼óó ²²²²² óó² óó²óóóóóóóó óóóóóó
óó óó ôóóóó óóóó óóóó óóó²óóóóóó óóóó
²²² óóóóó²ó óóó²ó óó óóóó ²óóóó ²÷²²ò
óóóó ²óó óó óóóó²óó óóóóôóóó óóóóó
óóóóó óó²óóó ó ²óóó²óóóóó óó óóóóóóóóó²ó
óóó ò²óóóóóóó ²÷ç²ó óóóóó óóó²ó óó óóóóó
óóóóó óó óóóóóóóóóó ²²óóóó óóóóóó óóóóó
ó²ó óó óó²ó ²íçóíó²ò óóóóóóóó ó²ó
²óóó ó²óóóóó óóóó óóó²óóóóóó óó²óó
óóóóóó óó ó²ó ó²óóóó²óóóó óóóó óóó
óóóóó óó óóóóóóóó óóóó ²óóóóò
²óóóóóóóó²óóó ò²óóóóóóóó óóóó²²óóó
óó²óóóóóóó óóó óóóó ôóóóó óó óó óó²ó
óóóó óóó óóó ²óóóóóóóóóó óó óóóó ²óóóó
óóóóó óóóóóóóóóó óó² óóóóó óóóó óó ó²óóóó
óóóó óóó ²óóóóóóóó óóóóóóóóóó óó ó²²óó
óóóóó ²í÷óíí²ò ¼ó ²ó²óóóóóóóó² ó óóóó
óó óóóóóóóóó²óóó ò²óóóóóóó óó ²²²²²
óóóóóò ²ó óó óóó²²ó² óóóó óóóóóóóó óóóóóó
óóóó²ó²óóóó² óóóóóóóóó óó²²óóó óó²óó²
²ó²óóóó² óó²óóóóóóóó óó óó²óóóóóóó
óóóó²²óóóó óóóó²óó óóóóóóóóóóóóóóó
óó óóó óó²óóóóó óó²óóó² ²íó²ò ²óóóó
óóóóó óóó óóóó óó óóó²óóóó óóó óóóóóóóóó
ó²óóó óóóóó²² óóóóóó óóóóó óóó óóóó
óóóóó óó óóóóóóó ó²óóóóóó óó² ²óóóóó
óóóó óó ó óóóóóóó óó óóóó óóóóó ²íôóíó²ò
¼ó óóóó²óóóó óóóó óóó óóóóóóó óóóó óó
²óóó óóóóóóóóó²óóó óóóóóóóó óó²óóó ó²óó
óóóóóóóó óóóó óóóóóó óó óóóóó óóó óóóóó
óóóóó óóóó ó óó²²óóóóó óó óóóóóóóóóóóó
óóóóóóóó óó² óóó óóóóóóóóó óó óóó óóóó
óóóóóóó óóóóóóóó óó óóóóóó²óóó ²óóóó
óóóóó óóóóóóóóóò óóóó óóó²²óóóóó óó ²óó
²óóóóóó² óó ó²ó óó²óóóó óóóó óóó óóóó
óó²óóó² óóóó óó óóóóóóóóó²óóó óóóóóóóó
óóóóóó²ó² óóóó óó²²óó² ²²²²² ²óóóôóò
óóó óó²ó æ²óóóóóó óóó óóó ó²ó
¬¼²æææ î
æ­¹®¹­ ææ ÑçÑ¼ÜÜÜÜÜÜÜÍÜ¼ Ü ÜÜÜÜ ÜÜ ÜÜÜÜÜÜ ÜÜÜÜÜ ÜÜ ÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜÜÍ ¼¼Ü¼´ÍÜ´´ ÷­÷ ÜÜÜÜÜÜ ÜÜ²ÜÜÜÜÜÜ
ÜÜÍ ÷­÷ ½ ÜÜÜÜÜ ÜÜÜÜÜ ÜÜ²ÜÜÜÜÜÜ ÜÜÍ ÜÜÜÜÜÜ ÜÜÜÜ ÜÜÜÜÜÜÜÍ ÜÜÜÜÜÜÜÜÍ ´ÍÜ´´ ÷§÷ ÜÜÜÜÜÜ ÜÜ²ÜÜÜÜÜÜ ÜÜÍ ÷­÷ ½ ÜÜÜÜÜ
ÜÜÜÜÜ ÜÜ²ÜÜÜÜÜÜÜ ÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜÍ ÍÜÜÜÜÜÜÜ ÜÜ ÑçÑ ÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÍÜ
æææææææ±å ææ±æææææ ÜÜÜÜÜÜ ÜÜ ´ÜÜÜÜÜÍ ´ÍÜ´´Ü ÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜ ÜÜ
ææææææææææ çÜÜÜÜÜ çççç ÜÜÜÜÜÜ ççÜÜÜÜÜÜÜÜ çççç ¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹ îî®
óóóóó óóóó óóóóó óóóóóó² ²óóóóóóóóóóò
²óó óóóóóóóó ó²óóóóóóóóó óóó óóó ²²óó
óóóóóóóó óóóóóóóó óó ²²²²² óó ²²²
óó²óóóó² óóóó ó²óóóó óó² ²²² óóóóó
óó óóó óóóóó æ²óóóóóó óó ²óóóóóóóóóóóó²
óóóóóóóóó²óóó óóóóóóóóò ²ó óóóó óóóóó²óó
óóóóóó²óóóóó óóó ²²² óóóóóó óóóóó óóó
óóóó²ó² ²óóó óóóôóó óó ²²²ó óóó
ôóóóó óó óóóó ó²óóóóóóóóó ó²²óóóó óó
²óó²óóó²óóó ó²óóóóóó ò²óóóóóóóó óó²
óóóóó ò²óóóóóóó ²íóóí²²ò ²ó ó²óóóóó
²óóóóóóóó óóóóóóóóó óóó óóó ó²óóóóóó
óóóóóó óóóóóóó² óó óóó óóóóôóóó ó í óóó
óóóóóóó óóóó ²²²ó²²²²²ò ²ó óóóó óóóó
óóóó óóó²²óóóóóó ó²²²óóò²óóóóóóóóó
óóóóóóóó óó óó²óóóóóó óóóóóó²ó² óó óó
óóó²óóóóó óó óóó óóóóóóó óóóó óóó²óóó
óóóóó ²²² ó²²óóóóóóóóóóóó óóóóó²óó
óóóóó²óóóóó óó²óóóóó óóóóóóóó óóó²óóó
óóóóó óó óóóóóóóóó²óóóó²óóó óó²óóóóó
óóóóóóóóóòóóóóó ²í²óíç²ò óóóóóóó ó²ó
óóóóóóóóó óóó óóó ²óóóóóóóóóó óóóóóóó
ó²óóóóó ²²²²² óóóóóó óó² ²²² óóóóó
óóó óó óóó ó²óóóóóó² óóóóóóóó ó²óóóóóó
óó² óóóóó ó²óóóó óóó óóóó ó²óóóóóóò
²²ó óó²²ó óó² óó²óóóóóóóóò ¼ó óóó
óóóó óóóóóóóóóòó óóó²ó óóó ²óóóó²óóó
²óóóóóóó² óóóóó² ó²ó óó²óóóóó óó²
ó²ó²óó óó²²óóó óóó óóó²ó² óó ²ó²óóó
óóóó² óóó óóóóóóóóó óóóóóóó óóóóóóóó
óóóóôó²óó óó²óóóóó óó²óóóóóóóóó óó²
²óóóóóóó² óó²óóóóóóóó óóóóóóóóò ²²ó
ó²óóóóóóóóó óó óóó óó²ó ó í óóóóó
óóóó²óóóóóóóó óóóóó óóóóóóóó óóóóóó² óó
²²² óó² óóóóóó ²ó óóó óóó²ó ó²óóóóó
ó²óóóóóóóóóóóóò ²óóó²óó óóóóóóóóó óóóó
óóóó óóóóó óó óóóóóóóóóóóó óó²óóóóóóó
óóôó óóóóóóóóóó óó óóóóó ó²óóóóó óó óóóóó
ó²óóóó²óóóó óóó²ó² óó óóóóóó²ó² óó
óóóóó óóó óóóóó óóó óóóóó óó ²óóóóóóóó
²óóóóóóóò
óóóóóóó óó²óóóóóóó óó ó²ó óó óóóó
óóóóóóóó óóó óóó óóóó óóòóóóó² ²óóó óó
²²²ó²²²²²ò ²²ó ²²²ó²²²²²ó ²óó
²óóóóóó óóóóóó ²óóóóóóóó ²óóóôó óó
óóó óóóóó²óóóó²óóóóóóóó óóóóó² ²ó²ó
óóóóó óóóóó² ²ó óó óóòóóó óóóó ²óóóó óó
óó²²óó ó ó²óóóóóóó óóóóóó óóóóóó óó ó²ó
²óóóò ó²óóóóóóóó óó óóó óóóóóó óó ó²ó
óóóóó óóóóó óóóó²óóóôóóóóóó óóóóóóó
óóóó óó ó²óóóóó ²ó²óóóóóóóóóò çóóóóó
óóóóóóóó óóóó óó²óóóóóóó óóóôóóó² ó²ó
óóóóó²óóóóó óóóó²óó óó óóó óóó óóó
óóó²ó² óó ó²óóóóó ó²ó óóóóóóóóó óóó
óóóóóóóó ²óó óó² óóóó²óó ²óóó óóóóóó
óóóóóó óóó²²²óóóóóó ²²² óóóóóóóóó ²óó
óóó óó²²óó óó²óóóóóóó óóóóóóóó óóó
óóóóóò
²ó óóóóó²óóóóó óó ²óóóó²óóó ó²óóóóó
óó óóóóóó²ó² óóóó óóóó ²óóóó óó ²óóóó
óóóóóó óóóóóóó óóóóóóóó óóóóóóó ²²óó óó
óóóóó²óóó² óóóó óóó óó óóóóóó ²óóóóó
óóóó óóóóóóó ²óóóóóóóó óóóóó óó² ²óó
óóóó óóóó²²ó óóóó óó óóóó ó²óóóóóó óó²
óó²óóóóóóóó óóóóóóóóò
ææææææææææææææææ ¼ó óóóóô ²óóóóó ²óóóóóó
óó² ²óóóóó ó²ó óóó óóóóóó²óóó óóóó ó²óóóó²óóóó
óó² óóóóóóóóóó ó²²²óóóóóóóóóó²óóóóó ²óóóò óóó
¬¼²æææ ë
æ­¹®¹­ ææ
ÜÜÜÜÜÜÜ ÷­÷ Ü ç ÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÍÜÜÜÜÜ
ÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÍÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜ½ï
ÜÜÜÜÜÜÍÍÜÜÜÍ ÷­÷ Ü ç ÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÍ
ÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜçïòÜÜ½ïÜÜÜÜÜÜÍÍÜ ÷§÷ÜÜÜÜÜÜÜÜÜÜÜÜ¼
ÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÍÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜÜçï
ÜÜÜÜÜÜÍÍÜ ÷­÷ÜÜÜÜÜÍÜ ÜÜÜÜÜÜÜÜ Ü ç ÜÜÜÜÜÜÜÜÜÜ¼¼
ÜÜÜÜÜÜÍÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÍÜ Ü ç ÜÜÜÜÜÜÜÜÜ¼ÜÜÜÜ¼
ÜÜÜÜÜÜ´¼¼Ü¼ÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÍ ÜÜ ÜÜÜÜÜÜÜÜ
ÜÜÜ ÜÜÜÜÜÜ»ÜÍÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜ­ÜÜÍ§
ÍÜÜÜÜÜÜÜÜÜÜÜÜÜ»ÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÍÜÜÜÜÜ Ü ç ÜÜÜÜÜÜÜÜÜÜ
÷­÷ÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜ½ÜÜÜÜÜÜÜÜÜÜÜÜÜÍ
ÜÜÜÜÜÜÜÜÜÜÜ ÜÜÜÜ ÜÜÍ½ ÜÜÍÜÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜÜ¼¼Ü¼´ÍÜ´ ÜÜÜÜÍ
ÜÜ ÜÜÜ ÜÜÜÜÜÜÜÜÜÜÜÜ½ÜÜÜÜÜÜ½Ü®ÜÜ ½ç ÜÜ ½ Ü´ÜÜÜÜÜÜÜÜÜ¼
çççÜ½
æææææææ±å ææ±æææææ ÜÜÜÜÜÜ ÜÜ ´ÜÜÜÜÜÍ ´ÍÜ´´Ü ÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜ ÜÜ
îî® ¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹ ææææææææææ çÜÜÜÜÜ çççç ÜÜÜÜÜÜ ççÜÜÜÜÜÜÜÜ çççç
óóóóó ¬óóóó²óóóóó²óóó ²ó²ó óó óóôóóóóó²óó² óóó
óóóóóó²óóó óóó óóóóóóóóóóó óóóóóóóóò
ææ²æææ¼æææ
óò ²óóôóóó ²óó óóóóóóó ²óó ¬óòó²ó ²²ó
çóóóó ²²ó ²ó²óóóóôó ²²ó ²ó ¬óò ²óóóóóóóó
óó ó²²óó óóóóóóóóóóóó óó óóóó óó ó íóóóóó
óóóó² ²óóóóóóó óóóóóóóóó ó²óóóóóò çóó
²ó² óçç²åôæó÷í²ó÷óò
÷ò óó²²óóó ¬ó ²óóóóóóóóóó ²²ó ²óóó²ó ²ó
¬óô ²ïò ²²²óóóóó² óóóóóóóóóó óóó óóóóóóóóó
²óóóóóóó óó óóóóóóó²óóóó óó² ó²óóóóó óóóóóó
óó óóó ó²²ó²ó óóóó²óóó²óóò ²ó²ó ²óóóóó ²óó
²óó ÷ççóå²æí²ó²ôç÷ò
íò óóó ¼ó ¼² »ó óóóó ¬ó óóó ²ó óóóó ²óó
óóóó óò ²ó óóóóó óó² óó óóóó óóóóóóóóóóòóó
óóóó óó óôó²óóóóóóó² óóóóóóóó ó ó²²óóóòó²
²óóóóóóóóó óóóóóó²ó óóóóóóó óóóóóóóó ó íò
óóóóóó ²óó ÷ççóåóóæçó²í²çó²óò
ôò óóó ¼ó ²óóó ²¼ó óóóó ¬ó óó óóò ²óóóó²óó
óóóóóó² óóóóóóóóóóóó² æ²óóó²² ²óóó óóó ó²ó
óóóóó ó²²óó óóóó²óóó²óó óó óóóóóó ó²óòóóóóò
çóóó ²óóó ÷ççóåóæóóç²ó²óò
óò ²óóóó óó ï²óóó² ²ó ¼óóóóó óóó óó óóò ²óóó
óóóó óóóóóóóóó óó ó²²óó óóóóóóóóóóóó óó
²²²óóóóò²óóóó² ²óóóóó²óóó ó²óóóóóóó²óóó
óóóóó óóóó ó²ó²ó óóóóóóóóó ²óóóó ó óóóóóóóó
óòóóó ²óóóóóóó óóóóóóóóó óóóóóóóò óóóóóó
²óó ÷çç²åó²æóóóó²óóó÷ò
óò óóóóóó ó²ó ²óóóó ²²ó ²óóó ïóó óó óóò ó
óóóóó²ó²ó²óóóó óóóóóóóóóó óó óóó óóóóóóóó
ó í óóóóóóóó ²óó²óó óóóó ó²²óó óóóóóó óó²
óóó ²óóóóóó²óóó óó óóóóóóóóóó²óó óó ²óóóóó
óóóóóò óóóóóó ²óó óçç²åó²æóçíç²óçíóò
²ò ¬óóó ï²ó ¼ó²óóó ²²ó ²ó²óó ²óó óó óóò çóóóó
ó²óóó ²óóóó²óó ó óóóóóóóó óóóóóóóóóóóæ óó²ó
óóóóóóóó óóóóóóóóóóó óóóóóóó óóóó ôóóóó óóó
óóóóóóóóóó óóóóóóóóóóò óóóóóóóóóó ²óó óçççå
óçæçóç²çó²ò
²ò ¬óóóóó ²²ó ²óóóóó ¼óó ¬óóó óó óó óóò
²óóóóóóóó óó óóóóóó óóóóóóóó²ó óóóóóóóóóóó
óóóóóóóó ² ó í² óóóóóóóóóóóò ï ²ó² óóó²
óçç²åôçæ÷÷²ç²÷÷ç÷ò
çò ²óóóóó ²óó ²óóóóóó ²ó óóóóô ïó óó óóò ²óóóóó
óóóóóóóóóóóóó óó óóóóó²óó óó² óóóóóó²óóóóóó
óóóó² ²óóóóó²óóóó óóóóóóóó óóóóóó óóó ²óó
óóó²óóó ó²óóóóó óó ó íóó²óóóóóóóó óóóóóò
²óó ²²óóóóó ÷ççôåíæó÷ó²óíôò
óçò ²óó²óóóôó ²ó ó²óóóóó ïó ¬óóóóóóóó ¼ó óó óóò
²óóóó²óóó óóóóóóóó óó óóóóóóóóóóóó óóóó
óóóóóóó² ²óóóóóó²ó² ó²óóóóóæ óóóóó óóóóóóó
²óóó óó óóóóóóóóóóóóóó óóóóóóó óóóóóóóò ²óó
óóóóóó óóóó ÷çç²å²æóçó²óççò
óóò óó² ó²ó óó² ²óó óóóóóóóó² óó óó óóò ²ó óóóó
óóóóóóóóóóóó² ò²óóóóóóóóó ó²óóóóó óó óóóóó
óóóó ó í óó óó óóóóóóóóóó óóóóóóóóóó²ó
²ó²óóò ²óó ²²óóóóó ²óóó ÷ççóå²æíóó²í÷íò
ó÷ò ¼óóóóó ²²ó óóó²óóóóó ²²ó ¬óóóóóó óó
óó óóò ²óóóó²óóó ó²óóóóó óó óóóóóóóóóóóó óó
óóóóóóó ó²ó÷ óóóóóó ó²²óóó ²óóóó ó óóóóó
íóóóóóóóó² óóóóóóóóóóóó óó² óòó óóóóó
²óóóóóóó óóóóóóóóó ó²óóóóóò óóóóóó ²óó
÷ççíåóíæó²í²²ó²ôíò
óíò óó²óóóó ²ó ¼óóóó ¼óó ²óóó óïó óó óóò
çóóóóóóóóóó óóó²óóóòóóóóó óó óóó óóóóóóóó²
ó í óóóóóóóó óó óóóóóó óóóóóóóó óó óóóóóóóó
ó²óóóóóó óó²óóóóóóó óó² ôó²¼ô²óóóóóóó
²²²ò ²²ó² ²ó² ÷ççóå÷æó²çò
óôò óóóó óó óó² »ó óóó²ó ²ó óó óóò ²óóóóóóó²
óóóó²óóóóóó óóóóó²óæ óôó² óóóóóóóó óó²
²óó ó²óóóóó óó óóóóó ó²²óó ó íóóóóóóóóó
ó²óóóóóóóóò ï ç²óó ²ó² ÷ççôåôóæó²²ó²
ó²²íò
óóò ïóó ²ó ²óó ïó »óóó ²ó óó óóò çç²óóóóóóóóó²
óóóóóó ²²²ó¬ ²ó²²óóæ óóóóóóó óóóó²óóóóó óóó
²²óóó ó²óóóóó óó óóóó²ó óóóóóóóó ó í ó²ó
óóóóóóóóò ²óóóóóò²ó óóó² ÷ççóåó²æóçóç²
óç²óò
óóò ²ó ²²ó ¼² ²ó óóóó ¬ó óóóó ¼óó óóóó óò
óóóóô óóó²óóóóó óóó ²ó²²¼óóóóóóóóó óó ²²²
óóóóó²óó óó² ²óóóó²óó ó²óóóóó óó ó²²óó
óóóóóóóó ó í ó²óóóóóóóóò ²óóóóóò²ó óóó²
÷çç²åó²æóç²²²óççôò
ó²ò óó²óó ²ó ²óóó²óóóó óó ²óóóóóóó ²¼ó
ó²óóóóóóó çò ó í óó² óóóóóóóóóóó ó²óóóóó
óóóó óó óóó²óó óóóóóóó ó²óóóóó óóóóóóóóóó
óóóóóæ óóóó óó óóóó ó²óóóóóó óó² óóóó óóóóóóóóóó
óóóóò ²óóóóóó ²óóóó óçççå²óæ÷óô²÷óçò
ó²ò ²óòôóóóóó ²ó ¬ó²óòóòóó ïóó ¼óóóóóóô óó óó óóò
ó í óóóóóóóóóóóóóóóóóó óó óóóóóóóóóóóóóóóóó
óóóóóóó ó²²óóó óóóó ó óó²óóóóóóóó² ²²²
óóóóó²óò ²óó ï óóóóóó ÷çç²åó÷çæóçó²óóçò
óçò óóóóóó ²ó ²óóóó²óò ïóó ²²ó² ²ò ó í óóóóó
óóóó óóó²óóóóó óóóóó²óóó ²ó²²²óóó²²óó² óóóó
óóóóóóóóóóóóó óó² ó²óóóóóó óó óóóóóó óóóóóóò
²óóóóóóó ÷ççóå÷ôæí²óç²í²²íò
÷çò ó²óóóóóóó ²ó óóó ²óó ²ó²ó ²ó ²óóóóóóó² ²ó
²óóóóó óó ²óóóóóóóóó óó ²óóóó óóò ²óóóó
óóóó ó í óóóóóóóó óóóóóóóó óó² óóóóóóóóó
óóóóóóóóó óó óóó²ó² óó²óóò óóóóóó ²óó
÷çç²åó²æ÷óçí²÷²ççò
÷óò ²óóó óïó ²óóó² ó²ó óóóóóóó ïó óó óóò
ôó²¼ôóóóóóóóó²²² óóóóóóóó ó²óóóóóó óóó
²óóóóóóó óóó ó²óóóóó óó ó í ó²óóóóóóóó
óó óóó óóóóóóó²óóó²óó óó óóóóóóóó óóóó
óæ²ó²ó²ó óóóó óóóóóóó²ó óó óóó óóó² óó²
óóóôò óóóó óóóóóó ²óó ÷çç²åóíæóóóç²
óóóóò
÷÷ò ²ó ïó óóó óó ²óóó óó óó óóò óóóóóóóóó óóóóó
óóóó ó í óóóó óóóóóóó ó²óóóóóóóó ó²óó²óóó
óóó²óóó ó²óóóóóó² óóóóóóóóóóó²óóó óóóóóóóó
²óóò ²óó ²óóóó ²óó ÷çç²åíçæóó²²óóóò
÷íò ¬óóóóóóóó ¼ó ²óóóóóóóóóó ²ó ²óóóó óò óóóó
óóóóó óóóóó óó² óóóóóóóóóóóó óó óóóóóó ó²²óó
óóóóóóóóóóóó óó óóóó óó ²óóóóóóó óóóóóóóóó
ó²óóóóóò ó²óó ²ó² óóó² ÷çç²åóôæ²²²çóò
÷ôò ²²ó²óó ¼ïó ²óóóòôóóó ²ïó óóóóóó ï¼ó óó óóò
²² ó²óóóóó óó² ò²óóóóóóóóó ²óóóóóóóóó
óóó ó²óóóóóóóóóóó óó óóóóóóóó² ó²²óó óó²óó
óóóóó²² ²óóóó ó óó²ó²óó óóóó²óó óóóóóóóó
óóóóóóò ¼ó²ó² ï ÷ççóåóçæ÷çç²²÷çóçò
÷óò óóó ïó óóóó ¬ó ²óó ó»ó óó óóò ²óóóóó²óóó
ó²²²²ó¬²óóóóóó² ¼óí²ô óóóóóóóóóóóóó óó²
óóóóó óóóóóóó óóóóóóóóó óó óóóóóóóó ó íóóóóó
ó²²óó óóóóóò ï ó² óóó² ²óó ÷çç²åóíçæ
²óô÷²²óôíò
÷óò ¼óóóóóó ²ó ¼óóóóóó óò ²óóóó²ó ²²²² óóó
óóóóóó óóó óóóóóóóóóóóóóóóóóó² óóóóóóóóóó
óóó óó óóóóó óóóóó óó óóóóóóóó ²óóóóóóóóó óóó
²óóóóóó óó óóóóóò ï ²óóóóóóóó ²óóóóó óççóå
ó²æóçç²÷ççò
÷²ò ²óóóóó² ó²ó ó²ó²ó ²²ó ²óóóó óïò ²óóóó²
óóó²óóó óóóóóóóóóó óó óóó óó²ôóóóóó óóó
óóóóóó óóóóóóóó ó²óóóóóó² óó ó²²óó óó²ó
óóóóóóóóò ï ²óóó óóó² óçç÷å÷ó²æóí²çó²
óíçç÷ò
÷²ò óóóóóóóòóó ²ó ²óóó²²²óó óó ²óóóó²óó²óóóó ïó
²óóóóóóóó ²»ò ó²²óó ²óóóóóóóó óóóó²ó
óóóóóóó ²óóóó óóóóó ó í óóóóóóóó óóóóóóò
ï çó²óóóóóóó ÷çççåôóæóíó²óôôò
÷çò ²²ó ¼ó ²óóóóóóóó ¼²ò ²óóóóóóó óóóóóóóóóó
²²óóóó ó²²óó óóóóóóóóóóóò çóó ²óó ²óó óóóó
²óóó ÷ççôåóæ²óó²²÷óò
íçò ²óóóó ²óó ²²óóó óó óóó óóó²óó ²¼ó óóóóóó
²óó ²²óóó ²¼ò óóóóóóóóó óó²²óó² óó óóóóó
óóóóóó óó óóóóóóóóó²óóó óóóóóóóò ï óóóó ²óóó
óççôåó÷óæôçí²ôóóò
íóò óó²óóóóóóóóóóóóó óó óóóó ²²ó óó² ²óó
óó óóò óó²óóóóóóóó óóóóóóóóó óó²²óó² óó óóóóó
óóóóóó óó óóóóóóóóó ó í óó² ó ó óóóóóóóó
óóóó²ó²ó ²óóóóóóóó óóóóóóóóò ²óóó² ÷ççóå
óçóæôíóí²ôíóóò
í÷ò óóó²óóóô² ¬ó óóôóóó ² ïóó ²óóóóó ²ó ¼óóóó
¼ó óóó ²óó ¼ò ²óóóóóó ²óóóó²óóóóóó óó óó
óó²óóóóó ó²óóóóóóóó óó óóóóóóóóóó ó²²óó
óóóóó óóóóóóó óó óóóóóóóó ó²óóóóóóóó óóóóò
óóóó óççóåóóæóç²²óóçò
ííò ²óóó ó¬ó ¼óóóóóó²ó ²ó ²óóó ²ó ²ó²ó óó
óóóóóóóóóóó ²ò ó óó²óóó óóóó óóó óóóó²óóóóó
óó óóó óóóóóóóóóó óóó² ó²óóó²ó óó óóóóóó
óó²óò çóó²óó óçç²åíç÷æóçç²óçíò
íôò ²òóóóóó² ²²ó çóóóóó ¼ïò ²óóóóóóóó²ó²óó
óóó² óóóóó²² óóóóóóóóó óó² óóó²óóóóóó óó óóóó
ó²óóóóóó óó óóóóóóóóó²óóó óóóóó²²ò ²óóóóó
óóóó óçç²åóçæô²²óóò
íóò ²óóóóóóò ²óó ²óóóóóóóóóó ¬ò ó óóóóóóóóó
²ó²óóóó óóó óóóó óó óóóóóóóóó²óóó óóóóó²² óó
óó²óóóóóóóó óóóóó óó óóóóóóóóóó óóóó óóó²óó
óóóó óóóó ó ²óóóó óóóó óó ó²óóóóóóò ï ²óóó
óóó² óççôå÷óçæóóóíí²óóóí²ò
íóò ²óóóóóóóóó²óó »²ó ²óóó ²ó ²óóò ²ó óóóóó
²ó² ²óó ²óóó²óóóóó ²ó çóó²óó ²ò ²óóó²óó
óóóóóó óóó²²óóóóóó óó ²²² ó²²óó óóóóóóóóóó
óóóóóóó óóóóóóó²ó óóóóó ó²ó²óóóó óóóó ó²óóó
óóóó ²ó²óóóó² óó ó²ôô óó² óó óóóóóóóóóóò
²óóóóóó ²óóóó ÷çç÷å²ôæ÷çó²íç÷ò
í²ò ²óóóóó ²ó ó²²ó²ó »ó ¬óóóóóóôó óó óóó²óóóó
óó ¬²óòó²óó²óóóóó ²óó çóó²óó ²ò ²ó óóóó
ó²óóóóó óó óóó óóóóó²óó óóóó²óó²óóó óó óó
óóóóóóóóó óó óóó óóóóóóóóóó óó² óó óóóóóóó
óóóóóóó²ó ó²²óóóò óóóóóó ²óó ÷çç²åó²æ
çó²ç²çó²çò
í²ò ²óóóóó ²²ó ¼óóóó ¼²ó ²óóó ï²ò ²óó²óóóóóó
óó óó²óóóóóóóóó ó²óóóóó óóóóóóóóóóóóóó óó²
óóóóóóóóóó óó óóóóóóóóó óóóóóó óóóóóó óóóóóó
óóó ó óó óóóó²óóóóóò ²óó ²óóó óóóó ÷ççóåóóæ
óô²÷íò
íçò ²óóòóó ¼ó óóóóóó ²ó ²óóóóó ²ó óó óóò óóóó²ó
óóóóó óó²óóóóóóóó óóó²óóóóó óóó óóóóóóóó óó
²óóóæ ó óóóóóó óóóóó ²ó²óóó óó óóó óóóóóó
óóó²ó óóóóóóó óó²óóóóó óó² óóóóóóóó ó²óóó
óóóóò ï óóóó ²óó ÷ççóåóó²æô²óó²ôô²²ò
æææææææ±å ææ±æææææ ÜÜÜÜÜÜ ÜÜ ´ÜÜÜÜÜÍ ´ÍÜ´´Ü ÜÜ ÜÜÜÜÜ ÜÜÜÜÜÜÜÜÜ ÜÜ ÜÜ
ææææææææææ çÜÜÜÜÜ çççç ÜÜÜÜÜÜ ççÜÜÜÜÜÜÜÜ çççç ¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹¹ îîç
  
1 
Fluorescent magnetoliposomes as a platform technology for functional and molecular MR 
and optical imaging 
 
Michael Hodenius
a,f,*
, Christian Würth
b,*
, Jabadurai Jayapaul
a
, John Wong
d
, Twan Lammers
a
, Jessica Gätjens
a
, 
Susanne Arns
a
, Natascha Mertens
a
, Ioana Slabu
e
, Gergana Ivanova
e
, Jörg Bornemann
g
, Marcel De Cuyper
c,f
, Ute 
Resch-Genger
b,**
, Fabian Kiessling
a,**
 
 
a Chair of Experimental Molecular Imaging, University of Aachen (RWTH), Aachen, Germany;  
b Federal Institute for Materials Research and Testing, Berlin, Germany; 
c Interdisciplinary Research Centre, K.U.Leuven-Campus Kortrijk, Kortrijk, Belgium; 
d Chemical Process Engineering, University of Aachen (RWTH), Aachen, Germany; 
e Applied Medical Engineering, Helmholtz-Institute, University of Aachen (RWTH), Germany;    
f IMIR (In vivo Molecular Imaging Research group K.U.Leuven); 
g Elektronenmikroskopische Einrichtung  (EME), University of Aachen (RWTH), Aachen,  
* Michael Hodenius and Christian Würth contributed equally to this manuscript.  
** Corresponding authors: F. Kiessling, Chair of Experimental Molecular Imaging,  
University of Aachen (RWTH), Pauwelsstrasse 20, 52074 Aachen, Germany. (Tel): +49-241-8080116; (fax): +49 241 
803380116; E-mail: fkiessling@ukaachen.de; U. Resch-Genger, Federal Institute for Materials Research and Testing, Richard-
Willstätter-Straße 11, 12489 Berlin, Germany. (Tel): +49-30-8104-1134; (fax): +49-30-8104-1157; E-mail: Ute.Resch@bam.de.  
 
 
1. INTRODUCTION 
Numerous imaging modalities like magnetic resonance imaging (MRI), positron emission tomography (PET), 
computed X-ray tomography (CT), and optical imaging (OI) and their combinations such as PET-CT, PET-MRI and 
SPECT-CT have been developed to optimize the visualisation of pathologic conditions (1). For instance, in 
combining MRI and OI, a high spatial resolution, excellent soft tissue contrast and high anatomical detail provided 
by MRI can be combined with the high sensitivity of fluorescence imaging.  
Frequently used MRI probes, such as the FDA approved Endorem and Resovist are superparamagnetic iron oxide 
nanoparticles (SPIO), which are routinely employed for the detection of malignant liver lesions (2). Ultrasmall SPIO 
(USPIO) with hydrodynamic diameters (Dh values) below 40 nm have an enhanced blood circulation time and are 
able to extravasate, which was proven to be promising for lymph node and bone marrow imaging (3,4). The 
comparatively few studies pursuing specific (U)SPIO accumulation in other malignant tumor tissues, include mainly 
dextran-coated USPIO, conjugated to e.g. human transferrin or tumor-specific monoclonal antibodies (5,6). 
However, dextran can desorb from the iron oxide surface, and may elicit allergic reactions (7,8).  
Biocompatible magnetoliposomes (ML) are very attractive alternatives, which are built up of magnetite nanocores 
coated with a phospholipid bilayer. The inner layer phospholipids are tightly bound to the iron oxide surface by 
strong chemisorption forces (9), whereas the outer layer can be easily doped with fluorescent molecules and probes, 
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functionalised lipids, and differently charged amphiphiles enabling e.g. a finetuning of optical properties and the 
surface charge (10,11). 
Although there is an increasing interest in fluorescent and magnetic materials, a systematic assessment of the 
influence of magnetic species like iron oxide on dye photophysics is rare. For example, a reduction in dye emission 
is been often reported for fluorescent magnetic particles for cell labelling and small animal imaging, yet not 
quantified (12-14).This motivated us to characterise the physicochemical of fluorescent ML containing dimyristoyl-
sn-glycero-3-phosphoethanol-amine-N-(lissamine rhodamine B) (DMPE-L-R) in detail using steady state and time 
resolved fluorometry. In particular, the influence of the presence of superparamagnetic iron oxide cores, the number 
of DMPE-L-R molecules per particle, and the overall particle (DMPE-L-R) concentration, on the fluorescence 
properties of these materials were studied. Finally, the cytotoxicity and intracellular uptake of these new imaging 
reagents were investigated using human prostate cancer (PC-3) cells. The overall goal was here to underline the high 
potential of fluorescent ML as bimodal contrast agents for functional and molecular MR and optical imaging and to 
address the need for a better characterisation of the signal-relevant physico-chemical properties of such 
nanomaterials for future probe design and applications. 
 
 
2. RESULTS AND DISCUSSION         
2.1. Characterisation of classical and fluorescent ML and SUV   
2.1.1. Core diameter, chemical composition, and Dh- and zeta values  
Statistical analysis of the magnetite core diameter distribution by number as determined from transmission electron 
microscopy (TEM) images revealed average diameters of 9.9±3.2 nm, 9.7±3.1 nm, and 9.2±3.2 nm for the ML 
without DMPE-L-R (C-ML), and the fluorescent ML containing a low and a high molar DMPE-L-R fraction (FLU-
ML 1 and 2, respectively). These values are very similar to the average core diameter of 9.4±2.8 nm for laurate (LA) 
coated magnetite particles acting here as the magnetic precursor cores for ML production (15).With FLU-ML 2, for 
instance, 76 % of the core diameters are between 6 and 12 nm (see SI). The almost uniform values for the 
phospholipid to Fe3O4 ratio ([PL]/Fe3O4 ratio) of the ML in the order of 0.39 - 0.47 M/kg, testify that in C-ML and 
both fluorescent ML the lipid content of the coating is not affected by including DMPE-L-R in the lipidic envelope. 
The hydrodynamic diameters (Dh values) measured for the final ML preparations were between 91.5 and 100.1 nm. 
Accordingly, the overall diameter of our fluorescent magnetoliposomes is about tenfold bigger than the single 
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magnetite core diameter and three- to fourfold bigger than the Dh values of the corresponding small unilamellar 
vesicles (SUV) (25.5 - 33.5 nm). The size of the Dh values suggest that the ML colloids exist as clusters of particles. 
Thus, the kinetic barrier for particle growth is apparently reached at Dh values of 90 - 100 nm (15). Although the 
various ML types are less negatively charged (zeta potential (ζ) values of -22.8 mV to -36.0 mV) compared to the 
LA-coated magnetite particles (ζ value: -47.3±1.4), the colloidal stability of the starting magnetic fluid is not 
hampered by substituting the LA molecules by phospholipids.   
Concerning the chemical composition of the ML coat, it is remarkable that the molar DMPE-L-R fractions of 0.67 % 
and 1.97 % in FLU-ML 1 and 2, respectively, exceed that of the corresponding starting SUV (FLU-SUV 1: 0.31 % 
DMPE-L-R and FLU-SUV 2: 0.84 % DMPE-L-R) by a factor of about 2. This observation can be rationalised 
considering the difference in membrane curvature of the SUV (Dh = 25.5 - 33.5 nm) and that of the ML (Dh = 91.5 - 
100.1 nm). In the case of differently sized liposomes, it is well known from the literature that lipid packing shows 
less defects in structures with a bigger radius as compared to liposomes with a small radius as in the case of SUV. 
Since DMPE-L-R contains two negative charges at the pH conditions used, it will be very prone to escape from the 
vesicles and, at equilibrium, it will preferentially reside in the larger ML. Also the idea of a stronger anchoring of 
lipophilic molecules, e.g. the cationic 1,2-distearyl-3-trimethylammonium propane in ML complexes as compared to 
liposomes was put forward by Soenen et al. (16). Similarly, Zhang et al. found a slower, more sustained release of 
the lipophilic anticancer agent paclitaxel from intraveneously applied ML compared to conventional liposomes in 
grafted tumors of BALB/C mice (17).  
 
2.1.2. Fluorescence intensities of DMPE-L-R containing SUV and ML  
The fluorescence spectra of SUV doped with DMPE-L-R show that the resulting emission intensities (rel. FIem.) are 
proportional to particle concentration (see also SI, inset Figure S2A and S2B). Concentration-normalised emission 
intensities (FIem.660, normalisation at an emission wavelength of 660 nm) were calculated and plotted vs. the DMPE-
L-R concentration (Figure 1A and B). As follows from Figure 1A, for FLU-SUV 1 and 2, the FIem.660 values 
decreased linearly by approximately 20 % with increasing DMPE-L-R concentration from 15 to 4500×10
-9
 M.  
The corresponding emission spectra normalised at 626 nm at the vibronic shoulder do not reveal a red shift of the 
spectral position of the emission maximum and the blue wing of the emission band which are characteristic for inner 
filter effects. This is exemplary shown for FLU-SUV 2 in Figure 1C. The 20 to 26 % decrease of the FIem.660 for 
FLU-SUV 2 compared to FLU-SUV 1 (Figure 1A) can be ascribed to the higher molar DMPE-L-R fraction of the 
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FLU-SUV 2 that increases the probability for the formation of non or barely fluorescent aggregates or other traps 
acting as energy sinks. The latter can involve fluorescence resonance energy transfer (FRET) from fluorescent 
monomers to non or only slightly emissive aggregates or FRET between chemically identical, yet spectroscopically 
different species differing in fluorescence quantum yield (18-20). 
Also the fluorescent magnetoliposomes FLU-ML 1 and 2 (molar DMPE-L-R fractions of 0.67 and 1.97 %, 
respectively) revealed substantial fluorescence intensities at 15×10
-9
 M and higher DMPE-L-R concentrations (S2C 
and S2D in the SI). At low ML concentrations, the spectral shape of their FIem.660 spectra match that of their 
magnetite-free counterparts (Figure 1D and SI (Figure S3)). However, the resulting FIem.660 were much lower than 
those observed for the corresponding SUV within the whole DMPE-L-R concentration range studied (Figure 1A and 
B). Moreover, the drop of the FIem.660 signal observed for FLU-ML 2 reached 63 % compared to only 20 % for FLU-
SUV 2 upon increasing the DMPE-L-R concentration from 15 to 4500×10
-9
 M. These effects are attributed to the 
strong absorption of both excitation and emitted light by the magnetite core (inner filter effects). Also fluorescence 
quenching e.g. due to the heavy atom effect and superparamagnetism of iron oxide may contribute to the reduction in 
the measured emission intensities (21-23).  
 
2.1.3. Absolute fluorescence quantum yields (Φf) and fluorescence decay behaviour  
For a better understanding of the operative fluorescence quenching pathways, the Φf and the fluorescence decay 
behaviour of FLU-SUV were investigated for a DMPE-L-R content ranging from 0.31 to 4.81 mol %. For the 
measurements of f with the integrating sphere, re-absorption of emitted light due to the considerable spectral 
overlap of the absorption and emission band of FLU-SUV (see Figure 1C) was considered as previously described 
(24). For the extensively studied FLU-SUV 1 and 2 (DMPE-L-R fraction of 0.31 % and 0.84 %), the Φf were 
determined to 0.55±0.01 and 0.47±0.02, respectively. As shown in Figure 2 (right panel), the fluorescence quantum 
yield and the mean fluorescence lifetime τint are diminished with increasing DMPE-L-R concentration. This is 
consistent with earlier discussed FRET models in membranes (25,26). 
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Figure 1.  FIem.660 as function of the particle (DMPE-L-R) concentration for both fluorescent SUV (A) and ML types (B). 
Normalised absorption spectrum (574 nm) and normalised uncorrected fluorescence spectra (626 nm) for varying DMPE-L-R 
concentrations for FLU-SUV 2 (C) and FLU-ML 2 (D). Excitation was at λ = 532 nm.  
 
The straighforward determination of the Φf of FLU-ML was hampered by i) the strong absorption of the iron oxide 
nanoparticles at the excitation wavelength of 535 nm and ii) within the emission wavelength region of DMPE-L-R 
(ca. 550 nm to 750 nm) as well as by iii) self-absorption of the emitted photons by the fluorophore itself. The 
absorption of the iron core at the excitation wavelength was considered (see SI), whereas both the absorption of 
emitted photons by the magnetite core and DMPE-L-R-related re-absorption effects were neglected. Based on these 
assumptions, the Φf of FLU-ML 1 and 2 were determined to be 0.16±0.04 and 0.13±0.06, respectively. These values 
present lower limits of the actual fluorescence quantum yields of these materials.  
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Figure 2.  left panel: Fluorescence decay kinetics of FLU-SUV 1 and 2 and FLU-ML 1 and 2 in bi-distilled water and instrument 
response function (gray): right panel: Φf  () and mean fluorescence lifetime τint () as function of molar DMPE-L-R fraction in 
FLU-SUV. 
 
 
The considerably high measurement uncertainties found for FLU-ML 1 and 2 compared to those of the FLU-SUVs 
originate from the relatively high absorbance of the magnetite core at the excitation wavelength, compared to the 
absorbance of the fluorophore (see SI). The fluorescence decay kinetics of FLU-SUV 1 and 2 and FLU-ML 1 and 2 
in bi-distilled water are summarised in Table 1 and Figure 2 (left panel). In all cases, double or tri-exponential decay 
kinetics are observed that display a clear influence of the DMPE-L-R content and the presence of superparamagnetic 
iron oxide nanoparticles on both the size and amplitude of the different decay components. Significantly, only the 
FLU-ML reveal a short-lived decay component with a lifetime τ3 of 0.12 ns to 0.14 ns that is absent for the FLU-
SUV. 
Contrary, for FLU-ML 2 containing the highest molar DMPE-L-R fraction, the long lived decay component with a 
lifetime τ1 of ca. 2.7 ns to 2.9 ns is absent. The influence of the fluorophore fraction and the presence of 
superparamagnetic iron oxide are similarly reflected by the average lifetimes of the samples (Table 1 and Figure 2).  
The fluorescence lifetime τ2 (1.32 ns to 1.78 ns) which is present for all samples lies very close to the fluorescence 
lifetime of 1.3 ns to 1.7 ns reported for rhodamine B dissolved in water (27,28).The lifetime τ1is comparable to the 
fluorescence lifetime of rhodamine B of 2.3 ns to 2.7 ns found in less polar ethanol (27). The most plausible 
explanation for the double exponential decay kinetics of FLU-SUV and the lifetimes τ1 and τ2 found for FLU-ML 1 
seems to be two different surroundings of the rhodamine B molecules. The longer lifetime τ1 is attributed to 
fluorophores in a less polar or more rigid environment that prevents or slows down TICT (twisted intramolecular 
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charge transfer) in rhodamine B (29). The absence of this lifetime in FLU-ML 2 may be ascribed to an enhanced 
FRET compared to FLU-ML 1 due to the higher fluorophore density. 
Table 1. Fluorescence decay kinetics of FLU-SUV 1 and 2 and FLU-ML 1 and 2 in bi-distilled water. i represent the lifetimes 
of the different decay components, A(τithe fractional Intensities, τint the (intensity-weighted) mean lifetime and  ² a parameter to 
judge the quality of the fits (see SI). 
 
sample molar DMPE-L-R 
fraction [%] 
1)  
[%] 
1 
[ns] 
2)  
[%] 
2 
[ns] 
3)  
[%] 
3 
[ns] 
Int  
(eq. 3) ² 
FLU-SUV 1 0.31 83.0 2.89 17.0 1.78 - - 2.74 0.98 
FLU-SUV 2 0.84 71.8 2.69 28.2 1.40 - - 2.33 0.97 
FLU-ML 1 0.67 49.1 2.75 43.4 1.32 7.5 0.119 1.93 1.04 
FLU-ML 2 1.97 - - 88.5 1.48 11.5 0.142 1.33 1.13 
 
The very short lifetimes τ3 of 0.12 ns to 0.14 ns found exclusively for the FLU-ML (Table 1) can be ascribed to 
rhodamine B molecules located in the very close neighbourhood of the fluorescence quenching superparamagnetic 
iron oxide core, i.e., to DMPE-L-R molecules in the phospholipid leaflet directly attached to the magnetite 
nanoparticle surface. Possibly, these strongly quenched rhodamine B molecules act as acceptors and energy sinks for 
other fluorophores residing in the outer phospholipid layer in a distance sufficiently small for FRET. The reduction 
in average τint and Φf parallels the considerable decrease in fluorescence intensity of the FLU-ML compared to the 
FLU-SUV shown in Figure 1.  
 
2.1.4. MR relaxivities. 
 Linear regression (least square method) of the blank-corrected transversal relaxation rates (R2corr. values) as function 
of iron concentration revealed T2 relaxivities (r2 values) of 465±9 s
-1
mM
-1
 and 440±4 s
-1
mM
-1
 for FLU-ML 1 and 2 
as compared to the r2 value of 554±11 s
-1
mM
-1
 found for C-ML (see Figure S5 in the SI). These values exceed the r2 
value of the LA-coated precursor particles (332±15 s
-1
mM
-1
) by a factor of ca. 1.5 and are even about twice as high 
as the r2 value of 233±1 s
-1
mM
-1
 obtained for the commercial SPIO contrast agent Resovist, which is a FDA 
approved MRI contrast agent with a core diameter of 4.2 nm, and a Dh value of 60 nm (R2corr. values not shown in 
Figure S5). Since the ML particles form small clusters (Dh value: 91.5 - 100.1 nm), their extremely high r2 values are 
in agreement with the data reported by Roch et al. (30) which report an increase in T2 relaxation by proton diffusion, 
induced by magnetic field gradients around particle aggregates with enhanced magnetization.  
In contrast to the T2 relaxation, T1 relaxation depends on a fast proton exchange between the bulk water phase with 
slow T1 relaxation, and protons at the surface of magnetic particle aggregates, where T1 relaxation is fast. Since the 
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residence time of protons (τD) is roughly proportional to the square of the particle size, this can explain the observed 
two- to threefold lower r1 values of the ML of 3.590.13 s
-1
mM
-1
 (C-ML), 2.060.03 s-1mM-1 (FLU-ML 1), and 
2.730.27 s-1mM-1 (FLU-ML 2), respectively, compared to Resovist (6.84 s-1mM-1).  
 
2.2. In Vitro Studies on human PC-3 Cells  
2.2.1. Viability of ML-incubated cells  
In order to determine whether C-ML, FLU-ML 1, and FLU-ML 2 and the corresponding SUV show a potential dose- 
and time-dependent cytotoxicity on PC-3 cells, uptake studies with these materials were performed and the cells´ 
plasma membrane integrity and mitochondrial activity were evaluated by the trypan blue and MTT assay. The trypan 
blue assay revealed completely retained viabilities after 3 h incubation with all samples incubated at Fe 
concentrations of 0.03×10
-3
 M, 0.3×10
-3
 M and 3×10
-3
 M (data not shown). Incubation for 24 h reveals a viability 
decrease of 7 to14 % for the highest concentration of the ML (Figure 3A). Since under these conditions, no toxicity 
was noticed with the SUV-based structures (Figure 3B), the observed ML toxicity apparently originates from the 
magnetite cores. Incubation for 24 h with ML concentrations equaling 0.3×10
-3
 M and 3×10
-3
 M Fe, however, 
yielded apparent viabilities above 100 % with the MTT assay. This can be ascribed to a progressive accumulation of 
the magnetite particles in the lysosomes and subsequent formation of reactive oxygen species (ROS) (31,32). ROS 
species have been suggested to alter the cellular redox equilibrium state, and, as a result can enhance the reduction of 
the MTT salt used (16). 
 
2.2.2. Visualisation of internalised ML in labelled PC-3 cells with TEM and fluorescence 
microscopy.  
Detection of internalised fluorescent ML in PC-3 cells was done by TEM. After 3 hours of incubation with FLU-ML 
2 (3×10
-3
 M Fe) and subsequent removal of excess ML, the images point to a moderate ML uptake, with the MLs 
mainly appearing as larger aggregates embedded in the endosomal and lysosomal vesicles as indicated by the arrows 
in Figure 4 (right). 
Internalised fluorescent ML could be also visualised by fluorescence microscopy. PC-3 cells incubated with FLU-
ML 2 and 1 (3×10
-3
 M Fe concentration) for 3 h are shown in Figure 5A and 5B (to localise the cells, the nuclei were 
stained with 4’-6-diamidino-2-phenylindole (DAPI)). Excitation at 557 nm yielded bright red emission from the 
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cytoplasm of the PC-3 cells treated with FLU-ML 2 and a less intense fluorescence with FLU-ML 1 under the same 
conditions. These observations are in line with the above described relative fluorescence intensity measurements of 
the aqueous ML samples, revealing a more than twofold higher fluorescence intensity for FLU-ML 2 compared to 
FLU-ML 1 at virtually the same particle concentration. 
 
 
Figure 3.  Relative viability measured by the trypan blue assay after 24 h incubation of PC-3 cells with 0.03, 0.3 and 3×10-3 M Fe 
concentrations of nonfluorescent and fluorescent ML (A) and the corresponding SUV (B). For the SUV preparations, the [PL] 
was carefully taken to be identical to those encountered in the corresponding ML systems. The viabilities are given relative to that 
of control cells not incubated with ML, but otherwise treated identically. The error bars indicate standard error of the mean (± 
SEM (n = 3)). 
 
 
Figure 4.  TEM images of PC-3 cells incubated with FLU-ML 2 for 3 h. The left TEM image shows an overview of a PC-3 cell 
slice. The right TEM image depicts the enlargement of the lower left part of the cell slice showing both magnetic particles lying 
free in the cytoplasm and clustered within endosomal and lysosomal vesicular structures (indicated by arrows).  
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To rule out unspecific background fluorescence, e.g. originating from proteins or other biomolecules in the 
cytoplasm, control experiments were performed with C-ML (Figure 5C) and cells incubated with ML-free medium 
for 3 h (Figure 5D). These images revealed no purple overlay spots, indicating the absence of ML in the nucleus. 
 
 2.2.3. T2 and T1 relaxation rates of incubated PC-3 cells in 10 % gelatine. 
The traceability of incubated PC-3 cells in phantoms (10 % gelatine; 3.67×10
7
 cells/mL) was controlled with MR 
relaxometry at 3 T after incubation for 3 h with LA-coated magnetite, C-ML or FLU-ML 2. For each particle type, 
the Fe concentrations were 0.03×10
-3 
M, 0.3×10
-3 
M, and 3×10
-3 
M, respectively. PC-3 cells incubated with C-SUV 
or FLU-SUV 2 at the same [PL] as used in the corresponding ML samples or with pure medium served as controls.  
 
Figure 5.  Fluorescence microscopy images of the DMPE-L-R and DAPI fluorescence of PC-3 cells incubated with (A) FLU-ML 
2, (B) FLU-ML 1, and (C) C-ML for 3 h. The Fe concentration was adjusted to 3×10-3 M for all ML. An image of PC-3 cells 
incubated with ML-free medium for 3 h is shown as additional control (D). The nuclei were stained with DAPI.  
 
As shown in Figure 6 , at the lowest iron concentration, the R2 value of 2.43±0.09 s
-1
 was slightly increased with 
LA-coated magnetite compared to PC-3 cells in pure medium (R2: 1.96±0.10 s
-1
) For the ML, no changes were 
observed. 
However, incubation at higher Fe concentrations (0.3×10
-3 
M and 3×10
-3 
M Fe) of LA-coated magnetite, C-ML and 
FLU-ML 2 led to increased R2 values of 3.01 - 3.69 s
-1
, and even higher R2 values of 5.29 - 5.70 s
-1
. To determine 
the r2 value of ’’internalised’’ magnetite, we first subtracted the R2 value of 1.96±0.10 s
-1 
for PC-3 control cells in 
pure medium from the averaged R2 of 3.27±0.37 s
-1
 for incubated PC-3 cells (0.3×10
-3 
M Fe concentration of LA 
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coated magnetite, C-ML and FLU-ML 2) yielding a corrected, averaged R2 value of 1.39±0.23 s
-1
. This value was 
divided by 1.43×10
-5 
M Fe, which is the corresponding Fe concentration of the PC-3 cell suspensions incubated with 
0.3×10
-3 
M Fe after correction for the blank Fe concentration. This calculation yielded an averaged ’’internalised r2 
relaxivity’’ of 97.2±15.8 s-1mM-1 for the three magnetic colloids. Thus, the r2 value of the magnetic particles was 
decreased by a factor 4.6±1.9 upon their internalisation, considering the averaged r2 value of 450±112 s
-1
mM
-1
 for 
free particles in water.  
Similarly, Bulte et al. found an approximately five-fold decreased r2-value of internalised magnetodendrimers in 
human cervix carcinoma (HeLa) cells compared to magnetodendrimers in solution (33).We assume that the observed 
internalisation-induced decrease in r2 relaxivity was the consequence of the predominant accumulation of the 
particles as larger clusters in endosomal and lysosomal compartments. This leads to a strong decrease of exchange 
velocities of bulk water phase molecules with the rapidly-relaxed protons residing at the magnetic structures and 
induces a strong increase of the D to the ms scale of compartmentalised magnetic particles compared to free 
particles in water, which have a D in the µs range (34).  
Concerning longitudinal relaxation, no increased R1 were observed  for the incubated PC-3 cell suspensions 
compared to control cell suspensions (data not shown). This is a consequence of the comparably low r1 relaxivities of 
LA-coated magnetite, C-ML, and FLU-ML 2 in the range of 2.73 - 4.90 s
-1
 mM
-1
 in water. 
 
Figure 6.  T2-relaxation rates (R2) of untreated PC-3 cells (medium), and PC-3 cells incubated with LA-coated magnetite, C-
SUV, C-ML, FLU-SUV 2, and FLU-ML 2 for 3 h, respectively. Fe concentrations were 0.03, 0.3 and 3×10-3 M during incubation 
with magnetic colloids. During incubation with C-SUV and FLU-SUV 2, [PL] were 1.047×10-3 M, 10.47×10-3 M, and  
104.7×10-3 M (C-SUV), and 1.155×10-3 M, 11.55×10-3 M, and 115.5×10-3 M (FLU-SUV 2). These [PL] correspond to the 
respective concentrations used for C-ML and FLU-ML 2.   
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3. CONCLUSIONS  
 
Fluorescent magnetoliposomes are valuable diagnostic systems due to their excellent colloidal stability, low 
cytotoxicity and dose dependence of the MR signal.  
In this context, the lower unspecific cellular uptake of these bimodal contrast agents as compared to most 
commercial USPIO will be a great advantage for all targeted MR and optical imaging approaches. 
Although the fluorophore’s normalised fluorescence, quantum yield and life time are 
substantially reduced when increasing the number of fluorophore molecules per particle and upon attachment to 
superparamagnetic iron oxide cores, the FLU-ML internalised in PC-3 cells can still be visualised with fluorescence 
microscopy. Moreover, based on the results from our fluorescence studies, the quenching influence of the 
superparamagnetic iron oxide cores could be quantified. This underlines the potential of time-resolved fluorometry 
for the characterisation of such bimodal contrast agents. With this respect and for the design of bimodal probes with 
improved fluorescence properties, more systematic studies with systems where the fluorophore-iron oxide distance 
can be better controlled are of interest. Such studies should be extended to the use of fluorescence lifetime imaging 
thereby providing an extra parameter for probe and thus tumor location and possible the removal of undesired 
autofluorescence by time-gated emission.   
 
4. EXPERIMENTAL 
4.1. Materials 
DMPC, DMPG, and DMPE-L-R ammonium salt were purchased from Avanti Polar Lipids Inc. (Birmingham, AL, 
USA). All other chemicals were from Sigma-Aldrich (Steinheim, Germany). Throughout this work a 5×10
-3
 M N-
tris[hydroxymethyl] methyl-2-aminoethanesulfonic acid (TES) buffer (pH 7.0) was used. McCoy’s medium (10 % 
FBS + 1% of penicillin/streptomycin) for cell culture was purchased from Invitrogen/GIBCO.  
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4.2. Production and characterisation of classical and fluorescent magnetoliposomes 
4.2.1. Production of classical and fluorescent ML  
ML were produced based on a method developed by De Cuyper et al. (11). In brief, classical SUV (C-SUV) 
composed of DMPC and DMPG (DMPC/DMPG molar ratio: 90/10) were prepared in TES buffer pH 7.0 by probe 
sonication (UP 200S titanium probe-tip sonicator; Hielscher). In a similar way, two fluorescent SUV (FLU-SUV) 
with initial molar DMPC/DMPG/DMPE-L-R ratios of 90/10/0.33 (FLU-SUV 1) and 90/10/1 (FLU-SUV 2) were 
synthesised. Each SUV type (total phospholipid content of 10 mg/mL) was then mixed with an aqueous ferrofluid 
(iron content of the ferrofluid stock solution of 179.4 mg/mL) consisting of superparamagnetic magnetite crystals 
(mean diameter of 10 nm) stabilised with a laurate (LA) coating (35). The phospholipid/iron weight ratio in the 
different liposome - iron oxide incubation mixtures was 6.9. The mixtures were subsequently dialysed. During this 
step, the fatty acids originally attached to the iron oxide surface were substituted by phospholipid molecules. Non-
adsorbed lipids were removed by high gradient magnetophoresis as detailed in De Cuyper et al. yielding purified C-
ML and FLU-ML 1 and 2 (36). 
 
4.2.2. Physicochemical characterisation  
Diameter size distribution of the ML magnetite cores, Dh values  and  values were determined by TEM, dynamic 
light scattering (DLS) and combined laser Doppler velocimetry and phase analysis light scattering, respectively.  
 
4.2.3. Quantification of total phospholipid and iron concentration, and molar DMPE-L-R fraction 
Total phospholipid ([PL]) and iron concentrations were determined spectrophotometrically as described in detail 
previously (36). DMPE-L-R molar fractions were obtained by lyophilising defined volumes of SUV and ML samples 
and extracting the phospholipids from the residues with 2.0 mL methanol. DMPE-L-R concentrations of the extracts 
were then determined by measuring the relative fluorescence at 600 nm (rel. FIem.600) (excitation at 530 nm). The 
molar DMPE-L-R fraction was then calculated by dividing the DMPE-L-R concentration by [PL]. Details about the 
devices used and the exact protocol followed are described in the supporting information (SI). 
 
4.2.4. Measurement of rel. FIem. spectra, fluorescence quantum yields ( f) and fluorescence decay behavior 
Uncorrected emission spectra (FIem. spectra) in the wavelength region of 560 to 850 nm (excitation at 532 nm) were 
taken for the various fluorescent SUV and ML types using a microfluorescence spectrometer (Infinite M200 
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microplate reader; TECAN Austria GmbH). The DMPE-L-R concentrations were selected between (5 – 4500)×10-9 
M (FLU-SUV 1 and 2), (5 – 3000)×10-9 M (FLU-ML 1), and (5 – 9000)×10-9 M (FLU-ML 2), respectively. Rel. 
FIem. spectra of the diluted solutions of C-SUV and C-ML containing an identical [PL] as the fluorescent samples 
were measured under identical conditions and were taken as blanks. The absolute f of the FLU-SUV and FLU-ML, 
equaling the number of emitted photons (Nem) per absorbed photons (Nabs), were determined with a custom-designed 
integrating sphere setup at the Federal Institute for Materials Research and Testing (BAM). This setup enables 
spectrally resolved measurements of absolute fluorescence quantum yields in the wavelength region from ca. 400 nm 
to 950 nm (Würth, C.; Resch-Genger U. et al., own unpublished results). Fluorescence decay curves were measured 
by time-correlated single-photon counting (TCSPC) at 25 ° C using the FluoTime200 lifetime spectrometer of 
Picoquant GmbH equipped with a PMA182 detector, a PicoHarp300 TCSPC module, and a PDL800-B laser driver. 
The FLU-SUV and FLU-ML were excited at 532 nm, and the time-dependent fluorescence intensity profile was 
measured with the emission monochromator set to 590 nm. Details about the measurement conditions, software for 
analysing the fluorescence decay curves and equations for the calculation of fluorescence lifetimes are described in 
the SI.  
  
4.2.5. MR relaxometry  
Phantom measurements on all ML types used were performed by Nuclear MR relaxometry using a clinical 3.0 T 
whole body MR system (Philips Achieva, The Netherlands) in combination with a knee coil (sense-flex-M). ML 
particles were diluted in water in a concentration range between 3×10
-7
 to 2.5×10
-3
 M Fe and 300 µL of each dilution 
was filled in a well of a 96 well microtiter plate (flat bottom, transparent; Sigma-Aldrich). Transverse relaxation 
times (T2) were measured in a 2 D scan mode using a multi-slice, multi shot spin echo sequence with a 90° excitation 
pulse followed by a train of equally spaced 180° refocusing pulses  [TR = 1500 ms, mTR = 1189 ms, TE = 8.1 ms 
(shortest), number of echoes = 20, FOV = 130 x 162.5, reconstruction matrix = 64 x 81, voxel size = 2 x 2, slice 
thickness = 3 mm, slice orientation = coronal, scan mode = multishot]. T2 relaxation times were calculated by a linear 
fit of the logarithmic region of interest (ROI) signal amplitudes versus echo time (TE). Longitudinal relaxation times 
(T1) were determined using a multi shot spin echo sequence with a 10 ° excitation pulse without refocusing pulse [TR 
= 6.8 ms, TE = 3.3 ms (shortest), number of echoes = 1, FOV = 170 x 148.75 mm, reconstruction matrix = 152 x 
130, voxel size = 1.12 x 1.11, slice thickness = 5 mm, slice orientation = coronal, scan mode = 2 D]. T1 and T2 
relaxivities were calculated from the linear fit of the corrected relaxation rates, R1corr. and R2corr., as a function of the 
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iron concentration. R1corr. and R2corr. are the longitudinal and transversal relaxation rates of the ML containing 
samples corrected for the respective relaxation rates of water.   
 
4.3. Cellular response to classical and fluorescent magnetoliposomes  
4.3.1. Determination of dose dependence of uptake by PC-3 cells with MR relaxometry  
Cellular ML uptake was tested with PC-3 cells cultured in McCoy’s medium at 37 °C in a 5 % CO2 atmosphere in a 
C150 incubator (Binder). 1.1×10
7
 cells per flask (T75 cellstar tissue culture flask; Greiner, Sigma-Aldrich) were 
incubated for 3 h with 10 mL of C-ML, FLU-ML 2, LA-coated ferrofluid, C-SUV or FLU-SUV 2 in the growth 
medium or 10 mL pure growth medium. Iron concentrations in the growth medium were 3×10
-5 
M, 3×10
-4 
M, and 
3×10
-3
 M Fe for C-ML, FLU-ML 2, and LA-coated ferrofluid, respectively. Each experiment was done in triplicate. 
Control experiments with C-SUV or FLU-SUV 2 containing the same [PL] as used for the corresponding 
experiments with C-ML and FLU-ML 2 were carried out. After incubation, cells were trypsinised and washed three 
times with 50 mL PBS. Then, the cells were suspended in 300 µL 10% gelatine and transferred into the wells of a 96 
well microtiter plate (flat bottom, transparent; Greiner, Sigma-Aldrich). The uptake efficiency was determined by 
measuring the T1 and T2 MR relaxation times as described in the former section. Subsequently, the iron concentration 
of the gelatine cell suspensions was measured with inductively coupled plasma optical emission spectrometry (ICP-
OES) as detailed in the SI. 
 
4.3.2. Cell viability 
The cell viability of the different ML and SUV samples was analysed using the trypan blue exclusion (trypan blue 
stain, Invitrogen Corp.) and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (37). 
Both viability tests were performed at iron concentrations of 3×10
-5
 M, 3×10
-4
 M, and 3×10
-3
 M Fe of the C-ML, 
FLU-ML 1 and FLU-ML 2 at incubation times of 3 h and 24 h, respectively. Control experiments were carried out 
with 1 mL of C-SUV and FLU-SUV 1 and 2 containing the same [PL] as the corresponding ML samples. Each 
experiment was performed in triplicate. For the trypan blue test, 2 mL suspensions of 1.6×10
6
 trypsinised cells were 
incubated at 37 °C, 5 % CO2 and 95 % air humidity for 24 h, washed once with 2 mL PBS buffer, and incubated with 
1 mL of C-ML and FLU-ML 1 and 2 or medium free of particles for 3 h or 24 h. The cells were then washed once, 
trypsinised, and centrifuged at 1000 g (Heraeus Multifuge 1L) for 5 minutes. After resuspending with 0.5 mL 
medium, 50 µL of the cell suspensions were transferred into 1.5 mL Eppendorf tubes and mixed with 50 µL of 
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trypan blue stain solution. The amounts of living and dead PC-3 cells were counted with a Cedex XS cell counter 
(Roche Innovatis AG).  
 
4.3.3. Fluorescence microscopy of internalised particles  
For the detection of internalised fluorescent ML by fluorescence microscopy, 1 mL suspensions containing 5×10
5
 
cells were trypsinised and incubated as described above. Then, FLU-ML 1 or 2 (Fe concentration of 3×10
-3
 M) were 
added and the cells were incubated for 3 h. Similar experiments performed with 1 mL of C-ML (3×10
-3
 M Fe) or 
with the growth medium only, were taken as control. All experiments were done in triplicate. Then, the cells were 
washed three times with 2 mL of PBS buffer. Fixation of the cells on the coverslips was achieved by treatment with 
0.5 mL pure ethanol. For nucleus staining, the cells were treated with 0.4 mL DAPI (5 µg/mL) for 30 minutes and 
the cells were rinsed with water. The internalised particles were viewed with an AxioObserver epifluorescence 
microscope (Carl Zeiss GmbH). The images were acquired with a digital AxioCam MRm camera and processed 
using the digital Axio Vision 4.7.2 software (both Carl Zeiss GmbH).  
 
4.3.4. TEM of internalised particles.  
1.1×10
7
 cells were trypsinised and incubated in T75 cellstar flasks for 3 h as described above. 11 mL of  FLU-ML 2 
(3×10
-3
 M Fe) were added. The experiment was done in triplicate. Adherent cells were trypsinised and washed once 
with 50 mL PBS buffer. PC-3 cell pellets were fixed in 5 mL of 3 % glutaraldehyde (Agar Scientific) in 0.1 M 
Soerensen's phosphate buffer pH 7.4 (13×10
-3
 M NaH2PO4 × H2O and 87×10
-3
 M Na2HPO4 × 2H2O) for 22 h, 
washed with 0.1 M Soerensen's phosphate buffer overnight, embedded in 2 % agarose, rinsed with bi-distilled water, 
and dehydrated with ethanol (30 % - 100 %). Finally, tissues were processed for embedding in Epon (Fluka), 
polymerised for 8 h at 37 °C and 56 h at 60 °C, cut into 70 - 100 nm thick slices, and stained with uranyl acetate and 
lead citrate (Ultrostain 1 and 2, Leica). The samples were analysed with a PHILIPS EM 400 T at 60 kV and 
micrographs were taken by a MORADA CCD-Camera (Olympus Soft Imaging Solutions GmbH). 
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